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ABSTRACT
To identify novel genes that may be involved in Schwann cell lineage development and 
in myelination, we combined microarray based gene expression profiling with a refined 
bioinformatic analysis. We compared mRNA from rat sciatic nerves at embryonic day 
14 (E l4), E l8, postnatal day 7 (P7), P12 and in the distal stump of P I2 sciatic nerves 
cut five days previously and in which, therefore, all the myelin related genes should be 
strongly down-regulated. 1609 genes and expressed sequence tags (ESTs) were found to 
have at least a two-fold change in their level of expression either during development or 
after nerve injury. On this set of genes/ESTs a statistical analysis was performed to 
identify those that were significantly different between two time points. This was then 
followed by a sequence mapping and a protein structural and functional annotation 
carried out with Biopendium™ software, which enabled us to substantially minimise 
the number of unknown sequences. We identified agrin and two members of the 
collapsin response mediated protein family (CRMP) as possibly involved in the 
transition between Schwann cell precursors (E l4) and immature Schwann cells (E l8). 
Our data also suggest that the cartilage related proteins type II collagen and 
chondromodulin-1, and the cytoskeletal protein synuclein-1 may have important 
functions during peripheral nerve myelination. In addition, to clarify the role of 
transforming growth factor beta (TGF|3) during Schwann cell development in vivo, mice 
carrying a floxed segment of the TGF|3 type II receptor have been crossed with mice in 
which the CRE recombinase is expressed under the control of the P0 myelin protein 
promoter. Although myelination appears to occur normally, we found that Schwann 
cells death and proliferation rate are impaired in the perinatal period, both during 
normal development and after nerve injury, indicating a key role for TGF|3 in 
controlling these events.
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CHAPTER 1
GENERAL INTRODUCTION
Myelin is a multilamellar membrane that surrounds and supports axonsin both the 
central nervous system (CNS) and the peripheral nervous system (PNS). Its main 
function is to isolate axons and facilitate rapid saltatory conduction. In myelinated 
vertebrates, two types of myelinating cells exist: oligodendrocytes in the CNS and 
Schwann cells in the PNS. Both synthesize similar sets of protein, but each has unique 
proteins that may account, at least in part, for the differences in myelin structure and 
formation that characterise each nervous system. In the mature CNS a single 
oligodendrocyte can ensheath many axons via multiple processes, while in the PNS a 
single Schwann cell myelinates a single axonal segment.
Myelinating and non-myelinating Schwann cells are undoubtedly the major glial cells in 
the peripheral nerve. They were first described in 1839 by Theodor Schwann, the 
pioneer of the cell theory, whose name they would later bear (Shepherd, 1991). Ramon 
y Cajal was the first to appreciate and to describe in incredible detail the intricate 
relationship between the various components of the nervous system (Ramon y Cajal, 
1928; Ramon y Cajal, 1999-2002, edited translation). However, due to the limitations of 
light microscopy, he failed to realize that myelin was an extension of glial cells, and not 
foreign to them. The advent of the electron microscope allowed the ultrastructure and 
morphology of both Schwann cell forms to be revealed (Geren and Raskind, 1953; 
Geren 1954). It was thus elucidated that mature myelinating Schwann cells form 1:1 
relationships with larger diameter nerve axons, while non-myelinating Schwann cells 
support a number of smaller diameter axons in membrane invaginations.
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Development of the Schwann cell lineage
Most of the Schwann cells within the developing nerve derive, through a series of 
characteristic steps, from the neural crest, a population of migratory cells (Le Doutrin et 
al, 1991; Anderson, 1997). The formation of mature myelinating and non-myelinating 
Schwann cells from the neural crest involves the generation of two main intermediates, 
the Schwann cell precursor and the immature Schwann cell (Dong et al, 1995,1999; 
Jessen and Mirsky, 1999), and therefore, the overall process involves three main 
transitions: from crest cells to precursors, from precursors to immature Schwann cells 
and finally the formation of the two mature Schwann cell types (Mirsky and Jessen, 
1996; Jessen and Mirsky, 1999, 2002).
Neural crest
The neural crest is a transitory, migrating group of cells that segregate from the tips of 
the neural folds just before or just after they fuse to give rise to the neural tube. Neural 
crest cells will develop into a complex array of cell types, including the sensory and 
autonomic components of the peripheral nervous system as well as a range of non- 
neuronal tissues (LeDouarin and Smith, 1988: LeDouarin and Kalcheim, 1999). A 
major part of the newly formed neural crest cells will form the myelinating and non­
myelinating Schwann cells, as well as the other glial cell types in the PNS, such as the 
satellite cells, the teloglia and the enteric glial cells (Le Douarin and Smith, 1988, Le 
Douarin et al., 1991, Anderson, 1997). Yet, some studies conducted in the chick seem 
to suggest that the ventral neural tube itself contributes some Schwann cells that 
localize in the proximal part of the peripheral nerve in vivo (Rickmann et al, 1985; Lunn 
et al, 1987) or migrate away from ventral neural tube explants in vitro (Loring and 
Erickson, 1987). In contrast more recent investigations suggest that glial cells
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populating ventral roots are of neural crest origin (Carpenter and Hollyday, 1992a, 
Bhattacharyya et al., 1994; Golding and Cohen, 1997). Finally, a recent paper indicates 
that boundary cap (BC) cells, a population of cells that forms clusters at the entry and 
exit points of peripheral nerve roots, could represent a source of components of the PNS 
(Maro et al., 2004). Taken all together these data suggest that the vast majority of 
Schwann cells are derived from neural crest but that a small minority may be ventrally 
derived.
The induction of the neural crest
Prior to their migration, neural crest cells are an integral part of the neuroepithelium. 
Thanks to a morphogenetic conversion that causes these epithelial progenitors to 
become mesenchymal, the neural crest cells become motile and engage in migration 
(LeDouarin and Teillet, 1974; Bronner-Fraser, 1995; LaBonne and Bronner-Fraser, 
1999). The formation of neural crest precursors at the neural plate border involves many 
signalling events. Wnt proteins, Bone Morphogenetic Proteins (BMPs) and Fibroblast 
Growth Factors (FGFs) have all been shown in various assays to mimic the tissue 
interactions that induce neural crest (reviewed in Gammil and Bronner-Fraser, 2003). 
Another factor, called Noelin-1, appears to be of crucial importance in the timing of 
neural crest formation (Knecht and Bronner-Fraser, 2002). A Wnt protein, Wnt6, seems 
to be the inducing signal from non-neural ectodermal tissue (Garcia-Castro et al, 2002), 
while the BMP signal is required only after the initial induction step, indicating that 
BMPs might serve for maintenance of the induction process (Selleck et al, 1998) or for 
initiation of migration (Sela-Donenfeld and Kalcheim, 1999). In amphibians FGF 
signalling can induce neural crest in neuralized ectoderm (LaBonne and Bronner-Fraser, 
1998; Mayor et al, 1995).
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Neural crest extrinsic markers
Extrinsic markers have also been applied to neural crest precursor cells. Initial studies 
used donor tissue labelled with tritiated thymidine (Weston, 1963). However this 
technique has a main limitation in the fact that the label rapidly becomes diluted as a 
result of cell proliferation. The modem versions of this approach are more efficient and 
involve the use of vital dye such as Dil or DiO for staining the premigratory crest cells 
(Stem, 1990; Serbedzija et al, 1989,1990; Hatada and Stern, 1994). The dye, 
incorporated in the cell membrane, is transferred to the daughter cells through a certain 
number of generation and provides a means for marking for 2-4 days.
LeDouarin developed an elegant method based on the observation that quail cells have a 
nuclear marker that distinguishes them from chick cells (LeDouarin, 1973, 1982). When 
quail cells are transplanted into a chick embryo the cells from each species retain their 
nuclear characteristics and can be identified in the chimera. The technique is so 
powerful that a single quail cell can be identified in a chick tissue.
Neural crest intrinsic markers
Different methods have been used to shed light on the pathways of neural crest cell 
migration: extirpation or in situ destruction of the neural crest, often used in lower and 
higher vertebrates, have yielded significant information, but the results obtained are 
relatively crude (reviewed by Hdrstadius, 1950; Weston, 1970). More precise 
information on the migration process and on the fate of neural crest cells have been 
obtained by means of cell marking experiments. In pioneering experiments cytoplasmic 
inclusions or differences in cell size have been used (Raven, 1937; Triplett, 1958). More 
recently other experiments have followed neural crest cells by labelling them with
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monoclonal antibodies HNK-1 and NCI. These antibodies recognise a glucuronic acid- 
containing carbohydrate carried by several surface glycoprotein and glycolipids (Chou 
et al, 1986). However, the epitope is only transiently expressed on some neural crest 
cells (Dupin et al, 1990), is present only in a subset of rat neural crest cells and no 
reactivity could ever be detected with mouse neural crest cells (Erickson et al, 1989, 
Pomeranz et al, 1993). Because of this most of the work using HNK-1 has been done in 
avian embryos. The low-affinity neurotrophin receptor p75 has in some cases been used 
to study migration of murine and rat neural crest cells (Stemple and Anderson, 1992; 
Chalazonitis et al, 1997).
The transcription factor51ug, a member of the zinc finger family isolated in chick 
embryos (Nieto et al, 1994) is expressed at high level in neural crest precursor cells 
prior to the onset of motility. Its close relative Snail is expressed in mouse and fish 
(Locascio et al, 2002). Both seem to be target of neural crest induction and, 
interestingly, Slug promoter contains a binding site shown to mediate transcription in 
response to Wnt6 (Wu et al., 2003). Inhibition of Slug/Snails inhibits the migration of 
the neural crest cells (LaBonne and Bronner-Fraser, 2000). Their targets are not known 
yet, but recently they have been shown to regulate the epithelial-mesenchymal transition 
(EMT) in vitro via repression of E-cadherin and Claudins/Occludins, thus triggering the 
breaking of adherens and tight-junctions (Cano et al, 2000; Ikenouchi et al, 2003).
The transcription factor Sox-9 is a marker for murine premigratory and migratory neural 
crest in fish, mouse and chick (Mori-Akiyama et al, 2003; Cheung and Briscoe, 2003), 
while Sox-10 in these species marks only migratory neural crest cells (Cheng et al, 
2000; Britsch et al, 2001). Other markers such as Pax-3 and Notch are expressed in the 
neural plate but elevated in the neural crest (Monsouri et al, 2001; Coffman et al, 1993; 
Williams et al, 1995). The transcription factor Pax-3 is mutated in the Splotch mouse, in
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which the development of the neural tube is severely affected (Epstein et al, 1991). 
Notch is a membrane-anchored protein that is activated through binding of ligands 
expressed by neighboring cells. Upon binding to one of the ligands such as Delta, the 
intracellular domain of Notch is cleaved and translocated to the nucleus (Kopan, 2002). 
Although Delta/Notch signalling is required for neural crest formation (Endo et al,
2002), overexpression of Notch results in a loss of neural crest derivatives (Coffman et 
al, 1993) stressing the importance of having finely tuned levels of Notch/Delta in the 
neural crest. The transcription factor AP-2, initially expressed at the neural plate border 
is later enhanced in neural crest migrating from the cranial neural folds (Mitchell et al, 
1991; Luo et al, 2002). Null mutation of this gene revealed its importance for the 
development of many cranial facial structures, including the cranial ganglia (Schorle et 
alt 1996). During peripheral glia development, AP-2 appears to play a role in the timing 
of Schwann cell formation, since its down-regulation coincides with the precursor- 
immature Schwann cell transition (Stewart et al., 2001). Finally RhoB, a target of BMP 
signalling, that is expressed in the dorsal neural tube and in migrating neural crest is 
necessary for the delamination of neural crest cells, although it is not required for neural 
crest specification, (Liu and Jessel, 1998; Henderson et al, 2000).
Pathways of migration in the trunk
In the trunk of vertebrate neural tube two main directions of migration have been 
recognized: a first one, ventral, between neural tube and somites that gives rise to cells 
in the dorsal root ganglia (DRG), sympathetic ganglia, adrenomedullary cells, aortic 
plexuses and Schwann cells (Weston, 1963; Le Douarin and Teillet, 1974; Erickson et 
al., 1992) and a second, lateral, over the entire dorso-lateral surface of the somite, that
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will mainly give rise to melanocytes, the pigment cells of the skin and of fur in 
mammals or feathers in avians (Erikson et al., 1992; Erikson and Goins, 1995). 
Moreover, the work of Le Douarin and colleagues with the chick-quail chimeras has 
revealed the existence of three additional migration pathways: an intersomitic group of 
cells, a longitudinal population migrating along the neural tube and another longitudinal 
group that migrates along the dorsal aorta (Le Douarin et al, 1982; Teillet et al, 1987).
The pattern of migration of neural crest cells is largely mediated by inhibitory signals 
that actively exclude cells from the caudal halves of the somites. In fact, in elegant 
experiments in which the somites were rotated 180°, so that the anterior-posterior axis is 
reversed, neural crest cells will migrate only through what was originally the anterior 
portion of the somite (Bronner-Fraser and Stem, 1991). Several molecules in the 
posterior half of the somites are inferred as inhibitory, among them extracellular matrix 
molecules (ECM) such as collagen IX, F-spondin, versican, chondroitin 6-sulfate-rich 
proteoglycans and ephrin B2 (Perris et al, 1991; Ring et al, 1996; Landolt et al, 1995; 
Debby-Brafman et al, 1999; Smith et al., 1997; Wilkinson, 2001). Some permissive 
ECM-associated signals have also been identified; fibronectin for example has been 
shown to play an important role in the migration of the neural crest in vivo and 
enhances its motility in vitro (Thiery et al, 1982; reviewed in Duband et al, 1986). 
Diverse type of collagen, including collagen I, IV and VI are also able to mediate neural 
crest cell motility in vitro (Perris et al, 1993).
The multipotentiality of the neural crest
The question of how crest cells are able to generate such a diversity of cell types is of 
great interest for developmental biologists (reviewed in LaBonne and Bronner-Fraser
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2000; Kalcheim, 2000; LeDouarin and Dupin, 2003). Many experiments conducted in 
vivo and in vitro suggest that neural crest is composed of an heterogeneous population 
of cells endowed with different proliferation and differentiation potentials. For example, 
the fate of individual cells can be changed by transplanting them to different locations 
along the neural tube or exposing them to different factors in vitro (Dupin et al., 1990; 
LeDouarin et al, 1993). Rare totipotent progenitors, able to generate all the different 
derivatives (neurons, glial cells, mesenchymal cells, melanocytes) were identified 
(BarofFio et al., 1988,1991). Yet, if post-migratory crest cells are transplanted back into 
the neural crest of younger hosts they can no longer give rise to the full array of 
derivatives (LeDouarin, 1996). Evaluations in vitro indicated that more of 70% of the 
progenitors were fate restricted by 30-36 hours after leaving the neural tube (Henion 
and Weston, 1997). This suggests that as migration proceeds, neural crest cells 
gradually undergo a restriction o f their potentiality. Neural crest cells have the 
capability of self-renewal in culture (Stemple and Anderson, 1992) and recently the 
presence of a population of neural crest stem cells in the peripheral nerve has been 
suggested on the basis of expression of p75 low affinity NGF receptor and myelin 
proteins (Morrison et al, 1999). These cells, accounting around 10% of the total cells in 
E14 peripheral nerves, appear to be both multipotent and capable of self-renewal 
(Morrison et al., 1999, 2000).
A large amount of work in vivo, through the analysis on mouse mutants, as well as in 
vitro, has led to the identification of several growth factors/receptors implicated in the 
development of specific neural crest derivatives (reviewed in Anderson, 1997; Sieber- 
Blum, 2000). Melanocyte lineage differentiation is stimulated by endothelin-3 (ET3) 
and stem cell factor (SCF) (Opdecamp et al, 1998: Yoshida et al, 2001). The
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ET3/endothelin receptor B (ETRB) pathway plays a crucial role also in enteric 
gangliogenesis, a process in which glial derived neurotrophic factor (GNDF) is also 
involved (Kruger et al, 2003; Airaksinen and Saarma, 2002). In humans Hirschsprung 
disease is linked with a defect in these signal pathways, and the colonization of the gut 
by neural crest cells is abnormal (McCallion and Chakravarti, 2001; Iwashita et al,
2003). In the PNS, gliogenesis is regulated by the neuregulin family of growth factors 
(discussed in more details below), that signals through the ErbB-receptors family (Shah 
et al, 1994; reviewed in Jessen and Mirsky, 2002, 2004). Since in the PNS neurons and 
glia differentiate in the same environment the question of how they choose to adopt 
either neuronal or glial fate has been puzzling. In vivo BMPs (in particular BMP2), 
regulatory genes and cell-cell interaction interplay to generate neurons first and glial 
cells later (Morrison, 2001) and in vitro studies showed that BMP neurogenic activity is 
dominant over the gliogenic effect of neuregulin (Shah and Anderson, 1997). Recent 
work has suggested that the activation of the Notch signalling pathway initiates the 
irreversible switch from neurogenesis to gliogenesis (Wakamatsu et al, 2000; Morrison 
et al, 2000; Kubu et al., 2002). The soluble form of the Delta-1 ligand promotes 
Schwann cell differentiation in cultured neural crest stem cells even in the presence of 
BMP2 (Morrison et al, 2000). This effect seems to be regulated by the relative 
expression of Notch and its antagonist Numb: cells that express Numb will go through a 
neuronal fate while those that don’t express it will become glial cells. Accordingly, 
over-expression of Numb in crest cells culture promotes neuronal differentiation 
(Wakamatsu et al, 2000; Kubu et al, 2002). Neural crest stem cells (NCSC) from the 
peripheral nervous system show also some intrinsic differences. In fact E l4 NCSC 
isolated from gut are more responsive to neurogenic factors than NCSC isolated from 
sciatic nerves, which are more responsive to gliogenic factors (Bixby et al, 2002).
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However, one possible explanation for this difference may reside in the method used to 
isolate these cells. They have in fact been FACS sorted as Po’ and p75+ with an anti-Po 
antibody that is probably not suitable for this purpose, leading many to believe that this 
population of cells represent Schwann cell precursors (Jessen and Mirsky, 2004). This is 
also supported by the observation that the population that sorts as Po+ and p75' does not 
form Schwann cells in the presence of neuregulin-1 (Morrison et al., 1999), raising 
many concerns about the technique used in these experiments.
Neural crest derivatives maintain partial plasticity and a recent paper demonstrated that 
ET3 is capable of reprogramming the melanocyte phenotype in vitro inducing de- 
differentiation and subsequent activation of glial markers (Dupin et al, 2000). Recently 
the converse transition from Schwann cell to glial-melanocyte precursors has been 
obtained after exposure to ET3 (Dupin et al, 2003), underlying the relative instability of 
neural crest derived pigment and glial cells in vitro.
Axon/Schwann cell relationships during peripheral nerve development
Several groups have carried on experiments aimed at a better understanding of the close 
interaction between axons and Schwann cells in the early stages of nerve development, 
and many different animal models have been used, such as frog (Harrison, 1924) chick 
(Weston, 1963; Carpenter and Holliday, 1992a, b) and rat (Jessen et al, 1994). 
Development seems to follow a rostro-caudal pattern and also a proximo-distal gradient 
along the nerve outgrowth from the spinal cord. Some authors have suggested that 
Schwann cell may act as pioneer cells, migrating ahead of the axon and guiding 
peripheral nerve outgrowth (Noakes and Bennet, 1987). This theory appears to be ruled 
out by the findings in transgenic mice lacking neuregulin or its receptor ErbB3. In fact 
in these mice, although Schwann cells are basically absent in the nerve, axons grow and
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reach their target normally (Mayer and Birchmeier, 1995; Riethmacher, 1997). 
Similarly, in the splotch mouse, the absence of Schwann cells does not impede motor 
neurons from projecting correctly, although it results in motor neurons migration from 
the spinal cord in to the periphery (Grim et al, 1992; Vermeren et al., 2003). Rather, it 
seems that the presence of the neurite outgrowth from the ventral motor axon is 
necessary for guiding Schwann cells into their final position in the peripheral nerve 
(Bhattacharyya et al, 1994).
The Schwann cell precursor
During rat development, axons project into the hind limb between embryonic day 13 
(E13) and E14 (E11 -E l2 in the mouse). Ultrastructural analysis reveals bundles of 
small diameter axons tightly packed with apparently no extracellular matrix within 
them, and surrounded along their perimeter by glial cells separating the axons from the 
mesenchymal tissue (Jessen et al, 1994). By this stage the glial cells associated with the 
outgrowing axon display specific characteristics that differentiate them from both 
migrating crest cells and immature Schwann cells, and are therefore named Schwann 
cell precursors (Jessen et al, 1994). Unlike migrating crest cells, Schwann precursors 
express the growth-associated protein 43 (GAP-43), the brain fatty acid binding protein 
(B-FABP), and the myelin proteins PO, PLP and PMP-22 (Jessen et al, 1994; Kurtz et 
al, 1994; Lee et al, 1997; Hagedom et al, 1999; Britsch et al, 2001). If dissociated from 
the axon and plated, precursor cells undergo rapid apoptotic death (Jessen et al, 1994; 
Dong et al, 1995), unlike mature Schwann cell that survive in vitro owing to autocrine 
loops (Meier et al, 1999). Schwann cell precursor death in vitro can be rescued by 
incubation with lOOpM of p-neuregulin-1 (Jessen et al, 1994; Dong et al, 1995), a 
growth factor that is likely to be the axonal signal responsible for precursor cell survival
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(reviewed in Mirsky and Jessen, 1999). When plated, Schwann cell precursors exhibit a 
morphology markedly different from that of neonatal and adult Schwann cells; instead 
of a bi- or tri-polar shape, they are more flattened and tend to cluster together in a 
pavement-like array, while Schwann cells from later stages grow more evenly 
distributed. Moreover, in vitro studies showed that precursor cells are much more motile 
than mature Schwann cell, with a migration rate similar to that of crest cells (Jessen et 
al, 1994).
The brief period spanning between E l6 and E l7 (El4/E 15 in the mouse) sees the 
transition of Schwann cell precursors into immature Schwann cells (also called pre­
myelinating Schwann cells). These cells are clearly distinguishable from precursors 
thanks to their cytoplasmic immunoreactivity for the calcium binding protein S I00 
(Jessen et al, 1994). Shortly after S I00, immature Schwann cell start expressing the 
surface lipid 0 4  (Dong et al, 1999). When in vitro, they tend to assume a bi- tri-polar 
shape, have low motility and proliferate in the presence of fibroblast growth factor 
(FGF) (Jessen et al, 1994; Dong et al, 1999). Probably the most striking characteristic 
of immature Schwann cells is that when removed from the axon they do not die by 
apoptosis, having established an autocrine survival loop (Dong et al, 1999; Meier et al, 
1999). This means that during development there is a change in survival regulation: the 
survival of Schwann cell precursors depends on axonal signals, whereas Schwann cell 
survival is axon independent. The nature of this loop has been studied in detail, and 
different experiments aimed at mimicking the positive effect of Schwann cell 
conditioned medium on Schwann cell cultures, suggested that the main component of 
the autocrine survival process is a cocktail of three growth factors, NT-3, IGF-2 and 
PDQFBB (Meier et al, 1999). Other potential autocrine Schwann cell survival factors
21
include leukaemia inhibitory factor (LIF) and lysophosphatidic acid (LPA)(Dowsing et 
al, 1999; Weiner and Chun, 1999).
Neuron-Schwann cell signals
As already mentioned, Schwann cells from E l8 onwards have the capability to survive 
when dissociated from the axon, while Schwann cell precursors undergo rapid death by 
apoptosis in this condition, but can be rescued by the growth factor p-neuregulin-1 
(Dong et al, 1995). At present, the Neuregulin family accounts for four different genes, 
NRG1, NRG2, NRG3 and NRG4, whose signals, implicated in many different systems, 
are transduced via the ErbB-receptor family (reviewed in Adlkofer and Lai, 2000; 
Garrat et al, 2000; Falls, 2003). Neuregulin-1 is the best known, and encodes for many 
different isoforms, isolated in various systems, and named Neu differentiation factor 
(NDF; Wen et al, 1992), heregulin (Holmes et al, 1992), glial growth factor (GGF; 
Marchionni et al, 1993), acetylcholine receptor inducing activity (ARIA; Falls et al,
1993) or sensory and motor neuron derived factor (SMDF; Ho et al, 1995). The term 
"neuregulin" stems from the contraction of Neu differentiation factor and heregulin, the 
first two published by groups seeking for the ligands of the ErbB2 receptor.
Structure of NRG1
The Neuregulin-1 gene has been recently sequenced and assembled (Stefansson et al, 
2002). The gene is on the short arm of chromosome 8, it is about 1.3 megabases long, 
but only less than 0.3% of it encodes for protein. Thus the rich alternative splicing and 
use of multiple promoters, result in at least 15 different isoforms (reviewed in Lemke,
1996). With respect to the in vivo functions and cell biological properties, three
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characteristics of the molecules play crucial roles: the epidermal growth factor-like 
(EGF-like) domain, the N-terminal sequence and whether the isoform is initially 
synthesized as a transmembrane (TM) or not TM protein. The EGF-like domain on its 
own seems sufficient for ErbB receptor activation (Holmes et al., 1992; Wu et al.,
1994). Alternative splicing gives rise to variants in the C-terminal part of this domain, 
originating “a ” or “P” forms, with different affinities for the ErbB receptors (Pinkas- 
Kramarski et al., 1998; Jones et al., 1999; reviewed in Adlkofer and Lai, 2000). The N- 
terminal region can contain either an immunoglobulin-like (Ig-like) domain, or a 
cysteine rich domain (CRD), the latter one mainly found in the neuregulins predominant 
in the nervous system (Ho et al., 1995).
Receptors for NRGs
Neuregulin-1 signalling involves binding to members of the EGF-receptor subfamily of 
phospho-tyrosine kinases (PTKs) known as the ErbBs. The name derives from the avian 
virus oncogene v-Erb-B, found in avian erythroblastosis, where it encodes for a mutated 
form of the EGF receptor (Adlkofer and Lai, 2000). The activation of these receptors in 
various cell types results in cellular responses that include differentiation, proliferation, 
apoptosis, migration and adhesion (reviewed in Yarden and Sliwkowski, 2001; Peles et 
al., 1992; Falls et al., 1993). Although NRG1 was first identified by groups seeking for 
ligands for the ErbB2 receptor, it is now known that NRG1 binds initially to the high 
affinity receptors ErbB3 and ErbB4, and that the activation of ErbB2 takes place 
indirectly after its heterodimerization with either Erb3 or ErbB4 (Riese et al., 1995, 
Sliwkowski et al., 1994; Carraway and Cantley, 1994). In the past years various 
experiments have indicated that while NRG1 signals mainly through ErbB2/ErbB3 or 
ErbB2/ErbB4 heterodimers, NRG2 preferentially activates the ErbBl/ErbB3
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heterodimer and the ErbB4 homodimer (Pinkas-Kramarski et al., 1998; Jones et al., 
1999; Carraway et al., 1997; Crovello et al., 1998). These findings support the general 
idea that the different bioactivities of NRG 1 and NRG2 are a direct consequence of the 
activation of different ErbB receptor combinations.
Role of NRGs in Schwann cell development
The first implication of the importance of NRG in Schwann cell biology comes from in 
vitro experiments that identified GGF as a Schwann cell mitogen (Raff et al., 1978; 
Marchionni et al., 1993). Moreover, as mentioned previously, work on crest cell clones 
showed that the addition of NRG1 to the cocktail in which the cells were grown, 
strongly pushed the crest cells towards a glial choice, selectively suppressing the 
generation of neurons (Shah et al., 1994; Shah and Anderson, 1997). Further in vitro 
studies on Schwann cell precursors have shown that p-neuregulin-1 is capable of 
blocking apoptosis and can stimulate precursor proliferation (Dong et al, 1995). Even 
more striking is that this work demonstrated that, in the presence of NRG-1, Schwann 
cell precursors generate Schwann cells with a time course similar to the one seen in vivo 
in peripheral nerve (Dong et al., 1995). Additionally, the effect of NRG on Schwann 
cell is abolished via the exposure to a soluble form of the EGF-like domain of ErbB4 
(Dong et al., 1995). Taken together, these data strongly suggested that the interaction 
NRG/ErbBs was the axon-derived signal responsible for Schwann cell survival, 
proliferation and differentiation.
A powerful boost to these studies arrived from the analysis of null mutant mice for 
NRG1, ErbB2, ErbB3 and ErbB4 (Lee et al., 1995; Meyer and Birchmeier 1995; 
Riethmacher et al., 1997; Gassman et al., 1994). NRG -/- and ErbB2 -/- mice die at 
midgestation, due to the arrest of trabeculation of the heart ventricle. However, already
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at E 10.5'fis possible to notice in these mice a significant reduction in the number of 
Schwann cell precursors (Meyer and Birchmeier, 1995). This phenotype is shared by 
the ErbB3 -/- mice, which have proven to be particularly informative since around 20% 
of these mice survive until birth. Their analysis reveals a complete loss of Schwann cell 
precursors and around 80% reduction in motor and sensory neurons (Riethmacher et al.,
1997). The loss of neurons could be due to a lack of all the Schwann cell derived factor 
such as CNTF, PDGF, LIF, and proves the importance of Schwann cells as trophic 
partners for neurons. The essential role of ErbB2 for peripheral nerve development has 
been underlined in elegant experiments where the cardiac defect has been rescued 
(Morris et al, 1999; Woldeyesus et al., 1999). These groups have created transgenic 
mouse lines in which the ErbB2 cDNA is expressed under the control of either the heart 
specific promoter Nkx2.5 or the heart muscle actin promoter. These mice lack mature 
Schwann cells as well as other crest derivatives, and although axons project relatively 
normally, motor and sensory axons are severely defasciculated and disorganized. 
Similar results are seen in mice in which only the CRD-NRG-1 isoform is missing, 
underlying that this is the predominant isoform in peripheral nerve (Wolpowitz et al, 
2000).
Neuregulin and myelination
The role of NRG in later events of Schwann cell differentiation, including myelination, 
is less clear. Neurons, including motor and large sensory neurons, express neuregulin-1 
in the adult nervous system (Chen et al, 1994; Bermingham-McDonogh et al., 1997). 
These findings are consistent with a possible role of neuregulin-1, in the adult, in the 
maintenance of the myelin sheath. According with this hypothesis, the conditional 
ablation of ErbB2 in developing nerve, via a Krox-20/Cre allele, results in a deficit in
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Schwann cell number and in myelin thickness (Garratt et al., 2000b). In contrast, 
addition of the soluble isoform of neuregulin-1, GGF, in co-cultures of dorsal root 
ganglia neurons and Schwann cell, results in block of myelination in a dose dependent 
manner. If GGF is added to co-cultures where myelin had already formed, the result is a 
striking demyelination accompanied by Schwann cell dedifferentiation and proliferation 
(Zanazzi et al., 2001). These results are consistent with the findings that neuregulin and 
expression of ErbBs is substantially increased in Schwann cell during Wallerian 
degeneration (see below) and demyelination, suggesting a possible autocrine signalling 
mechanism (Carroll et al., 1997; Hall et al., 1997). Taken together, these data suggest a 
role for neuregulins and ErbB-receptors not only during Schwann cell generation and 
maturation but also in later events of peripheral nerve development and in the adult. 
Nevertheless, recent experiments with transgenic mice challenge the idea that Nrg is a 
demyelination signal.
Neuregulin-1 type III controls myelin thickness
Recent experiments with mutant and transgenic mice have shown that neuregulin (in 
particular neuregulin-1 type III) is the key axonal signal for the regulation myelin 
thickness (Michailov et al., 2004). In this paper the authors show that mice 
heterozygotes (+/-) for Nrg-1 produced a thinner myelin sheath than normal littermates 
and had reduced conduction velocity. In contrast when Nrg-1 type III is specifically 
overexpressed postnatally by motorneurons and DRG neurons in transgenic mice, 
thanks to a Thy 1.2 promoter, there is a dramatic increase in myelin thickness and in the 
number of wraps. Moreover many small caliber axons are myelinated (Michailov et al.,
2004). However, the precise mechanisms that link neuregulin expression and axon 
diameter are still unclear.
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The role of Endothelins in the timing of Schwann cell generation
The generation of Schwann cells from their precursors can be broadly reproduced in 
vitro under simple conditions. Thus, E l4 precursors, plated in defined medium 
containing neuregulin-1, generate, after four days (E14+4=E18), cells that show the 
phenotype of immature Schwann cells rather than that of precursors (Dong et al., 1995). 
However, a percentage of the cells, calculated to be around 15%, do not convert to 
Schwann cells. Therefore, it is probable that other factors contribute to the Schwann cell 
precursor to Schwann cell transition in vivo. Endothelins (ET), acting through the 
endothelin B receptor, are likely to be one of these factors (Brennan et al., 2000). ETs 
1,2 and 3 are encoded by three different genes, and share strong sequence and structural 
homology (Yanagisawa et al., 1988). Similarly to neuregulin, all of them can support 
the survival of Schwann cell precursors in vitro but, unlike neuregulin, they do not 
induce proliferation in precursors. Moreover, if cultured in the presence of ETs for four 
days, Schwann cell precursors tend to remain precursors instead of converting to 
Schwann cells. If E l4 precursors are cultured in the presence of both neuregulin and 
ET, the Schwann cell generation rate is an intermediate of that seen with neuregulin 
alone or ET alone (Brennan et al., 2000). These data indicate that ET act as a brake on 
Schwann cell generation, a finding confirmed by the accelerated precursor to Schwann 
cell transition in mice deficient for the endothelin B receptor (Ceccherini et al., 1995; 
Brennan et al., 2000). Interestingly, in the presence of ET, Schwann cell precursors 
convert to Schwann cells after 7 days, even in the absence of neuregulin, indicating that 
the action of ET is not to block, but rather to delay the generation of Schwann cells 
(Brennan et al., 2000). On the other Wawul this also means that neuregulin is not 
absolutely required for the generation of Schwann cells, although it promotes this 
process. Finally, it has been shown that in vitro, the addition of FGF2 to neuregulin,
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accelerates Schwann cell maturation (Dong et al., 1999). Taken together these 
observations indicate that a fine regulation of these factors is necessary for a perfectly 
timed glial development in peripheral nerve.
In this respect of highly coordinated gene control, it is surprising that, to date, only one 
transcription factor, AP2a, has been implicated in this process. AP2a in fact, is strongly 
down-regualated in vivo during the precursor to Schwann cell transition, and its 
overexpression in vitro delays the generation of Schwann cells (Stewart et al., 2001).
Signals that promote Schwann cell survival
As discussed above, there is now strong evidence that the survival of Schwann cell 
precursors is acutely dependent on axonal signals produced by neuregulin-1. However, 
the survival of Schwann cells must rely on different signals, since the transection of 
adult nerves does not lead to Schwann cell death (Grinspan et al., 1996; Syroid et al., 
1996; Trachtenburg and Thompson, 1996). In fact, in the distal stump of transected 
nerves, Schwann cell can survive for a considerable time, although they decline in 
number and become less responsive to extrinsic signals (Li et al., 1998; Sulaiman and 
Gordon, 2002). This ability of Schwann cells to survive in the absence of the axon is 
crucial for nerve regeneration and for remyelination after injury, since Schwann cell 
create a permissive environment that promotes axonal growth. The establishment of an 
autocrine loop is a major reason why Schwann cell survive (Cheng et al., 1998; Meier 
et al., 1999; Dowsing et al., 1999; Weiner and Chun, 1999).
Schwann cell proliferation and death
Co-culture of DRG neurons and Schwann cells have been extensively used to 
investigate Schwann cell proliferation, establishing that neuregulin-1 is the primary
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axonal mitogen for Schwann cells (Morrissey et al., 1995; Bunge et al., 1996). Schwann 
cell DNA synthesis and proliferation can also be studied in purified culture. In this 
second case, the presence of cAMP, or of factors that mimic it, is necessary, since, with 
the exception of NRG-1 and HGF, in the absence of cAMP the mitogenic response of 
Schwann cell is minimal (reviewed in Mirsky and Jessen 2001; Jessen and Mirsky, 
2004). Using purified cultures, in the presence of cAMP, it has been found that several 
growth factors, including TGFps, PDGF-BB, FGF-1 and -2, and Reg-2 act as Schwann 
cell mitogens. The additional presence of IGFs potentiates the effect of most Schwann 
cell mitogens, including neuregulin-1 (Stewart et al., 1996; Cheng and Feldman, 1997; 
Cheng et al., 1999; Conlon et al., 2001). Proliferation in damaged nerves appears to be 
regulated by different mechanisms than those involved in nerve development, as 
indicated by the study of cyclin D1 and D2 null mice ( Kim et al., 2000; Atanasoski et 
al., 2001). This issue, and the role of TGFps in Schwann cell proliferation will be 
addressed extensively in chapter 5.
In addition to signals that promote Schwann cell survival and proliferation, there are 
factors that play a key role in Schwann cell death by apoptosis, during development an 
after nerve damage. (Trachtenberg and Thompson, 1996, Syroid et al., 1996, Grinspan 
et al., 1996, Nakao et al., 1997). Two factors, nerve growth factor (NGF) and TGFp 
have been directly implicated in these processes (Soilu-Hanninen et al., 1999; 
Parkinson et al., 2001). These findings are discussed in detail in chapter 5.
Early transcription factors in Schwann cell lineage development
In eukaryotes, a great deal of biological regulation takes place at the transcriptional 
level. Cells from tissues phenotypically different, such as brain and muscle, share 
identical genotypes but possess a different spectrum of cellular mRNA. It is nowadays
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clear that gene regulation is the basis for forming such diverse phenotypes. Apart from 
containing coding regions, genes are sprinkled with “enhancer” and “silencer” sites, 
often located near the promoter, but sometimes thousand of base-pairs distant from it. 
Transcriptional activators and repressors act at these sites, recruiting the transcriptional 
initiation machinery to a gene’s promoter. The identification of the mechanisms that 
regulate gene transcription in a precise temporal and spatial pattern is fundamental to 
our understanding of the development of the multicellular eukaryote. Transcription 
factors are responsible for the modulation of tissue specific gene expression and for the 
control of gene expression seen during development. To date several different 
transcription factors have been identified in mammalian development and they are 
grouped into classes based upon the structure of the DNA binding domain. Schwann 
cells have been shown to express a number of representatives from the different classes 
of transcription factors, which modulate the expression of distinct set of genes that both 
mark and lead Schwann cell differentiation (reviewed in Topilko and Meier, 2001). To 
date, a first group of transcription factors, including Sox-10 and Pax-3, is known to be 
present during neural crest specification, migration and during the subsequent Schwann 
cell precursor development. These can be considered early transcription factors. A 
second group, comprising Oct-6 and Krox-20, is then involved in Schwann cell 
differentiation, and are here termed late transcription factors. However, it should be 
noted that these two groups often overlap and, as we will see, act coordinately to control 
Schwann cell development.
Sox-10
The sex determining factor, SRY, encodes a transcription factor characterised by a 
DNA-binding motif known as the high mobility group (HMG) domain. The Sox (SRY
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box) gene family consists of genes related to SRY, with a sequence homology to the 
HMG box, which is involved in developmental regulation in a number of different 
systems (reviewed by Wegner, 1999). The HMG domain is not highly conserved 
(>50% amino acid hom ology), binds the heptam eric sequence 5 ’ 
(A/T)(A/T)CAA(A/T)G 3’ and, unusually for a transcription factor, binds the minor 
groove of DNA. Binding of the Sox protein results in strong DNA bending that could 
facilitate the interaction of other transcription factors in either side of the Sox binding 
site (Pevny and Lovell-Badge, 1997). The transcription factor Sox-10 appears to be 
directly involved in glial development from the neural crest (Kuhlbrodt et al., 1998; 
Britsh et al., 2001; Paratore et al., 2001; Peirano et al., 2000). Sox-10 was isolated 
using degenerate PCR from primary Schwann cell cultures, revealing a protein of 466 
amino acid residues and 56 kD in size (Pingault et al., 1998; Kuhlbrodt et al., 1998) 
with greater than 90% homology to murine Sox8 and 9 (Wright et al., 1993). Sox-10 
expression, at least at the mRNA level, is seen mainly in the nervous system. In the 
CNS, it is found in the brain where it localises in the oligodendrocytes of white matter 
tracts, such as the internal and external capsules and the corpus callosum (Kuhlbrodt et 
al., 1998). In the PNS, expression of Sox-10 mRNA is seen in the dorsal aspect of the 
closing neural tube, and then, more crucially, in the migrating neural crest (Kuhlbrodt et 
al., 1998, Southard-Smith et al, 1998, Britsch et al., 2001; Paratore et al., 2001). Sox-10 
is subsequently down-regulated in early neurons, but remains expressed in the 
developing glia, both in the ganglia and along the nerve trunks emanating from them. 
This latter expression, localised to Schwann cells, continues into early adulthood, 
although at lower levels (Kuhlbrodt et al., 1998, Southard-Smith et al, 1998, Britsch et 
al., 2001, Lange and Jessen, unpublished observation). This data suggests that Sox-10,
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at least at the mRNA level, is expressed throughout Schwann cell development. 
However it remains unclear if the relative levels of Sox-10 fluctuate temporally. 
Heterozygous mutations in the human SOX-10 gene are associated with isolated cases 
presenting growth retardation, impairment of both the central and autonomic nervous 
system, and, in some circumstances, peripheral neuropathy with hypomyelination and 
deafness (Touraine et al, 2000; Pingault et al, 2000). It is possible that this neuropathy 
associated with hypomyelianation is due to reduced myelin protein zero (Po) expression. 
Sox-10 expression is in fact sufficient to induce Po in a neuroblastoma cell line, and as 
this effect is absent in known Sox-10 mutants (Peirano et al, 2000).
Mutations in the Sox-10 gene have been associated with Waardenburg-Hirschprung’s 
disease or Waardenburg-Shah syndrome (WS4), which are human hereditary disorders 
arising due to neural crest abnormalities and resulting in deafness, pigmentary loss and 
aganglionic megacolon(Herbath et al, 1998, Kuhlbrodt et al, 1998b, Pingault et al,
1998). The Dominant Megacolon (Dom) Hirschprung’s mouse, a naturally occurring 
mutant, characterised by a nonsense or frameshift mutation in the Sox-10 gene 
(Southard-Smith et al, 1998, 1999), has been widely used to study the effects of Sox-10 
inactivation. These mice show homozygote embryonic lethality and a failure to produce 
melanoblasts, while heterozygous animals show intestinal aganglionosis and spotted 
pigmentation (Lane and Liu, 1984).
Sox-10 expression continues during the diversification of both the melanocyte and glial 
lineages, while it is down-regulated in other neural crest cell derivatives (Herbarth et 
al., 1998, Kuhlbrodt et a l , 1998, Pusch et al, 1998). The role of Sox-10 in peripheral 
glia development has been investigate further in Sox-10 null mice (Britsch et al., 2001). 
In this study, a Sox-10 null mutant was generated by LacZ gene insertion and in the 
heterozygous state a phenotype including pigmentation and megacolon defects, similar
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to the WS4 and Dom mutants, was obtained. Even more significantly, in homozygous 
Sox 10 null mice early peripheral glial cells, which can be identified by expression of 
the brain-specific fatty acid binding protein (B-FABP), are missing. This applies to both 
Schwann cell precursors in peripheral nerve and to satellite cells in the DRGs where, on 
the other end, sensory neurons are initially present in normal numbers, although they 
start dying later (Sonnenberg-Riethmacher et al., 2001). One reason for this could be 
the reduction of the neuregulin-1 receptor, ErbB3, which is observed in Sox 10 null 
mice. (Britsch et al, 2001). Neuregulin-1 signalling does not appear to be essential for 
the survival of migrating crest cells in vivo (Britsch et al., 1998), but neuregulin-1 and 
its receptor ErbB3 are then important for the survival and proliferation of Schwann cell 
precursors (Britsch et al., 1998; Dong et al., 1995; 1999). It follows that one of the 
consequences of the reduced expression of ErbB3 receptor in Sox-10 null mice could be 
the death and decreased proliferation of those crest cells that have started glial 
differentiation, resulting in a severely reduced number of Schwann cell precursors in 
nerve trunks. This however does not account for the lack of glia in the DRGs in Sox-10 
null mice. In fact, in mice in which neuregulin-1 signal has been inactivated DRG glia 
develop normally (Garrat et al., 2000; Woldeyesus et al., 1999; Meyer and Birchmeier,
1995). It is therefore possible that one of the major functions of Sox 10 is in glial 
specification, the process by which crest cells change to become early glia (Britsch et 
al., 2001).
In another derivative of the neural crest, the melanocyte, a number of other possible 
downstream target genes of Sox-10 have been identified (Lee et al., 2000, Potterf et al.,
2000). One study noted that pigmentation deficiencies similar to those observed in the 
Sox-10 heterozygous mice, were present in mice with mutations in the microphthalmia 
gene (Mitf) which encodes a transcription factor essential for the development of the
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melanocyte lineage (Lee et al, 2000). Sox-10 can directly bind and activate the Mitf 
gene, and this activation is enhanced by Pax-3, whereas a mutant form of the Sox-10 
genes acts as a dominant negative repressor of Mitf expression (Potterf et al, 2000; Lee 
et al, 2000, Bondurand et al, 2000).
Sox-10 remains expressed, although at lower levels, in postnatal nerves, and has been 
shown to synergise with Pax-3, Oct-6 and Krox-20, functioning as a transcriptional 
modulator (Kuhlbrodt et a l , 1998). In vitro studies have shown that Sox-10 in synergy 
with Krox-20 strongly activates connexin-32 expression by directly binding to its 
promoter (Bundurand et al., 2001), suggesting a possible role for Sox-10 in the 
regulation of myelin genes. This is in agreement with experiments that have 
demonstrated that Sox-10 is able to bind the Po promoter and could have a role in the 
expression of this gene, which encodes for the major protein in peripheral myelin 
(Peirano et al., 2000).
Pax-3
Pax-3 belongs to the murine Paired box (Pax) DNA binding domain transcription factor 
family, and encodes a 479 amino acid protein containing both paired domain and paired 
type homeodomain (Goulding et a l, 1991) and therefore binds DNA through its 
bipartite DNA-binding domains (Phelan and Loeken., 1998). Pax-3 mRNA is 
expressed in the roof plate of the neural tube, in the neural crest and in somitic 
mesoderm (Goulding et a l, 1991). Mutations in a number of Pax genes have been 
shown to result in developmental defects in human and mice (Mansouri et al., 1996). In 
humans, disruption to the Pax-3 gene results in Waardenburg syndrome, while the 
fusion of Pax-3 with the forkhead gene is the cause of the childhood cancer 
rhabdomyosarcoma (Galili et al., 1993; Shapiro et al., 1993). Two naturally occurring
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Pax-3 mouse mutants, splotch (Sp) and splotch delayed (Spd) have also been identified, 
the former having a deletion in the homeodomain (Epstein et al, 1991) and the latter a 
point mutation in the paired domain (Moase and Trasler, 1990; Franz, 1993). 
Homozygous Sp mutants die at around E l4 showing central nervous system deficits 
such as excencephalus and spina bifida, a lack of musculature and defects in the PNS 
and in pigmentation (Epstein et al, 1991). Sp mice embryonic nerves have no Schwann 
cells in the lower trunk (Grim et al., 1992), while Spd mice, which survive until E l8 
(Moase and Trasler, 1990) have severely reduced numbers of Schwann cells (Franz, 
1993). Other neural crest derivatives are disrupted in these mutants, including neurons 
in the spinal ganglia and melanocytes (Gruss and Walther, 1992). These data indicate 
that Pax-3 has a role in the early emergence and development of neural crest cell 
derivatives and is required for normal Schwann cell development. However, Pax-3 is 
not restricted to these early developmental stages and its mRNA is detectable in the 
sciatic nerve throughout embryonic development and after birth (Blanchard et al., 1996; 
Kioussi et al., 1995). Interestingly, micro-injection of exogenous Pax-3 into Schwann 
cells in vitro causes down-regulation of myelin markers such as Po and MBP, and up- 
regulation of those associated with non-myelin forming Schwann cells such as GFAP, 
LI, N-CAM and p75NTR (Kioussi et al., 1995). These results are in agreement with the 
finding that in adult nerve Pax-3 expression is confined to non-myelin forming 
Schwann cells. Moreover, Pax-3 can repress the MBP and PO promoters in co­
transfection assays. Taken together these data suggest that Pax-3 has a role in Schwann 
cell terminal differentiation, favouring the generation of non-myelinating Schwann cells 
by suppressing the myelin-forming pathway.
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Myelination
The process of myelination represents one of the most striking examples of cell-cell 
cooperation. The differentiation of myelin-forming Schwann cells is governed and 
dependent on the contact with another cell, the neuron, via specialised processes, the 
axons. All Schwann cells have the potential to form myelin, but they only do so after 
contact with certain axon, the large diameter ones. As we have seen, neuregulin-1 type 
III plays a crucial role in determining myelin thickness, but the participation of 
additional axonal signals and growth factors in the overall process cannot be ruled out 
(Michailov et al., 2004; reviewed in Mirsky and Jessen, 2004).
Myelinating Schwann cells polarize along the axon, with an abaxonal plasma membrane 
that is in contact with the extracellular matrix and interacts with it, and an adaxonal 
membrane which is in direct contact with the axon (Bunge et al, 1986). The abaxonal 
membrane directs the formation of a basal lamina, an essential prerequisite for 
myelination (Bunge et al, 1986), while the adaxonal membrane is enriched in myelin- 
associated glycoprotein (MAG) (Trapp et a l, 1984; reviewed in Trapp et a l , 2004). 
Immature cells destined to become myelinating Schwann cells begin to express the 
glycolipid galactocerebroside (GalC) at around E l9 (Jessen et a l, 1985). Shortly after, 
they start to segregate the bigger axons forming 1:1 relationships with them, while 
smaller caliber axons remain in polyaxonal pockets, surrounded by a single Schwann 
cell (Webster, 1971). The process of axonal segregation and Schwann cell myelination 
continues until all appropriate axons are myelinated. In the PNS, lp,m is on average the 
smallest myelinated fibre present (Ritchie, 1983). Schwann cells at the 1:1 stage have 
stopped dividing and are found in the sciatic nerve at birth in both rat and mouse 
(reviewed in Jessen and Mirsky 2002, 2004). The first wrappings of the myelin sheath 
are seen at this time together with high level expression of the major myelin proteins:
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the glycoprotein protein zero (Po), peripheral myelin protein 22kDa (PMP22), myelin 
basic protein (MBP), proteolipid protein (PLP), myelin associated-glycoprotein (MAG), 
plasmolipin, myelin and ^mphocyte protein (MAL), P2, periaxin (Prx) and CNPase 
(Jessen and Mirsky, 1999; 2002).
The development of non-myelinating Schwann cell is delayed compared to the 
myelinating ones. They do not express galactocerebroside until shortly before 
elaborating their distinctive pattern of multi-axonal support, which does not begin until 
the third postnatal week (Diner et al, 1965, Jessen et al., 1985; Jessen et al., 1987a).
Myelin structure
The myelin sheath that Schwann cells synthesise around a single axon is a multilamellar 
membrane that acts as an insulating conduit. The sheath is discontinuous along the 
length of the axon. At the junction of adjacent Schwann cells there are specialised areas 
of electrically excitable axon surface, known as the node of Ranvier. Action potentials 
are propagated from one node to the next in a process known as saltatory conduction 
(Ranvier, 1878, Webster, 1971; Ritchie, 1983). In unmyelinated axons the conduction 
velocity is directly proportional to the root of the diameter of the axon. For this reason, 
invertebrates such as the squid, that need rapid nerve conduction but have only 
unmyelinated axons, have developed “giant axons” with large diameter. Myelin, and 
thus saltatory conduction, increases the velocity of a given action potential up to ten 
times, compared to a similar sized unmyelinated axon (Jacobson, 1993, Ritchie, 1983). 
Every Schwann cell forms a single internode, which can be divided in two distinct 
domains, compact myelin and non-compact myelin. The Schwann cell nucleus is 
usually positioned in the middle of the internode. Compact myelin accounts for the 
majority of the myelin in the intemode, and, if observed with a Transmission Electron
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Microscope (TEM), appears as a lamellar structure, alternating dark and light lines that 
wraps a central axon. The spiral membranes of compact myelin have a periodicity of 13 
to 19 ran, depending on the technique used to measure it (Kirschner and Sidman, 1976; 
Kirschner and Hollingshead, 1980). The periodicity derives from the presence of dark 
major dense lines, 2.5 nm thick, separated by paler interperiod lines. The major dense 
line is formed by the fusion of two intracellular lipid bilayers, with the squeezing of the 
cytoplasm, while the interperiod line is formed by the two extracellular surfaces of the 
Schwann cell membrane (Alberts et al., 1994; reviewed in Trapp et al., 2004). Non­
compact myelin, on the other hand, provides cytoplasmic continuity over the length of 
the myelinating Schwann cell. It includes the cytoplasmic channels at the abaxonal and 
adaxonal surfaces and Schmidt-Lanterman incisures, that radially transverse the 
compact myelin. A major channel that extends the entire length of the intemode 
contains the outer mesaxon. At either end of the myelinating Schwann cell, approaching 
the node of Ranvier, the major dense line opens up to accommodate cytoplasm, forming 
the paranodal loops. These loops are a major site of myelin axon adhesion via a series 
of septate-like junctions and provide a diffusible barrier and preventing lateral diffusion 
of membrane proteins (reviewed in Peles and Salzer, 2000; Scherer et al., 2004). The 10 
-15 nm area of the myelin intemode adjacent to the paranodal loops is known as 
juxtaparanodal region. In TEM it is basically indistinguishable from the intemode, but it 
is enriched in delayed-rectifier potassium channels and in the protein Caspr 2, a 
homologue of Caspr (Peles and Salzer, 2000). The node of Ranvier is a small stretch of 
bare axolemma (axonal plasma membrane), directly exposed to the extracellular milieu, 
that separates myelin segments along individual nerve fibers. This area is extremely rich 
in voltage-gated Na channels, and is therefore directly responsible for saltatory 
conduction (Scherer et al., 2004). The nodal axolemma is surrounded by Schwann cell
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microvilli, which extend from the outer border of the adjacent myelin intemodes and 
contain F-actin, ezrin, radixin and moesin (reviewed in Scherer et al., 2004).
Myelin composition
Since the major function of compact myelin is to insulate the axon, it does not need to 
be a particularly complex and dynamic structure. Myelin membrane comprises -75%  
lipids and -25%  proteins, which serve mainly, but not only, a structural function. 
Myelin proteins are encoded in the CNS and PNS by an overlapping but not identical 
set of genes. As we shall see, natural mutants and man-made transgenic mice have been 
widely used for the analysis of the function of these proteins, showing that they are 
involved in several stages of Schwann cell development.
Po
Myelin protein zero (Po) is the main protein in the myelin of the PNS, accounting for 
more than 50% of the total proteins (Greenfield et al., 1973). The Po gene encodes a 
single RNA species of 1.9 Kb which results in a protein consisting of a 29-residue 
signal peptide, a 124-residue extracellular domain, a 26-residue transmembrane domain 
and a 69-residue intracellular domain (Sakamoto et al., 1987; reviewed in Kirschner et 
al., 2004). Po is therefore a 28-30 kDa, glycosilated, integral membrane protein, that 
belongs to the immunoglobulin gene superfamily, thanks to its extracellular 
immunoglobulin(Ig)-like domain (Lemke and Axel, 1985, Lemke et al, 1988). The 
presence of this Ig-like domain, found in cell adhesion molecules such as N-CAM (for 
review see Edelman, 1983), and the abundance of Po in PNS myelin, suggested that Po 
could be somehow involved in both the extracellular and intracellular membrane 
adhesion, which result in compact myelin (Lemke and Axel, 1985). The homophilic
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adhesive nature of Po has been demonstrated by transfection assays where increased 
cell-cell attachment occurs (D’Urso et al, 1990, Schneider-Schaulies et al, 1990, Filbin 
et al., 1990). To date, only the recombinant extracellular domain corresponding to the 
sequence for rat has been crystallized, showing that this domain has to assemble into a 
tetrameric complex in order to serve such an adhesive function (Shapiro et al., 1996).
Po is expressed almost exclusively in Schwann cells and at dramatically high levels 
during myelination (Trapp et al., 1981, Webster and Favilla, 1984, Kirschner et al., 
2004). However, Po mRNA has been detected in the notochord, in otic placode and 
vesicle, in the enteric neural crest and in olfactory ensheathing cells (Lee et a l , 2001). 
Prior to birth, Po mRNA first appears in a subset of neural crest cells and this probably 
represenfcthe first sign of glial commitment. Subsequently it remains expressed, at basal 
levels, in Schwann cell precursors and immature Schwann cells (Bhattacharyya et al., 
1991; Lee et al., 1997). After birth, both Po mRNA levels and protein synthesis rise 
about 3 0 -4 0  fold in myelinating Schwann cells, and peak during the second post-natal 
week before dropping off in the adult (Lemke and Axel, 1985; Trapp et al, 1988; Stahl 
et al, 1990; Baron et al, 1994). Schwann cells require continuous axonal contact to 
maintain high level Po expression (Trapp et al, 1988; Mirsky et al, 1980; Lemke and 
Chao, 1988; Jessen and Mirsky, 1991; Fernandez-Valle et a l, 1993; Scherer et al, 
1994; Gupta et al, 1993). Po expression regulation is thought to occur mainly at the 
transcriptional level (Stahl et al, 1990; Lee et al, 1997). So far, the strongest evidence 
for a direct regulation of the Po gene is for the Sox-10 transcription factor. Sox 10, in 
fact, up-regulates both endogenous Po expression as well as the Po promoter 10- to 20- 
fold when ectopically expressed in neuroblastoma cells, while this effect is absent when 
known Sox 10 mutants are used in the same assays (Peirano et al, 2000). Moreover, the 
authors show that the Po promoter contains two probable Sox-10 binding sites.
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The function of the Po protein has been extensively studied thanks to a series of 
transgenic mice. Homozygous and heterozygous null mice have shown that not only Po 
is involved in myelin compaction during development but it is also required for the long 
term maintenance of the myelin sheath via protein turnover (Giese et a l, 1992). 
Moreover, a series of observations indicates a role for Po in axon maintenance. In fact, 
Po null mice develop axonal degeneration (Giese et al., 1992; Frei et al., 1999; Martini 
et al., 1995), and several point mutation in the Po gene cause the axonal form of 
Charcot-Marie-Tooth disease (CMT2)(reviewed in Wrabetz et al., 2004). Human 
peripheral neuropathies such as CMT and Dejerine-Sottas syndrome (DSS) have been 
identified that are linked to various mutations in the Po gene (reviewed by Keller and 
Chance, 1999; Wrabetz et al., 2004). Work on Po overexpressing mice has suggested 
that myelin assembly employs a process linking the various constituents in a mechanism 
that closely controls the final stoichiometry (Wrabetz et al, 2000). In this work, a 
series of transgenic mice overexpressing Po has been generated by introducing extra 
copies of the Po gene. It was found that increasing dysmyelination occurred with 
increased Po gene dosage. Surprisingly, increased Po mRNA expression resulted in 
reduced Po protein expression and interestingly, also caused a reduction of normal 
levels of MBP, highlighting the importance of dosage and stoichiometry of the different 
myelin genes in the production of a stable myelin sheath.
MBP
MBP is the second most abundant protein in peripheral myelin, accounting for up to 
16% of the total proteins (Greenfield et al, 1973). MBP is encoded by a gene 105kb in 
length in the mouse and 180kb in humans, and consists of at least six different isoforms,
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ranging form 14 to 21.5 kDa, generated through alternative splicing of the gene 
(reviewed by Lemke and Barde, 1998; Campagnoni and Campagnoni, 2004). A second 
family of MBP proteins, the golli-MBPs, is generated from a different transcription start 
of the gene. The golli proteins are present in the nervous system but at levels 
signifibantly lower than the MBPs, and are also expressed in the immune system, 
including spleen and thymus (Campagnoni et al., 1993). MBP, in all its classic 
isoforms, is located on the intracellular face of compact myelin in the major dense line, 
and its major role appears to be that of structural component. Both oligodendrocytes and 
Schwann cells target MBP proteins to the sheath via free ribosomes located close to the 
site of myelin formation (Colman et al, 1982, Trapp et al, 1987, Ainger et al, 1993). 
The shiverer (shi) mouse is a naturally occuring mutant that has been shown to be 
deficient in MBP. In these mice the major dense line fails to form within CNS myelin, 
while in the PNS myelin is formed and functional, but it is slightly thinner than in a 
normal mouse (Privat et al, 1979; Popko et al, 1988; Kirschner and Ganser, 1980, 
Rosenbluth et al, 1980). One reason for this difference probably lays in the fact that 
MBP is much more abundant in the CNS (30% of myelin proteins) and therefore has a 
more important function than in the PNS. Moreover, the other main protein in the CNS, 
PLP, does not have a cytoplasmic tail, whereas Po in the PNS does. Therefore MBP is 
probably needed in the CNS for myelin stability while it is not crucial in the PNS. Shi 
phenotype includes tremors, convulsions and early death that can be rescued by the 
introduction of the wild-type MBP gene (Readhead et al, 1987, Kimura et al, 1989). 
Shi mice also exhibit double the number of Schmidt-Lanterman incisures in myelin 
forming Schwann cells, although the meaning of this difference is not yet clear (Gould 
et al, 1995). Double mutants have been generated deficient for both Po and MBP. 
These mice show a severe hypomyelination, and the thin myelin sheath formed is
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devoid of major dense lines, indicating that in the PNS both MBP and Po proteins are 
required for normal myelination (Martini et al, 1995).
PMP22
PMP22 is a 22 kD glycoprotein that is a minor component of the myelin sheath of 
peripheral nerve. It belongs to a family of proteins characterised by four transmembrane 
domains and conserved amino acid motifs (Jetten and Suter, 2000). PMP22 expression 
pattern is similar to that of other myelin gene products, and it is localised to compact 
myelin (Snipes et al, 1992, reviewed in Werner et al, 1998; Suter, 2004). PMP22 is 
widely expressed in neural and non-neural tissues during embryonic development and 
also in the adult (Notterpek et a l, 1999). PMP22 protein is most highly expressed in 
myelinating Schwann cell where it is detectable after MAG but before MBP onset in 
rodents (Notterpek et al, 1999). In the mature nerve PMP22 is found in the plasma 
membrane of non-myelinating and myelinating Schwann cells, and in the compact 
portion of myelin (Snipes et a l , 1992, Haney et a l , 1996). The PMP22 gene spans 
approximately 40kb in humans and consists of six exons (Patel et al., 1992). On the 
transcriptional lavel, two different promoters, PI and P2, have been identified (Suter et 
al., 1994). While PI appears to control myelinating Schwann cell-specific expression, 
P2 is more widely active (Suter et al., 1994). PMP22 and Po are regulated in a similar 
way during development, myelination and after nerve injury, and colocalise in compact 
myelin. This raises the hypothesis of an association between these two proteins, where 
PMP22 would interact with the Po tetrameric complex (D'Urso et al., 1999). This idea 
fits well with the finding that mutations affecting PMP22 and Po result in similar 
inherited demyelinating neuropathies (Scherer, 1997; Snipes and Suter, 1995; Wrabetz 
et al., 2004).
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Most of the knowledge about the role of PMP22 in peripheral nerve comes form 
genetics, since PMP22 is the most common cause of neuropathies in humans and 
rodents. The mouse mutants trem bler (Tr) and Tr-J display peripheral myelin 
uncompaction and hypomyelination together with increased Schwann cell proliferation, 
associated with abnormal myelin degradation and remyelination (Suter et al., 1992a, b; 
1993). These mice carry a point mutation in hydrophobic regions of the PMP22 protein, 
indicating that the transmembrane domains may be important for myelin compaction 
and for maintenance of mature myelin (Suter et al., 1992b, Suh et al, 1997). These two 
mutations are now well characterised: Tr mutants have a G150D mutation in the last 
transmembrane domain that causes a transport arrest of PMP22 in the endoplasmic 
reticulum (ER) (Naef et al., 1997, D’Urso et al., 1998). Tr-J mice have a Leul6Pro 
mutation and PMP22 proteins are also transported abnormally (Notterpek et al, 1997, 
Tobbler et al, 1999). To better understand the function of PMP22, PMP22 deficient 
mice have been generated by the complete disruption of the PMP22 gene. These 
animals display walking difficulties due to progressive limb weakness. From a 
morphological point of view they display a mildly delayed onset of myelination 
followed by hypermyelination and demyelinating peripheral neuropathies in both the 
homozygous and heterozygous state, characterized by tomacula, onion bulbs and 
aberrant Schwann cell proliferation and death (Adlkofer et al, 1995, 1997; Sancho et 
al., 1999; 2001).
Recently, transgenic mice and rats overexpressing increasing numbers of copies of the 
PMP22 gene have been created (reviewed in Wrabetz et al., 2004). Overexpressing 
mice show that peripheral neuropathies develop when 4 copies or more of the transgene 
are present and that with 7 copies hypomyelination is severe (Huxley et a l, 1996,
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1998). Moreover, it has been found that TrJ mutants and mice with 7 copies of the 
PMP22 gene are able to form 1:1 associations with axons but that many fibers were not 
completely surrounded by Schwann cell cytoplasm (Robertson et al., 1999). Delays in 
the onset of myelination have also been observed in mouse and rats overexpressing the 
mouse PMP22 gene (Magyar et al., 1996, Sereda et al, 1996). Further analyses of 
these PMP22 overexpressing rats shows that myelination is blocked at the 
promyelinating stage, not simply delayed, and Schwann cell differentiation at the 
mRNA level is not perturbed (Niemann et al., 2000). Thus it is likely that PMP22 is 
involved early on in the process of myelination, immediately after the establishment of 
1:1 relationships with axons.
In humans PMP22 mutations are associated with three different neuropathies: Charcot- 
Marie-Tooth (CMT) disease, Dejerine-Sottas syndrome (DSS) and hereditary 
neuropathy with liability to pressure palsies (HNPP) (reviewed in Keller and Chance 
1999; Wrabetz et al., 2004). Duplications of the complete PMP22 gene account for 
most cases of CMT1A, although point mutations also exist (Lupski et al., 1991, 
Raeymaekers et al., 1991). Intriguingly, a Dutch family with a Leul6Pro mutation, the 
same that occurs in Tr-J mutants, shows a severe DSS, with an 80% reduction in 
myelinated fibre density as compared to 20% in the Tr-J mouse (Valentijin et al., 1992; 
Gabreels-Festen et al., 1995, Robertson et a l, 1997)
The large variation in severity in neuropathies seen both in patients with mutations in 
the PMP22 gene and animal models suggest that these mutations, as well as mutations 
in Po, could act via at least two different mechanisms, gain of function or loss of 
function. In the latter case, as a result of the mutations, the protein is either not 
produced at all or is quickly degraded. Loss of function is therefore the likely cause of 
the less severe phenotypes observed. In the gain of function mechanism, the mutated
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proteins gains an abnormal or toxic function that perturbs the biology of the cell much 
more severely, and usually results in the more severe phenotypes (reviewed in Wrabetz, 
2004).
To conlude, all these observations indicate that PMP22 may have two roles in the PNS; 
an earlier role in the establishment of a complete Schwann cell to axon association and 
a later role as a component of mature compacted myelin.
PLP
The PLP gene, located on the X chromosome, spans around 17kb, consists of seven 
exons and is controlled by a single promoter region (Stoffel et al., 1984; Diehl et al.,
1986). PLP exists in two isoforms, PLP (24 kDa) and DM20 (20 kDa) as a result of an 
uncommon exonic alternative splicing (reviewed in Suter and Snipes, 1995). PLP is 
mainly expressed in the CNS where it contributes 50% of total myelin proteins whereas 
in the PNS much lower amounts are present. Two transcription initiation sites have 
been identified in the PLP gene (Milner et al., 1985). Both are employed in the CNS, 
while the downstream one is predominant in the PNS (Kamholz et al., 1992; Scherer et 
al., 1992). The significance of this seems to lie in the influence of promoters on splice 
site selection. The upstream promoter selectively drives the expression of PLP, and as a 
result, this is the form predominant in the CNS. The downstream promoter selectively 
expresses DM20, which is the major isoform expressed in the PNS, although 
myelinating Schwann cell also express PLP. Of the two genes, during development of 
oligodendrocytes DM20 is initially expressed at higher levels but is later superseded by 
PLP at the peak of myelination (Schindler et al., 1990, Timsit et al., 1992, 1995; 
Scherer et al., 1995; reviewed in Hudson, 2004). PLP is localised in the interperiod line 
in mature myelin and is therefore proposed to have a structural role. Gene targeting of
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the PLP locus has generated PLP null mutant as well as mice lacking both PLP and 
DM20 or DM20 only (Boison and StofFel, 1994; Boison et al., 1995; Klugmann et al., 
1997; Stecca et al., 2000; Sporkel et al., 2002; Uschkureit et al., 2001). In each 
transgenic model, oligodendrocyte development occurrs normally, and they assemble 
myelin. However, this myelin, in the PLP/DM20 double mutant, has defects in the 
intraperiod line, with reduced conduction velocity and impaired neuromotor 
coordination (Boison and Stoffel,1994). An age-related degeneration of 
oligodendrocytes is also seen in PLP and PLP/DM20 mutants (Klugmann et al., 1997; 
Sporkel et al., 2002; Stecca et al., 2001; Yool et al., 2001). Interestingly, while 
PLP/DM20 double KO mice show axonal swelling and loss of compact myelin in small 
caliber axons (Yool et al., 2001), these defects are spared in mice that express only 
DM20 (Boison et al., 1995), suggesting a possible redundancy for these two proteins.
In humans, mutations in both PLP and DM20 cause Pelizaeus-Merzbacher disease 
(PMD), an X-linked a leukodystrophy and, in some cases, a dysmyelinating neuropathy. 
The range of mutations is extremely varied, from point mutations to deletions to 
duplication (reviewed in Yool et al., 2000). The relationship between genotype and 
phenotype is remarkably close in the animal models and the PMD cases, making them 
useful models for studying the mechanisms of PLP gene-related disease. As a result, it 
has become clear that the PLP gene plays a wider role in neural development in addition 
to its function as a structural component of myelin. It has also emerged that duplications 
of the PLP gene are the commonest mutation in PMD. Genetic disorders arising from a 
dosage effect may be more common than previously recognized.
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MAG
MAG is a type I membrane glycoprotein consisting of an N-terminal extracellular 
domain, a single transmembrane domain and a small cytoplasmic domain (Lai et al., 
1987; Scherer et al., 1987). The gene spans approximately 16kb and is composed of 13 
exons. MAG protein is encoded in two isoforms, 67 kD (S-MAG) and 72 kD (L-MAG) 
forms, with the former predominantly in Schwann cells and the latter localised to 
oligodendrocytes of the CNS as well as Schwann cells. In the PNS MAG constitutes 
less than 1% of peripheral myelin, and is found mainly in non-compact myelin, such as 
the mesaxon, Schmidt-Lanterman incisures and paranodal loops but not in compact 
myelin and is expressed before the massive up-regulation of the other myelin genes 
(Hudson et al., 1990; reviewed in Georgiou et al., 2004). This observation has 
suggested a role for MAG in mediating axon-myelin sheath interactions, and supported 
a role for MAG in the initial stages of myelin formation (Georgiou et al., 2004). The 
extracellular portion of MAG contains 5 Ig-like domains, which as already seen for P0, 
are often associated with adhesive properties. The adhesive properties of MAG have 
been demonstrated experimentally with different approaches. The use of antibody 
against MAG prevents the binding of oligodendrocytes to neurons (Poltorak et al.,
1987), and recombinant MAG confers adhesive properties to liposomes and to different 
cell types, such as fibroblasts (Johnson et al., 1989; Afar et al., 1991). One of the first 
insights into the role of MAG in mediating axon-myelin sheath interactions came from 
the naturally occurring Quaking mouse mutant. The mutation, which does not occur in 
the MAG gene but in the QKI gene, directly affects MAG mRNA and protein 
expression and MAG localisation (Trapp et al, 1988; Bartoszewics et al., 1995; Fujita 
et al., 1988). MAG deficient mice, on the other hand, reveal only a subtle phenotype 
within the PNS, although the onset of maturity is accompanied with progressive
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axonopathy, axonal degeneration and onion bulbs formation, suggesting that MAG may 
also stabilize myelin (Yin et a l, 1998; Weiss et al., 2001). Moreover, in MAG null 
mice enhanced regeneration following sciatic nerve injury has been reported (Li et al., 
1994, Montag et al, 1994, Filbin, 1995). This latter finding is in agreement with other 
studies in the CNS where has been reported that, while during early development MAG 
promotes axonal growth, it becomes an inhibitory molecule for axonal regrowth in the 
adult (reviewed in Georgiou et a l , 2004).
The fact that the neuropathology in MAG knockout is not severe together with the 
ability to detect it only later in life, suggest that MAG mutations in humans would be 
difficult to diagnose, and in fact, to date, no human mutation in the MAG gene has been 
identified.
Periaxin
Periaxin (Prx) is a member of the PDZ domain protein family and is primarily 
expressed by myelinating Schwann cells, where it associates with the cytoskeleton. The 
periaxin gene, located in mouse on chromosome 7, is composed of seven exons and 
encodes two mRNAs of 5.2 and 4.6kb, resulting from different splicing, which translate 
into two periaxin forms: S-periaxin (16kDa) and L-periaxin (147kDa) (Gillespie et al, 
1994, Dytrych et al, 1998; Gillespie et a l , 2000). It has been reported that, in human 
PNS, the smaller mRNA is predominant, suggesting that L-periaxin is the main isoform 
in human Schwann cells (Boerkoel et a l , 2001). Both isoform contain a PDZ domain, 
which is believed to be involved in protein-protein interaction at the plasma membrane. 
In the mouse, although they have similar abundance, only L-periaxin is localized to the 
Schwann cell plasma membrane while S-periaxin is distributed within the cytoplasm 
(Dytrych et al, 1998).
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In Schwann cells, periaxin expression is detectable early in development, at around the 
time when precursors start to differentiate in immature Schwann cells, and peaks during 
the first two weeks after birth, the period of active myelination (Gillespie et al, 1994; 
Sherman and Brophy, 2000). Initially, L-periaxin expression is nuclear, but just as 
myelination starts, it concentrates at the adaxonal membrane and progressive 
myelination sees a shift in this localisation to the abaxonal Schwann cell membrane 
(Gillespie et al., 1994; Scherer et al, 1995; Sherman and Brophy; 2000). The meaning 
of this early nuclear localisation is not clear yet: one explanation is that the nuclear 
targeting serves to sequestrate the protein from the cytoplasm, avoiding inappropriate 
interaction in the cytoplasm. Alternatively, it is possible that L-periaxin may have a role 
in co-transcriptional regulation in embryonic nerve (reviewed in Sherman and Brophy, 
2004). Similarly to MAG periaxin is localized, in the cytoplasm-filled periaxonal 
regions of the sheath but is excluded from compact myelin, suggesting that it may be 
involved in the early process of axonal ensheathment (Gillespie et al, 1994). Periaxin 
expression is axonally regulated, in a similar fashion to myelin genes and is down- 
regulated following nerve injury. Interestingly, periaxin expression in developing and in 
regenerating nerves predates major myelin gene expression being, for example, 
detectable in advance of P0 (Scherer et al, 1995).
To study periaxin function further, null mutant mice (Prx'A) have been generated. These 
mice are able to form and assemble compact myelin, but, already at 6 weeks, the sciatic 
nerves contain some tomacula (Gillespie et a l , 2000). With ageing, Prx'A mice show 
severe demyelination and associated reduced nerve conduction velocities (Gillespie et 
al, 2000). It appears then that L-periaxin in needed to stabilise myelin and the axon- 
Schwann cell unit. One way by which this could happen is through complexes that 
periaxin forms with the dystrophin-related protein 2 (DRP2), a member of the
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dystrophin-like protein family. This family of proteins, which comprises dystrophin, 
utrophin and dystrobrevin, binds with the plasma membrane protein dystroglycan. The 
study of DRP2-L-periaxin-dystroglycan complexes in Prx "/_ mice has demonstrated 
that they are fundamental for stable axon-glia interaction (Sherman et al., 2001). 
Mutations in the periaxin gene have been reported in peripheral neuropathies in 
humans, including DSS (Boerkel et al., 2001) and an autosomal recessive form of CMT 
termed CMT4F (Guilbot et al., 2001; Takashimi et al., 2002). It is likely that the 
identification of novel components of the DRP2-Prx-dystroglycan complex, will lead to 
possible candidates for other forms of CMT.
Recently, it has been demonstrated that in Prx'7' mice longitudinal bands of cytoplasm 
are missing, intemodal lengths are reduced and, as a result, nerve conduction velocity is 
slower (Court et al., 2004). Moreover, with brilliant experiments using chimaeric mice, 
the authors showed that the ability of Schwann cells to elongate in response to axonal 
growth is cell-autonomous (Court et al., 2004). Taken together these data are the first 
experimental proof that intemodal length directly influences nerve conduction velocity.
Connexin 32 and Connexin 29
The connexins family is composed of at least 21 different genes (Willeke et al., 2002). 
Connexins encode a group of channel forming proteins that share a common four 
transmembrane domain topology (Bruzzone et al., 1996; White and Paul, 1999; 
reviewed in Scherer and Paul, 2004). Gap junctions are intercellular channels that allow 
the passage of small molecules such as ions, second messengers and metabolites (<1000 
Da), and control cell proliferation and differentiation (reviewed by Bruzzone and 
Ressot, 1997; Simon, 1997). They consist of two apposed hemichannels, each
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composed of six connexins arranged to form a central pore. Interestingly, only some 
combinations of connexins are functional.
Connexin 32 (Cx32), the first connexin to be cloned (Paul, 1986), is expressed in the 
myelin-forming cells of the CNS and PNS, where it parallels the expression of myelin- 
related genes (Scherer et a l, 1995; Sohl et al., 1996). Two candidates for Cx32 
regulation in the PNS are the transcription factors Sox-10 and Krox-20. In fact, theCx32 
promoter contains putative binding sites for these two transcription factors (Bondurand 
et al., 2001; Musso et al., 2001). In the mature PNS myelin, Cx32 is localized to the 
paranodal region and Schmidt-Lanterman incisures and may therefore form a pathway 
for diffusion across areas of non-compacted myelin (Scherer et al., 1995, Paul, 1995). 
Cx32 deficient mice have been generated and they display a late-onset peripheral 
neuropathy (Balice-Gordon et al., 1998). This neuropathy is characterized by the 
progressive appearance of onion bulbs, thin myelin sheath and increased periaxonal 
collars, suggesting that Cx32 is important for myelin maintenance (Anzini et al, 1997). 
In mice that are Cx32 "/" and Po haplo-deficient the resulting peripheral neuropathy is 
accelerated compared to either individual mutant. This suggests that both of these 
proteins, despite having different sub-cellular localizations, may have a combined effect 
on myelin stability (Neuberg et al, 1998). In humans more than 80 mutations in the 
Cx32 gene have been identified as associated with peripheral nerve degeneration, which 
is called X-linked form of Charcot-Marie-Tooth disease (CMTX). In some of these, the 
mutation is not in the open reading frame (ORF), but instead it can be found in non 
coding regions (Bergoffen et al, 1993, Bruzzone et al, 1994, Ionasescu et a l, 1994, 
Bondurand et a l, 2001).
Connexin 29 (Cx29) has been recently identified (Altevogt et al., 2000). Its expression 
appears to be restricted to myelinating glial cells both in the CNS and PNS (Sohl et al.,
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2001; Altevogt et al, 2002). In myelinating Schwann cells Cx29 is expressed earlier 
than Cx32, but in the adult its levels are lower than those of Cx32. It localizes in 
particular in the juxtaparanodal region of myelinating Schwann cells, and in the inner 
mesaxon, incisures and paranodal loops (Altevogt et al., 2002).
P2 and CNPase
The product of the P2 gene is a small, 14.8 kDa protein, that accounts for less than 1% 
of total myelin proteins, and is only found within compact myelin where is believed to 
function by regulating the synthesis and transport of long chain fatty acids (Hahn et al., 
1987; Hudson 1990). Similarly, the product of the 2’, 3’-cyclic nucleotide 3’- 
phosphodiesterase (CNPase) gene is thought to play a role in myelin assembly 
(reviewed by Hudson, 1990).
CNPase is a cytoplasmic protein, found as two isoforms (46 and 48 kDa) within glial 
cells as well as other non-neuronal tissues (reviewed in Braun et al., 2004). In the PNS 
it comprises only 0.4% of total myelin protein. While in the CNS the developmental 
expression of CNPase parallels that of other myelin-related proteins, in the peripheral 
nerve it peaks around birth but decreases gradually in older animals, making its role in 
myelination unclear (Stahl et al., 1990). The generation of CNPase null mice is very 
recent (Lappe-Siefke et al., 2003). These mice develop a normal myelin but adults 
manifest a severe neurodegenerative disorder, characterized by axonal swelling and 
degeneration, suggesting a role for CNPase in axonal survival, although the 
mechanisms involved are still unknown. Moreover, a role for CNPase in RNA 
metabolism, regulation and degradation has been proposed, based on structural studies 
that revealed a resemblance of CNP with some bacterial RNA ligases (Hudson, 1990; 
Mazumder et al., 2002).
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Plasmolipin and MAL
Plasmolipin and myelin and lymphocyte protein (MAL/MVP17) are, like PLP and 
PMP22, members of the four transmembrane domain protein family.
The plasmolipin gene encodes a single 1.7kb mRNA which results in a 157aa, 18kDa 
protein (Fisher and Sapirstein, 1994). Plasmolipin was initially thought to be restricted 
to nervous system and kidney, but successive work demonstrated that it is in fact 
expressed in a variety of tissues, including thymus, lung and thyroid gland (Hamacher 
et al., 2001). In the PNS, plasmolipin mRNA expression is restricted to myelinating 
Schwann cells, and its regulation during neural development and sciatic nerve 
regeneration shows a tight correlation with myelination (Gillen et al., 1996; Bosse et 
al., 2003). Interestingly, plasmolipin expression after nerve cut is induced even when 
axonal regeneration in prevented by ligation of the nerve stump (Bosse et al., 2003), 
suggesting an additional role for plasmolipin different from myelin biogenesis and 
maintenance. Moreover, plasmolipin in mature myelin has a distinct lipid rafts (see 
below) association, indicating a possible role for plasmolipin in intracellular protein 
trafficking (Bosse et al., 2003).
Plasmolipin shares some structure and expression similarity with MAL/MVP17. The 
MAL gene encodes for a 153aa, 17kDa protein that is expressed in kidney, spleen, brain 
and peripheral nerve, with the highest mRNA levels during CNS and PNS myelination 
(Kim et al., 1995; Schaeren-Wiemers et al., 1995). In the PNS, MAL is strongly 
expressed in myelinating Schwann cells where it colocalizes with MBP and PLP in 
compact myelin (Frank et al., 1998). MAL immunoreactivity is also detectable in 
immature Schwann cells and persists in non-myelinating Schwann cells (Frank et al.,
1999). In epithelial cells, it localizes in the apical plasma membrane, where specific 
glycosphingolipids such as sulfatide and galactosylceramide are enriched. These lipids
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are also enriched in myelin, and MAL associates with them in myelinating Schwann 
cells and oligodendrocytes (Carduff et al., 2001; Kim and Pfeiffer, 2002). Therefore, 
one possible role for MAL is in the formation and stabilization of this specific lipids 
microdomains (reviewed in Frank, 2000).
Integrins.
Integrins are glial cell surface receptors that mediate local interactions between cells 
and the ECM and provide the cues necessary for myelination and that may also mediate 
cell migration, proliferation and differentiation (Hynes, 1992; 2002; ffrench-Constant, 
2004). Each integrin is composed by heterodimers of a  and p subunits, coded by 
separate genes; each subunit comprises a short intracellular domain directly liked to 
cytoskeleton molecules such as vinculin and talin, a single transmembrane domain and 
a large extracellular domain. The combination of two extracellular domains creates a 
ligand binding site (Hynes, 1992). So far, 26 subunits have been identified (18 a  and 8 
p), that have been shown to form 24 differing a /  p heterodimers (Hynes and Zhao, 
2000; reviewed in Previtali et al, 2001). Each integrin heterodimer has specificity for a 
single ligand or range of ligands, that include members of the ECM (Ruoslahti et al.,
1996) and surface proteins of the Ig superfamily, such as LI and Thy-1. The binding 
with these ligands is called in -trans  binding, while the binding with cell- 
surface/cytoskeletal proteins such as tetraspan molecules is termed in-cis binding 
(Previtali et al, 2001).
Various integrins are expressed throughout Schwann cell development but the 
heterodimeric combinations seen vary according to the specific stages of Schwann cell 
differentiation. In vivo studies of chick neural crest cells have shown that these cells 
express the laminin receptors a l p l  and a6 p i. Integrin antibody blocking experiments
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cause disruption of neural crest cell migration. Similarly, peptides competing for ECM 
ligands and growth factor receptor mutants show disruption of migration (Previtali et 
al, 2001). a ip i  integrin is expressed in the neural crest, is down-regulated to very low 
levels during the transition to Schwann cell precursors but is high again in mature non­
myelin forming Schwann cells. It is probably regulated by axonal contact, being up- 
regulated in myelinating Schwann cells following nerve injury (Stewart et al., 1997, 
Perris et al, 1997). In mature Schwann cells of chick, rodent and human, at least seven 
integrin heterodimers have been identfied: a l p l ,  a 6 p i, avp8, a 2 p l, a6p4, a5 p l and 
avP3 (Previtali et al, 2001). These data suggest that the specific stages of Schwann 
cells development are accompanied by differential integrin expression.
During embryonic development, a6  is associated with p i, but it switches partner, to p4, 
at the onset of myelination. In both rats and humans the expression of p4 integrin 
subunit dramatically increases in myelin forming Schwann cells, is localised abaxonally 
and is axon dependent (Einheber et a l , 1993, Feltri et a l,  1993, Niessen et al, 1994). 
P4 sub-unit null mutants have been generated but, unfortunately, die shortly after birth 
allowing only a glimpse at the onset of myelination, but show that myelination can 
occur normally and that p4 is not required for Schwann cell differentiation (Frei et al,
1999). However, the possibility that p4 may have a role in the longer term in myelin 
maintenance cannot be ruled out.
Studies of integrin function in the PNS using null mutants have been of limited success, 
many resulting in embryonic lethality such as integrin p i, or without phenotype as in 
a l  and a  7 integrin knockouts (reviewed in Previtali et al, 2001; Previtali et al., 2003). 
Cre/loxP technology can be used to overcome the problem of embryonic lethality, and 
to ablate a given gene in a cell specific way (see chapter 5). This approach has been 
applied to ablate integrin p i specifically in Schwann cells (Feltri et al., 2002). In this
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work, mice carrying floxed p i alleles have been crossed with mice in which the ere 
recombinase is expressed under the control of the PO promoter. These mice show a clear 
phenotype, characterized by a peripheral neuropathy, due to the inability of Schwann 
cells to form and maintain proper contact with the axon. Migration, proliferation and 
survival of precursors cells occur normally, indicating that pi integrin is not required in 
the embryonic stages of development. Interestingly, in some cases, the block of 
myelination can be overcome, and Schwann cells synthesise myelin, albeit with a delay. 
An explanation for this could be a compensatory mechanism via dystroglycan or a6p4 
(Feltri et al., 2002). Taken together these data suggest that pi integrin is required for 
Schwann cells to interact properly with axons. Further similar studies will be required to 
understand the role of other integrins in Schwann cell development.
Laminin
Laminins comprise a large family of glycoproteins made up of 3 sub-units: two light 
chains, 200 kDa, and one heavy chain, 400 kDa, that together form a cruciform 
structure (Nissinen et al., 1991). Schwann cells express large amounts of laminin, the 
major component of basal lamina (Combrooks et al, 1983; Podratz et al., 2001). Both 
myelin forming and non-myelin forming Schwann cells synthesise a basal lamina that, 
in myelinating ones, is necessary for axon ensheathment (Bignami et al., 1984, Bunge 
et al., 1986; reviewed in Bunge, 1993). Interestingly, laminin deposition on the 
Schwann cell surface is sufficient for the onset of myelination even in the absence of a 
basal lamina (Podratz et a l , 2001). On the Schwann cell surface, integrins a6 p i, 
a6p4and dystroglycan are the major receptors for laminins (reviewed in Previtali et a l ,
2001). The main form of laminin expressed by Schwann cells consists of pi and p2 
light chains and the a2  heavy chain (merosin) (reviewed in Reichardt and Tomaselli,
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1991). Mutations in merosin have been identified in both a naturally occurring mutant 
mouse known as dy/dy, and in merosin-deficient congenital muscular dystrophy (CMD) 
patients (Xu et al., 1994; Sunada et al., 1995) Both human and mouse disorders result in 
a peripheral neuropathy, characterised by abnormal bundles of naked axons not 
surrounded by any Schwann cell process, particularly in the dorsal roots, and by a 
discontinuous basal lamina (Bradley and Jenkinson, 1973, Madrid et al, 1975, Uziyel et 
a l, 2000). Taken together, these findings and the data from mutant in integrin and 
transgenic mice, point at the laminin-integrin complex as a crucial actor in the process 
of peripheral nerve myelination.
Laminin and leprosy
Leprosy is a disease caused by the bacterium Micobacterium leprae and is characterised 
by infiltration and infection of the Schwann cells of sensory nerves that often result in a 
rapid immune response that cause extensive inflammation. Laminin2 interacts with the 
phenolic glycolipid-1 (PGL-1) of the bacterium. This disrupts the interaction of laminin 
with dystroglycan, and in myelinating Schwann cells result in rapid demyelination and 
dedifferentiation, while in non-myelinating Schwann cells bacteria are taken up 
(Brophy, 2002; Sherman et al., 2001; Rambukkana et al., 1997; 1998; 2002). The 
binding of PGL-1 to myelinating Schwann cells is sufficient to induce their de­
differentiation, probably following disruption of the dystroglycan-DRP-2 complex. The 
de-differentiation makes myelinating Schwann cells similar to non-myelinating ones 
and thus more susceptible to bacterial invasion (Rambukkana et al, 2002; Brophy et al, 
2002).
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The role of non-myelinating Schwann cells
As the name suggests this Schwann cell type does not make myelin and does not 
express high levels of the myelin genes. Rather non-myelin forming Schwann cells 
support bundles of up to 20 smaller diameter axons (less than 1 pm), in membranous 
channels that may or may not completely enclose each axon, allowing the axons to be 
isolated from one another. Unlike myelin forming Schwann cells, adjacent non-myelin 
forming Schwann cells overlap one another so that no part of the axonal surface is 
exposed to the extracellular space (Eames and Gamble 1970). Intercellular 
communications between non-myelin forming Schwann cells are facilitated by gap 
junctions, small ionic pores located at the interphase of two cells. This suggests that 
non-myelin forming Schwann cells act as a continuous chain of support cells (Konishi, 
1990), an idea supported by the fact that unmyelinated fibres are surrounded by a 
continuous basal lamina.
Non-myelinating Schwann cell express markers associated with developing Schwann 
cells such as the low affinity neurotrophin receptor, p75 (P75NTR), the adhesion 
molecules neural cell adhesion molecule (N-CAM) and LI and a distinct set of 
cytoskeletal proteins, including glial fibrillary acid protein (GFAP). All of these 
molecules are expressed in all Schwann cell during development and subsequently 
down-regulated in myelin forming Schwann cells. P75 a 75 kD cell surface associated 
glycoprotein that is able to bind the neurotrophins, including NGF and in adult sciatic 
nerve is present only in non-myelinating cells (Hosang and Shooter, 1985, Chao et al 
1986; Jessen et al., 1980).
Both N-CAM and LI are members of the large Ig superfamily, with Ig-like domains in 
combination with fibronectin Ill-like domains, facilitating homophilic binding
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(reviewed Edelman and Crossin, 1991, Schachner, 1990). LI and N-CAM have been 
shown to promote neurite outgrowth in vitro, LI being the most potent, suggesting an 
important function in axon growth both in development and following injury (reviewed 
Schachner, 1990).
In the mouse a small amount of N-CAM expression remains in the periaxonal space 
(Martini and Schachner, 1986) while in the rat N-CAM is not detectable on myelin 
forming Schwann cells (Jessen et al., 1987a, Mirsky et al., 1986).
LI is a large, 200 kD, cell surface adhesion molecule expressed on mature non-myelin 
forming Schwann cells and their axons (Rathjen and Schachner, 1984, Martini and 
Schachner, 1986). Precisely, a shorter form of LI, Lies, that has a four amminoacids 
deletion in the cytoplasmic domain, is expressed by Schwann cells, while the complete 
LI is expressed only by neurons (Uyemura, 1993). In vitro assays have demonstrated 
that addition of LI antibodies prevent myelination suggesting that LI binding is 
required for the process of myelination and more specifically the establishment of 
adhesion between axon and Schwann cell (Selheimer et al., 1989, Wood et al., 1990).
LI deficient mice have been generated and they display normal development of non­
myelin forming Schwann cells and associated unmyelinated axons within the sciatic 
nerve (Haney et al., 1999). However, in the mature adult sciatic nerve many 
unmyelinated axons were either partially surrounded or completely bereft of Schwann 
cell processes and these Schwann cells showed a discontinuous basal lamina. A degree 
of degeneration was also seen, due to a sensory deficit caused by a sensory axon loss in 
LI deficient mice (Haney et al., 1999).
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Myelin lipids
Around 70.5% o f m yelin is com posed o f lipids. The ratios o f 
sphingolipids:glycerolphospholipids:sterols are 28:44:28 in the myelin sheath (Norton 
and Cammer, 1984; Morell et al., 1994; Taylor et al., 2004). Although there are no 
myelin specific lipids, myelin is particularly enriched in certain lipids, such as 
galactocerebroside (GalC) and cholesterol. However, a mice deficient in UDP- 
galcatose:ceramide galactosyltransferase, an enzyme necessary for GalC byosynthesis 
has surprisingly normal myelin in the PNS (Coetzee et al, 1996a; 1996b, 1998). 
However, during development a significant number of axons loose contact and pull 
away form their myelin sheath (Dupree et al., 1998). On the other hand, a mouse 
deficient in cholesterol has severe hypomyelination (Saher et al., 2002).
It is now clear that myelin can no longer be seen as a inert insulating material that 
simply assists fast nerve conduction. Rather, myelin is part of a complicated network 
between the environment, the Schwann cell and the axon. Lipids play a crucial role in 
this event. For example phospholipids, such as diacylglycerol (DAG) has a function of 
signal transduction and, in particular in the CNS, various gangliosides may have a role 
in the maintenance of myelin stability and in the control of nerve regeneration 
(reviewed in Taylor et al., 2004).
Recently it has been proposed that both in the CNS and the PNS glycosphingolipids and 
cholesterol can form specialised microdomains, called lipid rafts, with which proteins 
may or may not interact (Simons and Ikonen, 1997; Simons and Toomre, 2000). In the 
CNS, MBP and PLP have been shown to associate with these microdomains, while in 
the PNS, Po, PMP22 and plasmolipin interact with the rafts (Hasse et al., 2002). 
Although the raft hypothesis is still subjected to strong criticisms, possible functions for
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these structure have been proposed, including protein trafficking and signal transduction 
(reviewed in Taylor et al., 2004).
Late transcription factors
Myelin formation represents a huge task for the Schwann cell. The transcription, 
synthesis and targeting to the right site of all the membrane components (proteins and 
lipids) requires a finely tuned cascade of events. Microtubules, consisting of 
heterodimers of a  and p tubulin (Dustin et al., 1984), play a crucial role in this process, 
by organizing organelle distribution and by providing the substrate for the translocation 
of myelin constituents along the length of the intemode (reviewed in Trapp et al., 
2004). Recently, neuregulin-1 type III has been indicated as the axonal signal 
implicated in controlling myelin thickness and the wraps number (Michailov et al., 
2004).
One field in which major progress has been made is the analysis of transcriptional 
control. In particular, two transcription factors, Oct-6 and Krox-20 play crucial roles in 
myelination (Monuki et al., 1990; Bermingham et al., 1996; Jaegle et al., 1996; Topilko 
et al., 1994; Murphy et al., 1996; Zorick et al., 1999; Parkinson et al., 2004; for a 
review see Topilko and Mejier, 2001).
Oct-6
Oct-6 (SCIP/ Tst-1) is a member of the POU domain transcription factor family. The 
name POU derives from the discovery of these proteins in three different systems, Pit-1, 
Oct-6 and Unc (reviewed by Latchman, 1999). This protein family is characterized by a 
POU binding domain that can be subdivided into a POU-specific and a POU
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homeodomain. POU proteins bind the consensus sequence 5’-ATGCAAAT-3’ with the 
POU-specific domain interacting with the initial 4 bases and the POU homeodomain 
interacting with the last four bases (Klemm et al., 1994). Oct-6 was isolated from three 
different systems simultaneously: embryonic stem cells of the central nervous system, 
sciatic nerve, and testes (Suzuki et al., 1990; Monuki et al., 1989; He et al., 1989; 
Meijer et al., 1990). Oct-6 mRNA and protein have been detected in Schwann cell 
precursors and persist at least until postnatal day 12 (PI2) (Blanchard et al., 1996). Its 
expression reaches a peak around birth, prior to maximal myelin gene expression and is 
then progressively down-regulated (Monuki et al., 1990, Scherer et al., 1994, Arroyo et 
al, 1998). Oct-6 expression in vivo requires axon-Schwann cell contact, while, in vitro, 
elevation of intracellular cAMP induces Oct-6 (Scherer et al., 1994; Monuki et al.,
1989). In Oct-6 deficient mice Schwann cells form typical 1:1 ensheathment 
relationships with axons but in the majority of them myelination is severely delayed 
(Bermingham et al., 1996, Jaegle et al., 1996).
In this mutant line the mRNA levels of Krox-20 (see below) and of other myelin genes 
such as Po and MAG fail to be elevated at the appropriate time (Jaegle et al., 1996). 
However, after about two weeks, Schwann cells of Oct-6 deficient mice start to 
myelinate and express high levels of Krox-20 and myelin genes. There is now evidence 
that this is due to the action of a second transcription factor, Bm-2, which is closely 
related to Oct-6 (Jaegle et al., 2003). The Bm-2 expression pattern is very similar to that 
of Oct-6, but Brn-2 deficient mice do not show any abnormality in myelination. 
However, in nerves lacking both Oct-6 and Bm-2 myelination is even more delayed 
than in Oct-6 null mice alone. Moreover, overexpression of Bm-2 can partially rescue 
the Oct-6 phenotype (Jaegle et al., 2003; Ghazvini et al., 2002; Sim et al., 2002). 
Intriguingly, even in Oct-6/Brn-2 double mutants myelination eventually occurs,
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although whether this is due to the intervention of other transcription factors or to 
different mechanisms is not yet clear.
Analysis of the Oct-6 promoter has demonstrated the existence of Schwann cell specific 
enhancer (SCE) elements, which are probably regulated by axonally-induced 
transcription factors. One of the SCE, situated 12kb downstream of the transcription 
initiation site, is sufficient to correctly drive Oct-6 expression, both during development 
and regeneration (Mandemakers et a l , 2000; Ghazvini et al., 2002).
Krox-20
The gene Krox-20 (Egr-2/ NGF-IB) takes its name from biippel box and encodes for a 
zinc finger transcription factor characterized by three zinc finger motifs. It was isolated 
from both PC 12 and 3T3 fibroblast cell lines following induction by nerve growth 
factor (NGF) (Hazel et al, 1988; Ryseck et al., 1989; Milbrandt, 1988). Krox-20 is 
expressed in a number of different tissues, including heart, muscle, thymus, testes, 
spleen, lung and both CNS and PNS (Chavrier et al, 1988; Watson and Millbrandt,
1990). Expression has been described in the CNS, e.g. in the neocortex, striatum, 
hypothalamus, amygdala and olfactory bulb (Bhat et al, 1992; Mack et a l, 1992; 
Herdegen et al, 1993).
In the CNS, during embryonic development, Krox-20 is a fundamental component of 
hindbrain segmentation (Wilkinson et al, 1989). It is expressed in rhombomeres 3 and 
5 and in Krox-20 deficient embryos these rhombomeres are either ablated entirely or 
only partially formed (Schneider-Manoury et al, 1993). Furthermore, Krox-20 has 
been shown to directly regulate two homeobox genes, Hoxb-2 and Hoxa-2 in 
rhombomeres 3 and 5 via cis-activation. Transfection experiments demonstrate that 
Krox-20 can induce ectopic expression of Hox genes acting via conserved Krox-20
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binding sites found in the enhancer elements of these genes (Sham et a l, 1993; 
Nonchev et al, 1996b; Seitanidou et al, 1997).
In the PNS Krox-20 is crucial for the development of myelinating Schwann cells 
(Topilko et al, 1994; reviewed in Topilko and Meijer, 2001). In those cells that have 
been signaled to myelinate, Krox-20 starts being expressed around E l6 (in mouse), 
approximately 1-2 days after Oct-6 (Blanchard et al, 1996; Topilko et al, 1994; Zorik 
et a l , 1996, 1999). This pattern of expression co-ordinates with the appearance of 
Schwann cell markers, such as S100, and is dependent on continuous axonal contact. In 
fact, after nerve transection, Krox-20 levels fall sharply, and Krox-20 is re-expressed in 
regenerating nerve (Murphy et al, 1996; Zorik et a l , 1999). In Krox-20 deficient mice 
myelination does not occur. In these mice Schwann achieve the 1:1 relationships with 
axons, and continue to wrap the axon about 1-2 turns before becoming stalled at this 
point (Topilko et al, 1994). In Krox-20 null mice, markers of myelination, such as the 
myelin proteins Po and MBP, are present at very low levels, suggesting that Krox-20 is 
required for and controls transcription of the genes required for myelination (Topilko et 
al, 1994). Moreover, in these mice, Oct-6 is expressed on time and remains expressed 
at a higher level than normal after birth, suggesting that Krox-20 could negatively 
regulate Oct-6. Schwann cells in Krox-20 null mice also have a higher DNA synthesis 
and death rate, indicating a possible role for Krox-20 in controlling these events 
(Ghazvini et a l , 2002; Zorik et a l , 1999; reviewed in Topilko and Meijer, 2001). This 
data supports the theory that Schwann cells are stalled at a particular stage in 
development, most likely to be the promyelinating phase, and continue to cycle as they 
would in the late embryonic/ newborn animal well into the second postnatal week.
The hypothesis that Krox-20 is directly involved in regulating myelin genes has been 
reinforced by recent gene expression profiling of cultured Schwann cells in which
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Krox20 expression has been adenovirally enforced (Nagarajan et al., 2001). The authors 
showed that under these conditions, myelin-related genes and lipid genes, as well as a 
series of other genes, are up-regulated by Krox-20 (see chapter 3 for further comments). 
Further work carried on in our laboratory, has demonstrated that enforced expression of 
Krox-20 alone is sufficient to determine a range of phenotypic changes in cultured 
Schwann cells, associated with the transition from proliferating immature Schwann 
cells to quiescent myelinating ones (Parkinson et al., 2002a,b; 2003 a,b). In fact, these 
experiments show that in addition to the up-regulation of myelin-related genes such as 
Po and periaxin, and the down-regulation of LI, neuregulin-1 induced proliferation and 
TGFp induced death are prevented, similarly to what happens at the beginning of 
myelination in vivo. There is now evidence that at the basis of these changes is the 
ability of Krox-20 to inhibit the JNK/c-Jun pathway. This pathway is necessary for 
blocking myelination and to promote Schwann cell proliferation and death, meaning 
that, by preventing the action of this pathway, Krox-20 exerts direct control on 
Schwann cell proliferation, death and myelination (Parkinson et al., 2003a). Most 
interesting, Krox-20 is also able to induce the expression of myelin specific genes in 
NIH 3T3 cells, which are completely unrelated to Schwann cells. This ability points to 
Krox-20 as a master regulatory gene (Parkinson et al., 2004; reviewed in Jessen and 
Mirsky, 2004).
The mechanisms by which Krox-20 is regulated by the axon are not yet clear. As for 
Oct-6 (above), specific Schwann cell enhancers (SCE) have been identified in the Krox- 
20 regulatory region. In particular, the Krox-20 promoter contains two elements: an 
immature Schwann cell element (ISE) and a myelinating Schwann cell element (MSE). 
The ISE is active only in pre-myelinating cells, while the MSE is active from E l8 
onwards, in myelinating cells. Both enhancers are up-regulated in regenerating nerves
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(Ghislain et al., 2002). Interestingly, the MSE appears to be dependent on Oct-6 for 
activation, and contains multiple Oct-6 binding sites (Ghislain et al., 2002).
As we have seen previously, Sox-10 can function synergistically with Oct-6 in 
modulating Pax-3 positively and Krox-20 negatively (Kuhlbrodt et al., 1998). In turn, 
once activated, Krox-20 probably down-regulates Oct-6.
Other transcription factors identified in Schwann cells
In adult PNS, Krox-20 is expressed only in myelinating Schwann cells. This pattern 
contrasts with that for another closely related transcription factor, Krox-24, which binds 
to some of the sequences recognised by Krox-20 too (Topilko et al., 1997). Krox-24 is 
highly expressed early in development, remains expressed in non-myelinating Schwann 
cells of the adult and is up-regulated during Wallerian degeneration (Topilko et al., 
1997). In Krox-24 null mice myelination occurs normally, but increased death rates are 
observed after nerve transection of neonatal nerves (Topilko et al., 1998; Harris, PhD 
thesis, University of London, 2001).
The expression of Krox-24 is regulated in Schwann cells by the B class helix-loop-helix 
(HLH) factor Mash2 (Kury et al., 2002). Mash2 has been identified in adult Krox-20 
positive Schwann cells, is down-regulated after nerve transection and inhibits Schwann 
cell proliferation in vitro (Kury et al., 2002). Moreover, all the four HLH Id genes are 
expressed during Schwann cell development. In particular, Idl and Id3 are present in 
the embryo, then downregulated at P10 (around the peak of myelination) and up- 
regulated again in the adult. In addition, both are up-regulated after nerve transection 
and inhibit myelin gene expression (Stewart et al., 1997; Thatikunta et al., 1999).
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Finally, in coculture of neurons and Schwann cells in vitro, the transcription factor NF- 
kB is expressed before Oct-6, and its inhibition prevents myelination, indicating that 
NF-kB may have a role in myelination (Nickols et al., 2003).
Wallerian degeneneration
One of the most striking characteristics of Schwann cells is their plasticity. If axonal 
contact is lost, due to injury or cell dissociation, the Schwann cell in the distal stump of 
the nerve start to de-differentiate, proliferate and down-regulate all the myelin genes 
(see also chapter 3). At the same time adhesion molecules, neurotrophins, cytokines and 
their receptors are up-regulated to create an environment that allows axonal re-growth. 
All the events taking place distal to the site of nerve injury are known as Wallerian 
degeneration, (reviewed in Stoll and Muller, 1999; Scherer and Salzer, 2001). In the 
first week after axotomy, distal axons fragment and disappear, and myelin breaks down 
into so-called ovoids. Myelin debris is rapidly cleared by macrophages and Schwann 
cell themselves, probably to facilitate axonal re-growth, since it has been shown that 
myelin inhibits axonal regeneration (reviewed in Filbin et al., 2001). While myelin 
degenerates, the basal lamina is maintained by Schwann cells, which organise 
themselves in columns called bands of Bungner. It is still unknown whether Wallerian 
regeneration begins with a positive signal resulting form axonal degeneration or it is 
due to the interruption of the supply of neuronal factors that maintain the myelinating 
phenotype. The slow Wallerian degeneration mouse (Wld(S)) (formerly known as Ola) 
is a natural mutant in which myelinated axons remain phisiologically active for weeks 
after axotomy. Schwann cell proliferation, down-regulation of myelin genes, up- 
regulation of NGF, tenascin and p75NGFR, as well as macrophages infiltration are also
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delayed (Lunn et al., 1989; Thomson et al., 1991; Fruttiger et al., 1995). The genetic 
mutation is a 85Kb tandem triplication on mouse chromosome 4. This results in the 
formation of a chimeric protein formed via the fusion of the N-terminus of the multi- 
ubiquitination factor Ube4b and a novel gene, D4Colele/Nmat, a NAD synthesising 
enzyme (Lyon et al., 1993; Conforti et al., 2000; Mack et al., 2001). A third gene lies in 
the area of the triplication, the retinoic binding protein Rbp7, and is therefore 
overexpressed in the Wld(S) mice. However, northern blot experiments failed to detect 
the mRNA for Rbp7 in the nervous system and is therefore not a likely candidate for 
Wld(S) (Conforti et al., 2000). Although it is known tht ubiquitination plays an 
important role in axonal degeneration, the mechanism by which the fusion gene 
Ube4b/Nmat protects the Wld(S) gene from degeneration are still unclear.
Axonal regeneration
Degenerating peripheral nerve represents the best substrate to support axonal 
regeneration (Ide et al., 1990; Dahlin, 1995; reviewed in Scherer and Salzer, 2001). 
Axonal regeneration is not effective in normal untransected nerve stumps or in distal 
nerve stumps of Wld(S) mice (Brown et al., 1991). Two factors seem to play a key role 
in regeneration: the degradation of myelin in lesioned nerves and the presence of 
Schwann cells. Axon can regenerate partially even in the absence of Schwann cells, 
when only the extracellular matrix is present, but regenerates much better in nerves that 
contain Schwann cells (Sketely et al., 1989). Schwann cells in fact maintain their basal 
laminae, which form the bands of Bungner, through which re-growing axons can travel 
(Ramon y Cajal, 1928; Bunge et al., 1987; reviewed in Fu and Gordon, 1997). In vitro 
studies have been performed by culturing neurons on cryo-sections of nerve. In these 
assays, degenerated nerve promotes neurite out-growth much better than normal nerve,
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and the presence of Schwanns cell is a crucial factor (Bedi et al., 1992; Agius and 
Chochard; 1998). The changes occurring to Schwann cells after nerve axotomy are 
discussed further in chapter 3.
Schwann cells control neuronal survival and perineurium formation
As we have seen, Schwann cells rely heavily on axonal signals for their survival, in 
particular during development. However, it is now becoming clear that they are not just 
passive targets of extrinsic signals, but that Schwann cell are a source of signals which 
are crucial for peripheral nerve development and neuron survival. In ErbB3 "/" and 
ErbB2'/_ mice with a targeted rescue of the heart defect (above), Schwann cell are 
severely reduced in number (Riethmacher et al., 1997; Woldeyesus et al., 1999; 
reviewed in Mirsky and Jessen, 2001; Mirsky et al., 2002). Surprisingly, in these mice 
most of DRG neurons were missing by E l4, while motor neurons died in the trunk limb 
region slightly later, being reduced by ~80% at El 8. Since at E l4 most axons have not 
yet reached their target, the most likely explanation for death of DRG neurons is the 
lack of survival signals from Schwann cell precursors. Motor neuron death is instead 
likely to depend on the lack of signals from immature Schwann cells. This idea as been 
strengthened by the observation that Sox-10'7" mice, where neither satellite cells nor 
Schwann cell precursors are generated, have severely reduced numbers of DRG neurons 
and motor neurons (Britsh et al., 2001). The nature of the glial-derived neuronal 
survival signals has not been identified yet, but neurotrophin-3 (NT-3) and glial-derived 
neurotrophic factor are possible candidates.
In addition to promoting neuronal survival, Schwann cells also control Na+ channels 
clustering at the node of Ranvier, and can influence axonal calibre and neurofilament
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phosphorylation in myelinating axons (reviewed in Mirsky et al., 2002; Mirsky and 
Jessen, 2001).
Schwann cell and Schwann cell precursors, besides signalling to neurons, are also 
involved in the formation of the perineurial sheath that surrounds and protects 
peripheral nerve (Bunge et al., 1989; reviewed in Mirsky and Jessen; 2001). Work in 
our lab has shown that in desert hedgehog (Dhh) null mice, the perineurium in much 
thinner than in normal nerves and perineurial cells have a patchy basal lamina. 
Moreover, the epineurial collagen sheath is often disrupted and there is infiltration of 
perineurial cells in the endoneurium, indicating that the nerve-tissue barrier is 
compromised (Parmantier et al., 1999).
Taken together these observations indicate that in peripheral nerve Schwann cells are 
involved in the regulation of three main cell types: neurons, connective tissue cells and 
the Schwann cells themselves.
AIMS
As we have seen, there is much left to learn about the complex mechanisms taking place 
during the transition from Schwann precursors to immature Schwann cells and in the 
myelination of peripheral nerve. To try to add valuable information to the knowledge of 
these events, and to identify genes of potential functional importance that have not been 
previously implicated in Schwann cell development, we have performed, using 
Affymetrix GeneChip Technology, gene expression profiling on mRNA extracted from 
rat sciatic nerves at different embryonic stages, during myelination and after nerve 
injury. DNA microarrays and their possible applications are discussed in detail in 
chapter 3. In chapter 4 I will analyse the expression and localisation of a series of genes 
that have been identified through the gene profiling as possibly involved in Schwann
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cell differentiation and myelination. Finally, in chapter 5 I will discuss the phenotype of 
transgenic mice in which the TGFp receptor type II has been ablated specifically in 
Schwann cells thanks to a PO CRE transgene and in which, therefore, TGFp signalling 
is not active in Schwann cells.
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FIGURE 1.1. Differentiation m arkers in embryonic Schwann cell development. In
grey are highlighted those markers shared by neural crest cells, Schwann cell precursors 
and immature Schwann cells. In blue, those markers present on migrating neural crest, 
on Schwann cell precursors but not in immature Schwann cells. In green are highlighted 
markers present on Schwann cell precursors and immature Schwann cells, but absent 
from the migrating neural crest, (from lessen and Mirsky, 2004).
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CHAPTER 2
MATERIALS AND METHODS
Reagents for molecular biology
Random hexamers, Oligo-dT, RNAsin and AMV-Reverse Transcriptase were from 
Promega Corporation (Promega, Madison, USA). Taq DNA-polymerase, RNase H, 
Reverse Transcriptase (superscript II), T4 DNA ligase, T4 buffer, Klenow (DNA 
polymerase), DNA Polymerase I, dNTPs , 1KB plus DNA ladder, TRIzol reagent and 
agarose were from Invitrogen (Invitrogen Ltd, Paisley, UK). EDTA disodium salt, 
e th id ium  brom ide, sodium  ch lo ride , sodium  c itra te , tw een20 , 
phenol:chloroform:isoamyl alchool 25:24:1, chloroform:isoamyl alchool 24:1, 
phenylmethylsulphonylfluoride (PMSF) and bromophenol blue were from Sigma 
(Poole, UK). ECL Plus Kit, western blot Stripping Kit and Hybond-N nitrocellulose 
membrane were from Amersham Pharmacia Biotech (UK). Absolute ethanol, 
isopropanol, methanol, sodium dodecyl sulphate (SDS), sodium chloride (NaCl) and 
glycerol were from BDH Lab. Supplies (Poole, UK). Kaleidoscope pre-stained 
standards were from Biorad (CA, USA). Bromodeoxyuridine, terminal transferase and 
biotinylated-d-UTP were from Roche Diagnostics (Germany), diethyl pyrocarbonate 
(DEPC) was from Fluka Chemicals Ltd. (Buchs, Switzerland).
Reagents for tissue culture
Transferrin, selenium, putrescine, triiodothyronine (T3), thyroxine (T4), progesterone, 
insulin (10 M), bovine serum albumin (BSA), cytosine arabinoside (Ara C), poly-D-
lysine, poly-L-ornithine, lysine, dibutyryl-cAMP (dbcAMP - 1 mM) and laminin were 
obtained from Sigma (Poole, UK). Collagenase was obtained from Worthington (Lome
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Laboratories, Reading, UK). Dulbecco’s modified Eagles medium (DMEM), minimum 
essential medium (MEM) Ham’s F-12 medium, L-15 medium, trypsin, glutamine, 
penicillin, streptomycin were from GibcoBRL (GibcoBRL Life Technologies, Paisley, 
UK). Foetal calf serum (FCS) was from Bioclear, UK. Tissue culture petri dishes and 
24-well plates were from Falcon (Becton-Dickinson, Cowley, UK), NDF-|3 and TGFp-1 
were from R&D Systems (Oxford, UK) and forskolin was from Calbiochem (CA, 
USA).
Reagents for immuno-labelling
Paraformaldehyde was obtained from Fluka Chemicals Ltd. (Buchs, Switzerland).Triton 
X-100 and Hoechst dye H33258 were from Sigma (Poole, UK). Citifluor was from 
Citifluor Ltd. (London, UK).
Reagents for histology and Electron Microscopy
Glutaraldehyde, OCT compound (Tissue Tek), araldite CY212, DDSA, BDMA, 
dibutryl pthalate and rubber coffin moulds were from Agar Scientific(UK). DPX 
mountant and 13mm coverslips were from Merck (Poole, UK), and Superfrost Plus 
microscope slides were from BDH.
Animals
Rats
Sprague-Dawley rats, maintained in the Main Biological Unit at UCL, were used. 
Embryos from ages El 1-18 were removed from pregnant females; the day of the 
vaginal plug was taken as day 0.
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Transgenic mice
TGFpRIIf/fmice (129sv/BALB/c) were from Dr. Jurgen Roes (UCL, London, UK). PO 
CRE mice (FVB) were from Dr. Lawrence Wrabetz (San Raffaele Scientific Institute, 
DIBIT, Milan, Italy). Synuclein null mice (C57BL/6J inbred strain from Harlan UK) 
were from Dr. Ralf Shoepfer (UCL, London, UK).
Generation of PO CRE/ TGFpRIIf/fmice
TGF|3RIIf/f mice were initially crossed with PO CRE mice, to generate PO CRE/ 
TGF|3RIIf/+ mice (1/2 of the offspring). These TGF|3RIIf/f mice, called N l, were then 
back-crossed with TGF|3RIIf/fmice to obtain the PO CRE/ TGFpRIIf/f genotype (1/4 of 
the offspring). The littermates (TGFpRII^, TGFpRII^, PO CRE/ TGFpRII^) were used 
as controls. The genotypes were determined by PCR on genomic DNA extracted from 
tail samples.
Genomic DNA extraction and genotyping
Tail samples were placed in 500 pi of SNET (10 mM Tris/Hcl pH 8.0, 5 mM EDTA, 
0.25M NaCl, 1% SDS) plus 5 pi of 20mg/ml proteinase K, and incubated overnight at 
55°C in a waterbath. The day after the DNA was phenol ichloroform extracted, ethanol 
precipitated and resuspended in 100 pi TE, pH 8.0. lp l of DNA solution was used for 
PCR amplification in a standard PCR mix (see below, in the paragraph entitled “semi- 
quantitative RT-PCR”). The conditions for the P0 CRE PCR where: 94°C for 4 minutes 
followed by 94°C 30 seconds, 50°C 1 minute, 72°C 1 minute, for 30 cycles. Primers for 
P0 CRE amplification were as follows: P0 CRE sense 5’-GCTGGCCC- 
A A AT GTT GCTGG-3 ’; P0 CRE AS2 5’-CCACCACCTCTCCATTGCAC-3’. In the 
presence of the CRE transgene a sinlge band of ~ 480bp resulted from the amplification
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reaction. For the TGF|3RII floxed PCR the conditions were: 94°C 2 minutes, followed 
by 94°C 30 seconds, 63°C 1 minute, 72°C 2 minutes, for 30 cycles. Primers for 
TGFpRII floxed PCR were as follow s: T|3RII sense 5’-CATGA-
AGTCTGCGTGGCCGTGTG-3’; T|3RII AS 5’-TGTAATCGTTGCACTCTT- 
CCATGT-3’. In case of TGFpRII f/fmice, a sinlge band of 1.7kb resulted from the 
amplification reaction. In case of TGF|3RII ^  mice, two bands of 1.7 (floxed) and 1.5kb 
(wt) were amplified.
Southern blotting
To establish the percentage of recombination we performed Southern blotting on DNA 
extracted from tails (control) and purified Schwann cells from POCRE/TGFpRIIf/f and 
POCRE/TGFpRII ^  mice. 10 [xg of DNA were digested with the restriction enzyme 
Ncol, at 37°C, overnight. The day after the digested DNA was separated by 1% agarose 
gel electrophoresis. The DNA was then transferred to a nylon membrane (Hybond-N+) 
by upward capillary transfer (Southern, 1975; Sambrook and Russell, 2001). Briefly, 
after electrophoresis the gel was soaked in denaturing solution (1.5M NaCl, 0.5M 
NaOH) for 45min and then neutralized in re-naturing solution (1M Tris, 1.5M NaCl) for 
30min. After neutralization the DNA was transferred to the membrane with capillary 
transfer for 16-18 hours; the transfer buffer was 20xSSC. After the transfer the DNA 
was crosslinked to the membrane with a Stratalinker (Stratagene).
Probe preparation
TGFpRII exon II probe (Cazac and Roes, 2000), was radiolabelled with high specific 
0activity (> 10 cpm/pg) a  P-dCTP (Amersham Biosciences), using Nick Translation 
Kit (Amersham Biosciences) following the manufacturer’s instructions. The probe was
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then run onto a TE pre-equilibrated Microspin S-200 HR column (Amersham 
Pharmacia Biotech, Inc.).
Hybridisation and washing
The membrane was inserted in a glass tube and equilibrated in Hybridisation Solution 
(Research Genetics, USA) for 2 hours at 42°C in a rotating oven. The exon II probe was 
added and the tube left to rotate for at least 18 hours. The membrane was then removed 
and submerged in a tray containing 500ml of 2x SSC, 0.1% SDS and left with gentle 
agitation in a water-bath at 42°C for 30min. The rinse solution was then substituted with 
500ml of fresh 2x SSC, 0.1% SDS and the tray incubated at 50°C for 30min, with 
agitation. Finally, the membrane was rinsed in 0.2x SSC, 0.1% SDS for 30min at 65°C 
for 25min.
Autoradiography
After washing, the membrane was wrapped in Saran Wrap and placed in an 
autoradiography cassette and exposed to a Biomax X-ray film (Kodak), for 24 hours. 
The film was then developed with a X-Ograph Compact X2 automatic developer. The 
percentage of recombination was calculated with a program called MCD Basic.
Peripheral Nerve Injury Experiments
All the experiments where animals were involved were performed following the UK 
Home Office guidelines.
Sciatic nerve transection
Seven days old (P7) Wistar rats and adult transgenic mice were anaesthetised with 
halothane, and the right sciatic nerve was exposed at mid-thigh level. The sciatic nerve 
was then cut and the distal end diverted to limit the possibility of re-ligation. Resulting
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wounds were sutured with 3/0 black polyamide monofilament, mersilk 
(Johnson&Johnson, USA). Two, five or seven days following transection, the animals 
were culled and both the distal stump of the right, transected sciatic nerve and the 
contralateral control nerve were excised, frozen and immediately processed for RNA 
extraction.
RNA isolation
Total RNA was isolated from rat sciatic nerves at different time points using TRIzol 
reagent (Invitrogen Ltd, Paisley, UK), following the manufacturer’s instruction. The 
RNA was then quantified using a spectrophotometer and analysed for integrity on a 1% 
agarose gel under denaturing conditions. When the RNA was used for the preparation of 
targets for microarray analysis a supplemental clean-up step using the Quiagen RNeasy 
isolation kit (QUIAGEN Ltd, UK) was performed.
Target preparation for microarrays analysis
All the procedures in the following paragraphs were performed as indicated in the 
Affymetrix Expression Analysis Technical Manual (Affymetrix Inc., MA, USA). Note 
that "probes" are the oligonucletides synthesised on the surface of the arrays and that 
"target" is the biotin labelled cRNA that is being interrogated.
First strand cDNA synthesis
Total RNA (5-40pg) was resuspended in a total of x pi DEPC-treated water, where
x= 20- (8+z*) (i.e. final reaction volume 20 pi), lul of T7-(dT)24 primer (lOOpM/pl) 
was added and the mix is incubated for lOmin at 70°C. 4pl of 5x first strand cDNA
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buffer, 2pl of 0.1 M DTT, lp l of lOmM dNTPs mix were added and the mix incubated
at 42°C for 2min. z pi of SSII RT were added and the reaction incubated at 42° for 1
hour.
The volume z* depended on how much RNA there was in the initial step:
For 5-8pg RNA use 1 pi RT 
For 8.1-16pg RNA use 2pl RT 
For 16.1-24pg RNA use 3 pi RT 
For 24.1-32pg RNA use 4pl RT 
For 32.1-40pg RNA use 5pi RT
Second strand cDNA synthesis
The first strand reaction was placed on ice and 91 pi DEPC-treated water, 30pl 5x 
second strand buffer, 3pl of lOmM dNTPs mix, lp l of 10 U/pl DNA ligase, 4pl of 
lOU/pl DNA Polymerase I, lp l of 2U/pl Rnase H were added. After incubation at 16°C 
for 2 hours 2pl of 5U/pl T4 DNA Polymerase were added and the mix re-incubated at 
16°C for lOmin. The reaction was inactivated with lOpl 0.5M EDTA. The double 
stranded cDNA was then cleaned with a phenol: chloroform extraction, ethanol 
precipitated and resuspended in 12pl DEPC-treated water.
Synthesis of biotin-labelled cRNA (in vitro transcription. IVT)
This reaction was performed using the HighYeld RNA Transcript Labeling Kit (Enzo 
BioArray, NY, USA) following the manufacturer's instructions. 6pl of the double 
stranded cDNA (corresponding to 12-15pg of total RNA) were reverse transcribed and
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labelled in a reaction containing 16|xl RNAse free water, 4p,l of lOx hybridisation 
reaction buffer, 4pl of lOx biotin labelled riboligos, 4pl of 0.1 M DTT, 4^tl of RNAse 
inhibitor mix and 2pl of 20x T7 RNA polymerase. The reaction was incubated for 4 
hours at 37°C and the resulting cRNA was cleaned with Quiagen RNeasy kit. The 
cleaned biotin labelled cRNA was then fragmented with 5x fragmentation buffer 
(200mM Tris-acetate pH 8.1, 500mM KOAc, 150mM MgOAc) for 35min at 94°C. The 
yield and size distribution of labelled transcript was estimated with a gel electrophoresis 
through a 1% agarose gel.
Target hybridisation
The fragmented cRNA (x ul, to have 15pg) is mixed with 5pl of 3nM control 
oligonucleotide B2, 15pl of 20x eukaryotic hybridisation controls, 3pl of lOmg/ml 
herring sperm DNA, 3pl of 50mg/ml acetylated BSA, 150p,l of 2x hybridisation buffer 
and water to a final volume of 300pl. This hybridisation cocktail is heated for 5min at 
99°C while the probe arrays is equilibrated with 200pl of lx hybridisation buffer. The 
cocktail is then transferred at 45 °C for 5min and, following the removal of the buffer 
from the array, is hybridised to the probes. The hybridisation is carried on in a rotisserie 
box in a 45°C oven for 16 hours.
Washing, Staining and Scanning the Probe Arrays
Washing and staining
The GeneChip Fluidics Station 400 (Affymetrix, MA, USA) was used to wash and stain
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the probe arrays. It is operated using GeneChip software. The Antibody Amplification 
Washing and Staining Protocol (EukGE-SW2) was used.
After the 16 hours the hybridisation cocktail was removed from the probe array and 
replaced with the appropriate volume of Non-Stringent Wash Buffer.
Table 2.1: fluidics protocol
EukGE-WS2 protocol
Post Hyb Wash 1 10 cycles o f  2 mixes/cycles with Wash Buffer A at 25°C
Post Hyb Wash 2 4 cycles o f  15 mixes/cycles with Wash Buffer B at 50°C
Stain Stain the probe array for lOmin in SAPE solution at 25°C
Post Stain wash 1 10 cycles o f  4 mixes/cycles with Wash Buffer A at 25°C
2nd Stain Stain the probe array for 10 min in antibody solution at 25°C
3rd Stain Stain the probe array for 10 min in SAPE solution at 25°C
Final Wash 15 cycles o f  4 mixes/cycles with wash Buffer A at 30°C. The holding temp, is 25°C
•Wash Buffer A= non-stringent wash buffer 
•Wash Buffer B= stringent wash buffer 
•SAPE= Streptavidin Phycoerythrin 
Scanning
After the completion of the hybridisation procedure, the chips were scanned with an 
Agilent scanner. This scanner uses an argon-ion laser, and is also controlled by the 
GeneChip software. It performs a 2x Image scan at a wavelength of 570nm.
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Data Analysis
Analysis with Affymetrix Suite 5.0
The first data analysis was performed with GeneChip Expression Analysis Software, 
Affymetrix Suite 5.0. The software applies a series of computational techniques 
(algorithms) to analyse the data generated from the Expression Analysis probe arrays. 
The algorithms are used in two types of analysis: an Absolute Analysis, used to 
determine whether transcripts represented on the probe array are detected or not within 
one sample and a Comparison Analysis, used to determine the relative change in 
abundance for each transcript between a baseline and an experimental sample. This 
second analysis employs Normalisation or Scaling techniques to minimise differences 
in overall signal intensities between the two arrays allowing for more reliable detection 
of biologically relevant changes in the sample. A first Absolute Analysis is used as the 
source of Baseline data and a second probe array experiment as the source of 
experimental data to be compared to the Baseline. Some of the Comparison Analysis 
metrics are used in a decision matrix to derive a Signal Log ratio, which indicates 
whether a transcript has increased (I), decreased (D), marginally increased (MI), 
marginally decreased (MD) or exhibits no change (NC) in expression level.
Analysis with GeneSnring
After the experiments have been validated with the Affymetrix Suite 5.0, the data from 
all the 14 experiments were loaded onto Genespring software (Silicon Genetics, USA) 
for statistical analysis. Only chips with acceptable data distributions (assessed using 
Genespring), 5’3’ ratios, % call, spike-in sensitivity, background and noise levels were 
included in the analysis. Data were normalised to the median expression level within,
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and per gene across arrays. Genes that fell below the level of confident detection (p > 
0.06 in MAS5) in two or more of the triplicate samples were excluded from the 
analysis. We next excluded genes with less than a two-fold change in expression level 
(signal log2 ratio>l), either during development from E l4 to P I2 or after nerve injury. 
1609 genes/ESTs that passed this first restriction were considered for downstream 
analysis. The following step was a restriction by statistical group comparison, using the 
ANOVA/Welch’s approximate t-test (p<0.05), not considering variances equal, 
between the time points E l4 and E l8, E l8 and P I2, P I2 and P12cut. The probes that 
were significantly changed between any two conditions were subjected to cluster 
analysis to identify genes with similar expression profile across multiple experiments. 
Both a Hierarchical clustering and a K-means clustering were performed.
Hierarchical clustering
In hierarchical clustering, the genes are connected iteratively based on their similarity. 
The genes with similar expression patterns are grouped together and are connected by a 
series of “branches”, which is called dendrogram (or clustering tree). To make the 
dendrogram, GeneSpring calculates the correlation for each gene with every other gene 
in the set. Then it takes the highest correlation and pairs those two genes, averaging 
their expression profiles. GeneSpring then compares this new composite gene with all 
of the other unpaired genes. This is repeated until all of the genes have been paired. In 
our case the similarity of gene expression patterns has been calculated with GeneSpring 
using Pearson correlation. The Pearson correlation coefficient is often used in 
microarray data analysis because it is sensitive not only to the direction of change 
(increasing or decreasing), but also to magnitude of change.
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K-means clustering
K-means clustering divides genes into groups based on their expression patterns. The 
goal is to produce groups of genes with a high degree of similarity within each group 
and a low degree of similarity between groups. K-means clusters are constructed so that 
the average behavior in each group is distinct from any of the other groups. For 
example, in a time series experiment k-means clustering can be used to identify unique 
classes of genes that are up-regulated or down-regulated in a time dependent manner. 
GeneSpring’s k-means clustering algorithm divides genes into a user-defined number 
(k) of equal-sized groups, based on the order in the selected gene list. It then creates 
centroids (in expression space) at the average location of each group of genes. With 
each iteration genes are reassigned to the group with the closest centroid. After all of the 
genes have been reassigned, the location of the centroids is recalculated and the process 
is repeated until the maximum number of iterations has been reached. It is also possible 
to perform a "Test Additional Random Starting Clusters", a feature that makes 
clustering as tight as possible by performing clustering several times, each time starting 
from a different random grouping of genes, and choosing the best result. We have used 
this test when generating our clusters in all the comparisons, so that the number of 
clusters obtained is the one considered optimal by the GeneSpring sofware.
Data Availability
All data were saved in MAGE-ML files and combined with experimental information in 
MIAME compliant format using a locally designed tool (MEditor) for submission to the 
Array Express database (EBI, Hinxton UK).
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Bioinformatic Analysis
This part of my work was performed in collaboration with Dr David Michalovich and 
Dr Morris Paterson at Inpharmatica.
Mapping the Probes to Transcripts
Inpharmatica's Biopendium™(http://www.inpharmatica.co.uk/biopendium.htm) was 
used to identify protein for each of the probes found to be differentially expressed. This 
probe-to-protein mapping was generated with an automated technology in which probes 
were first mapped to appropriate transcripts and then to the corresponding protein. In 
this process, the ‘target’ nucleotide sequence for each probe set was obtained from 
Affymetrix (http://www.affymetrix.com/index.affx), and aligned to the rat genome 
(version 3.1, http://www.hgsc.bcm.tmc.edu/projects/rat/) using a rapid alignment tool 
BINSEQ (unpublished results). Transcripts that overlapped with the target sequence, or 
that were 2kb upstream were identified using a database of genomic annotations. 
Assignments were made using in an order of descending confidence Refseq 
(http://www.ncbi.nih.gov/RefSeq/), Genbank (http://www.ncbi.nih.gov/Genbank/index 
.html), ENSEMBL (Bimey et a l , 2004) and then TWINSCAN (Korf et a l , 2001). 
Exonic relationships were confirmed using a BLASTN search of the target nucleotide 
sequences against the Refseq, GENBANK, ENSEMBL, then TWINSCAN nucleotide 
coding sequences. Probe mappings were assigned confidence level "high", "medium" or 
"low" depending on how much each probe overlapped with each exon. The 
corresponding protein sequence was identified for each transcript by cross-referencing 
to protein databases. Probes that were not confidently mapped automatically were 
examined by hand. In cases where the rat gene had not been publicly identified an 
orthologous human or mouse protein was taken forward for annotation when 
appropriate.
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Annotating the Proteins
Once an amino acid sequence had been identified for each probe set, protein functional 
annotation was generated using Biopendium™ and publicly available data sources. In 
this application, family alignments were derived from secondary databases (for 
example, PFAM, CDD, PRINTS) and converted to a standardised PSI-BLAST 
(Altschul et al., 1997) profile format. For structural classification of proteins (SCOP), a 
domain-delineated profile is generated by running PSI-BLAST across a database of 
non-redundant protein sequences. These profiles were then added into the pre-calculated
' p i  /    T N / f
Domain Professor . Structural annotation was made using the GenomeThreader 
application within Biopendium™. Matches of only 100% confidence to a PDB (protein 
database) structure were displayed. In addition, to describe each protein sequence, the 
HUGO Gene Nomenclature Committee (HGNC) curated gene title and gene symbol 
was used by preference. Failing this, the description was taken from a Refseq or 
SWISSPROT or Genbank. Keywords were extracted from SWISSPROT (or Genbank) 
protein sequences that were over 95% ID and 90% length of our sequences. Gene 
Ontology (GO) annotation was obtained for each protein sequence using gene to GO 
mappings from both LocusLink (http://www.ncbi.nlm.nih.gov/LocusLink/) and GOA. 
OMIM identifiers were also extracted from Locus Link.
To assess the chances of the protein being secreted, SignalP (Nielsen et al., 1997) was 
used. If both the NN and HMM method identified a signal peptide, the protein was 
described as ‘highly likely’. If one method found a signal peptide, signal peptide was 
assigned as ‘likely’, if neither prediction method was positive the signal annotation was 
assigned as, ‘unlikely’. TMHMM (Krogh et al, 2001) was used to predict the number 
of transmembrane regions.
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Primer design
Oligonucleotide primers per specific mRNA (20-25 nucleotides in length) were 
designed by eye using the sequence information available in the NCBI databases. They 
were designed in such a way to minimise hairpin structures in individual primers and 
dimerisation between primer pairs and were checked against databases using the 
BLAST software to ensure specificity. The sequence of the specific primers used in this 
study are detailed in Table 2.2.
Semi-quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA (200ng-l|xg) was reversed-transcribed in a 20pl reaction mix containing 
50mM Tris-HCl, pH 8.3, 75mM KC1, 3mM MgCl2, 10mM DTT, ImM dNTPs, 1U 
RNAsin, 2U RNase H, 20ng oligo-dT and 200U AMV Reverse Transcriptase as 
recommended in the manufacturers' protocol (Promega Ltd, UK). After incubation for 
5 min at 70°C followed by 10 min at room temperature and 1 hour at 42°C, 30pl TE pH 
8.0 were added, and the cDNA aliquoted. For the analysis of ESTs expression total 
RNA (500ng) was reversed-transcribed in a 50pl reaction mix containing 50mM Tris- 
HCl, pH 8.3, 75mM KC1, 3mM MgCl2, lOmM DTT, 0.5mM dNTPs, 20ng random 
hexamers primers and 200U RNase H- Reverse Transcriptase (superscript II) as 
recommended in the manufacturers’ protocol (GibcoBRL Life Technologies, Paisley, 
UK). After incubation for 90 min at 42°C followed by 15 min at 70°C, RNA was 
removed by digestion with both RNase H (2 units) and RNase A (O.lpg/pl) for 30 min 
at 37°C.
The relative amount of cDNA synthesized from each sample was determined by PCR 
amplification using specific primers for Gapdh mRNA. Equal amounts of cDNA, from 
the various samples, were used for PCR together with a water control with
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oligonucleotide primer pairs. PCR was performed in 25pi reaction volumes containing 
20mM Tris-HCl, pH 8.4, 50mM KC1, 1.5mM MgCL, 0.2mM dNTPs, 50pmoles of each 
primer and 2.5 units Taq DNA-polymerase. The reaction conditions for each primer pair 
were optimised with respect to MgCL concentration, annealing temperature, extension 
time and cycle number.
PCR reactions were performed in a MWG Biothec Primus96 Thermal Cycler or in a 
Perkin Elmer Gene Amp 2400 thermocycler (the latter for genotyping only). Cycling 
conditions were one initial cycle of 4 min at 94°C followed by 28-35 cycles of 30 sec at 
94°C, 1 min at specified annealing temperatures (see Table 2.2) and 1 min at 72°C 
before a final extension period of 10 min at 72°C. Upon completion, loading buffer 
(lOx) was added to each sample and lOpl of each reaction was electrophoresed on 1 % 
agarose gels including ethidium bromide in lx Tris Acetate EDTA (TAE) buffer in a 
Horizon 58 gel apparatus (BRL-Life Technologies, Gaithersburg, MD). Loading buffer 
consisted of 0.5M EDTA, pH 7.5, 10% SDS, 50% Glycerol and 0.25% bromophenol 
blue.
Western Blotting
Frozen tissues were pulverized, transferred into lysis buffer (25 mM Tris-HCl, pH 7.4, 
95 mM NaCl, 10 mM EDTA, 2%SDS, ImM PMSF and protease inhibitors), and 
homogenized with a Dounce homogenizer. Protein inhibitor cocktail: antipain 
(0.5pg/ml), pepstatin (0.5pg/ml), amastatin (0.5pg/ml), apoprotein (3U/ml), leupeptin 
(0.5p,g/ml), bestatin (0.5p,g/ml) and trypsin inhibitor (0.5p,g/ml) all from Roche 
diagnostics (Germany). Subsequently the lysates were boiled and centrifuged, and 
protein concentration in the supernatant was determined with the Biorad protein assay 
kit (Biorad, CA, USA), according to the manufacturers’ instructions.
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Samples (usually 5-30 pgs of protein extract) were separated using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) under denaturing conditions, with a mini Protean II 
gel electrophoresis apparatus (Biorad, CA, USA). Kaleidoscope pre-stained molecular 
weight standards (Biorad) were included to enable band size identification. Separated 
proteins were then transferred to a nitrocellulose membrane, Hybond-N, in a mini gel 
transfer tank (Biorad).
Non-specific binding sites on the membrane were blocked overnight at 4°C using 5% 
fat free milk powder in PBS/0.05% Tween 20. The following day, primary antibodies 
were incubated in 1% fat free milk powder in PBS/0.05% Tween 20 for 1 hour at room 
temperature, on a slow rotator (Gallenkamp, UK). The blots were then washed in PBS 
containing 0.05% Tween 20, usually 1 x 1 5  min followed by 4 x 5 minutes at room 
temperature. Subsequently, the membranes were washed and incubated with 
horseradish conjugated secondary antibody diluted in the same solution as the primary 
antibody, and developed with ECL chemioluminescent reagent (Amersham Biosciences 
Ltd, UK). The blots were covered in Saran Wrap film and placed in an autoradiography 
cassette with intensifying screens (Appligene, USA) and visualised by brief exposure to 
Kodak BioMax Mr-1 film which was developed from 45secs to 10 min later in an X- 
Ograph Compact X2 automatic developer.
Immunohistochemistry
Cryostat sections, 6-8fxm thick, were collected on Superfrost Plus microscope slides 
(BDH) and air dried for at least 1 hour. Teased nerve preparations were obtained by 
dissecting out sciatic nerves into L I5 medium on ice and desheathing followed by the 
teasing of small nerve pieces using fine needles. These were also left for at least 1 hour 
at room temperature, to allow the nerve fibres to dry and adhere well to the slide. Unless
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stated otherwise for fresh frozen tissue, teased nerve preparations and coverslips, fixing 
was 10 min in 4% paraformaldehyde at room temperature followed by 3, 5 minutes 
washes in lxPBS. Tissue was then blocked using antibody diluting solution, known as 
ADS (PBS containing 10% calf serum, 0.1% lysine and 0.02 % sodium azide), for one 
hour at room temperature. Antibodies were diluted in ADS and applied overnight at 
4°C. The following day the slides were washed three times for 5 min each in lxPBS and 
incubated in secondary fluorescent antibodies for 25 min at room temperature. In those 
cases were a three layer system was used, biotin was applied as second layer for 25 min 
at room temperature. The slides or coverslips where then washed three times for 5min 
each in lxPBS. The third layer was usually streptavidin conjugated FITC or Cy3 
applied for 20 min at room temperature. Samples were washed again, mounted using 
Citifluor antifade mountant and sealed with nail varnish. As control, primary antibody 
exclusion from a single sample in each experiment was employed to ensure that the 
second or third antibody layers used did not cause any non-specific background.
Primary antibodies
Anti protein zero (Pn) Rabbit polyclonal antibody against rat protein zero was generated 
and characterized in the laboratory by Louise Morgan essentially as described by 
Brockes et al., 1980 (Morgan et al., 1994). The antiserum was purified by S. Namini.
Fresh frozen tissue and cells were prefixed in ice cold methanol for 10 min followed by 
fixation in 2N HC1 for 15 min, washed in PBS then further neutralized with 0.1M 
sodium borate solution for 10 min. The cells were then blocked for 2 hr with antibody 
diluting solution, washed and incubated overnight with anti-Po. The antibody was used
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at a dilution of 1:500.
Anti protein zero fPn) mouse monoclonal antibody against protein zero was a gift from 
J. Archelos, and used at a dilution of 1:1000.
Anti calcium binding protein S I00 Rabbit polyclonal antibody against cow S I00 
protein was from Dako Immunoglobulins (Dakopatts, Copenhagen, Denmark.) and used 
at a final dilution of 1:1000.
Anti svnuclein-1 mouse monoclonal antibody (IgGl) against a-synuclein was from BD 
Transduction Laboratories (UT,USA), and used at a final dilution of 1:500.
Anti collagen type II mouse monoclonal antibody against collagen type II (clone 
CIIC1), in the form of ascites, was from Developmental Studies Hybridoma Bank 
(University of Iowa, USA), and used at a final dilution of 1 TOO.
Anti collagen type II Rabbit polyclonal antibody against collagen type II was a gift from 
Dr L. Sandell, (Washington University School of Medicine, St. Louis, USA) and used at 
a dilution of 1:2000.
Anti a-B-crvstallin mouse monoclonal antibody against B-crystallin (Stressgen 
Biotechnologies, CA, USA) was used at a final dilution of 1:2000.
Anti aerin mouse anti-agrin antibody was from Stressgen (Stressgen Biotechnologies, 
CA, USA), and used at a final dilution of 1:100.
Anti Sox-9 rabbit polyclonal antibody against Sox-9 was a gift from Dr. M. Wegner 
(Institut fur Biochemie, Erlangen, Germany) and used at a final dilution of 1:2000.
Anti chondromodulin-I Rabbit polyclonal antibody against chondromodulin-I was a gift 
from Dr. Haraki and Dr. Sukunami (University of Kyoto, Japan) and used at a final 
dilution of 1:600.
Anti Jip-1 mouse monoclonal antibody against Jip-1 was a gift from A. Whitmarsh 
(University of Manchester, Manchester, UK), and used at a dilution of 1:200.
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Anti LI rat monoclonal antibody (clone 324) was a gift from Dr. R. Martini (Martini et 
al., 1994). This antibody was used in the form of hybridoma supernatant and diluted 
with MEM-H 10% calf serum (CS) 1:1 and placed on prefixed cells. Incubation was for 
1 hr at room temperature, followed by Cy3-conjugated anti-rat Igs for 30 min. 
Anti-L-periaxin Rabbit polyclonal antibody against L-periaxin was a gift from Prof.
P.J. Brophy (University of Edinburgh, Scotland, UK) and used at a final dilution of 
1:8000.
Anti-neurofascin Rabbit polyclonal antibody against neurofascin was a gift from Prof. 
P.J. Brophy, and used at a dilution of 1:100.
Anti Gapdh mouse monoclonal antibody against Gapdh (Abeam Ltd, Cambridge, UK) 
was used at a dilution of 1:5000.
Anti phospho-histone-H3 Rabbit polyclonal antibody against phospho-histone H3 
(PH3) (Upstate, Inc., USA) was used at a final dilution of 1:5000.
Anti Smad4 mouse monoclonal antibody against Smad4 was purchased from Santa 
Cruz Biotechnologies Inc. (CA, USA), and used at a diluition of 1:400.
Anti Smad2 mouse monoclonal antibody against Smad2 was purchased from BD 
Bioscience, and used at a dilution of 1:500.
Anti-MUPP-1 rabbit polyclonal antibody against Mupp-1 was a gift from E. Peles 
(Weizmann Institute of Science, Rehovot, Israel), and used at a final dilution of 1 TOO. 
Anti p75NTR rabbit polyclonal against p75NTR (Advance Targeting Systems, CA, 
USA), was used at a final dilution of 1:1000.
Secondary antibodies
Goat anti-mouse Ig conjugated to tetramethyl rhodamine. (used at a dilution of 1:100) 
and goat anti-rabbit Ig conjugated to fluorescein (used at 1:600) were from Cappel
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(Cappel Organon Teknika Corp, PA, USA). Donkey anti-rabbit Ig conjugated to biotin 
(used at 1:100), sheep anti-mouse Ig conjugated to biotin (used at 1:100), streptavidin 
conjugated to fluorescein (used at 1:100) and streptavidin conjugated to Cy3 (used at 
1:50) were from Amersham (Amersham Pharmacia Biotech, UK). Goat anti-rat Ig Cy3 
(used at 1:200) was from Jackson laboratories (Pennsylvania, USA).
In situ hybridisation
Tissue preparation
Sciatic nerves dissected from P3 rats were fixed in 4%PF for 4-6 hours and transferred 
to 30% sucrose (in 0.1M phosphate buffer) for 24 hours. The nerves were then 
embedded in OCT compound, and 15-20p,m sections were cut and collected onto 
Superfrost slides. The sections were dried for 30min-lhour at room temperature, fixed 
in 4%PF for lOmin and washed 3x in PBS for 3 min each time. Sections were then 
acetylated (29.5 ml dFhO, 0.4ml triethanolamine, 0.05 ml concentrate HC1, 0.075 ml 
acetic anhydride) for lOmin with shaking, washed 3x in PBS, 5min each and dehydrated 
with 50%, 75%, 80%, 90%, 100% ethanol, 2 minutes each and then air-dried. 
Hybridisation
200-300p,l hybridisation buffer (lx  salts, 50% formamide, 0.1 mg/ml yeast total RNA, 
10% w/v dextran sulphate, lx  Denhardt’s) were placed on each slide, and incubated at 
room temperature at least 2h in a closed box containing 2xSSC, for pre-hybridisation. 
The pre-hybridisation solution was carefully removed and replaced with 200pJ 
hybridisation buffer containing the DIG labelled probe at 200-400 ng/ml, previously 
heated at 80°C for 5min. Each slide was covered with a piece of plastic bag, and the 
hybridisation box (humidified) placed in an oven at 65 °C overnight. “Total” collagen 
type II and “II A” probes were a generous gift from Dr. Linda Sandell (Washington
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University School of Medicine, MO, USA).
Washing and staining
Each slide was submerged in 0.2xSSC in Coplin jars at room temperature and 
subsequently transferred to preheated 0.2xSSC at 65°C for lh, with rocking. The slides 
were then transferred to room temperature 0.2xSSC for 5min and then in buffer 1 (Bl) 
(0.1M Tris pH 7.5, 0.15M NaCl) for 5min. The slides were then incubated for lh  with 
B2 (Bl plus 1% heat inactivated sheep or goat serum) at room temperature. 0.5ml of 
anti-DIG antibody (diluted 1:4000 in B2) were then placed on each slide, and incubated 
at 4°C overnight in a humidified box. The day after, the slides were washed 3x with Bl, 
equilibrated for 5min with B3 (0.1M tris pH 9.5, 0.1M NaCl, 50mM MgCh), and 
incubated for 6h-3 days in solution B4 (2xB3 in 1:1 solution with polyvinyl alcohol, 
plus 3.5 pi of NBT per ml of solution, 3.5pl BCIP, 0.24 mg/ml levamisole). The reaction 
was stopped placing the slides in PBS; the slides were mounted in aquamount and 
allowed to dry.
Cell Culture Experiments 
Coverslips preparation
Round 13 mm coverslips (Merck) were baked at 140°C for 8 hr under dessicated 
conditions and coated with 1 mg/ml poly-D-lysine (PDL) in dH20 for 4 hours at room 
temperature. Coverslips were then washed in distilled water 3 times at room 
temperature on a shaker, before being air dried in a flow cabinet and stored dessicated.
Isolation and Culture of Schwann Cells
Schwann cells were prepared using the method of Brockes et al., (1979). Newborn 
Sprague-Dawley rats were killed by decapitation and the sciatic nerves dissected out
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using a dissection microscope. Nerves were placed in L I5 medium, and kept on ice. 
The epineurial sheath was removed and the cells dissociated by digestion in 0.25% 
trypsin, 0.4% collagenase in DMEM at 37°C and 5%C02 and 95% air for 50 min with 
single trituration at the half way stage. The cells were then washed in DMEM with 10% 
FCS and centrifuged for 10 min at 500xg at 4°C to pellet, resuspended in the same 
medium and cultured on PDL and laminin coated coverslips. For non-myelinating 
Schwann cells, 6 week old rats were killed in a CO2 chamber and the sympathetic trunk 
was dissected out. The epineurial sheath was removed and the cells dissociated with 
trypsin and collagenase, resuspended in defined medium (DM), and plated on PDL and 
laminin coated coverslips for 24 hours. After the 24 hours the cells were fixed for 10 
minutes in 4% PF and immunolabelled with the antibody of interest.
For the db-cAMP stimulation assay, P3 sciatic nerve Schwann cells were plated in DM 
+ 0.5% foetal calf serum (FCS) for 3 days, and subsequently stimulated with ImM db- 
cAMP for 24 hours.
Defined Medium (DM) contained 1:1 Hams F I2/ DMEM supplemented with lOOpg/ml 
glutamine, 0.03% bovine serum albumin (BSA), lOOpg/ml transferrin, 16pg/ml 
putrescine, 38ng/ml dexamethasone, 60ng/ml progesterone, 400ng/ml thyroxine (T4), 
5ng/ml insulin (low insulin) or 5pg/ml (high insulin), 10 ng/ml triiodothyronine (T3), 
160ng/ml selenium and lOOU/ml each of penicillin/ streptomycin.
Immunopanning
For immunopurification, Schwann cells from rat or mouse sciatic nerves were purified 
by negative immunopanning on dishes coated with Thy 1.1 antibodies as described in 
Dong et al., (1997). Briefly, 2-3 90mm Petri dishes (Falcon) were coated with anti­
mouse or anti-rat IgG (Thy 1.1, Dako, final concentration 50-60pg/ml in 7 ml 50mM
96
Tris pH 9.5), wrapped in nescofilm and left overnight at 4°C. The following day the IgG 
solution was removed from the plates and replaced with a solution containing 4ml Ox-7 
supernatant, 2ml L I5 and 400pl 35% BSA. After 2 hours at room temperature the Ox-7 
solution was removed and the dishes washed 3 times in PBS. The Schwann cells, 
dissociated from the sciatic nerves as described previously, were resuspended in 7-8 ml 
DM and transferred to the Thy 1.1 coated dish. The dishes were shaken vigorously and 
incubated at 37°C for lOmin. The dishes were shaken once more and incubated for a 
further lOmin. The cell suspension is transferred to another coated dish and the two 
previous steps are repeated. The cell suspension was collected, spun, and the cells 
resuspended in the relevant medium. The cell purity was determined with S100 staining.
Schwann Cell Precursor Cultures
Schwann cell precursor cultures were prepared according to the method form Jessen et 
al. (1994). Sciatic nerves were dissected from E14 rat embryos. The nerves were cut in 
small pieces and incubated with 600p<l enzyme cocktail solution (2mg/ml collagenase, 
1.2 mg/ml hyaluronidase, 0.3 mg/ml trypsin inhibitor) for 1 hour, before being triturated 
through a 1ml pipette and then through a 200|xl pipette. They were then re-incubated for 
a further 15min before being triturated again. The cell suspension was then transferred 
to a centrifuge tube and the volume made up to 10ml with defined medium (DM), in 
order to dilute the enzymes. The tube was then centrifuged for lOmin at lOOOrpm and 
the cells were counted and resuspended at a concentration of 3000 cell in 15pl in the 
relevant growth factor (usually P-neuregulin). These cells were plated on PLL and 
laminin coated glass coverslips and after 2.5-3 hours topped up in DM containing p- 
neuregulin. After 6, 24 or 48 hours the cells were fixed and stained with the antibody of 
interest.
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Neural crest cell cultures
Neural crest cell cultures were prepared essentially as described in Woodhoo et al., 
2004. Neural tubes were dissected out from E ll  rat embryos and plated on a 
PDL-fibronectin-coated 35-mm Petri dish containing 2 ml of DM supplemented with 
insulin (10-9 M), bFGF (3 ng/ml),Nrg-l (10 ng/ml), IGF-1 (100 ng/ml) and N-acetyl 
cysteine (1 mM). After 24 hours at 37°C, 5% C02, the tubes were removed from the 
dish, the cells fixed with 4% paraformadehyde (PF) and immunostained with the 
antibody of interest.
FACS sorting
P3 rat Schwann cells were resuspended in L I5 medium + 10% FCS and 
immunolabelled with anti-mouse GalC supernatant (Ranscht et a l, 1987), at a 1:1 
dilution. Anti-mouse FITC was used as second layer. The cells were then centrifuged 
and resuspended in L15+10%FCS to a final concentration of 1-6 million cells/ml. GalC 
positve and negative cells were selected using a EPICS Elite ESP flow cytometer 
(Beckman Coulter).
Cell Proliferation and Cell Death assays 
Cell Proliferation
Phospho-histone H3 (PH31 staining
The ratio of cells undergoing proliferation was measured with PH3 immunlabelling. 
Cryostat sections, 6pm thick, were cut from fresh frozen sciatic nerves at different ages, 
mounted on Superfrost slides and allowed to dry for 45min-l hour at room temperature. 
Sections were fixed for 10 mniutes with 4% PF, and, after washing, they were blocked
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using ADS for 1 hour. PH3 antibody, diluted 1:5000 in ADS, was applied either for 1 
hour at room temperature or overnight at 4°C. Sections were then washed and incubated 
with anti-rabbit FITC for 30 minutes. Nuclei were labelled with Hoechst (diluted 
1:1000 in ADS) and the sections mounted in Citifluor mounting medium.
Cell Death Assay
Cells in the process of apoptotic cell death were analysed using sections to estimate in 
vivo cell death by in situ labeling of DNA fragmentation using terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). 
Cryostat sections of fresh-frozen nerves, of various ages, were cut at between 6 and 
8pm and mounted on Superfrost Plus microscope slides. Tissue was allowed to dry for 
45 min and then fixed by submersion in 4% paraformaldehyde for 10 min at room 
temperature. The sections were washed, usually 3 x 5  min in PBS and then pre­
incubated in terminal transferase (TdT) buffer (30mM Tris buffer pH 7.2, 140mM 
sodium cacodylate and ImM cobalt chloride) for 15 min at room temperature. Terminal 
transferase and biotinylated-d-UTP were added to the sections in a TUNEL reaction 
mixture, as recommended in the manufacturers’ protocol and incubated at 37°C for 60 
min. The reaction was terminated by washing 2 x 5  min in ultrapure H2 O and once in 
PBS. Non-specific binding sites were blocked using PBS with 10% FCS for at least 60 
min at room temperature. The sections were then incubated with streptavidin conjugated 
to Cy3, at a concentration of 1:50 in ADS with 0.1% Triton X-100 for 30 min at room 
temperature. Nuclei were then labelled with Hoechst dye and the sections mounted in 
Citifluor anti-fade mounting medium.
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TGFp survival assays
The sciatic nerve was dissected and dissociated from newborn entire litters, of PO 
CRE/TGFpRII mice. Following centrifugation the cells were resuspended in DM + 
0.5% FCS, counted with a haemocytometer and plated at 3000 cells per coverslips onto 
Pdl and laminin coated coverslips in triplicate. Following incubation for three hours at 
37°C and 5%CC>2 and 95% air, one set of coverslips, representing a sample of cells from 
each animal of the litter were fixed for immunocytochemistry. The remaining two sets 
of cells were topped up with DM + 0.5% FCS and treated with 20ng/ml TGFp-1 for 24 
hr. These cells were then also fixed into 4% PF for 10 min, washed twice with PBS, and 
Hoechst dye was used for nuclear staining.
Quantification of Schwann cell survival
The number of living Schwann cells in the above experiment is expressed as survival 
percent and was carried out using a method previously described (Meier et al, 1999, 
Parkinson et al., 2001). Survival percent is the number of living cells present at 24 hr 
on the coverslip as a percentage of the number of cells that had attached to the substrate 
in sister cultures at 3 hr.
Microscopy and quantification
Slides were mounted in Citifluor (Citifluor, Ltd, UK) and examined with a fluorescence 
microscope (Eclipse E800, Nikon). Images were captured with a digital camera 
(DMX1200, Nikon), and ACT-1 acquisition software (Nikon). UMAX PowerLookll 
was used to digitalize the images.
TUNEL-positive and BrdU stained nuclei were counted as a percentage of all nuclei 
within a given field, using a 40x objective lens or by importing images into NIH image,
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using Photoshop 5.0 on an Apple Macintosh G4 computer. At least 1000 cells were 
counted and each experiment repeated at least five times. All images were directly 
imported into Photoshop.
Statistical analysis
Unless otherwise stated, the statistical significance of data was evaluated using the 
paired students t-test.
Electron Microscopy (EM)
Mutant and control mice of various ages were killed with a method appropriate for the 
age of the animal. The sciatic nerves were rapidly dissected out, with care to avoid any 
mechanical stress and placed in freshly prepared 2% glutaraldehdye in 0.1M sodium 
phosphate buffer pH 7.4 at 4°C. The next day the tissue was washed three times for 15 
min in 0.1 M phosphate buffer, pH 7.4 and then stained with 1% osmium tetroxide for 
45 minutes. The tissue was washed three more times incubated with 2% uranyl acetate 
in H20 for 45 minutes, and then dehydrated as follows; 25% ethanol (5 min), 50% 
ethanol (5 min), 70% ethanol (5 min), 90% ethanol (10 min), 100% ethanol (10 min x 
4) and propylene oxide (10 min x 3). Tissue samples were then embedded in araldite in 
two stages; overnight incubation in 50% araldite and 50% propylene oxide mixture 
followed the next day by an 8 hour infiltration in araldite alone, all at room temperature. 
Araldite consisted of equal parts araldite CY212 and DDSA with accelerator, BDMA 
and plasticizer, dibutryl pthalate. The tissue samples were then placed into a rubber 
coffin mould and thermo-cured at 65°C for 48 hours. Semi-thin sections, 1 pm and ultra- 
thin sections, were taken using an Ultracut E ultramicrotome (Leica, Germany). Semi- 
thin sections were taken using fresh glass knives and collected on microscope slides and
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ultra-thin sections on copper grids (Agar Scientific, UK). Semi-thin sections (STS) were 
stained with 0.1% toluidine blue in ethanol, rinsed with distilled water, dried and 
mounted in DPX mountant. These sections were then analysed by light microscopy. 
Ultra-thin sections (silver), for higher power work, were collected on copper New 200 
grids (Agar Scientific, UK). Grids were stained for 15 min in lead citrate solution, 
washed in distilled water and dried. Grids were viewed in a Jeol 1010 electron 
microscope (Jeol, Japan) and images captured on X-ray Film (Ilford, UK). Films were 
printed using a Deverre enlarger on Ilford multigrade paper using Ilford multigrade gel 
filters (Ilford, UK).
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Table 2.2, primers for RT-PCR: Ann. T. cycles
Col2al sense 5'-TCGGGGCTCCCCAGTCGCTGGTG-3'
Col2al AS 5'-TCCAGGGGTACCAGGTTCATC-3'
58°C 30
ChM-1 sense 
ChM-1 AS
5'-GGAAGGCAAGATCATGCCAG-3'
5'-ACACCATGCCCAAGATGCGG-3'
56°C 32
Snca sense 5'-TGC-TGTGGATATTGTTGTGG-3'
Snca AS 5'-AGGT GCGT AGTCTC AT GCTC-3'
Cry-ab sense 
Cry-ab AS
Jip-1 sense 
Jip-1 AS
Sox9 sense 
Sox9 AS
5'-CTTCTCTACAGCCACTTCCC-3' 
5'-G ACTCC AT CCG AT G AC AGGG-3'
5'-CGACTGTCTGTCATCCCCAG-3' 
5 ’-CAT AG AC AGT GGC AG AGT CG-3 ’
5'-GAATCTCCTGGACCCCTTCA-3f
5'-CCCTTCAGCACCTGCTGACC-3'
54°C
57°C
57°C
54°C
33
32
35
37
COUP-TFI sense 5’-AGCCATCGTGCTGTTCACC-3’ 
COUP-TFI AS 5'-CCTGCCCTGATACCAGCATC-3'
55°C 33
Agrin sense 
Agrin AS
cMAF sense 
cMAF AS
5 -CCGT AAGGG AT G ACT GT G AA-3' 56°C 32
5 '-TT GGTT GCG AG ACT GGTT-3'
5 '-GT GAT GGCT CTTTT G AATT GGG-3' 56°C 35
5'-AGAGGCTGGGAAACACAGCAAG-3'
CRMP-1 sense 
CRMP-1 AS
5 '-AT AG AC ACG AGCC AAG ACCTT AGC-3' 
5'-ATTACCGCACCATCCTCAAGGC-3'
55°C
CRMP-3 sense 
CRMP-3 AS
5'-CCCCTCCCCATAAACTCTCTTTTTGG-3' 
5 '-CTGG AAAGTT C AC AGGCT GG-3'
57°C
Gapdh sense 
Gapdh AS
5'-ACCACAGTCCATGCCATCAC-3'
5'-TCCACCACCCTGTTGCTGTA-3'
63°C
H33426 sense 
H33426 AS
5'-GAATCTCTTCTGCCTCCACCTACC-3'
5'-CTCAGCCTTGAACAAACACCATC-3'
55°C
AA892486 sense 
AA892486 AS
5'-T G AC AGC AG AG AGT AAGCCG AAC-3' 
5'-CAACCTACGCACTGACAAGACTTTC-3'
57°C
AA892798 sense 
AA892798 AS
5'-AAACCGATGGCACCGAAGGTCAAG-3' 
5'-CAC AGAACA-TTTC ACAAAGGGGC-3 ’
55°C
33
33
28
32
33
30
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CHAPTER 3
Gene profiling and bioinformatic analysis of the Schwann cell lineage 
INTRODUCTION
As already discussed in the general introduction, the great majority of Schwann cells in 
the peripheral nervous system derive from the neural crest (Le Dourain et al, 1991; 
Anderson, 1997). Two main intermediates, the Schwann cell precursor (E l4-15 in the 
rat, E l2-13 in the mouse), and the immature Schwann cell (from E l7 in the rat, from 
E l5 in the mouse), are then involved in the formation of mature myelinating and non­
myelinating Schwann cells (Dong et al., 1995,1999; Mirsky and Jessen, 1996; Jessen 
and Mirsky, 1999, 2002). The transition from Schwann cell precursor to immature 
Schwann cell is a process that takes place somewhat abruptly. Immature Schwann cells 
are clearly distinguishable form precursors thanks to their in vitro bi-polar shape, 
immunoreactivity to S I00 and 04  {in vivo), and ability to survive in the absence of 
axonal contact, due to autocrine loops (Jessen et al., 1994; Dong et al, 1999; Meier et 
al, 1999). The precursor/Schwann cell transition is also accompanied by the down- 
regulation of the transcription factors Sox 10 and AP-2, while the expression of the 
transcription factor Oct-6 increases during this period (Kuhlbrodt et al, 1998; Britsch et 
al.’, 2001 Stewart et al, 2001; Blanchard et al., 1996). However, much remains to be 
learned about the molecular regulation of this event and the change in gene expression 
profile involved in this transition.
In Chapter 1 we have seen that the cells destined to myelinate carry out large amounts 
of membrane synthesis and wrapping to form the myelin sheath. Myelin proteins, such 
as Po, M BP and PLP, are strongly up regulated, and so are the genes involved in lipid 
synthesis. One of the most striking features of this process is its reversibility: if axonal 
contact is lost, the Schwann cells de-differentiate, proliferate and the myelin related
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genes are down regulated, while adhesion molecules, neurotrophins, cytokines and their 
receptors are up-regulated to create an environment that allows axonal re-growth 
(reviewed in Stoll and Muller, 1999; Scherer and Salzer, 2001). To date, five 
transcription factors have been shown to be involved in Schwann cell development and 
in the myelination programme: Sox 10 (Kuhlbrodt et al., 1998; Britsh et al., 2001), Oct- 
6 (SCIP/Tst-l;Monuki et al., 1990; Bermingham et al., 1996; Jaegle et al., 1996), Bm-2 
(Jaegle et al., 2003), NF-kappaB (Nickols et al., 2003) and Krox-20 (Topilko et al., 
1994; Murphy et al., 1996; Zorick et al., 1999). The latter has recently been suggested 
to act as master regulatory gene, due to its capability to drive the expression of myelin 
specific genes in cell types other than Schwann cells (Parkinson et al., 2004). Still, 
many of the molecular mechanisms involved in the myelination process remain poorly 
understood.
Schwann cell response to nerve injury
Axonal loss results in all the Schwann cells distal to the site of injury assuming the 
phenotype of denervated Schwann cells. This can be considered as a third phenotype of 
Schwann cells along with myelinating and non-myelinating Schwann cells. Denevated 
Schwann cells are broadly similar to non-myelinating ones, and are characterised by the 
expression of p75NTR, GAP-43, N-CAM and L I. This means that after nerve injury the 
bigger changes are seen in myelinating Schwann cells that dramatically decrease their 
synthesis of lipids and myelin-related proteins. However, even non-myelinating 
Schwann cells are affected by axonal loss, and reduce their expression of 
galactocerebroside and sulphatide (reviewed in Scherer and Salzer, 2001).
The switch to denervated Schwann cells is accompanied by a massive increase in 
proliferation, attributable to both Schwann cell forms (Abercrombie and Johnson, 1946;
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Abercrombie et al., 1959; Bradley and Ashbury, 1970; Clemence et al., 1989). 
Subsequently, as reinnervation occurs, Schwann cell stop proliferating, and those 
Schwann cells destined to re-myelinate down-regulate LI, N-CAM, p75NTR and GAP- 
43 and start expressing MAG and other myelin-associated genes (Taniuchi et al., 1988; 
Martini and Schachner, 1988; Hall et al., 1992).
As already mentioned in Chapter 1, denervated Schwann cells create a favourable 
environment for axonal regeneration. Besides eliminating myelin debris and forming 
persistent basal lamina tubes, denervated Schwann cells also secrete a series of 
extracellular matrix (ECM) molecules, including F-spondin, collagen P200, laminin, 
tenascin-C and flbronectin, which appear to be permissive for axonal regrowth 
(Burstyn-Cohen et al., 1998; Chemousov et al., 1999; Patton et al., 1997; Scherer and 
Salzer; 2001). Moreover, denervated Schwann cells up-regulate the expression of cell 
adhesion molecules, including N-CAM, LI, N-cadherin and ninjurin (Martini, 1994; 
Araki and Milbrandt, 1996; Scherer and Salzer, 2001). In particular, LI and N-CAM 
have been shown to increase dramatically on the surface of de-differentiating 
myelinating Schwann cells, and to remain highly expressed in non-myelinating ones 
(Martini and Schachner, 1998; Jessen et al., 1987).
The injured nerve is quickly invaded by macrophages, which mediate demyelination 
and influence Schwann cell proliferation and successive remyelination (reviewed in 
Kiefer et al., 2001). Macrophages are recruited to the injury site as well as the distal 
nerve portion and their principal function is to phagocytose degenerating myelin (Perry 
et al., 1987; Stoll et al., 1989; Monaco et al., 1992). The macrophage complement 
receptor type 3 is the main surface receptor involved in myelin recognition and uptake 
(Bruck, 1997). Schwann cell are also responsible for myelin clearance in vivo (Stoll et
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al., 1989). Interestingly, while myelin phagocytosis by Schwann cells appears to be 
lectin mediated, myelin phagocytosis by macrophages is opsonin-dependent (reviewed 
in Hirata and Kawabuchi, 2002). Other roles have been attributed to macrophages, 
including the secretion of Schwann cell mitogens and the release of interleukin-1 
(Baichwal et al., 1988; Heumann et al., 1987).
Degenerating peripheral nerve, and in particular formerly myelinating Schwann cells, is 
also the source of trophic factors. This idea was already suggested by Ramon y Cajal 
(1928), who also suggested that these factors could also have guidance effects on the 
regenerating axons. It is now widely accepted that Schwann cell are the main source of 
factors such as neurotrophins, cytokines and TGFps.
Neurotrophins
The neurotrophin (NTs) family consists of four members, brain derived neurotrophic 
factor (BDNF), nerve growth factor (NGF), neuroptrophin-3 (NT-3) and -4 (NT-4) 
(reviewed in Lewin and Barde, 1996; Ip and Yancopolous, 1996). They signal through 
high-affinity tyrosine kinase receptors (Trks) and low-affinity p75NTR.
NGF expression at both the mRNA and protein level is sharply increased in the distal 
stump of transected nerves (Rush et al., 1995; Heumann et al., 1987). NGF activation is 
enhanced by the addition of macrophages, suggesting that they may modulate Schwann 
cell synthesis of NGF (Heumann et al., 1987; Robertson et al., 1995). The expression of 
the NGF receptor p75NTR is also increased in Schwann cells, and is not influenced by 
macrophages (Heumann et al., 1987). P75NTR up-regulation is seen 24 hours after 
transection, peaks at around 1 week and is maintained for up to 10 weeks, and axon 
regeneration down-regulates p75NTR (Robertson et al., 1995; Taniuchi et al., 1988).
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P75NTR activates the transcription factor NF-kB, which could be involved in re- 
myelination (Carter et al., 1996; Nickols et al., 2003).
BDNF, NT-3 and NT-4 are also up-regulated after nerve injury, but with a temporal 
pattern retarded compared to NGF (Acheson et al., 1991; Funakoshi et al., 1993). 
Formerly myelinating Schwann cell, rather than non-myelinating ones, appear to be the 
main source of BDNF (Friedman et al., 1996). BDNF and NT-3 have been shown to 
promote axonal regeneration, and exogenous NT-3 promotes the regeneration of motor 
neurons and their reinnervation of skeletal muscle (Utley et al., 1996; Sterne et al., 
1997a, 1997b). The interaction of regenerating axons with the Schwann cell suppresses 
the expression of BDNF and NT-4. In recent years various experiments have shown that 
BDNF and NGF promote Schwann cells myelination, while NT-3 appears to inhibit it 
(Chan et al., 2001; Chan et al., 2004). On the other hand, NT-3 enhances Schwann cell 
migration while both BDNF and NGF inhibit it (Yamauchi et al., 2003; Yamauchi et 
al., 2004). These data indicate that neurotrophin have a key role not only during the 
degeneration/regeneration process but also during normal Schwann cell development.
Cytokines
Ciliary neurotrophic factor (CNTF), interleukin-6 (IL-6) and leukaemia inhibitory factor 
(LIF), are a family of structural related cytokines the expression of which has been 
detected in Schwann cells (Scherer and Salzer, 2001). The membrane protein g l30 is 
the signal transduction subunit common to these three factors. G130 interacts with LIFp 
receptor, IL-6a receptor and with CNT-Fa receptor to transduce the signal of LIF, IL-6 
and CNTF respectively (reviewed in Ip and Yancopoulos, 1996).
CNTF has a trophic effect on a variety of PNS and CNS neurons (Sendter et al., 1994). 
In the PNS, CNTF is expressed by myelinating Schwann cells, and its levels fall
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dramatically after nerve injury, indicating that CNTF could be a trophic factor for 
uninjured neurons, an hypothesis sustained by the observation that CNTF null mice 
eventually develop motor neuron disease (Sendtner et al., 1996; 1997). During 
Wallerian degeneration CNTF is released in the extracellular space, but the mechanism 
is unknown (Sendtner et al., 1997).
LIF levels increase sharply after nerve injury, and Schwann cells appear to be the main 
source (Curtis et al., 1994; Ito et al., 1998). LIF enhances axon re-growth, and in 
CNTF/LIF double mutants motor neuron death is increased compared to CNTF alone 
null mice (Sendtner et al., 1996).
Similarly to LIF, IL-6 expression is induced by nerve axotomy, but the cellular source is 
not clear (Bolin et al., 1995; Ito et al., 1998; Hirota et al, 1996). Recent work indicates 
that Schwann cell derived IL-6 and LIF are involved in the recruitment of macrophages 
to the nerve after injury, suggesting that Schwann cells are also active regulators of the 
inflammatory response, rather than simply passive targets of extrinsic signals (Tofaris et 
a l , 2002).
TGF0s
Schwann cells express all the three forms of transforming growth factor-|3 (TGFP), 
TGFp-1, -2, and -3. The role of the TGFp family during Schwann cell development 
will be discussed in chapter 5.
Transcription factors expressed after nerve injury
The oncogene c-Jun and c-Fos have been shown to be highly expressed at both the 
mRNA and protein level some 12 hours after nerve injury (De Felipe and Hunt, 1994; 
Liu et al., 1995; Stewart et al., 1995; Shy et al., 1996; Parkinson et al., 2004). C-Jun
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and c-Fos are able to form homo- and heterodimers, therefore their expression after 
axotomy forms the basis for a signal cascade involved in nerve regeneration that is not 
fully understood yet (Kerppola and Curran, 1993; Soares et al., 2001).
In adult nerves, Oct-6 expression is transiently up-regulated around 2 days after injury, 
while Krox-20 expression is strongly down-regulated (Monuki et al., 1990; Scherer et 
al., 1994; Topilko et al., 1997). Krox-24 is up-regulated in Schwann cell following 
sciatic nerve transection, and there is an indication that its up-regulation is necessary for 
p75NTR induction (Topilko et al., 1997; Nikam et al., 1995).
To try to elucidate further the events accompanying Schwann cell development and 
myelination I have performed a gene expression profiling study of embryonic, 
myelinating and de-differentiating Schwann cells, using Affymetrix Gene Chip 
Technology. In the following paragraphs a brief overview on DNA microarrays, their 
history and applications is provided.
DNA microarrays: an overview
The fundamental principle of DNA microarrays is the process of hybridisation, which 
has been used for decades by molecular biologists as the basis for techniques such as 
Southern and Northern blotting. In these methods a small sequence of DNA, an 
oligonucleotide, often radioactively labelled, is used to hybridise to complementary 
fragments of DNA or to a messenger RNA. If the oligonucleotide is radioactive, the 
hybridisation can be visualised as a band on a photographic film. In the case of 
Northern blotting the intensity of the resulting band depends, to some extent, on the 
amount of messenger RNA and therefore on its level of expression.
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Southern and Northern blotting, although powerful techniques, allow the study of a 
single gene and messenger at a time. The first example of large-scale analysis was 
introduced in the late 1970s, and was named dot-blot (Kafatos et al., 1979). In this 
technique multiple hybridization targets, instead of being distributed in a gel containing 
DNA or RNA, are attached to a filter and can be analysed in parallel. Moreover, 
imaging methods allow parallel measurement of the signals as well. Hoheisel et al, 
(1994), took this approach a step further and used multiple libraries arrayed on filters at 
high density for cross-correlating cloned sequences. The high density spotting was 
achieved by replacing manual procedures with robotics, which increased the speed of 
the operation, improved the accuracy of placing the samples and removed human errors. 
This represented the first step towards microarrays.
What really distinguishes a DNA microarray from a dot blot is that while in the dot blot 
multiple targets are arrayed on the support (usually a nylon membrane) and the probe, 
normally a single sequence, is applied under hybridisation conditions, in a microarray 
multiple probes are attached to the support and the target to be analysed is labelled. It is 
therefore to be noticed that, from now on, the term probe will be used for the nucleic 
acid of known sequence, which will be attached to the surface in the case of the 
microarray, and target will describe the collection of sequences to be analysed (total 
RNA or purified polyA+ mRNA).
There are currently two main types of DNA microarrays (or chips): in the first one, 
probes are synthesised in situ directly on a rigid support (usually glass), while in the 
second pre-synthesised probes are attached to the platform (nylon or glass). This 
second technology offers more flexibility, in that it is possible to design any probe for 
spotting on the array. On the other hand, the in situ technology is easier to control and 
results in greater uniformity of hybridization between chips, which can facilitate data
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analysis when comparing multiple experiments, and, although more expensive, is 
nowadays generally preferred (Schena, 1999; 2004; Knudsen, 2004; Baldi and Hatfield, 
2003).
Affymetrix GeneChip Technology
Probably, the most widely used in situ technology at the moment is Affymetrix 
GeneChip (Fodor et al., 1993; Pease et al., 1994). Affymetrix uses high density 
oligonucleotides photochemically synthesised on the surface of a glass support. There 
are up to 40 oligonucleotides (each one up to 25 bases long) for each gene spotted on 
the chip. These oligonucletides correspond to regions of the gene that are, presumably, 
the least similar to other genes, to guarantee the highest specificity for each gene (Chee 
et al., 1996; Lockhart et al., 1996; Lipshutz et al., 1999). From this region 11 to 20 
oligos are chosen as perfect matches (PM), meaning that they are perfectly 
complementary to the mRNA of that gene. In addition Affymetrix has generated 11 to 
20 mismatch (MM) oligos, which differ from the PM only in the nucleotide positioned 
at the centre of the sequence. These MM oligos serve as internal control and are able to 
detect background and non-specific hybridisation, which is extremely important for the 
quantification of weakly expressed mRNAs. As described in detail in Chapter 2, the 
target mRNA to be interrogated, is then labelled and applied to the chip for 
hybridisation. After the hybridisation is completed the chips are washed and scanned. 
Computation of the relative expression level of all the probes is performed by the 
Affymetrix software.
112
Application of DNA m icroarrays
The development of DNA microarray technology has made possible the analysis of the 
expression profile of thousands of genes simultaneously. This can potentially provide a 
snapshot of the level of expression of all the genes in a cell under a given set of 
conditions. These expression profiles can be used, among other possibilities, to 
determine the function of new genes, for studying development and evolution, to 
evaluate the effect of drugs on gene expression or to analyse alternative splicing 
(Lockhart and Winzeler, 2000; Smith and Greenfield, 2003; Levy, 2003; Shaw and 
Morrow, 2003; Holloway et al., 2002). Another powerful application of microarrays is 
in diagnostic and prognostic: DNA polymorphisms, first proposed as a tool for mapping 
the human geneome (Botstein et al., 1980), have allowed the isolation of a number of 
disease related genes. Analyzed on a large scale using microarrays, polymorphisms are 
expected to permit genetic studies aimed at finding the genes associated with common 
diseases and inherited diseases susceptibilities (Cargill et al., 1999).
The use of Bioinformatics in Arrays
The most common application of DNA microarrays is the comparison of gene 
expression levels under different conditions, and one of the most typical goals is to find 
genes that are statistically significantly up- or down-regulated. It is therefore important 
to make sure that the samples that we are comparing are really comparable. The chips 
have to be the same under the different conditions and also the amount of sample 
applied to each chip has to be comparable. It is then necessary to normalize the data, so 
that the quantified values would only represent true differences in gene expression. This 
process is automatically performed by Affymetrix Suite (See Material and Methods), as
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well as by other commercially available packages. But how do we determine whether an 
observed variation in the expression level of a gene in two or more different conditions 
is significant? At present the best way is to repeat the experiments and to measure the 
variation. Of course the lower the number of replicates, the more difficult it is to 
estimate the variance. It is now widely accepted that three is the minimum number of 
replicates that allows a reliable statistical analysis. Only after that normalization and 
statistical analysis have been performed can the real analysis of the results start.
DNA microarray in the study of peripheral nerve biology
DNA microarray technology has been previously used to study Schwann cell embryonic 
development (Buchstaller et al., 2004), and to decipher Schwann cell expression 
profiling during myelination and after nerve injury (Nagarajan et al., 2001; Araki et al., 
2001; Nagarajan et al., 2002; Kubo et al., 2002; Verheijen et al., 2003). The use of 
DNA microarrays to analyse the response of cultured Schwann cells to enforced 
expression of Krox-20, has shown that the mRNA levels for myelin proteins and lipids, 
as well as the mRNAs for a variety of unknown genes, are strongly up-regulated by 
Krox-20. This finding indicates that this transcription factor plays a crucial role in the 
transition from immature Schwann cells to myelinating ones (Nagarajan et al., 2001). 
Moreover, microarray analysis of the genes up-regulated after nerve injury in the adult 
sciatic nerve has given important indications about genes that could be important for 
nerve regeneration, such as the novel protein nin283 (Araki et al., 2001; Kubu et al., 
2002). Finally, a study of gene expression profiling during Schwann cell development 
from pre-myelinating to post-myelinating Schwann cells has led to the identification of 
a group of genes, maximally expressed in the adult nerve, linked with the metabolism of
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energy lipids, providing important clues about the association of peripheral neuropathy 
with diseases such as diabetes and lipodystrophy (Verheijen et al., 2003).
Noticeably, all of these peripheral nerve expression profiling studies have been 
performed in mouse. In our experiments we decided to use rat for several reasons. The 
main is a technical one: since we wanted to analyse mRNA expression in embryonic 
Schwann cells, we needed to collect a high number of sciatic nerves to obtain the ~30pg 
of total RNA that were necessary for each hybridisation at the time we started our study 
(2001). Dissecting sciatic nerves from E l4 rat embryos is much easier than from E l2 
mouse embryos (the time of appearance of Schwann cell precursors), and the number of 
pregnant females that we needed to sacrifice was thus much smaller. Moreover, most of 
the knowledge about Schwann cell development comes from studies performed in rat, 
where the Schwann cell precursor was first identified (Jessen et al., 1994), making rat a 
more obvious choice for our goals.
There are other novelties in our study. Contrary to previous experiments that have 
looked at genes involved in regeneration after nerve injury in the adult (Araki et al., 
2001; Kubo et al., 2002), in our transection studies we have used nerves at the peak of 
myelination. We have chosen to analyse in detail all those genes that are up-regulated in 
sciatic nerve after birth and sharply down-regulated following nerve injury, and which 
should be, therefore, involved in myelination.
Finally, in most expression profiling work, the number of sequences which are 
completely unknown or only weakly similar to an expressed sequence tag (EST) is very 
high, and this can result in a significant reduction of the information that can be 
extracted from an experiment. Therefore, the expression profiling that we performed 
was accompanied by a refined bioinformatics analysis using Biopendium™ software
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from Inpharmatica, an extensive database of sequence and structural relationships. This 
was aimed to minimise the number of unknown sequences among the differentially 
expressed genes. We found that with this approach nearly all the ESTs could be mapped 
either to rat genes or to the mouse or human orthologues, and that a large number of the 
encoded proteins could be subjected to a detailed structural and functional annotation.
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RESULTS
General approach
Affymetrix Rat U34A Chips were hybridized using cRNA probes obtained from E l4, 
E l8, P7, P I2 rat sciatic nerves and from P I2 nerves that have been cut five days 
previously. In Fig 3.1 a schematic explanation of the procedure is shown.
Since Schwann cells account for the vast majority of cells in peripheral nerve, and 
considering that the mRNA levels in the axons of sensory and motor neurons are 
supposed to be very low (Mohr, 1999; Mohr and Richter, 2000), our analysis should 
provide an accurate overview of the expression profile of Schwann cells, during the 
transition from Schwann cell precursors (E l4) to immature Schwann cells (El 8), and 
during the active phases of myelination (E18-P7-P12). Moreover the comparison 
between P I2 and P12cut (PI2 nerves previously cut at P7) will provide us information 
on the initial stages of Wallerian degeneration, a process during which all myelin- 
related genes are strongly down-regulated.
1069 probes have at least a two-fold change during PNS development or after 
nerve injury
The data obtained from the chip hybridizations, performed in triplicate for each time 
point to minimize the number of false positives and to allow a correct statistical 
analysis, were first analysed with the Affymetrix Suite 5.0 and subsequently loaded 
onto Genespring software. A first restriction by expression percentage was performed, 
to exclude those probes that did not have at least a two fold change (log2>l) between at 
least two of the developmental time points or after nerve cut. 1069 probes, out of the
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more than 8500 present on the U34A chip, passed this first restriction, and were 
considered for further analysis. Importantly, all the known myelin-related genes such as 
protein zero (Po), myelin basic protein (MBP), peripheral myelin protein 22 (PMP22), 
myelin associated glycoprotein (MAG), proteolipid protein (PLP), periaxin, and the 
transcription factors Oct-6 and Krox-20 were detected as changing, as well as many 
genes involved in cholesterol synthesis and in lipid metabolism. This finding, in 
agreement with previous papers on expression profiling in mouse peripheral nerve 
(Nagarajan et al., 2001; Verheijen et al., 2003; Buchstaller et al., 2004), represents a 
valid internal control for our system, since genes encoding for myelin proteins or for 
members of the cholesterol synthesis chain are expected to increase during peripheral 
nerve development and to decrease dramatically after nerve injury (Stoll and Muller, 
1999; Scherer and Salzer; 2001).
Clustering of the 1609 probes
Having performed multiple experiments over a series of time points, it made sense to 
try to group, or cluster, the genes that behaved in a similar way across the experiments. 
In fact, finding genes with similar expression patterns can lead to better understanding 
of the functions of genes. Gene clustering can be achieved using various procedures that 
apply different algorithms. One of the most widely used is hierarchical clustering (Eisen 
et al., 1998). It requires two main steps that are repeated in order to find the genes that 
are most similar. Basically, hierarchical clustering finds the pair of genes that are most 
similar, joins them together, and then identifies the next most similar pair of genes. 
This process continues until all of the genes are joined into one giant cluster (See 
Chapter 2 for details). The same process is applied to generate a tree for the
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experiments. Using Genespring, we performed Hierarchical clustering of the 1609 
probes and, in parallel, the clustering of the 14 experiments (triplicates for E l4, El 8, 
P I2, P12cut, duplicate for P7). This generated the mock-phylogenetic tree (often 
referred to as "dendrogram") shown in Fig 3.2. This kind of clustering provides 
information on the behavior of the genes considered and also on how similar and 
therefore reliable the replicates are.
To investigate further the changes occurring in between two successive time points we 
performed a statistical analysis followed by hierarchical and K-means clustering 
comparing E14 with E l8, E l8 with P I2, and P I2 with P12cut. K-means clustering 
divides genes based on their expression patterns. The goal is to produce groups of genes 
with a high degree of similarity within each group and a low degree of similarity 
between groups. K-means clusters are constructed so that the average behavior in each 
group is distinct from any of the other groups. For example, in a time series experiment 
k-means clustering can be used to identify unique classes of genes that are up-regulated 
or down-regulated in a time dependent manner (See Chapter 2 for more details). 
Moreover, using the Biopendium™ software from Inpharmatica to complement 
publicly available databases, we carried out a rigorous mapping and protein annotation 
of all the probes found to be statistically changed.
130 probes are statistically different between E14 and E l8
To try to elucidate the molecular mechanisms involved in the transition between 
Schwann cell precursors (E l4) and immature Schwann cells (E l8), the 1069 probes 
found to significantly change during nerve development were subjected to an 
ANOVA/Welch's approximate t-test (p<0.05) (not assuming variances are equal). 130
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were found to be statistically changed. Of those, 53 were up-regulated and 77 down- 
regulated.
Hierarchical and K-means clustering of the 130 probes statistically different at 
E14 compared with E18
On this set of 130 probes both hierarchical and K-means clustering were performed, to 
group genes that behaved in a similar way in our experimental conditions. The first 
resulted in the dendrogram shown in Fig 3.3, while K-means clustering, performed with 
the "random starting clusters" option, to allow the software to identify the optimal 
number of different clusters, resulted in 10 different sets (Fig. 3.4). K-means clustering 
can be more effective in time series experiments, to identify unique classes of genes that 
are up-regulated or down-regulated in a time dependent manner. Therefore, we decided 
to refer to the sets deriving from this kind of clustering for our subsequent analysis. 
Interestingly, for the vast majority of the 130 probes, the change in expression level was 
much more dramatic for those that were down-regulated when compared to those that 
were up-regulated. (See in particular set 3, 6 and 9 in Fig 3.4). The list of the 130 
probes, including the p values scored in the ANOV A/Welch’s t-test and the raw and 
normalized level of expression at all the time points analyzed, is provided in Table 3.1.
Mapping of the probe sets
The analysis of the molecular mechanisms involved in the transition between precursors 
and immature Schwann cells was complicated by the fact that 50% (65 out of 130) of 
the probes detected as changing corresponded to ESTs. To try to bypass this obstacle 
and to gather as much information as possible on each gene, we performed a 
comprehensive bioinformatic analysis using the Biopendium™ software from
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Inpharmatica (www.inpharmatica.com). First, an automated probe mapping technology 
was used to identify open reading frames (ORF) for each probe set identified. After 
alignment to the rat genome using the rapid tool BINSEQ, assignments were made 
using, in order of descending confidence, RefSeq, Genebank, ENSEMBL or 
TWINSCAN. The sequences that were not confidently mapped to an ORF yet, were 
examined by eye and hand mapped. In those cases where the rat gene had not been 
identified, the mouse or human orthologues were used for protein annotation, when 
appropriate. This analysis effectively allowed us to reduce the number of unknown 
sequence from the starting 65 (50%), to only 6 (~ 4%) of the total of the differentially 
expressed probes (Table 3.2).
Protein structural and functional annotation
Once the amino acid sequences had been identified, we generated a protein structural 
and functional annotation, using Biopendium™ complemented by publicly available 
databases. Initially, each protein was described using the HGNC gene symbol and, 
when available, Gene Ontology (GO) annotation was obtained from both LocusLink 
and GOA. We also assessed, using SignalP (Nielsen et al., 1997) whether it was likely 
or not for each protein to be secreted and, with TMHMM (Krogh et al., 2001), we 
predicted the number of transmembrane domains. Finally, Domain Professor™ and 
Genome Threader™, both part of the Biopendium™, were used for a complete 
functional and structural annotation of all the proteins identified. The resulting tables 
are added as Supplementary Material in the Appendix.
121
Categorization of the changed genes
The information obtained from this bioinformatic analysis was used to group the 
differentially expressed genes based on the probable biological function (examples are 
given in Tables 3.3.1 and 3.3.2). As shown in Table 3.3.1, among the up-regulated 
genes in the transition from E l4 and E l8, are adhesion molecules such as integrin 
alphal (Itgal) and decorin (Den), a chondroitin sulphate proteoglycan already known to 
be expressed by Schwann cells (Hanemann et al., 1993). Interestingly, a decorin-like 
molecule is up-regulated during mouse sciatic nerve regeneration (Braunewell et al., 
1995a,b), suggesting that decorin may have similar functions during sciatic nerve 
development and regeneration. The transcription factors NF1-X and Cebpd (also 
known as C/EBP-Delta), the latter recently identified as expressed in embryonic 
Schwann cells and in adult sciatic nerves on myelination (Buchstaller et al., 2004; 
Verheijen et al., 2003), are also up-regulated. At E14 they are essentially absent, a 
pattern of expression shared by the cytoplasmic protein alpha-Synuclein (Snca, see 
Chapter 4) and by the actinin associated protein Pdlim3.
Table 3.3.2 shows the categorization of the down-regulated genes. We found that the 
transcription factors Sox-10, Ets-1 and Id3, all known to be expressed in embryonic 
peripheral nerve (Kuhlbrodt et al., 1998; Parkinson et al., 2002; Stewart et al., 1997; 
Thatikunta et al., 1999), were strongly down-regulated. Likewise, the neural adhesion 
molecule LI, crucial for the adhesion of Schwann cells to the axon and for the 
formation of the first Schwann cell loops around the axons that will be myelinated 
(Martini and Schachner, 1986; Wood et al., 1990; reviewed in Martini, 1994) appeared 
to be down-regulated in peripheral nerve during embryonic development. Interestingly, 
we also found that cyclinDl (Ccndl), a gene previously identified as crucially involved 
in Schwann cell proliferation after nerve injury (Kim et al, 2000), was strongly down-
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regulated during the precursor to Schwann cell transition.
CRMP-1 and CRMP-3 are down-regulated during embryonic nerve development
Among the down-regulated genes, the cytoplasmic related proteins CRMPs and agrin 
intrigued us. Two members of the CRMP family, CRMP-1 and -3, thought to be 
expressed mainly by neurons, and involved in neuronal plasticity in response to 
semaphorin signals (Wang and Strittmatter, 1996; Rosslenbroich et a l, 2003), were 
strongly down-regulated. To confirm our finding, semi-quantitative RT-PCRs were 
performed on mRNA extracted from E14 and El 8 nerves. For both CRMP-1 and 
CRMP-3 a band of the expected size is clearly present at El 4 and is strongly decreased 
at E l8 (Fig. 3.5), suggesting that CRMPs are expressed by Schwann cell precursors and 
are down-regulated during the transition to immature Schwann cells.
Rat agrin is expressed in embryonic and perinatal peripheral nerve
It was also surprising to find that agrin (Agm), a molecule known to be of crucial 
importance for acethylcholine receptor clustering at the neuromuscular junction (NMJ) 
(reviewed in Bezakova and Ruegg, 2003), was strongly expressed by Schwann cell 
precursors. Again, to confirm the results of the microarray hybridizations, we performed 
a semi-quantitative RT-PCR, with primers specific for the neural form of agrin, which 
showed a clear band at E14 and a very reduced one by E l8 (Fig. 3.5). To investigate 
agrin expression further, we immunolabelled a series of nerves/cultures with an 
antibody that recognises all the active forms of agrin. Figure 3.6 shows that agrin 
protein appears to be already expressed in the migrating neural crest, the cell population
123
from which Schwann cells originate, and it is subsequently highly expressed by 
Schwann cell precursors. In newborn rat Schwann cell cultures, agrin protein expression 
was substantially lower than in precursors, and was restricted to Schwann cells, with no 
staining detectable in fibroblasts or other cell types, as confirmed by similar staining 
performed with antibody to the Schwann cell specific protein SlOOp (Fig 3.7). Thus, 
agrin could be used as a Schwann cell marker in dissociated cultures from perinatal 
nerves. Little or no staining was detectable in teased nerve preparations from adult rats, 
in agreement with the array results.
378 probes are statistically different between E18 and P12
As myelination takes place, myelin proteins and genes involved in lipid synthesis are 
strongly up-regulated. When axonal contact is lost, the Schwann cells de-differentiate 
and the myelin related genes are down regulated. We took advantage of this 
characteristic, and focussed our attention on those genes that were up regulated between 
E l8 and P I2, and also down-regulated at P I2 after nerve cut at P7.
To evaluate how many of the 1609 probes found to have at least a two fold change in 
our experimental conditions were statistically different between E l8 and P I2 sciatic 
nerves, we performed, with GeneSpring, an ANOVA/Welch's t-test (p<0.05, not 
assuming variances are equal). 378 probes resulted to be significantly changed. Of 
these, 361 were up-regulated, while only 17 were down-regulated.
Clustering of the 378 probes
As we have seen previously, clustering is a fast way to group genes based on similar 
expression profiles. Following a similarprocedure to that used in the first comparison
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(E l4 compared with E l8), we used GeneSpring to cluster the 378 probes that were 
statistically different between E l8 and P I2. Hierarchical clustering resulted in the 
dendrogram in Fig 4.8, while K-means clustering yielded 15 clusters as the optimal 
representation possible (Fig. 4.9).
237 probes are statistically different between PI2 and P12cut
To determine how many of the 1609 probes were significantly changed between P I2 
sciatic nerves and P I2 nerves cut five days previously (P12cut) the statistical test used 
in the previous conditions (Anova/Welch's t-test, p<0.05), was again applied. 237 
probes were differentially expressed; 162 were down-regulated, while 75 were up- 
regulated. Interestingly, the majority of the down-regulated probes (110 out of 162, see 
Table 3.4) were among the 361 that showed a significant increase in expression levels 
between E l8 and P I2. This once more emphasises the importance of axon-Schwann 
cell contact during myelination in peripheral nerve, and strongly points to those 110 
probes as myelin-related.
Clustering of the 237 probes
Hierarchical clustering of the 237 probes differentially expressed between P I2 and 
P12cut sciatic nerves resulted in the dendrogram in Fig 3.10. K-means clustering 
yielded 13 different sets as optimal representation, according to the GeneSpring 
software (Fig. 3.11).
Mapping of the 237 probes
As we found when comparing E14 and E l8 nerves, the number of ESTs present in this 
second comparison (96 out of 237 probes) was very high. Therefore, we carried out a
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bioinformatic analysis identical to the one performed for the embryonic comparison in 
order to map and annotate to proteins as many differentially expressed probes as 
possible. In the following paragraph this analysis will be illustrated for a particular 
probe, the EST AI639533.
Mapping and annotation of the rat ETS AI639533
The EST AI639533 was included in set 14 (Fig 3.11), alongside the myelin-related 
genes PLP, periaxin, Krox-20 and 3-hydroxy-3-methilglutaryl-CoA-synthase-l 
(HMGCS1), and was among the 110 probes up-regulated between E l8 and P I2 and 
down-regulated after nerve cut, strongly suggesting that it may play a fundamental role 
in myelination. Applying the bioinformatic analysis described previously, we were able 
to map this EST to the 3’UTR of a novel rat gene representing the orthologue of the 
mouse cDNA AK030342, which encodes the un-characterised protein BAC26192 (Fig 
3.12A). Using the mouse orthologue as a seed for the GENEWISE algorithim (Bimey et 
al., 2004), we were able to re-predict a rat open reading frame of 500 amino acids which 
shares 90% identity over the full length of the mouse orthologue and 79% identity over 
the full length of the human un-characterised protein AAH31099 (Fig 3.12B). The use 
of Biopendium™ GenomeThreader™ structural alignment tool allowed us to identify 
in BAC26192 a relationship with bacterial phospholipase D/nuclease structures (Fig 
3.12C). The consenus sequence SxK(x)4 D(x)6 GSxS, highly similar to the consensus 
HxK(x)4 D(x)6GSxN that defines phospholipase D/nuclease activity, is present, 
suggesting a similar function for the protein BAC26192 (Fig 3.12D). An identical result 
was found when threading the rat prediction. The EST AI639533 may therefore 
represent a phospholipase D with a role in myelination, although this awaits
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confirmation. A similar analysis was performed for all the other unmapped ESTs (See 
Supplementary Material, Appendix).
Categorisation of the differentially expressed genes
The bioinformatic analysis reduced the number of unknown sequences from the original 
96 (40.5%) to only 4 (1.7%) of the total of differentially expressed probes (Table 3.5). 
This, of course, was of invaluable help in the categorisation of the genes based on the 
probable biological function. As expected, among the up-regulated genes (Table 3.6.1) 
we found molecules involved in the inflammatory response, such as members of the 
major histocompatibility complex (MHC) and the C4 complement protein, known to be 
activated after peripheral nerve injury (Bonnard et al., 1997). We also identified 
molecules that are known to be involved in Schwann cell de-differentiation and 
proliferation, like the transcription factor c-Jun (De Felipe and Hunt, 1994; Stewart, 
1995; Shy et al., 1996; Parkinson et al., 2004), and others involved in nerve 
regeneration, such as the extracellular matrix protein tenascin (Tnn) (Martini et al., 
1990; Kieman et a l , 1999), which is important in creating a permissive environment for 
axonal regrowth.
Among the genes that were down regulated after nerve cut (Table 3.6.2), and also up- 
regulated between E l8 and P I2, there were many implicated in myelin synthesis and 
maintenance, whether because they are responsible for the expression of myelin 
constituents or because implicated in lipid metabolism. Here it should be noted that Po 
and MBP, although detected among the 1609 differentially expressed probes, did not 
make it through the statistical t-test for the P I2 versus P12cut comparison. This was due 
to the massive mRNA expression at P I2 of these two genes, which caused a saturation 
of the mismatch probes in the first hybridisation performed. The problem, imputable to
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scanner settings, was subsequently solved, but resulted in the two genes being too 
variable among the experiments to pass the t-test. Since these were the only two genes 
for which this occurred, we did not consider it necessary to repeat the experiment.
Semi-quantitative RT-PCR experiments confirmed the hybridisation results
In addition to genes that showed anticipated changes in expression levels, a 
considerable number of unexpected genes were found to be up-regulated during 
myelination and down-regulated in cut P I2 sciatic nerves. A selection of these genes 
(chosen based on the high level of expression and on the massive fold-change), 
including known genes and annotated ESTs, was subjected to semi-quantitative RT- 
PCR analysis, to confirm the hybridisation results. Gapdh, a housekeeping gene that 
does not vary in the different experimental conditions, was used as internal control, and 
the myelin-related protein periaxin as positive control (Parkinson et al., 2003) (Fig 
3.13A and 3.13B). In every case considered the RT-PCR results obtained were in 
agreement with the array data. Further analysis of these genes is reported in the sections 
below.
Snca, ChM-1 and PEA-15 are enriched in myelinating Schwann cells
To verify whether any of the selected genes shown in Figure 3.13, was specific for 
myelinating Schwann cells, we performed semi-quantitative RT-PCR experiments on 
mRNA extracted from P3 rat Schwann cells that had been FACS sorted using 
antibodies against galactocerebroside (GalC), which, a this stage of development, is 
specific for myelinating Schwann cells (Mirsky et al, 1980; Jessen et al., 1985). The 
confinement of periaxin expression to the GalC+ cell population confirmed the validity
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of this approach (Fig 3.14). Although all of the genes examined here were up-regulated 
between E l8 and P12 and down-regulated after nerve cut and therefore behaved like 
myelin-related genes (above), these experiments showed that, at this early 
developmental stage, most of them were equally expressed in both cell types. Three of 
them however, were clearly enriched in myelinating Schwann cells, namely the 
cytoplasmic protein aSynuclein (Snca), the cartilage related protein Chondromodulin-1 
(ChM-1, Lect-1) and a phosphoprotein enriched in astrocytes, 15-kd (PEA 15, annotated 
with Biopendium™ from the EST AA894345) (Fig 3.14).
Some of the genes down-regulated after nerve cut are induced by dbcAMP
It is well known that activation of cAMP pathways can, under certain conditions, 
partially mimic the initial steps of myelination, inducing the expression of genes like Po 
and periaxin (Monuki et al., 1989; Morgan et al, 1991; reviewed in Jessen and Mirsky, 
1991; 2004). We therefore tested the cAMP responsiveness of the genes examined in 
Fig. 13, including the three that were enriched in myelinating Schwann cells at P3. The 
periaxin gene was used as positive control (Parkinson et a l , 2003). In spite of the 
apparent axonal dependence of all these genes in vivo (Fig 3.13), only 5 of them, 
namely Collagen type II, Snca, ChM-1, PEA15 and the EST H33246 (mapped with 
Biopendium to a famesyl-diphosphate-famesyl-transferase-1), were clearly elevated 
following exposure of cultured Schwann cells to dbcAMP (Fig 3.15) (see Chapter 4 for 
further comments).
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DISCUSSION
Typically, expression profiling experiments reveal a high number of differentially 
expressed sequences that are either unknown or only weakly similar to ESTs. Often, 
this significantly limits the information that can be extracted from an experiment. 
Therefore, we combined the use of microarray based gene expression profiling with a 
refined bioinformatic analysis performed with the Biopendium™ software, to identify 
genes potentially involved in embryonic Schwann cell development and myelination. 
The Biopendium™ allowed us to considerably reduce the number of unknown 
sequences, and so to have a clearer view of the biological events taking place. 
Combining publicly available sources and the Biopendium™ it was possible to map the 
large majority of the ESTs identified in the screening studies and to provide a 
comprehensive biological annotation for the sequences identified.
In the present experiments in fact, 65 out of 130 differentially expressed probes in the 
first comparison (E l4 compared with E l8), and 96 out of 237 in the second (P I2 
compared with P I2 cut) were ESTs. Our approach allowed us to reduce the number of 
unmapped sequences to only 6 and 4 respectively, enabling us to better categorise the 
genes based on the biological function.
Genes regulated in the embryonic transition from Schwann cell precursors to 
immature Schwann cells
The number of repressed and induced genes in the transitional phase from Schwann cell 
precursor to immature Schwann cell was comparable (77 down-regulated, 53 up- 
regulated). It was however intriguing that the number of genes that were strongly
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suppressed in this transition was much larger than the number of those strongly induced. 
Thus, all of the 53 up-regulated genes showed only a moderate change in their 
expression levels, comparable to that shown by many of the down-regulated genes. A 
group of the down-regulated genes, however, showed a substantially greater degree of 
change in expression levels (set 3,6 and 9 in Fig 3.4 and Supplementary Material). It is 
possible that some of the extensive gene suppression at the El 4/E 18 transition is related 
to the narrowing of developmental options that characterises the transition form 
Schwann cell precursors to immature Schwann cells. E l4 Schwann cell precursors are 
highly motile cells that interact intimately with axons rather than with the extracellular 
matrix and many, perhaps most, of these cells retain some developmental plasticity, and 
can experimentally be diverted to other crest derived lineages. Immature Schwann cells, 
on the other hand, are less motile, anchored to the extracellular matrix and harder to 
divert to form other cell types (Sherman et al. 1993, Jessen and Mirsky, 1999; 2004; 
Morrison et al., 1999; Paratore et al., 2002).
Down-regulated genes
The categorisation of the down-regulated genes, based on their biological function, 
showed that at least three transcription factors, Sox-10, Ets-1 and Id3, already known to 
be expressed in embryonic nerve (Kuhlbrodt et al., 1998; Parkinson et al., 2002; 
Stewart et al., 1997; Thatikunta et a l, 1999), were repressed during the transition to 
immature Schwann cells.
As already discussed in the general introduction, Sox-10 is crucial for peripheral glia 
specification and development (Britsch et al., 2001). Our results confirm the general 
idea that Sox-10, although present throughout the Schwann cell lineage is expressed at
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much lower level after birth than in the embryo (Lange and Jessen, unpublished 
observation).
Previous observations had indicated that Id3 (and Idl) is expressed in embryonic nerve, 
down-regulated around the peak of myelination, and induced after nerve injury (Stewart 
et al., 1997). Moreover, Id3 can inhibit the expression of myelin genes (Stewart et al., 
1997; Thatikunta et al., 1999). Our data, showing that Id3 is already strongly down- 
regulated in immature Schwann cells, represent the first indication of a regulation of Ids 
transcription factors in embryonic nerve, and suggest that their suppression could be 
involved in the precursor to Schwann cell transition.
Several Ets transcription factors are known to be expressed by Schwann cells (Parkinsin 
et al., 2002), and their activity modulates the expression of neuregulin. It is therefore 
possible that Ets-1 down-regulation reflects the decreased dependency of immature 
Schwann cell on neuregulin for survival.
A number of receptors/signalling molecules are also down-regulated during the 
transition towards immature Schwann cells. Among them is the EST AA800790 that we 
mapped with Biopendium to the endothelin receptor type B. Endothelins (ETs) play a 
crucial role in the timing of the transition from precursors to Schwann cell (Brennan et 
al., 2000). In rats with a non-functional type B receptor Schwann cell generation is 
ahead of schedule, and various in vitro experiments indicated that endothelins act as a 
brake on the embryonic transition from precursors to Schwann cells (Brennan et al., 
2000). Consequently, it looks possible that endothelin receptor down-regulation is one 
of the mechanisms involved in the generation of immature Schwann cells. It is 
interesting to notice that recent work has suggested that, in the enteric nervous system, 
Sox-10 may directly regulate the spatio-temporal expression of the endothelin receptor 
B gene via binding to a specific enhancer (Zhu et al., 2004). Therefore there may be a
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direct correlation between the parallel embryonic down-regulation of these two genes 
observed in our microarray analysis.
Among the down-regulated genes, the ones related to the cytoskeleton showed the 
strongest downregulation. While the neurofilament protein NF-M was known to be 
transiently expressed in Schwann cells (Kelly et al., 1992; Fabrizi et al., 1997), the 
identification of CRMP family members and agrin was rather surprising. The CRMP 
(ULIP/DRP) family consists of at least five phosphoproteins, homologous to the C. 
elegans protein Unc-33, which are essential for growth cone collapse in response to 
semaphorin 3A signals (Wang and Strittmatter, 1996). They have been linked to other 
cellular events such as differentiation, apoptosis/proliferation and migration (reviewed 
in Charrier et al., 2003). Recently CRMPs have also been involved in neurite extension 
in response to signals from neurotrophins in DRG sensory neurons (Quach et al., 2004). 
Interestingly, a member of the family, Ulipl/CRMP4, has been identified as suppressed 
by the cAMP activator forskolin in cultured Schwann cells (Bermingham et al., 2001), 
in agreement with our array results that indicate these genes as strongly down-regulated 
during myelination. CRMPs may be involved in Schwann precursor cytoskeletal 
reorganization and possibly in their migration along the outgrowing axon, being then 
downregulated once the cell has reached a more stationary phase.
Agrin is an heparan sulfate proteoglycan initially isolated from the basal lamina of the 
neuro-muscular junction (NMJ) in Torpedo californica (Nitkin et al., 1987), and it is the 
nerve derived factor responsible for the assembly of the post-synaptic apparatus in vivo 
(reviewed in Hoch, 1999). Agrin deficient mice die around E l8 and show profoundly 
impaired post-synaptic differentiation (Gautam et al., 1996). More recently agrin roles 
in other contexts, such as the "immunological synapse" and cytoskeletal actin 
reorganisation have been elucidated (Khan et al., 2001; reviewed in Bezakova and
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Ruegg., 2003; Finn et al., 2003). It is also interesting that agrin and neuregulin-1 co- 
localise and have a synergistic effect on acetylcholine receptor expression in muscle (Li 
et al., 2004). In muscle, and other tissues, agrin binds to a-dystroglycan and laminins 
(O'Toole et al., 1996; Sugiyama et al., 1994; Matsumura et al., 1997), and an agrin 
"minigene" has been used to rescue dystrophic mice, through the stabilisation of the 
complex formed by a-dystroglycan and laminin a5 (Moll et al., 2001). Agrin has been 
previously detected in developing and adult Schwann cells in chick and frog, where its 
role has been related to acetycholine receptor clustering and synapse formation (Ma et 
a l., 1994; Yang et al., 2001). Our results, showing that agrin is present in the rat 
Schwann cell lineage as early as E l l ,  that its expression peaks in Schwann cell 
precursors while it is subsequently down-regulated, suggest an alternative function. 
Since agrin has been implicated in the control of the actin cytoskeleton and of a number 
cytoskeletal proteins in skeletal muscle (Bezakova and Lomo, 2001), it is possible that 
agrin has a similar role in Schwann cell development. This is also supported by the high 
expression of agrin in Schwann cell precursors that are much more motile than 
immature Schwann cells (Jessen et al., 1994). Alternatively, agrin could interact with 
dystroglycan and laminin complexes on the Schwann cell surface and have a role in 
their stabilization of the initial interaction between axons and glia, although the strong 
down-regulation of agrin observed after birth and in adult mice seems to be against this 
hypothesis.
Up-regulated genes
Among the up-regulated genes we found that the extracellular matrix protein decorin 
(Den) was strongly induced (see table 3.3.1). Decorin expression has been already 
documented in Schwann cells (Hanemann et al., 1993), and decorin-like molecules are
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up-regulated in regenerating peripheral nerve (Braunewell et al., 1995a,b). Taken 
together with our data, these findings suggest a role for decorin in both peripheral nerve 
development and regeneration.
Integrin a l  also appears to be up-regulated at the mRNA level in this transition. 
Integrin a l  is known to be expressed in the chick neural crest but is not expressed in 
Schwann cell precursors (Stewart et al., 1997). In adult nerve it is restricted to non­
myelinating Schwann cells (reviewed in Previtali et al., 2001). It is possible that the up- 
regulation that we observed represents integrin a l  expression by cells that will be 
destined to become non-myelinating ones.
Two transcription factors, Cebpd (Cebp/Delta, CELF, CRP3) and NF1-X are switched 
on, although at low levels, in the transition from precursors to Schwann cells. Cebpd 
has been previously detected as increasing in embryonic Schwann cells compared with 
neural crest cells (Buchstaller et al., 2004) and in mouse peripheral nerve during 
myelination (Verheijen et al., 2003). Depending on the cell type and physiological 
conditions, Cebpd has been shown to act on cell proliferation, differentiation and 
apoptosis (Darlington et al., 1998; Menard et al., 2002). Recent in vitro work has 
demonstrated that, in a melanoma cell line and in dissociated DRG cells, Cebpd can 
induce myelin gene expression and suppress the expression of GFAP and Pax-3 
(Kamaraju et al., 2004). Taken together these data suggest a role for Cebpd in the onset 
of myelination.
NF1-X belongs to the nuclear factor 1 (NF1) family of transcription factors, which are 
widely expressed in various tissues and regulate the transcription of many genes 
(Paonessa et al., 1988; Roulet et al., 1995). NF1-X binds with high affinity to the 
regulatory region of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (Osada et
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al., 1999), a gene involved in cholesterol metabolism, and could therefore be involved 
in cholesterol synthesis during myelination.
Overall, it was somehow surprising not to find any myelin-related gene as induced in 
immature Schwann cells. A more careful analysis of the raw data revealed that most of 
them (Po, MBP, periaxin, Krox-20 and Oct-6 among the others) were absent at E l4 and 
present at E l8 (based on the “call” with Affymetrix Suite 5.0; data available upon 
request in the MEditor database, ICH, London). However, the levels of expression at 
El 8 were low for all of them, and this caused their exclusion after the statistical test 
(p<0.05).
Genes regulated during myelination and after nerve injury
The genes that are directly involved in myelination are massively up-regulated in 
Schwann cells during the first three weeks after birth (reviewed in Jessen and Mirsky, 
2002, 2004; Garbay et al., 2000). Following nerve damage, in a process known as 
Wallerian degeneration, the Schwann cells in the distal stump de-differentiate, 
proliferate and strongly down-regulate all the myelin-related genes (reviewed in Muller 
and Stoll, 1998; Scherer and Salzer, 2001). In our experimental conditions we found 
that 378 genes were differentially regulated between E l8 and P I2. The vast majority of 
them (361) was up-regulated, and only 17 were down-regulated.
Genes down-regulated between E18 and P12
Among the down-regulated ones we found the neurofilament middle chain (NF-M), that 
we already found down-regulated between E l4 and E l8, and the calcium dependent 
adhesion molecule N-cadherin. The expression of N-cadherin has previously been
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shown to be sharply down-regulated in vivo at the precursors to Schwann cell transition, 
and it appears to mediate adhesion between Schwann cells (K.R. Jessen, personal 
communication; Wanner and Wood, 2002).
The mRNA for cyclin E was also found as suppressed between E l8 and P12. The 
down-regulation of genes involved in cell cycle is in agreement with the observation 
that while immature Schwann cells are actively proliferating, myelinating Schwann 
cells are quiescent (reviewed in Jessen and Mirsky, 2004). Various cell cycle related 
genes have been detected as down-regulated between E l7 and P0 in expression 
profiling experiments in mouse (Verheijen et al., 2003). Moreover, cyclin E has been 
indicated as the major down-stream target of cyclin D1 (Geng et al., 1999), that we 
found down-regulated in the transition from E14 to E l8, suggesting a possible cascade 
of event involved in blocking Schwann cell proliferation prior the onset of myelination. 
However it is important to notice that cyclin D1 is not r e q u ire d  for Schwann cell 
proliferation during development (Kim et al., 2000).
Genes up-regulated between E18 and P12 and down-regulated after nerve cut
237 genes were statistically changed after nerve cut. 162 of them were down-regulated 
and 175 were up-regulated. Importantly, 110 out of the 162 genes/ESTs down-regulated 
after nerve cut, were also induced during the active phases of myelination, a 
combination that strongly indicates that they are myelin related.
As expected, in this category we found numerous genes already known to be involved 
in myelin synthesis, including the transcription factors Oct6 and Krox20, the myelin 
proteins PLP, MAG, periaxin , plasmolipin and MAL, as well as many genes related to 
cholesterol and lipid metabolism.
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Previous studies had indicated that the expression of the transcription factor Oct6 peaks 
around birth and is subsequently rapidly down-regulated (Monuki et al, 1990, Scherer 
et al, 1994, Arroyo et al., 1998). Moreover, nerve cut in adult nerve induces a transient 
up-regulation of Oct-6 around two days after injury (Monuki et al., 1990, Scherer et al., 
1994). If the sciatic nerve is cut at PI, Oct-6 expression is instead sharply down- 
regulated (Scherer et al., 1994). Somehow surprisingly, we found that Oct-6 is strongly 
expressed at least until P I2, and according to the hybridisation's result, its expression is 
actually stronger at P7 and P I2 than not at E l8 (see Table 1), in agreement with 
previous work showing that Oct-6 immunoreactivity is present in Schwann cells at P I2 
(Blanchard et al., 1996). In our conditions, Oct-6 is down-regulated even when the 
injury is performed at P7, indicating that Oct-6 expression may need to remain 
sustained during myelination.
Perhaps even more surprising was the finding that Sox-10 is down-regulated after cut of 
myelinating nerves. As expected we found that Sox-10 expression is down-regulated 
from E l4 to E l8 (above) and from E l8 to P I2, but our result also indicate that the 
mRNA levels for Sox-10 remain sustained during myelination and are suppressed by 
loss of axonal contact. These findings are in agreements with previous observation 
indicating that Sox-10 binds Po and Cx32 promoters and could therefore be implicated 
in the transcriptional control of at least these two proteins in peripheral myelin (Peirano 
et al., 2000; Bondurand et al., 2001).
The use of Biopendium allowed us to map and annotate to proteins most of the ESTs 
that we found statistically changed between P I2 and P I2 cut. Two of them were 
particularly interesting, the ESTs AA639533 and AA894345.
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The EST AA639533 clustered, in the K-means clustering, with the myelin-related genes 
PLP, periaxin, Krox-20 and HMGCS1 (see Fig. 3.4 and Supplemental Material), 
indicating a possible role in myelination for this gene. Biopendium annotated this EST 
to an uncharacterized mouse protein that shares structural homology with bacterial 
phospholipase D. It is therefore possible that this novel protein has a phospholipase-like 
function during myelination. Phospholipase D catalyses the hydrolysis of 
phosphatidylcholine to phosphatidic acid and choline in response to various signals, 
including neurotrasmitters, hormones and growth factors (Exton, 1997). Phosphatidic 
acid is then broken down into two second messengers, diacylglycerol and 
lysophosphatidic acid (LPA). LPA, a normal constituent of serum, has various effects 
on Schwann cells, including survival, actin cytoskeleton reorganisation and myelin 
genes synthesis (Li et al., 2003). It is therefore possible that this new phosholipase D is 
involved in some of these complex events.
The EST AA894345 clustered alongside numerous genes involved in lipid metabolism. 
Semiquantitative RT-PCR experiments confirmed its regulation after nerve cut and 
suggested that the gene product is enriched in myelinating Schwann cells and up- 
regulated after db-cAMP treatment of cultured Schwann cells with cAMP, a series of 
findings that strongly point to this gene as myelin-related. Biopendium mapped the EST 
AA894345 to the gene encoding for a phosphoprotein enriched in astrocytes of 15kDa 
(PEA 15). PEA 15 was initially identified as a target of protein kinase C in astrocytes 
(Araujo et al., 1993). It is also called PED, for phosphoprotein enriched in diabetes. In 
fact it has been found to be up-regulated at both the mRNA and protein levels in various 
tissues, including adipose tissue and skeletal muscle, in patients with type II diabetes 
mellitus (Condorelli et al., 1998). It should be noticed that more than 30% of patients 
with type II diabetes mellitus develop also a peripheral neuropathy. This observation,
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taken together with our data that indicate that PEA 15 is highly expressed in myelinating 
Schwann cells make PEA 15 an interesting candidate for further studies in this field. It 
has also been shown that PEA15 could have a role in controlling cell proliferation by 
preventing ERK localisation in the nucleus (Formstecher et al., 2001). In fact, genetic 
deletion of PEA 15 leads to increased ERK nuclear localisation and c-Fos induced 
proliferation. Therefore PEA 15 could be part of the mechanisms that control Schwann 
cell proliferation. Finally, the generation of PEA15 null mice has demonstrated that this 
protein can also protect astrocytes from tumor necrosis factor (TNF)a induced death in 
vitro (Kitsberg et al., 1999). TN Fa, in combination with TGF{3, can also induce 
Schwann cell death in vitro. It would be interesting to investigate whether PEA 15 has a 
similar protective role in Schwann cells too.
The presence among the 110 genes of novel genes known to be related to cartilage/bone 
synthesis and maintenance or to cytoskeletal reorganization suggests that they may also 
have a role in peripheral nerve development and myelination. This group of genes will 
be analysed further in chapter 4.
Genes up-regulated after nerve cut
Although the identification of genes up-regulated during nerve degeneration was not 
one of our goal, a brief analysis of this group of genes was carried on, to validate, based 
on the existing literature, our general approach.
The injured nerve is quickly invaded by myelomonocytic cells, in particular 
macrophages, that are important in mediate demyelination and influence Schwann cell 
proliferation and successive remyelination (reviewed in Kiefer et al., 2001). The 
principal role of macrophages is to phagocytose and degrade myelin debris (Stoll et al., 
1989; Perry et al., 1987). It appears that Schwann cells themselves are able to degrade
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myelin, but to do so they require the presence of macrophages (reviewed in Fu and 
Gordon, 1997). Therefore, it was not surprising to find, among the up-regulated genes, 
molecules involved in the inflammatory response, such as at least two members of the 
major histocompatibility complex (MHC), also detected as induced after nerve injury in 
adult mice (Araki et al., 2001). We also identified other molecules involved in the 
immune response such as the leukocyte common antigen and |3 2-microglobulin. 
Moreover, we identified the C4 complement protein, which is known to be activated 
after peripheral nerve injury (Bonnard et al., 1997).
In agreement with the literature, we also identified molecules that are known to be 
involved in Schwann cell de-differentiation and proliferation, like the growth associated 
protein 43 (Gap-43), NGFR, the IL-6R and the transcription factor c-Jun (Hall et al., 
1992; Heumann et al., 1997; De Felipe and Hunt, 1994; Stewart, 1995; Shy et al., 1996; 
Parkinson et al., 2004; reviewed in Scherer and Salzer, 2001).
Similarly to previous work on gene profiling of injured nerve (Kubo et al., 2002; Araki 
et al., 2001), we detected various molecules involved in protein metabolism as up- 
regulated. Among them were the cathepsins L and S (Kubo et al., 2002), the matrix- 
metalloprotease Mmpl2 and kallikrein, a trypsin-like serine protease.
We also identified the extracellular matrix protein tenascin (Tnn), which is important in 
creating a permissive environment for axonal regrowth (Martini et al., 1990; Kieman et 
al., 1999). However, we did not identify any of the other adhesion molecules or 
extracellular matrix molecules known to be involved in the process of regeneration, 
such as LI, N-Cam, N-cadherins, laminin-2, spondin, P200, fibronectin or collagens 
(reviewed in Scherer and Salzer, 2001).
There are two possible explanations for this. The first is a technical one: not all of these 
genes are present on the rat U34 microarray (for example, P200 and laminin-2 are not
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present) and therefore for some of them the detection is not possible. The second 
possible explanation is that since we have harvested the nerves only five days after 
nerve cut, many of the genes involved in regeneration are not yet expressed at sufficient 
high levels to be detected as increased.
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Figure 3.1. Standard gene expression profiling assay. The basic concept behind the 
use of GeneChip arrays for gene expression is simple: labelled cRNA targets derived 
from the mRNA of an experimental sample are hybridized to nucleic acid probes 
attached to the solid support. By monitoring the amount of label associated with each 
DNA location, it is possible to infer the abundance of each mRNA species represented. 
Although hybridization has been used for decades to detect and quantify nucleic acids, 
the combination of the miniaturization of the technology and the large and growing 
amounts of sequence information, have enormously expanded the scale at which gene 
expression can be studied. (Adapted from Affymetrix GeneChip Technical Manual).
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Figure 3.2. Hierarchical clustering, performed with GeneSpring, of the 1609 
probes shown to have at least a two fold change at some point in our experimental 
conditions. The genes are connected iteratively, based on their similarity. The genes 
with similar expression patterns are grouped together and are connected by a series of 
branches (clustering tree, on top). With the same method, experiments with similar 
expression profiles are also grouped together (horizontal bars). The length of each 
horizontal bar tells how similar the replicates are. Colors: red, high level of expression; 
yellow, moderate level of expression; blu, low level of expression.
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Figure 3.3. Hierarchical clustering of the 130 probes statistically different between 
E14 and E18. Note the presence of two distinct groups of genes at E14, one with high 
level of expression (red group, on the upper left side) and one with low level of 
expression (blue group, upper right side). The genes with the highest level of expression 
are then massively down-regulated and remain very low in the following time points 
considered. One the other hand, the genes with low level of expression are only mildly 
up-regulated at E l8 but then their expression gradually increases, reaching the peak at 
P12. Most of them are then down-regulated following nerve injury. The substantial 
absence of horizontal bars in between the replicates for E l4 and E l8 indicates that the 
results from the replicates are very consistent.
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Table 3.1 LIST OF THE 130 PROBES DIFFERENTIALLY EXPRESSED BETWEEN E14 AND E18
Oentoaafc mccmmkm r n i t w F  v H w  E 14m C 1* E14 levels E18 wqnmkmlevels F7 e g r e s s io n la v a * M 2  s ip r is s ln n  levels M 2  c u t ao^raaatan  levels Cm m i m P s e c r lp t la a
A nova^W elch  t - t e s t  ( o < 0 . Normalised Saw Normah/ed Rjm Normah/ed Raw Normafc/ad I4aw Norrrwh/ad Raw
A A 891588 0 .0 5 4 .3 6 8 4 0 4 2 1 2 .9 0 0 0 1 1 .6 1 8 6 2 7 9 8 6 .6 0 .7 5 4 4 5 1 4 4 5 0 .7 2 8 7 4 9 3 3 2 0 7 .3 3 3 3 4 0 .9 1 0 6 1 9 2 2 2 5 .8 3 3 3 1 r c _ A A 8 9 lS 8 8  E S T 1 9 5 3 9 1  R a ttu s  n o rv e g ic u s  cONA
L I0 6 4 0 0 .0 4 9 4 7 .4 7 8 4 1 1 2 7 .3 3 3 3 3 6 1 .0 7 4 5 6 7 8 2 1 .3 6 6 6 6 7 0 .5 8 2 1 5 5 3 5 1 2 .3 5 0 .8 0 8 9 6 2 1 0 1 .9 3 3 3 3 4 1 .1 8 3 2 5 8 9 1 5 1 .S 6 6 6 7  A ctR lIB L 1 0 6 4 0  RATATCR116 R a t a c tiv in  ty p e  IIB  r e c e p to r  (A ctR lIB )
X S 2 8 1 5 0 .0 4 8 6 1 .9 6 9 3 7 7 5 3 4 5 7 .5 3 3 4 0 .8 9 3 1 0 3 9 1 7 0 4 .5 0 .4 5 0 3 7 7 3 9 3 8 .3 5 1 .1 7 4 5 6 2 1 1 6 1 6 .7 3 2 0 .6 0 0 2 6 1 7 8 7 7 0 .5 X 5 2 8 l5 c d s  RRGAMACT m R N A  f o r  c y to p la s m ic -g a m m a  iso fo rm  o f  a c tin
A A 8 9 3 6 1 8 0 .0 4 7 3 0 .4 0 9 1 2 6 7 1 1 .3 6 6 6 6 7 0 .9 2 0 6 0 7 8 3 5 .6 3 3 3 3 0 .6 7 0 6 5 8 7 2 3 .2 5 3 .0 6 0 9 6 9 4 5 7 9 .1 3 3 3 2 .1 4 1 7 5 8 7 5 4 4 .3 0 0 0 5  C rt rc > 4 8 9 3 6 1 8  E S T 1 9 7 4 2 1  R a ttu s  n o r v e g ic u s  cONA
A A B 00549 0 .0 4 7 0 8 0 .1 2 4 2 1 5 4 3 .6 6 6 6 6 6 7 0 .3 8 9 3 1 1 0 2 1 4 .9 5 .4 1 7 5 3 0 5 1 8 0 .1 5 7 .3 7 5 8 3 7 3 1 0 3 1 .6 3 3 3 1 .4 4 1 7 5 3 1 2 0 4 .5 9 9 9 9 rc_ A A 8 0 0 5 4 9  E S T 1 9 0 0 4 6  R a ttu s  n o r v e g ic u s  cDNA
A A 875288 0 .0 4 6 9 5 0 .3 9 3 4 2 8 6 8 2 6 .1 3 3 3 3 3 0 .7 7 6 4 8 0 3 6 9 .2 6 6 6 6 1 .2 3 1 9 7 6 3 1 0 0 .1 1 .8 1 7 7 6 9 8 6 8 3 1 .0 8 5 3 9 0 9 5 0 7 .4 3 3 3 5 rc_A A 87 5 2 8 8  U l-R -E O -< * -d -l0 -O -U !.s l R a ttu s  n o rv e g ic u s  cONA
A I6 3 9 0 4 5 0 .0 4 6 2 1 2 .0 8 0 7 8 7 4 1 7 3 .4 0 0 0 1 0 .8 1 2 5 9 0 6 6 8 0 .1 6 6 6 6 4 0 .6 5 7 3 2 8 6 6 8 .1 1 .0 9 6 7 4 8 7 4 4 2 .5 6 6 6 8 1 .0 3 2 5 2 1 7 5 5 4 .6 6 6 7 R a t m tx e d 'b s e u e  lib ra ry  R a ttu s  n o rv e g ic u s  cONA d o n e  rx 0 0 5 8 6
A A 800315 0 .0 4 5 8 7 2 .6 0 6 6 6 8 5 7 8 .3 6 6 6 6 0 .8 2 8 6 9 7 3 0 .4 3 3 3 3 2 0 .5 6 3 5 3 6 6 4 2 0 .5 5 1 .2 6 1 0 3 5 1 2 0 6 .6 6 6 6 9 0 .7 7 1 8 5 8 1 1 8 6 .5 3 3 3 6 r c > A 8 0 0 3 l S  E S T 1 8 9 8 1 2  R a ttu s  n o r v e g ic u s  cONA
A A 92S7S 2 0 .0 4 5 7 3 0 .0 4 3 7 0 6 5 4 3 .2 6 6 6 6 7 0 .8 3 1 0 7 5 8 5 7 6 .4 6 6 6 7 0 .8 2 3 6 6 9 1 7 8 .8 5 2 .5 5 8 2 9 7 6 1 0 5 6 .2 6 6 6 2 .8 9 2 3 3 3 5 2 0 9 2 .7 3 3 4 r c > A 9 2 5 7 5 2  U l- R -A l-e p -f -0 7 -O -U I.s l  R a ttu s  n o rv e g ic u s  cONA
A A S75261 0 .0 4 5 4 6 1 .7 2 3 7 1 7 9 1 6 5 .1 3 3 3 3 0 .8 8 4 4 1 3 6 6 1 0 6 .6 0 0 0 0 6 0 .2 7 6 4 9 6 3 8 3 2 .8 5 0 .7 9 7 7 S 2 9 3 8 3 .8 6 6 6 7 1 .0 5 4 9 2 4 7 6 4 3 rc_ A A 8 7 5 2 6 1  U I-R -E O -c e -a -0 6 -O -U I.s l R a ttu s  n o rv e g ic u s  cONA
A A 874803 0 .0 4 5 3 2 2 .9 5 8 0 5 2 6 1 1 1 .2 6 6 6 7 0 .8 3 9 6 1 7 4 1 .2 0 .5 5 7 0 9 6 2 2 6 .8 5 0 .6 8 4 2 0 6 8 7 1 6 0 .0 3 3 3 4 1 .3 2 4 8 8 2 3 6 2 .8 rc_ A A 8 7 4 8 0 3  u i-R -E O -b w -g -O S -O -U I.s l R a ttu s  n o rv e g ic u s  cONA
M 6 5 1 4 9 0 .0 4 4 8 5 0 .0 7 7 5 9 8 0 1 3 .6 6 6 6 6 6 5 0 .6 9 2 1 0 1 8 4 3 8 .3 9 9 9 9 8 1 .0 7 8 2 2 9 9 6 2 .8 0 0 0 0 3 2 .0 3 8 9 6 4 7 5 9 0 .1 1 .7 3 7 7 9 9 5 9 9 .6 9 9 9 6  CELF C /E B W M 6 5 1 4 9  R a t CELF mRNA
M 8 1642 0 .0 4 4 7 2 2 .5 0 6 0 2 5 7 2 3 .1 3 3 3 6 0 .7 5 1 6 7 9 2 2 5 5 .5 3 3 3 3 0 .2 5 8 9 9 6 7 9 2 .0 5 0 .7 1 9 6 9 2 0 5 1 0 4 7 .6 6 6 7 1 .2 5 5 6 2 6 3 2 4 0 6 .0 3 3 4  TRGPC M 8 1 6 4 2  R a t G -p ro te in  c o u p le d  th r o m b in  r e c e p to r
A l l 7 7 2 5 6 0 .0 4 4 2 9 0 .0 7 3 7 5 4 2 4 1 9 .5 6 6 6 6 6 0 .2 3 9 7 4 2 2 8 3 .6 3 3 3 3 1 3 6 3 .2 5 2 .4 3 5 8 4 0 4 3 2 9 4 .8 6 6 5 2 .1 9 4 9 0 4 6 3 3 6 3 .6 r c J U  1 7 7 2 5 6  E S T 2 2 0 8 7 0  R a t tu s  n o rv e g ic u s  cONA
A A 891871 0 .0 4 4 0 5 2 .2 8 3 6 5 0 9 2 4 1 .6 1 .0 8 5 2 2 1 3 1 2 7 .5 3 3 3 3 0 .8 1 5 0 8 6 2 1 0 4 .6 5 0 .9 6 1 4 4 4 2 6 6 1 .3 0 .7 8 5 2 6 8 7 6 6 1 .4 rc _ A A 8 9 l8 7 l  E S T 1 9 5 6 7 4  R a ttu s  n o rv e g ic u s  cONA
D 8 9 6 5 5 0 .0 4 3 4 9 0 .3 7 3 S 3 5 1 3 1 6 .3 1 .2 0 2 9 5 6 7 1 .1 6 6 6 7 1 .9 3 0 6 5 6 8 1 1 2 .3 2 .0 9 7 1 8 8 7 6 0 3 .0 6 6 6 5 2 .3 9 8 5 8 2 7 1 1 0 6  S r b l ,  S R -B i D 8 9 6 5 5  R a t m R N A  fo r  s c a v e n g e r  r e c e p to r  d a s s  B
M 3 5 8 2 6 0 .0 4 3 2 2 1 .7 3 2 8 7 6 1 4 2 0 7 .5 3 3 0 .8 5 2 4 7 0 9 2 2 0 3 .9 6 6 6 1 .4 3 2 0 6 0 1 3 8 9 2 .4 0 .8 8 4 8 4 9 2 5 8 5 6 2 .1 0 1 0 .4 7 3 4 8 2 3 4 7 0 9 9 .1 6 6 M 3 5 8 2 6 c d s  RATMTNO! m ito c h o n d r ia l N A D H -d eh y d ro g en a se  (N O !) g e n e
A A 8 9 1 6 8 9 0 .0 4 3 1 2 2 .1 7 3 0 7 5 7 7 1 .9 6 6 6 7 0 .8 9 8 9 4 0 7 3 8 .6 0 0 0 0 2 0 .6 0 2 1 4 8 5 3 2 4 .3 0 .7 0 3 7 2 1 9 4 1 3 7 .0 6 6 6 7 1 .4 0 5 9 5 7 5 2 9 5 .1 3 3 3 3 rc  A A 8 9 1 6 8 9  E ST 1 9 5 4 9 2  R a ttu s  n o rv e g ic u s  cONA
L 20681 0 .0 4 2 8 2 3 .2 2 8 7 9 1 7 1 7 5 .0 9 9 9 9 0 .9 0 6 5 9 1 9 5 0 .4 3 3 3 3 4 0 .6 3 6 1 0 6 5 5 4 2 .7 5 0 .9 2 1 2 1 2 2 2 7 9 .1 3 3 3 6 1 .3 5 5 0 0 6 8 5 6 5 .6  T o ll E ts-1  E tso o c  L 2 0 6 8 1  RAt p r o to - o n c o g e n e  (E ts -1 )
U 6 5 0 0 7 0 .0 4 2 4 8 0 .7 1 4 7 0 5 9 4 9 .7 9 9 9 9 9 1 .6 5 5 3 3 8 9 3 0 .5 6 6 6 6 8 0 .4 8 8 6 7 3 8 7 .7 1 .0 2 7 1 8 4 7 7 5 .7 6 6 6 6 1 .3 6 6 2 0 0 4 9 6 .5  Mgfr U 6 5 0 0 7  R a ttu s  n o r v e g ic u s  h e p a to c y te  g ro w th  fa c to r  r e c e p to r
U 1 6 8 0 2 0 .0 4 2 3 9 2 .4 4 6 4 3 7 6 7 .3 6 6 6 7 0 .4 1 0 1 8 0 1 5 1 3 .6 6 6 6 6 6 0 .7 5 5 2 6 9 3 2 6 1 .0 1 1 7 1 6 1 7 4 .6 6 6 6 6 1 .0 1 9 0 9 3 8 1 8 4 .9  CAPS U 1 6 8 0 2  R a ttu s  n o rv e g ic u s  C a 2 + - d e p e n d e n t  a c t iv a to r  p ro te in  (CA PS)
A A 8 9 2 0 1 4 0 .0 4 1 7 8 2 .5 8 9 1 6 9 5 9 1 4 .1 1 .1 5 5 9 2 2 4 5 8 .9 1 .0 6 2 3 7 2 7 4 4 5 .6 0 .8 9 9 7 5 9 6 1 5 8 3 .5 6 6 5 0 .7 2 6 5 6 0 1 1 8 7 7 .1 6 6 7 r c _ A A 8 9 2 0 l4  E S T 1 9 5 8 1 7  R a ttu s  n o r v e g ic u s  cONA
A F 00 2 2 8 1 0 .0 4 1 7 1 0 .5 2 5 0 1 8 5 6 3 .4 1 .5 4 1 5 7 8 8 2 1 0 0 .3 2 0 1 2 4 3 3 4 4 .6 1 .3 5 6 2 6 1 4 8 7 7 .3 6 6 7 3 .3 4 0 9 5 7 6 3 4 5 1 .7 3 3 A F 0 0 2 2 8 1  R a ttu s  n o rv e g ic u s  a ip h a - a c t in in -2  a s s o c i a te d  UM p ro te in
A I2 3 7 0 1 6 0 .0 4 0 7 3 2 .3 5 5 1 9 6 5 1 9 .6 6 6 7 1 .1 1 6 5 7 0 5 2 7 7 .8 3 3 3 4 0 .6 7 6 4 9 1 7 4 1 8 0 .3 5 0 .9 0 9 0 7 1 1 5 1 0 6 6 .9 3 3 3 0 .9 4 1 3 5 6 6 6 1 4 2 3 .5  H 2afy r c > 1 2 3 7 0 1 6  E S T 2 3 3 5 7 8  R a ttu s  n o rv e g ic u s
L 0 1 U 5 0 .0 3 9 9 1 1 .6 5 6 7 0 7 9 2 0 4 .2 6 6 6 8 0 .6 1 7 2 6 7 8 5 8 5 .5 1 .0 2 5 8 8 4 4 1 5 6 .8 0 .7 1 9 8 2 0 4 5 2 8 .7 3 3 3 4 0 .2 9 1 6 5 7 9 2 3 5 1 .2  A dcy6 L 0 1 U S  R a ttu s  n o r v e g ic u s  a d e n y ty i c y c la se  ty p e  VI mRNA
3 0 3 6 3 7 0 .0 3 9 3 0 .4 8 8 6 3 4 2 1 7 .7 0 .9 3 6 0 0 0 0 5 4 7 .2 3 3 3 3 0 .7 6 0 8 0 7 3 3 4 .4 1 .2 2 6 3 2 5 2 2 4 1 .3 6 6 6 7 1 .1 4 8 7 0 4 5 2 6 1 .7 6 6 6 6 3 0 3 6 3 7  R a t a ld e h y d e  d e h y d ro g e n a s e  mRNA
S 7 2 4 0 7 0 .0 3 8 8 8 0 .3 1 0 1 6 8 7 7 9 .5 6 6 6 6 7 1 .2 3 6 3 0 6 4 4 4 .5 3 3 3 3 3 1 .7 4 6 7 7 4 2 5 4 .1 0 .8 5 3 4 8 9 6 1 5 7 .6 3 3 3 3 0 .8 2 1 4 8 4 8 1 6 6 .8 3 3 3 4  le m m in  M su b u n it  S 7 2 4 0 7  la m in m  M su b u n it
A A 8 7 4 8 0 3 0 .0 3 8 6 3 2 .6 1 5 8 6 5 7 1 5 2 .9 3 3 3 3 0 .2 0 3 5 2 5 6 3 1 7 .7 0 .3 2 3 9 1 2 3 8 2 3 .8 0 .9 7 3 7 1 8 9 4 3 2 5 .1 2 .7 9 7 5 9 6 9 5 9 .4 6 6 7 rc > 4 8 7 4 8 0 3  U I- R - E 0 - b w - g - 0 8 -0 - U l.s i  R a ttu s  n o rv e g ic u s  cONA
AFO2 0 6 1 8 0 .0 3 8 5 6 2 .2 3 1 0 6 0 5 2 1 6 .6 6 6 6 6 1 .1 6 2 7 7 6 6 1 2 4 .6 6 6 6 7 0 .7 9 5 8 8 0 2 6 9 1 .1 0 0 0 0 6 1 .2 6 2 6 9 0 4 7 4 4 .6 0 .7 3 8 0 2 1 4 5 6 .3 3 3 3 AFO2 0 6 1 8  R a ttu s  n o rv e g ic u s  p ro g re s s io n  e le v a te d  g e n e  3 p ro te in
E 1 3 7 3 2 0 .0 3 8 5 1 0 .3 1 5 7 5 5 9 6 8 .8 6 6 6 6 7 0 .9 7 7 9 3 3 2 4 0 .6 0 0 0 0 2 0 .3 7 5 1 4 8 7 7 1 4 .2 9 9 9 9 9 1 .1 8 8 4 9 5 8 2 0 9 .6 6 6 6 9 1 .5 1 0 4 0 5 3 1 3 .8 E l3 7 3 2 c d s  cONA e n c o d in g  r a t  CC c h em ofcine  r e c e p to r  p ro te in
A I6 3 9 3 0 1 0 .0 3 8 2 3 2 .6 8 8 1 5 7 8 1 7 .4 0 0 0 0 2 1 .0 3 1 2 5 1 2 6 .4 3 3 3 3 3 4 0 .1 9 0 0 4 7 6 1 .3 5 1 .4 0 7 1 7 7 4 4 3 .1 0 .3 4 1 5 2 7 4 1 5 .9 R a t m ix e d - t is s u e  lib ra ry  R a ttu s  n o rv e g ic u s  cONA d o n e  rx 0 3 8 1 7
A A 8 9 4 0 8 8 0 .0 3 8 0 1 2 .0 3 1 8 4 8 2 1 6 0 .2 3 3 3 4 0 .9 5 2 3 7 6 2 5 8 5 .1 6 6 6 6 4 0 .8 7 3 4 4 6 1 8 1 .9 5 1 .0 6 2 8 2 4 1 4 5 2 .6 0 0 0 4 0 .6 7 2 7 6 0 6 7 3 8 5 .7 3 3 3 4 r c > A 8 9 4 0 8 8  E S T 197891  R a ttu s  n o rv e g ic u s  cONA
A A 8 9 2 8 1 8 0 .0 3 8 0 .2 0 2 0 3 6 1 0 .9 3 3 3 3 2 0 .7 2 3 4 5 5 6 5 2 .2 1 .2 4 2 3 8 2 8 9 0 .6 1 .5 3 4 3 9 2 1 5 1 7 .6 6 6 7 0 .8 0 5 9 8 3 3 6 4 0 2 .8 r c _ A A 8 9 2 8 1 8  E ST 1 9 6 6 2 1  R a ttu s  n o rv e g ic u s  cONA
A I0 1 2 5 8 9 0 .0 3 7 6 8 2 .2 2 0 2 3 0 8 1 3 4 9 .0 3 3 3 0 .8 0 3 3 6 9 1 5 4 2 .5 3 3 3 0 .6 7 5 6 6 8 2 5 0 1 .4 0 .8 9 1 4 5 3 8 6 3 1 7 2 .5 3 3 2 0 .7 2 0 6 7 5 6 5 3 8 7 0 .8 6 6 7  G s tp 2 r c _ A J 0 l2 5 8 9  E ST2 0 7 0 4 0  R a ttu s  n o rv e g ic u s  cONA
A A 893105 0 .0 3 7 5 6 2 .6 8 3 4 2 0 4 4 8 .3 9 9 9 9 8 1 .1 6 8 8 9 9 2 2 2 .5 9 9 9 9 8 0 .4 5 7 6 0 7 1 9 .8 0 .5 2 2 2 2 8 3 6 4 7 .9 6 6 6 6 7 1 .2 7 8 0 9 3 7 1 3 7 .0 3 3 3 3 rc> 4 8 9 3 1 0 5  E ST 1 9 6 9 0 6  R a ttu s  n o rv e g ic u s  cONA
A A 8 5 9 9 9 6 0 .0 3 7 1 8 2 .5 6 4 8 4 3 1 6 4 .2 0 .9 0 8 9 2 2 1 6 7 .0 6 6 6 6 6 0 .6 2 9 6 7 6 5 4 8 .4 0 .9 0 0 S 1 3 9 5 3 5 1 .2 6 6 6 6 1 .0 2 9 8 7 6 5 3 9 0 .9 0 0 0 2 rc_ A A 8 5 9 9 9 6  U I-R -E O -c a -b -0 4 -O -U l.s l R a ttu s  n o rv e g ic u s  cONA
AI0 0 8 6 3 8 0 .0 3 6 9 2 1 .6 7 9 6 1 2 2 5 8 7 0 .4 9 4 1 9 0 7 5 1 73 0 .6 6 2 5 8 1 4 2 8 3 .2 5 1 .3 7 6 7 5 9 9 2 8 0 4 .1 3 3 3 1 .4 3 4 3 2 8 1 3 2 2 4 .7 3 3  M fge8 rc _ A I0 0 8 6 3 8  EST2 0 3 0 8 9  R a ttu s  n o rv e g ic u s  cONA
S 4 9 0 0 3 0 .0 3 6 8 0 .8 7 9 7 8 1 3 7 1 3 6 .4 0 .3 1 7 0 6 2 6 5 5 0 .9 3 3 3 3 2 .1 6 8 0 8 5 3 3 9 6 .8 1 .8 4 5 5 6 9 3 1 4 8 3 0 .7 2 6 4 3 5 0 7 6 8 6 .5  s h o r t  iso fo rm  oro-1S 4 9 0 0 3  s h o r t  iso fo rm  g r o w th  h o rm o n e  re c e p to r
A A 900505 0 .0 3 6 2 9 2 .5 4 7 1 0 2 7 1 1 5 6 .1 3 3 3 0 .9 4 0 1 9 3 4 4 7 7 .1 9 9 9 8 0 .7 6 0 6 0 1 5 4 2 4 .7 5 1 .1 7 4 0 6 7 6 2 7 8 7 .8 3 3 3 0 .7 2 7 8 7 8 8 7 2 S 9 8 .9 6 6 8 r c _ A A 9 0 0 5 0 5  U I-R -E 0 -d l-b -0 7 -O -U l.s l R a ttu s  n o rv e g ic u s  cONA
K 0 1 9 3 2 0 .0 3 6 2 2 0 .0 6 8 1 4 9 4 4 1 .8 9 9 9 9 9 9 0 .3 1 8 7 9 9 4 4 9 .8 6 6 6 6 7 1 .3 6 2 4 5 5 6 4 0 .4 5 2 .7 3 9 9 0 4 2 3 1 9 .2 1 .6 8 5 9 5 9 3 2 9 K 0 1 9 3 2  R a t K ver g lu ta th io n e  S - t r a n s f e r a s e  Yc su b u n it  mRNA
A A 8 9 2 1 4 9 0 .0 3 6 1 2 1 .6 6 8 4 7 3 4 7 5 .3 0 .4 2 8 8 6 6 2 7 2 1 .0 6 6 6 6 8 0 .9 3 3 9 0 3 7 5 3 .1 9 9 9 9 7 0 .9 8 7 8 1 0 2 2 5 1 .1 6 6 6 6 0 .9 4 0 9 5 9 9 3 2 8 9 .0 6 6 6 5 rc _ A A 8 9 2 l4 9  E ST 1 9 5 9 5 2  R a ttu s  n o rv e g ic u s  cONA
A A 8 7 4 8 4 8 0 .0 3 5 7 0 .1 1 5 9 4 4 0 1 1 1 .7 3 3 3 3 4 0 .9 8 4 0 6 3 3 1 2 8 .8 6 6 6 7 0 .7 9 5 4 8 2 3 1 0 8 .2 5 2 .1 3 0 1 3 6 5 1 4 6 4 .2 7 .0 2 5 9 4 7 5 1 1 8 .2 3 3 4  T h y l rc_A A 87 4 8 4 8  U I-R -E O -c g -h -0 3 -O -U I.S l R a ttu s  n o rv e g ic u s  cONA
A I1 7 1 1 6 7 0 .0 3 5 4 9 0 .2 3 8 6 9 7 5 4 1 0 .7 3 3 3 3 4 0 .5 5 1 9 5 9 1 3 1 .4 3 3 3 3 2 1 .0 0 2 9 0 2 9 5 6 .5 2 .8 6 6 4 0 6 2 7 9 5 2 .3 7 4 8 1 3 6 8 4 1 .9 6 6 7 r c _ A I l 7 l l 6 7  E S T 2 1 7 U 6  R a ttu s  n o rv e g ic u s  cONA
M 1 5562 0 .0 3 4 9 3 0 .2 2 3 3 6 3 4 3 1 5 .7 0 .7 3 4 1 1 3 6 3 6 4 .6 3 3 3 3 0 .8 9 8 0 8 3 1 8 0 .6 0 0 0 0 6 3 .8 5 0 7 2 6 6 1 5 1 9 .8 6 6 7 1 5 .1 6 3 4 5 5 6 9 4 7 .2 6 6 6 M 1 5 5 6 2  R a t MHC d a s s  II R T i.u -D -a lp h a  c h a in  mRNA
A A 8 5 9 5 4 9 0 .0 3 4 5 9 3 .9 2 0 2 3 9 7 7 9 .1 3 3 3 3 1 .0 0 1 6 0 3 4 2 4 .4 0 .7 0 7 1 0 5 7 6 1 7 .2 5 0 .7 2 8 0 6 9 1 9 6 .9 3 3 3 3 4 1 .2 7 9 6 9 7 8 1 1 5 .4 3 3 3 3 4 r c > A 8 5 9 5 4 9  U I-R -E O -b r-d -lO -O -U I.s l R a ttu s  n o rv e g ic u s  cONA
A A 799755 0 .0 3 4 4 7 0 .2 3 7 8 3 5 5 9 9 .7 0 .9 2 5 0 1 9 3 4 9 .8 9 9 9 9 8 1 .0 8 5 7 4 0 1 5 8 .6 1 .7 3 7 0 4 0 2 4 7 3 .2 6 6 6 6 2 .3 4 0 1 3 3 8 8 7 .1 9 9 9 5 r c _ A A 7 9 9 7 5 5  E S T 1 8 9 2 5 2  R a ttu s  n o rv e g ic u s  cONA
A I6 3 9 4 2 7 0 .0 3 4 2 7 5 .4 2 4 5 7 3 4 4 6 9 .6 9 9 9 8 1 .5 5 7 9 5 1 6 1 4 9 .4 0 0 0 1 0 .2 8 1 3 0 3 3 5 3 0 .2 5 0 .9 7 7 5 9 6 1 4 6 2 .7 3 3 3 4 1 .0 4 9 6 2 6 1 5 4 1 .5 3 3 3 R a t m ix e d - t is s u e  lib ra ry  R a ttu s  n o rv e g ic u s  cONA d o n e  r x 0 0 1 3 3
A A 8 9 3 6 6 7 0 .0 3 4 0 2 1 .8 8 2 5 1 0 8 6 6 .6 3 3 3 3 0 .8 1 1 3 2 8 5 3 3 7 .0 6 6 6 6 6 0 .9 9 3 9 6 8 4 4 1 .6 0 .4 2 4 9 6 4 4 6 6 .8 1 .0 3 1 8 2 5 5 2 2 0 .9 3 3 3 2 rc_ A A 8 9 3 6 6 7  E S T 1 9 7 4 7 0  R a ttu s  n o rv e g ic u s  cONA
0 1 4 0 1 4 0 .0 3 3 5 3 2 .7 1 3 9 3 8 5 7 8 0 .2 1 .0 8 2 9 6 4 8 3 2 8 .6 3 3 3 3 1 .0 1 3 1 8 2 9 3 4 7 .6 0 .9 0 9 5 1 0 4 1 3 1 3 .2 0 .7 6 4 6 6 3 1 6 1 4 1 2 .5 6 6 7 0 1 4 0 1 4  RATCYCLOl R a t mRNA  fo r  c y d m  0 1
ABO1 0 9 6 0 0 .0 3 3 3 5 0 .4 0 1 3 6 5 0 7 3 1 .8 3 3 3 3 4 0 .8 2 4 3 9 1 5 8 1 .7 6 6 6 7 1 .3 7 0 6 1 8 2 1 3 4 .7 3 .8 5 6 8 3 9 7 1 7 0 3 .3 3 3 5 1 .9 2 5 7 2 4 5 1 4 2 6 .1 0 0 1  rrofr ABO1 0 9 6 0  R a ttu s  n o rv e g ic u s  mRNA  fo r  MIFR
D 8 3 9 4 8 0 .0 3 3 2 1 2 .1 2 5 9 9 7 1 7 4 .6 6 6 6 7 1 .1 4 6 6 9 5 1 1 1 1 .1 6 6 6 6 4 1 .2 3 9 5 2 6 1 2 3 .0 5 0 .6 8 4 2 5 4 8 2 9 6 .5 3 3 3 3 0 .6 5 8 3 0 5 0 5 3 3 1 .5 0 8 3 9 4 8 m R N A  R a t a d u lt  liv e r mRNA  fo r  S l - 1  p ro te in
U 5 2 1 0 3 0 .0 3 3 1 8 4 8 .2 6 2 4 3 6 4 2 2 .2 6 6 6 6 1 .7 8 9 3 6 8 6 1 8 .1 3 3 3 3 3 0 .6 4 9 2 2 4 6 6 .9 0 .5 1 1 4 9 4 6 2 4 .3 3 3 3 3 2 1 .0 0 3 0 2 4 2 44.4 C rm p 3 U 5 2 1 0 3  R a ttu s  n o rv e g ic u s  rCRM P-3 mRNA
L 2 9 2 3 2 0 .0 3 3 1 7 4 .5 9 8 4 4 7 1 9 1 .2 6 6 6 6 1 .8 3 6 6 7 0 2 8 0 .0 6 6 6 6 6 0 .4 3 7 1 5 1 3 4 2 1 .4 5 0 .8 9 4 0 8 5 1 1 4 7 .2 3 3 3 4 0 .7 6 0 9 8 2 7 1 7 7 .0 3 3 3 3 L 2 9 2 3 2  R a ttu s  n o r v e g ic u s  in su ltn -lik e  g ro w th  fa c to r  I r e c e p to r
A F 0 1 9 6 2 8 0 .0 3 3 1 1 0 .2 5 9 3 0 4 5 8 1 0 .8 6 6 6 6 7 0 .9 1 3 6 5 6 5 3 5 0 0 .8 1 3 6 1 9 7 4 6 .6 5 1 .1 7 5 1 6 9 1 2 6 5 .4 6 6 6 7 2 .1 5 8 3 9 6 7 7 0 7 .3 6 6 7  S u r2 A F 0 1 9 6 2 8  R a ttu s  n o rv e g ic u s  su lfo n y lu re a  r e c e p to r  2B
3 0 3 9 6 9 0 .0 3 0 5 7 2 .4 5 6 9 7 9 8 1 5 5 3 .3 3 3 4 1 .0 8 0 2 6 1 751 0 .8 3 9 8 6 0 8 6 2 5 .8 5 1 .0 4 1 9 3 1 7 3 2 2 4 .0 6 6 4 1 .0 1 4 9 8 1 5 3 8 9 7  B23N P X )3 9 6 9  R a t n u d e o ia r  p ro te in  B 23  mRNA
A B 0 1 2 2 3 4 0 .0 2 9 6 5 0 .1 6 6 4 7 7 3 4 1 1 .1 3 3 3 3 3 0 .8 6 0 8 1 0 7 6 5 9 .7 3 3 3 3 0 .1 2 7 5 4 6 5 5 9 .4 3 .4 0 2 6 5 8 7 1 4 6 3 .1 3 3 3 3 .7 8 8 0 6 9 5 1 9 0 7 .5 3 3 4  NF1-X A B 0 1 2 2 3 4  R a ttu s  n o rv e g ic u s  mRNA fo r N F l-X l
A A 859882 0 .0 2 9 6 2 5 .6 1 0 1 9 1 5 3 6 .2 3 3 3 4 1 .4 6 5 3 1 5 1 5 6 .1 3 3 3 3 0 .4 3 6 4 1 9 0 7 5 1 .3 0 .5 9 5 2 7 5 4 3 6 7 .8 3 3 3 4 1 .2 4 4 8 2 7 8 8 7 .3 6 6 7  U ch ll rc_ A A 8 S 9 8 8 2  U I-R-E0-CC-C-O 9-0-U I.S1 R a ttu s  n o rv e g ic u s  cONA
A A 875362 0 .0 2 9 4 8 4 .3 2 3 5 9 9 1 6 8 .4 1 .5 2 4 5 8 0 7 6 7 .3 6 6 6 7 0 .4 3 2 3 8 9 9 1 2 0 .0 5 0 .3 5 3 7 5 5 1 2 7 5 .1 1 .2 2 0 9 1 5 9 3 3 6 .4 6 6 6 7 r c _ A A 8 7 5 3 6 2  U I -R -E 0 -c o -< -1 0 -0 -U l.s l R a ttu s  n o rv e g ic u s  cONA
3 0 4 4 8 6 0 .0 2 8 6 2 .5 5 5 0 9 7 6 6 2 .7 3 3 3 3 4 1 .4 7 5 3 4 3 8 4 5 .1 0 .3 8 5 9 7 8 7 1 1 .3 5 0 .5 8 0 9 4 9 6 7 4 .0 3 3 3 3 0 .6 1 8 5 4 1 5 1 2 0 .5 9 9 9 9  ILGFBPA 3 0 4 4 8 6  R a t In su lin  g ro w th  fa c to r -b in d in g  p ro te in  mRNA
M 8 4488 0 .0 2 8 4 5 1 .6 9 9 6 2 2 5 5 1 .9 0 .5 7 0 1 3 6 6 7 1 9 .6 6 6 6 6 6 0 .1 4 0 3 9 9 2 6 5 .2 1 .0 9 5 8 1 7 1 6 3 .5 6 6 6 7 2 .0 7 0 5 9 2 9 4 8 2  VCAM1B M8 4 4 8 8  R a t v a s c u la r  ceil a d h e s io n  m o le c u le -1 mRNA
A A 8 9 4 2 1 0 0 .0 2 8 2 6 3 .0 8 0 6 8 1 8 1 1 7 .9 6 6 6 6 0 .7 4 8 6 9 2 9 3 7 .0 3 3 3 3 3 0 .8 0 7 2 1 7 7 3 8 .1 9 9 9 9 7 0 .9 6 9 9 2 9 3 4 1 9 8 .2 6 6 6 6 1 .1 3 4 4 9 0 5 2 S 6 .8 rc_ A A 8 9 4 2 1 0  E ST 1 9 8 0 1 3  R a ttu s  n o rv e g ic u s  cONA
A A 9 9 8 6 8 3 0 .0 2 7 8 4 0 .3 2 3 4 0 4 5 5 4 0 .9 6 6 6 6 7 1 .1 6 8 8 8 3 6 1 7 4 .2 9 9 9 9 0 .6 6 0 2 4 2 4 4 9 7 .5 5 1 .3 5 9 3 6 2 8 8 1 8 .2 5 .1 5 1 1 2 8 3 3 8 4 5 .6 3 3 3 r c _ A A 9 9 8 6 8 3  U I-R -C O -ig -h -0 6 -O -U I.s l R a ttu s  n o rv e g ic u s  cONA
U 5 2 1 0 2 0 .0 2 7 5 1 7 .4 3 1 0 6 1 3 3 3 6 .8 3 3 3 4 0 .7 2 4 2 3 0 3 3 4 .1 3 3 3 3 1 .0 5 2 6 6 9 3 5 8 .5 5 0 0 0 3 0 .8 2 3 0 5 0 5 6 1 9 6 .1 3 3 3 3 0 .9 4 2 5 9 6 4 2 8 6 .5 6 6 6 8  C r m p l U 5 2 1 0 2  R a ttu s  n o rv e g ic u s  rCRM P-1 mRNA
H 6 4 7 8 0 0 .0 2 7 3 3 6 .3 7 7 9 1 1 6 1 3 5 9 .7 1 .5 2 7 1 9 8 3 3 7 3 .2 3 3 3 4 0 .5 1 4 7 2 2 9 1 34 0 .9 1 2 7 3 8 4 1 0 3 8 .3 0 .9 9 9 5 5 2 8 5 1 5 6 3 .2  AGR M6 4 7 8 0  R a t a g r in  mRNA
A I6 3 9 4 2 0 0 .0 2 6 2 4 0 .2 0 5 6 5 2 1 3 4 .0 6 6 6 6 6 6 0 .5 3 6 4 1 1 1 7 1 3 .0 3 3 3 3 4 1 .1 4 0 1 6 6 2 6 .1 5 0 0 0 2 1 .8 2 9 7 1 2 5 1 8 1 .5 3 3 3 3 2 .1 1 1 1 8 6 3 2 0 2 .2 9 9 9 9 R a t m ix e d - b s s u e  lib ra ry  R a ttu s  n o rv e g ic u s  cONA d o n e  r x 0 2 7 i3
A A 859661 0 .0 2 6 1 7 0 .2 0 7 4 9 6 0 5 3 .9 6 6 6 6 6 7 1 .2 0 0 2 5 3 4 2 6 .2 0 .7 9 7 3 8 5 1 6 1 6 .8 5 2 .0 9 1 3 2 7 2 1 9 7 .2 1 .3 4 8 0 2 7 1 5 7 .2 rc_ A A 8 5 9 6 6 1  U I-R -E 0 -b s -c -0 4 -0 -U I.S l R a ttu s  n o rv e g ic u s  cONA
H 3 3 2 1 9 0 .0 2 5 5 6 0 .9 1 5 4 3 2 3 3 4 8 .9 6 6 6 6 7 0 .3 8 9 9 4 3 2 7 2 3 .7 0 .6 6 9 9 6 5 6 4 2 .6 5 1 .1 9 4 3 4 7 3 3 8 .4 6 6 6 7 1 .5 9 8 3 6 7 5 4 8 .8 3 3 3 r c _ H 3 3 2 l9  E ST 1 0 9 0 0 5  R a ttu s  n o rv e g ic u s  cONA
A A 892338 0 .0 2 5 4 3 0 .2 4 1 0 3 4 9 5 7 .8 1 .1 0 4 9 7 3 6 4 5 0 .8 4 5 3 7 3 8 7 3 4 .4 5 2 .3 6 7 7 5 2 3 4 2 1 .2 3 3 3 4 1 .9 0 5 5 1 6 1 4 9 3 .4 3 3 3 rc _ A A 8 9 2 3 3 8  E S T 1 9 6 1 4 1  R a ttu s  n o rv e g ic u s  cONA
A I0 0 8 0 2 0 0 .0 2 4 4 0 .1 4 1 1 7 1 8 9 6 .1 3 3 3 3 3 0 .8 4 8 7 4 1 5 4 1 .1 0 0 0 0 2 0 .7 4 4 7 9 6 3 3 1 .9 5 2 .7 3 2 0 2 3 5 5 1 7 .2 2 .3 7 1 5 8 0 4 4 6 7 .2  M el rc_A J0 0 8 0 2 0  E S T 2 0 2 4 7 1  R a ttu s  n o rv e g ic u s  cONA
A A 8 9 1 3 0 2 0 .0 2 4 0 7 2 .5 9 3 6 7 5 1 7 5 .3 6 6 6 7 0 .9 1 9 2 6 7 9 5 2 7 .6 3 3 3 3 3 0 .4 2 7 7 7 4 9 7 1 4 .4 0 .7 0 0 8 0 1 2 1 1 1 .1 2 .1 7 1 4 2 0 6 2 7 5 .7 3 3 3 4 rc _ A A 8 9 1 3 0 2  E S T 1 9 5 1 0 5  R a ttu s  n o rv e g ic u s  cONA
A A 8 0 0 7 9 0 0 .0 2 3 3 2 5 .4 5 4 8 1 4 1 7 8 2 .6 3 3 4 2 .1 3 1 9 4 5 4 7 6 6 .2 1 3 9 4 .5 5 0 .7 4 9 9 8 3 4 1 2 0 2 .5 3 3 4 0 .5 0 8 5 8 9 7 4 1 1 9 3 .6 6 6 7 rc_ A A 8 0 0 7 9 0  E S T 1 9 0 2 8 7  R a ttu s  n o rv e g ic u s  cONA
H 3 1 3 1 3 0 .0 2 3 1 4 2 .5 8 0 6 0 1 3 4 1 .9 3 3 3 5 1 .0 4 1 4 5 6 9 1 5 5 .9 3 3 3 3 1 1 5 9 .7 9 9 9 9 1 .3 8 4 5 1 9 5 1 0 2 6 .6 0 .5 0 2 9 0 7 5 4 4 2 .0 9 9 9 8 r c _ H 3 1 3 l3  E S T 1 0 5 2 3 0  R a ttu s  n o rv e g ic u s  cONA
X 0 6 9 1 6 0 .0 2 1 8 1 0 .0 2 8 9 4 1 4 2 1 7 .4 0 .1 3 6 4 2 3 6 3 9 5 .3 1 .0 0 0 0 0 0 1 7 0 3 .9 5 1 .8 2 3 0 2 4 2 5 5 8 1 .8 6 6 7 4 .1 5 0 2 1 3 2 1 2 0 0 5 .6 6 7  RNP9KA X 0 6 9 1 6  R a t g e n e  fo r p ro te in  p9 K a  h o m o lo g o u s  to  c a ld u m -b tn d in g  p ro te in
X 5 9 8 5 9 0 .0 2 1 7 6 0 .0 4 7 6 5 8 4 7 8 4 .2 0 .7 8 8 5 5 9 4 1 5 5 7 .9 3 .5 2 0 2 4 5 7 0 0 5 .7 5 2 .5 3 2 3 5 6 7 1 5 6 2 6 .4 3 5 2 .0 1 4 5 2 2 6 1 4 2 5 8 .7 9 9  DCN X 5 9 8 5 9  R .n o rv e g tc u s  DCN mRNA fo r d e c o n n
A A 7 9 9 3 8 9 0 .0 2 0 9 8 0 .5 6 4 1 5 5 3 4 2 4 .9 3 3 3 3 4 1 .0 3 5 4 4 4 6 5 7 .1 0 .9 3 6 6 4 7 5 5 0 .4 1 .0 2 2 9 5 7 7 2 4 1 .3 3 3 3 4 2 .6 7 5 7 5 6 6 6 4 .7 A A 7 9 9 3 8 9  EST 1 8 8 8 8 6  R a ttu s  n o rv e g ic u s  cONA
Z 1 2 1 5 2 0 .0 2 0 7 2 4 3 .3 1 8 1 5 3 1 2 5 8 .7 0 0 1 4 .9 2 4 1 1 3 3 1 7 1 .1 6 6 6 7 0 .6 6 6 5 3 6 5 2 2 .8 0 0 0 0 1 0 .7 6 1 8 7 5 9 1 1 7 .7 0 .3 4 3 5 3 1 5 5 7 3 .2 0 0 0 0 5  N efm Z 1 2 1 5 2  R. n o r v e g ic u s  mRNA  fo r n e u ro f l la m e n t  p ro te in  m id d le  (NF-M )
A A 799803 0 .0 2 0 4 8 0 .0 3 2 7 5 2 1 8 9 0 .1 1 4 8 0 6 9 6 3 8 .3 3 3 3 3 2 1 .0 0 5 6 6 8 3 3 2 4 .2 5 2 .5 3 8 0 4 9 2 4 1 9 1 .0 6 7 2 .2 5 6 0 9 9 S 4 9 2 7 .0 9 9 6 rc _ A A 7 9 9 8 0 3  E S T 1 8 9 3 0 0  R a ttu s  n o r v e g ic u s  cDNA
A A 7 9 9 6 6 6 0 .0 2 0 3 3 0 .1 8 4 6 8 8 8 4 3 .9 6 6 6 6 6 7 0 .8 0 2 7 3 1 5 2 4 .0 6 6 6 6 8 0 .5 2 8 1 2 4 1 14 .1 2 .0 1 8 0 7 9 2 9 0 .7 6 .8 6 3 7 4 3 1 3 7 4 .7 6 6 6 rc_ A A 7 9 9 6 6 6  E S T 1 8 9 1 6 3  R a ttu s  n o rv e g ic u s  cONA
A A 79948 8 0 .0 1 9 6 1 1 .2 5 3 3 0 5 8 7 2 .9 3 3 3 3 4 0 .3 9 4 0 5 7 4 2 3 .4 3 3 3 3 2 1 .3 4 0 7 3 8 9 4 .4 1 .1 5 0 8 0 5 5 3 4 2 .7 3 3 3 4 0 .4 7 3 4 3 2 2 0 0 .6 6 6 6 6 rc_ A A 7 9 9 4 8 8  E ST 1 8 8 9 6 5  R a ttu s  n o rv e g ic u s  cDNA
A A 8 0 0 X 3 0 .0 X 9 5 6 2 .1 3 9 3 5 0 4 1 3 0 4 .2 6 6 7 1 .1 0 2 5 7 7 1 7 8 0 .6 0 0 0 4 0 .5 4 6 1 3 9 6 4 0 1 .0 9 9 9 8 0 .8 5 7 2 3 8 2 3 2 8 3 4 .9 3 3 3 1 .0 1 6 1 2 9 4
M l5 8 8 0 0 .0 X 9 2 9 2 .8 2 5 0 6 3 2 1 6 3 .8 6 6 6 7 1 .0 2 9 8 8 7 7 5 .1 1 .0 8 9 5 4 4 8 7 4 .3 5 0 .7 9 5 2 0 9 1 7 2 4 7 .8 6 6 6 7 1 .0 6 6 7 5 8 9
A A 8 1 8 4 0 3 0 .0 X 9 1 3 3 .1 6 0 9 3 3 7 4 4 .6 0 .9 1 3 3 3 5 5 1 5 .3 3 3 3 3 3 0 .7 8 3 4 2 1 4 6 1 2 .6 5 1 .1 7 6 6 3 8 2 1 0 0 .0 3 3 3 3 0 .8 6 8 9 7 5 6
A I1 8 0 0 1 3 0 .0 X 8 8 9 0 .1 9 5 8 6 4 2 9 1 6 1 .5 3 3 3 3 0 .4 0 1 5 4 2 2 5 4 2 0 .9 1 1 0 2 9 .8 2 .0 4 4 4 7 3 4 8 9 3 9 .1 3 3 2 .4 5 4 2 7 0 4
A P 0 5 2 5 4 0 0 .0 X 8 1 2 0 .3 3 3 0 3 5 3 8 9 .2 1 .0 9 7 7 6 9 4 4 0 .3 3 3 3 3 6 0 .5 5 9 3 3 8 5 7 1 8 .8 1 .0 8 9 7 6 1 7 1 .1 6 6 6 7 3 .2 6 0 9 2 9
L 3 6 0 8 8 0 .0 1 7 9 6 0 .4 8 6 0 1 1 6 8 2 4 .2 6 6 6 6 6 0 .9 6 7 6 0 6 0 7 5 7 0 .9 8 7 0 0 9 0 5 5 8 .2 5 1 .0 6 9 0 6 8 3 2 9 9 .9 1 .3 8 0 S 0 1 2
1 2 0 4 6 8 0 .0 X 7 1 4 6 .6 7 3 8 1 8 2 1 7 .4 3 3 3 3 1 .2 2 9 6 3 5 5 4 7 .2 3 3 3 3 4 0 .8 9 6 4 1 4 9 4 3 4 .8 5 0 .9 7 3 2 1 1 7 7 1 8 3 .4 0 .8 6 0 2 2 1 3
A I2 3 6 S 9 7 0 .0 X 7 1 1 2 .1 1 3 2 3 3 8 1 0 3 .0 6 6 6 6 6 0 .7 6 0 9 4 5 1 4 4 3 .1 3 3 3 3 5 1 5 9 .2 1 .4 6 2 2 1 7 5 X 2 .0 6 6 6 5 0 .4 2 9 4 8 1 7 1
X 0 2 9 0 4 0 .0 X 7 0 4 2 .3 0 0 2 8 3 5 7 7 .6 3 3 3 0 .7 2 6 6 0 8 9 3 1 8 3 .7 3 3 3 4 0 .4 5 7 9 7 8 7 9 1 3 7 .4 0 .9 1 3 9 0 6 3 1 4 4 2 .8 9 9 9 0 .6 4 4 1 5 8 9
X 0 5 1 3 7 0 .0 1 6 5 4 .2 5 3 1 8 8 6 1 4 7 2 .1 6 6 7 1 .3 1 5 4 6 9 6 4 9 9 .1 9 9 9 8 0 .6 1 9 7 0 5 7 2 6 1 .5 0 .4 4 5 6 9 2 7 5 7 9 6 .9 6 6 7 1 .4 6 7 1 5 5 3
M 5 8364 0 .0 X 5 8 5 0 .1 3 5 8 8 3 9 2 .0 6 6 6 6 6 6 0 .8 8 1 7 7 9 1 6 .5 1 .4 3 9 2 0 5 5 2 5 .9 5 1 .3 3 6 3 4 2 5 1 2 5 .8 6 6 6 7 3 .9 6 1 1 8 6 4
A A 874791 0 .0 1 5 2 9 1 .6 7 4 6 0 6 8 2 0 8 .5 3 3 3 4 0 .7 7 5 9 5 5 1 4 1 2 1 .9 0 .4 7 9 9 6 4 7 1 .2 5 1 .1 3 1 2 6 4 4 6 4 4 .5 1 .0 4 4 2 2 8 8
A A 8 7 4 7 8 4 0 .0 1 5 1 7 1 .2 3 8 2 7 4 2 7 3 .1 6 6 6 7 0 .4 6 7 7 2 6 9 8 3 2 .2 3 3 3 3 4 0 .8 5 5 2 8 7 8 5 7 .6 5 0 .8 8 8 3 6 8 2 5 6 .1 3 3 3 6 2 .3 2 8 5 4 6 8
A l l 7 8 2 0 6 0 .0 1 4 9 4 2 .3 3 2 1 3 0 7 1 4 0 .4 3 3 3 3 1 .1 0 8 8 6 9 6 7 7 .9 6 6 6 7 0 .5 3 3 0 6 8 3 6 3 7 .5 5 0 .8 1 5 0 3 1 3 5 2 7 4 .0 6 6 6 8 0 .9 8 0 3 6 1 6
A F X 0 9 4 2 0 .0 X 4 8 2 2 .5 2 1 6 9 4 2 1 5 .7 6 6 6 6 1 .1 0 1 6 9 1 7 1 0 5 .5 0 .5 2 8 2 4 7 5 5 4 .4 1 .1 0 1 1 1 6 7 6 2 6 .6 9 9 9 5 0 .7 2 6 3 2 4 8 6
X 0 2 0 0 2 0 .0 X 4 7 9 0 .1 0 3 8 9 0 2 9 4 .0 6 6 6 6 6 6 1 .1 1 9 0 4 4 7 5 1 .6 3 3 3 3 5 0 .6 9 1 2 3 5 5 4 3 0 .2 5 1 .4 5 7 1 6 0 6 X 7 .9 3 3 3 5 2 .8 2 0 6 6 5 6
A 1 231292 0 .0 1 4 4 8 1 .0 1 6 8 3 4 4 1 1 6 1 .4 0 .3 5 3 5 7 0 3 4 4 2 3 .3 6 6 6 7 2 .2 3 0 9 8 3 7 2 9 6 4 .9 5 2 .1 8 5 2 0 1 2 8 7 1 9 .9 0 .7 7 3 6 6 7 6
M 2 3 5 6 6 0 .0 X 4 0 6 0 .0 7 2 0 1 7 9 8 2 5 .1 0 .1 7 4 3 2 1 9 2 7 5 .1 1 4 1 7 .6 1 .3 9 6 4 8 2 3 2 5 0 4 .2 2 .7 6 8 7 8 1 4
0 0 3 2 9 4 0 .0 X 3 9 9 0 .0 9 4 6 0 8 4 6 1 8 .1 3 3 3 3 3 0 .4 0 6 5 2 6 9 2 1 0 3 .9 6 6 6 7 1 .1 7 6 7 6 5 9 3 0 4 .1 3 .3 3 9 5 7 4 8 3 6 9 2 .1 3 3 3 2 .8 7 8 3 4 2 9
A 16 3 9 3 3 8 0 .0 1 3 9 5 0 .5 5 1 6 6 5 8 2 1 .3 0 .9 3 9 6 3 3 1 3 4 4 .6 6 6 6 6 8 0 .8 2 4 1 3 4 9 3 8 .6 9 9 9 9 7 1 .4 4 7 5 8 3 1 2 9 4 .4 6 6 6 7 2 .1 4 6 3 2 9 2
M 86341 0 .0 X 3 9 2 1 1 .0 2 4 8 7 1 5 3 .4 6 6 6 6 7 1 .1 1 8 9 8 2 7 .8 3 3 3 3 3 0 .6 5 8 8 4 5 9 3 .8 9 9 9 9 9 9 2 .3 3 5 4 5 9 7 3 .1 0 .6 3 3 8 9 5 8
U 9 5 0 0 1 0 .0 1 3 4 9 2 .2 6 2 2 7 1 6 1 2 4 3 .3 3 3 4 0 .6 6 0 7 2 8 8 4 0 7 .7 6 6 6 6 0 .7 6 0 0 0 7 1 4 5 0 5 .3 5 1 .1 0 7 0 4 2 2 7 1 4 .8 6 6 7 1 .2 8 3 5 4 6 1
A I1 0 4 7 8 1 0 .0 1 2 8 5 0 .3 1 8 9 3 2 9 2 8 .6 3 3 3 3 3 0 .7 7 9 0 1 0 0 6 2 8 .4 0 .6 7 3 9 7 2 4 2 2 .3 4 9 9 9 8 2 .4 7 7 5 0 9 7 3 6 4 .8 6 6 6 7 2 .9 5 8 8 6 1 4
A I1 7 1 5 0 6 0 .0 1 X 2 3 0 .2 7 2 1 4 1 4 6 5 .9 0 .9 2 1 3 2 9 4 4 2 6 .4 0 .4 5 3 6 8 8 0 3 13 1 .7 3 1 1 9 9 9 2 3 7 .8 3 3 3 4 1 .4 6 7 7 6 8 5
A F 0 5 4 8 2 6 0 .0 1 0 8 7 0 .2 4 2 1 6 5 3 9 1 1 .4 0 .8 0 9 7 9 5 2 4 6 .4 3 3 3 3 1 .7 0 7 4 2 1 1 9 6 .2 1 .8 7 2 1 3 7 3 5 1 0 .7 1 .5 4 0 6 7 6 2
A A B 00296 0 .0 X 0 5 1 0 .0 9 7 6 9 0 8 8 2 3 .9 6 6 6 6 7 0 .3 5 1 4 5 4 0 2 1 1 2 .7 6 6 6 7 2 .0 8 1 1 3 1 5 6 0 7 .0 5 2 .2 7 8 1 2 3 2 8 8 5 .8 6 6 7 1 .1 2 9 5 2 7 1
A J0 0 1 0 2 9 0 .0 X 0 4 8 3 .9 2 7 0 5 0 8 8 8 1 .1 6 6 7 1 .0 5 1 9 1 4 2 5 9 .3 3 3 3 0 .8 9 4 0 7 7 4 2 4 4 0 .8 8 4 3 X 7 1 0 9 1 .3 6 6 6 0 .2 0 7 0 5 5 4 5
A P 0 0 1 8 9 8 0 .0 1 0 4 3 0 .3 6 1 2 2 8 3 8 3 9 .1 3 3 3 3 5 0 .5 5 7 7 2 4 7 7 5 .0 6 6 6 6 6 1 .0 6 4 8 1 4 3 1 3 3 .7 9 9 9 9 4 .7 2 5 9 8 0 3 2 5 9 2 .1 6 6 5 1 .9 1 4 0 9 8 9
A A 8924X 4 0 .0 0 9 4 7 3 4 .1 9 3 8 4 7 6 2 3 .6 6 6 7 1 .0 3 0 7 5 4 3 1 6 2 .0 3 3 3 4 1 .0 4 8 2 9 0 1 1 8 7 .5 0 .8 2 4 4 2 2 9 6 4 5 1 .0 6 3 1 6 5 7
A A 7 9 9 4 4 8 0 .0 0 8 1 5 7 2 .1 5 6 8 9 5 9 2 2 1 4 .6 0 .6 2 1 3 3 4 5 7 5 0 .3 0 .3 6 2 9 9 8 1 4 5 0 .7 1 .0 7 7 8 9 5 6 5 8 2 7 .0 6 6 4 1 .2 7 5 1 4 2 1
X 6295X 0 .0 0 8 1 5 2 7 .4 9 4 5 0 0 6 1 5 1 5 .6 0 .9 1 7 8 7 3 1 4 1 8 9 .8 3 3 3 3 0 .9 3 6 3 7 6 2 2 2 7 .3 5 1 .1 6 9 3 9 7 8 1 3 7 3 .8 3 3 4 0 .5 6 9 3 7 1 7 6
X 04X 39 0 .0 0 7 9 6 3 0 .2 2 8 8 8 6 0 4 8 .4 3 3 3 3 3 0 .9 1 3 2 7 0 7 4 6 .2 1 .2 9 1 3 9 7 8 6 0 .6 9 9 9 9 7 1 .X 7 9 5 2 2 2 4 9 .2 3 3 3 4 1 .2 2 X 1 5 4
A P 0 0 9 3 2 9 0 .0 0 7 9 1 0 .3 6 1 0 8 0 2 3 8 .9 6 6 6 6 6 0 .7 3 0 3 2 5 9 4 2 3 .5 6 6 6 6 8 0 .6 4 2 2 4 4 2 1 8 .0 9 9 9 9 8 2 .2 3 3 4 5 1 1 2 8 9 .8 4 .3 9 3 2 4 4 7
A A 8 0 0 8 0 3 0 .0 0 7 2 5 4 .3 0 1 0 6 9 3 3 1 .2 6 6 6 6 1 .5 8 3 2 8 2 1 1 3 0 .9 3 3 3 3 0 .7 9 9 8 3 7 6 7 1 .9 5 0 .7 8 1 4 4 7 6 5 3 5 8 .8 6 6 6 7 0 .5 0 4 4 2 8 4
X 5 6 3 2 6 0 .0 0 7 2 3 7 2 8 1 .9 5 8 0 7 3 3 5 6 .6 3 3 3 7 5 .4 3 6 1 1 9 7 7 .9 1 1 4 .6 0 .4 0 6 5 0 6 2 7 2 3 .2 6 6 6 6 6 0 .4 6 5 5 3 S X
H 3 3 0 9 3 0 .0 0 7 0 6 1 2 .5 6 0 1 1 3 4 5 0 .0 6 6 6 6 6 0 .9 1 3 8 9 1 7 3 2 3 .4 6 6 6 6 5 0 .5 7 7 6 5 6 9 1 3 .7 5 0 .6 0 6 2 4 7 6 6 6 5 .2 0 0 0 0 5 1 .6 3 4 5 3 5 7
XX3 0 4 4 0 .0 0 6 6 8 0 .1 1 4 0 5 1 8 2 .8 0 .6 3 6 5 4 1 7 .9 3 3 3 3 4 1 .4 5 0 2 6 5 6 4 0 .8 0 0 0 0 3 3 .6 3 7 2 4 5 4 5 1 0 .5 3 2 .6 5 7 3 2
A A B 92146 0 .0 0 6 4 2 5 3 .4 2 3 8 6 8 4 2 .3 3 3 3 1 .0 9 9 8 4 9 8 2 9 9 .1 0 .3 4 2 5 7 9 8 7 1 0 1 .6 5 1 .0 7 8 2 2 5 6 1 5 4 5 .1 3 3 3 0 .9 1 9 0 5 5 2
M 847X 9 0 .0 0 4 6 1 4 0 .0 9 8 1 9 0 5 6 9 .6 0 .9 8 3 6 8 9 1 1 8 .6 6 6 6 6 4 0 .3 3 7 6 6 1 9 2 4 0 .5 5 0 0 0 3 1 .6 6 3 3 1 2 3 7 7 6 .8 6 6 7 1 .8 7 6 9 9 5 3
U 7 6 2 0 6 0 .0 0 4 3 4 3 0 .1 6 0 7 3 9 1 1 6 .5 0 .7 2 4 8 4 0 3 3 9 .7 3 3 3 3 4 1 .5 2 0 1 0 9 9 7 9 .8 9 9 9 9 4 1 .9 6 3 3 5 5 9 4 4 7 .8 6 6 7 1 .2 1 8 5 6 6
A A B 00686 0 .0 0 4 1 8 1 4 .5 3 4 0 5 8 6 3 4 2 0 .8 3 3 3 1 .3 0 0 6 1 8 8 1 0 6 2 .5 0 .3 3 0 2 4 4 5 4 2 9 4 .5 5 0 .6 7 8 3 6 5 8 2 4 8 1 .9 0 0 1 1 .1 8 7 4 X 1
X 59X 49 0 .0 0 3 1 8 5 6 .0 3 1 9 8 3 5 8 5 .6 3 3 3 6 1 .6 2 2 5 6 5 6 1 7 4 .7 3 3 3 4 0 .7 8 1 7 2 9 5 8 9 .8 0 .9 0 0 3 8 4 9 6 4 4 2 .0 9 9 9 8 0 .7 4 5 1 X 7 3
U 323X 4 0 .0 0 2 9 3 4 1 .1 4 6 0 4 3 7 5 1 .7 3 3 3 3 4 0 .8 5 4 8 1 5 8 4 7 .2 3 3 3 3 4 0 .6 4 2 3 5 3 5 3 3 .3 0 .8 3 3 4 0 2 7 2 2 2 .9 6 6 6 7 2 .0 0 8 7 7 6 2
U 3 6 9 9 2 0 .0 0 2 7 4 1 0 .1 1 4 4 2 3 5 7 5 .2 6 6 6 6 7 0 .5 1 6 1 5 5 3 6 2 6 .0 3 3 3 3 3 1 4 9 .5 1 .7 8 0 0 2 1 3 3 5 2 .2 3 3 3 4 2 .5 6 X 3 7 4
X 52X 40 0 .0 0 2 5 9 2 0 .4 6 3 3 2 2 0 4 3 7 .1 9 9 9 9 7 0 .9 5 6 6 2 8 8 6 9 7 .1 3 3 3 3 0 .2 3 7 0 4 9 2 5 2 2 .5 9 9 9 9 8 1 .7 4 6 9 6 8 0 7 .8 9 9 9 6 2 .5 5 1 2 0 4 2
AABX8593 0 .0 0 2 4 1 5 1 .0 7 7 1 2 9 2 2 6 3 .1 9 9 9 8 0 .4 8 8 1 0 4 5 1 4 1 .0 6 6 6 7 0 .9 3 9 9 9 7 8 5 2 6 5 .4 0 .9 7 3 5 1 1 6 4 1 2 0 6 .4 1 .1 X 1 6 9 1
A IX 71268 0 .0 0 2 3 0 7 3 .0 1 9 9 1 2 1 4 9 0 .8 3 3 4 0 .6 1 5 0 2 5 3 3 1 4 .4 0 0 0 2 0 .4 7 1 5 7 1 1 5 2 8 0 .0 5 0 .8 5 6 9 3 2 6 2 2 4 0 .7 6 6 6 0 .9 0 6 8 0 4 5
D 8 8 2 S 0 0 .0 0 2 1 9 2 0 .0 4 3 5 4 0 7 2 7 .1 3 3 3 3 3 0 .1 1 0 3 7 5 9 2 3 .9 3 3 3 3 4 0 .9 9 9 9 9 9 9 4 1 9 7 .9 2 .6 7 2 5 7 6 7 2 2 5 4 .7 9 9 8 3 .6 2 2 3 6 6
A P 0 0 7 7 5 8 0 .0 0 1 7 1 1 0 .0 8 6 5 0 8 0 1 6 .2 3 3 3 3 3 1 .0 6 3 3 7 9 8 1 0 1 .2 6 6 6 6 3 .0 2 6 5 9 9 2 7 7 .1 7 .1 1 0 3 7 3 2 6 7 4 .1 0 .4 X 5 1 5 8 8
A 16 3 9 3 0 8 0 .0 0 1 6 2 6 0 .9 9 4 4 0 2 7 1 9 .1 3 3 3 3 3 0 .3 8 7 6 4 2 5 3 9 .6 3 3 3 3 3 0 .6 7 3 7 0 5 0 4 1 5 .4 5 0 0 0 1 1 .7 7 8 2 3 5 8 1 6 3 .3 3 3 3 4 1 .2 0 5 3 6 5 7
M 6 4 7 8 0 0 .0 0 1 1 0 6 6 .1 0 2 5 9 1 5 1 4 8 4 .2 3 3 4 1 .4 0 4 0 6 2 4 3 8 3 .7 3 3 3 4 0 .7 7 5 3 9 6 2 1 9 .2 0 0 0 1 0 .7 2 9 7 2 2 8 6 9 9 9 .7 3 3 3 1 .2 9 4 0 6 9 8
3 7 1 8 .3 X 3 rc _ A A 8 0 0 X 3  E S T 1 9 0 3 X  R a t tu s  n o r v e g ic u s  CONA
4 5 7 .9 0 X 2  RATNPY02 N PY02 M 1 5 8 X  R a t n e u ro p e p tid e  Y mRNA
8 1 .8 rc_A A 81 8 4 0 3  s im ila r  t o  c y to c h r o m e  P 4 X  4 P 5  (C Y P4P5) mRNA
1 0 6 3 6 .3 9 9 rc _ A 1 1 8 X 1 3  E S T 2 2 3 7 4 4  R a ttu a  n o r v e g ic u s  CONA
7 0 6 .5  C a p n 3 A PD 52S 40 R a ttu a  n o rv a g lc u a  c a lp a M  la o to rm  L p85  mRNA
4 5 5 .3 9 9 9 6  R 3 , SETMKIR 136068 ( d o n a  R S T K -1) a a r ln a  th r e o n in e  k in a s e  r a c a p to r  ty p e  I mRNA
1 6 5 .7 1 2 0 4 X  R a ttu a  n o rv a g lc u a  c a r e b r o g ly c a n  mRNA
1 2 9 .1 3 X 5 IC J U 2 3 6 5 9 7  E S T 2 X 1 S 9  R a ttu a  n o r v a g lc u a  cONA
1 5 1 3 .4 3 3 3  G * tp2 X 0 2 9 0 4 c d a  RN G STP R a t m R N A  t a r  g lu ta tM o n a  S - t r a n a f a r a a a  P  a u b u n tt
3 0 8 2 .4  RNNGPRR X 0 5 1 3 7  R a t m R N A  to r  f a a t  n a rv a  g ro w th  f a c to r  r a c a p to r  (NG PR)
X 7 .9 6 6 6 7  G TP c v d o h v d ro la i! M SB364 R a t G TP c y d o h y d ro la e e  1 m R N A
6 4 6 .1 6 6 6 rc_ A A 8 7 4 7 9 1  U I-R -B O -b w -f-0 6 -O -tJI .S l R a ttu a  n o rv a g lc u a  cONA
7 9 7 .3 6 6 6 4 rc_ A A 8 7 4 7 8 4  u i-R -G O -b w -e -0 7 -O -U I .s l R a ttu a  n o rv a g lc u a  cONA
2 9 9 .1 rc_ A I1 7 8 2 0 6  E S T 2 2 1 8 7 3  R a ttu a  n o r v e g ic u s  cONA
5 1 2 .5 6 6 6 5  1D3 A P 0 0 0 9 4 2  R a ttu a  n o rv a g lc u a  10 3 a  mRNA
8 4 7 .4 6 6 7  C D 7 X 0 2 X 2  R a t th y - 1  g a n a  t a r  c a S -s u r fa c e  g ly c o p ro te in
5 5 6 5 .6 6 6 5  C * t3 rc _ A I2 3 1 2 9 2  E S T 2 2 7 9 X  R a ttu a  n o rv a g lc u a  cONA
4 2 3 4 .1 9 9 7 M 2 3 5 6 6 e x o n  RATA2MAC2 R a ttu a  n o rv a g lc u a  a to h a -2 -m a c ro o lo tx jlln  g a n a
4 3 0 5 .1 X 3  Lpl 1 0 3 2 9 4  R a ttu a  n o rv a g lc u a  a p o p ro te in  H paaa  mRNA
X 7 R a t m b ta d - tla a u a  lib ra ry  R a ttu a  n o rv a g lc u a  cON A  d o n a  r x 0 1 6 9 6
2 3 .4 0 0 0 0 2  ADPRHA M X 3 4 1  RATADPRHA R a t A O P -rlb o ay la rg ln ln a  h y d ro la s e  mRNA
4 2 4 3 .9 X  D RCF-5 U 9 5 X lU T R a i  R N U 9 5 X 1  d e v e ta p m e n ta H y - re g U a ta d  c a r d ia c  f a c to r  (D R C F -5)
4 8 2 .6 3 3 X  A lox5ap rc _ A U 0 4 7 8 1  E S T 2 1 4 0 7 0  R a ttu a  n o rv a g lc u a  CONA
2 1 0 .3 6 6 6 7  M a i r c _ A I 1 7 1 5 X  E S T 21 7 4 6 9  R a ttu a  n o rv a g lc u a  cDNA
6 3 7 .6 3 X A F 0 S 4 8 2 6  R a ttu a  n o rv a g lc u a  VAMPS mRNA
1 8 X .3 6 6 7 rc _ A A B X 2 9 8  E S T 1 8 9 7 9 5  R a ttu a  n o rv a g lc u a  cONA
3 7 3 .2  SOX10 A J X 1 0 2 9  R a ttu a  n o rv a g lc u a  m R N A  t a r  S o x lO  p ro ta ln
1 3 X . 0 X 7  ALDH A X 0 1 6 9 8  R a ttu a  n o rv a g lc u a  a ld a f iy d a  d e h y d ro g e n a s e  (ALDH) mRNA
9 0 9 .8 3 3 4 rc_ A A 8 9 2 4 1 4  E ST 1 9 6 2 1 7  R a ttu a  n o rv a g lc u a  cONA
6 9 3 3  3 6 6 rc _ A A 7 9 9 4 4 8  E S T 1 8 8 9 4 5  R a ttu a  n o rv a g lc u a  cONA
9 4 8 .4 X 62951m R N A  R N P 8U S 19  R .n o rv e g ic u s  (p 8 U S 1 9 )  w ltfi r a p a d t tv a  e le m e n ts
X 1 . X 3 3 4 X 0 4 1 3 9  R a t m R NA  3  r a g lo n  f ra g m e n t  fo r  p r o ta ln  U n a a a  C
7 1 1 .4 X 7  SH A RP-1 A P 0 0 9 3 2 9  e n h a n c a r -o f - a p l t t  a n d  h a iry - r e la te d  p r o te in  i  (SH A R P -1 ) mRNA
3 4 7 .2 rc _ A A 8 0 0 K 3  E S T 1 9 0 3 X  R a ttu a  n o rv a g lc u a  cONA
2 2 .7  e psH on  1 X 5 6 3 2 6 c d a  RNEP1GE R. n o rv a g lc u a  a p a * o n  l  g ta b m  g a n a
1 7 7 .1 rc_ H 3 3 0 9 3  K T 1 X 7 7 2  R a ttu a  n o rv a g lc u a  cDNA
5 2 1 4 .S X  1NVG34 X 1 3 0 4 4  R a t m R N A  fo r  M H C -a a a o d a ta d  I n v a r ia n t c h a in  g a m m a
1 5 7 4 .6 6 X rc_ A A 8 9 2 1 4 6  E S T 1 9 5 9 4 9  R a ttu a  n o rv a g lc u a  cONA
8 3 2 .1 3 3 X  RFM O IA M 8 4 7 1 9  R a t f lav ttv -c o n ta m m g  m o n o o x y g e n a a a  1 (FM O -1)
3 7 4 .8 9 9 9 6 U 7 6 2 X  R a ttu a  n o rv a g lc u a  VTR 1 5 - 2 0  r a c a p to r  mRNA
6 X 1 .5 9 9 6 rc_ A A 8 0 0 6 8 6  E S T 1 9 0 1 8 3  R a ttu a  n o rv a g lc u a  CONA
4 1 3 .6 0 0 0 4  NCAML1 X 5 9 1 4 9  R a t m R N A  t a r  n e u ra l  c a tt a d h e s io n  m o tc c t ie  LI
5 4 3  PC U 3 2 3 1 4  R a ttu a  n o rv a g lc u a  p y r u v a te  c a r b o x y la s e  mRNA
6 7 7 .6 3 3 3  C y p 7 b l U 3 6 9 9 2  R R U 36992  R a ttu a  r a t t u s  c y to c h r o m e  P 4 X  C y p 7 b l
1 3 7 0 X 5 2 1 4 0  R a t m R NA  to r  tn te g r tn  a lp h a - 1
2 1 1 8 .5 X 7 rc_A A 81 8 5 9 3  U I-R -A O -b c -g -O l-O -U I.s l R a ttu a  n o rv a g lc u a  cONA
2 X 5 . 4  103 rcu A I 1 7 l 2 X  E S T 21 7 2 2 3  R a ttu a  n o rv e g ic u s  cONA
4 3 2 0 0 X 2 5 0  R a ttu a  n o rv a g lc u a  m R N A  fo r  s e r in e  p r o te a s e
1 5 9 .0 6 X 7  S n c a A P X 7 7 X  R a ttu a  n o rv e g ic u s  a y n u d d n  1
1 4 5 .9 3 3 3 3 R a t m ix e d - t is s u e  lib ra ry  R a t tu s  n o rv a g lc u a  cONA d o n e  n t0 0 9 7 7
1 7 6 7 .6 3 3 3  AGR M 6 4 7 8 0  R a t a g r ln
Table 3.2 Mapping and annotation of the 130 genes/EST differentially expressed 
between E14 and E18
Total number of probes 130 (of which 65 corresponded to ESTs)
probes mapped to proteins 124 (94 mapped with Biopendium,
30 mapped by hand, 6 unmapped)
Proteins with Gene Symbol 110 (99 unique symbols)
Proteins for which Gene Ontology 
annotation was available
86
160
Table 3.3.1 Examples of genes up-regulated in t tie E14/E1 I transition
CATEGORY Set P value E14exp E l8 exp. Nr %
ECMtADHESION: 8 16%
X59859 Den 1 0.02176 84 1557
X52140 It gal 10 0.00259 37 97
SIGNALLING 9 18%
AA892338 Rassf2 10 0.02543 8 (A ) 45
AA799389 Rab3B 2 0.02098 29 57
A 1639338 Sla 2 0.01395 21 44
PROTEIN 6 12%
METABOLISM
AF052540 Capn3 8 0.01812 9 (A ) 40
D88250 C ls 10 0.00219 7 (A ) 24
CELL 8 16%
METABOLISM!
ENERGY 10 0.01043 39 75
AF001898 A ldhlal 1 0.03930 17 47
J03637 Aldh3al
MISCELLANEOUS 6 12%
AA799666 8 0.02033 4 (A ) 24
AF054826 Vamp5 2 0.01087 9 (A ) 40
CYTOSKELETON 4 8%
ORGANIZATION
AF007758 Syn-1 1 0.00171 6 (A ) 101
AF00228I Pdlim3 8 0.04171 63 210
TRANSCRIPTION 3 6%
FACTORS
M65149 Cebpd 10 0.04485 4 (A ) 38
ABO 12234 NF1-X 10 0.02965 11 (A) 60
CELL CYCLE 2 4%
REGULATION
NUCLEIC ACID 2 4%
METABOLISM
TRANSPORT 2 4%
IMMUNE 3 6%
RESPONSE
Set, set in which they cluster (Fig 3.4)
P value, value in the ANOVA/Welch t-test (p<0.05)
E l4 exp., raw level of expression at E l4 
E l8 exp., raw level of expression at E l8 
Nr, number of genes that fall in the category
%, percentage of genes that fall in the category relative to the total number of up- 
regulated genes 
(A), absent.
Table 3.3.2 Examples of genes down-regulated in the El 4/E 18 transition.
CATEGORY Set P value E14exp. E l8 exp. Nr %
TRANSCRIPTION 4 6%
FACTORS
AJ001029 S ox10 6 0.01048 881 259
L20681 Ets-1 5 0.04282 175 50
AF000942 Id3 3 0.01482 215 105
CELL METABOLISM1 11 15%
ENERGY:
M86341 Adprh 6 0.01392 53 7
A 1012589 Gstp-2 3 0.03768 1349 542
U32314 Pc 4 0.00293 51 11
SIGNALLING 10 14%
L10640 Acvrllb 6 0.04943 127 21
L29232 Igflr 6 0.03317 191 80
AA891302 Map4kl 5 0.02407 75 27
AA900505 RhoB 3 0.03629 1156 477
NUCLEIC ACID 9 13%
METABOLISM
U95001 Nudt4 5 0.01349 1243 407
D83948 RbmlO 3 0.03321 174 111
J03% 9 Npml 3 0.03057 1553 751
CELL CYCLE 6 8%
REGULATION
D 14014 Ccndl 3 0.03353 780 328
AF020618 M ydl 16 3 0.03856 216 124
CYTOSKELETON 6 8%
ORGANIZATION
U52013 Crmp-3 9 0.03318 422 18
U52102 Crmp-1 6 0.02751 336 34
Z12152 NF-M 9 0.02072 1258 171
M 64780 Agm 6 0.00110 1484 383
ECM/ADHESION 5 7%
L20468 Gpc2 6 0.01714 217 47
M84488 Vcaml 3 0.02845 51 19
X59149 LI 6 0.00318 585 174
MISCELLANEOUS 5 7%
IMMUNE RESPONSE 2 3%
TRANSPORT 2 3%
PROTEIN 3 4%
METABOLISM
UNKNOWN 3 4%
UNMAPPED 5 7%
Set, set in which they cluster (Fig 3.4);
P value, value in the ANOVA/Welch t-test (p<0.05);
E14 exp., raw level of expression at E14;
E l8 exp., raw level of expression at E l8;
Nr, total number of genes that fall in the category;
%, percentage of genes that fall in the category relative to the total number of 
down-regulated genes.
TABLE 3.4
LIST OF THE 110 GENES UP-REGULATED IN E18vsP12 AND DOWN-REGULATED IN P12vsP12CLTT
Accession number Gene
M 29249cds_at
rc_A A 894345_at
rc_A I045395_at
U 03416_at
U 67995_s_at
X 55286_g_at
A F003835_at
A F007758_g_at
rc_A A 800549_at
rc_A I072770_s_at
rc_A I177004_s_at
rc_A I228110_s_at
rc_H 33426_g_at
S53527mRNA_s_at
X62660mRNA_at
Z 49858_at
AF005720mRNA#3_s.
A J224879_at
M 72711_at
rc_A A 859980_g_at
rc_A A 892496_at
rc_A A 892500_at
rc_A I172293_at
rc_AI18 0 4 4 2_at
rc^A I638993_s_at
S 79711_g_at
U 02983_at
A J001029_at
Z12 1 52_at
D 30666_at
D 37920_at
LI 2 0 1 6_at
Ml 75 2 7 _ at
M 60322_at
rc_A A 799489_g_at
rcwA A 859980_at
rc_A A 892829_at
rc_A A 893982_at
rc_A I013107_at
rc_A I639294_at
U 75916_at
X 14265_at
J0 4 2 1 5 _ a t
L 01624_at
LI 3 6 1 9_g_at
M l5883_g_at
M55534mRNA_s_at
M 62763com plete_seq
M 73714_at
M89945mRNA_g_at
M 95591_at
M 95591_g_at
rc_A A 891797_at
M 29249cds RAT3H3M Rat 3-hydroxy-3-methylglutaryl coenzym e A reductase gene 
rc_AA894345 EST198148  Rattus norvegicus cDNA 
rc_AI045395 UI-R-C1-kg-a-11-0-Ul.sl Rattus norvegicus cDNA
U 03416 Rattus norvegicus neuronal olfactom edin-related ER localized protein (D 2Sut1e) mRNA 
U 67995 Rattus norvegicus stearyl-CoA desaturase 2 mRNA 
X55286 R.norvegicus mRNA for HMG-CoA reductase
AF003835 Rattus norvegicus isopentenyl diphosphate-dimethylallyl diphosphate isomerase mRNA
AF007758 Rattus norvegicus synuclein 1 mRNA
rc_AA800549 EST190046  Rattus norvegicus cDNA
rc_AI072770 UI-R-Y0-md-g-02-0-Ul.s1 Rattus norvegicus cDNA
rc_AI177004  EST220611 Rattus norvegicus cDNA
rc_A I228110 EST224805 Rattus norvegicus cDNA
rc_H 33426 EST109414 Rattus norvegicus cDNA
S53527mRNA S53517S3 S-100 beta  subunit
X62660mRNA RRGTS8 R.rattus mRNA for glutathione transferase subunit 8
Z 49858 R.norvegicus mRNA for plasmolipin
AF005720mRNA#3 Rattus norvegicus chloride channel (CIC-2) gene
A J224879 Rattus norvegicus mRNA for collagen alpha 1 type II
M 72711 Rat transcriptional repressor of myelin-specific genes (SCIP) mRNA
rc_A A859980 UI-R-E0-ca-h-07-0-Ul.s1 Rattus norvegicus cDNA
rc^A A892496 EST196299  Rattus norvegicus cDNA
rc_AA892500 EST196303  Rattus norvegicus cDNA
rc_AI172293 EST218294  Rattus norvegicus cDNA
rc_AI180442 EST224188 Rattus norvegicus cDNA
Rat mixed-tissue library Rattus norvegicus cDNA clone rxOI 608
S 7 9 7 1 1 CD3 gamma-chain
U02983 Rattus norvegicus secretogranin III (Sglll) mRNA
A J001029  Rattus norvegicus mRNA for Soxl 0 protein
Z12152 R.norvegicus mRNA for neurofilament protein middle (NF-M)
D 30666 Rat mRNA for brain acyl-CoA syn thetase  II
D37920 Rat mRNA for squalene epoxidase
LI 2016  Rat tricarboxylate transport protein mRNA
Ml 7 527  Rat GTP-binding protein (G-alpha-il) mRNA
M60322 Rat aldose reductase gene
rc_AA799489 EST18 8986  Rattus norvegicus cDNA
rc_A A859980 UI-R-E0-ca-h-07-0-Ul.s1 Rattus norvegicus cDNA
rc_AA892829 EST196632  Rattus norvegicus cDNA
rc_AA893982 EST197785  Rattus norvegicus cDNA
rc_AI013107  EST207782 Rattus norvegicus cDNA
Rat mixed-tissue library Rattus norvegicus cDNA clone rx05078
U 75916 Rattus norvegicus zonula occludens 2 protein (ZO-2) mRNA
X I4265  R.norvegicus CaMIII gene for calmodulin III
J0 4 2 1 5 Rat cell-binding bone sialoprotein mRNA
L01624 Rattus norvegicus serum and glucocorticoid-regulated kinase (sgk) mRNA 
LI 3619  RATCL6A Rattus ra ttu s insulin-induced growth-respons protein (CL-6) mRNA 
Ml 5883 Rat clathrin light chain (LCB2) mRNA 
M55534mRNA Rat alpha-crystallin B chain mRNA
M 62763completeSeq Rat 60 kDa protein and non-specific lipid transfer protein mRNA
M73714 Rat microsomal aldehyde dehydrogenase mRNA
M89945mRNA RATFARDIPH Rat farnesyl diphosphate synthase gene
M95591 RATSST Rattus ra ttu s hepatic squalene syn thetase mRNA
M95591 RATSST Rattus ra ttu s hepatic squalene synthetase mRNA
rc_AA891797 EST195600  Rattus norvegicus cDNA
rc_A A 892400_at
rc_A A 892557_at
rc_A A 893670_at
rc_A A 925248_at
rc_A I070277_s_at
rc_H 31550_at
U 31352_at
U 66470_at
U 67914_at
U 81037_at
X 55286_at
X 68101_at
rc_A A 799488_at
rc_A I103238_at
A F007758_at
A F022819_at
A F051425_at
D 86041_at
El 2625cds_at
M 22357_g_at
M 23601_at
M89945mRNA_at
rc_A A 892559_at
rc_A A 893032_at
rc_A A 894298_s_at
rc_H 31897_at
rc_H 33426_at
U 56839_at
X 04070_at
X 76489cds_at
D 78610_at
Ml 5944_at
M 25888_at
M 81225_at
rc_A I639012_at
rc_AI63 95 3 3 _g_at
U 31367_at
U 78102_at
X 52625_at
Z 29649_at
D 63834_at
D 84450_at
D 89983_at
L 14323_at
rc_A A 799340_at
rc_A A 800005_at
rc_A A 800576_at
rc_A A 892234_at
rc_A A 892557_g_at
rc_A A 893082_at
rc_A A 893581_at
rc_A I231292_at
rc_A I236145_at
rc_H 33491_at
S 45812_s_at
U41164_at
X 67788_at
rc_A A892400 EST196203 Rattus norvegicus cDNA
rc_AA892557 EST196360  Rattus norvegicus cDNA
rc_AA893670 EST197473  Rattus norvegicus cDNA
rc_AA925248 UI-R-Al-eh-h-08-0-Ul.sl Rattus norvegicus cDNA
rc_AI070277 UI-R-YO-ls-h-11-0-Ul.sl Rattus norvegicus cDNA
rc_H 31550 EST10 5682  Rattus norvegicus cDNA
U31352 Rattus norvegicus oxidosqualene cyclase mRNA
U 66470 Rattus norvegicus cell growth regulator rCGRl 1 mRNA
U 67914 Rattus norvegicus m ast cell carboxypeptidase A precursor (R-CPA) mRNA
U81037 Rattus norvegicus ankyrin binding cell adhesion molecule NrCAM (NrCAM) mRNA
X55286 R.norvegicus mRNA for HMG-CoA reductase
X68101 R.norvegicus trg  mRNA
rc_AA799488 EST188985  Rattus norvegicus cDNA
rc_A H 03238 EST212527 Rattus norvegicus cDNA
A F007758 Rattus norvegicus synuclein 1 mRNA
AF022819 Rattus norvegicus putative potassium channel TWIK
AF051425 Rattus norvegicus chondromodulin-1 (Chm-1)
D86041 Rat mRNA for N-G.N-G-dimethylarginine dimethylaminohydrolase 
El 2625cds cDNA encoding a ra t novel protein which is expressed with nerve injury 
M22357 Rat 1B236/m yelin-associated glycoprotein (MAG)
M23601 Rat monoamine oxidase B (Maobf3)
M89945mRNA RATFARDIPH Rat farnesyl diphosphate synthase gene
rc_AA892559 EST196362  Rattus norvegicus cDNA
rc_AA893032 EST196835  Rattus norvegicus cDNA
rc_AA894298 EST198101 Rattus norvegicus cDNA
rc_H31897 EST106437 Rattus norvegicus cDNA
rc_H 33426 EST109414 Rattus norvegicus cDNA
U56839 Rattus norvegicus P2u receptor protein
X04070 Rat liver mRNA for gap junction protein
X76489cds RNCD9 R.norvegicus CD9 mRNA for ceil surface glycoprotein
D78610 Rat mRNA for protein tyrosine phosphatase epsilon C
M15944 Rat enkephalinase (neutral endopeptidase) mRNA
M25888 Rat lipophilin mRNA
M81225 Rat farnesyltransferase alpha subunit
Rat mixed-tissue library Rattus norvegicus cDNA clone rx00627
Rat mixed-tissue library Rattus norvegicus cDNA clone rx02849
U31367 Rattus norvegicus myelin protein MVP17 mRNA
U78102 Rattus norvegicus krox20 mRNA
X52625 Rat mRNA for cytosolic 3-hydroxy 3-methylglutaryl coenzyme A synthase
Z29649 R.norvegicus (Wistar) mRNA for periaxin
D63834 Rat MCT1 mRNA for monocarboxylate transporter
D 84450 Rat mRNA for Na+,K+-ATPase beta-3 subunit
D 89983 Rattus norvegicus mRNA for antizyme inhibitor
LI 4323  Rattus norvegicus phospholipase C -beta lb  mRNA
rc_AA799340 EST188837  Rattus norvegicus cDNA
rc_AA800005 EST189502  Rattus norvegicus cDNA
rc_AA800576 EST190073  Rattus norvegicus cDNA
rc_AA892234 EST196037  Rattus norvegicus cDNA
rc_AA892557 EST19 6360  Rattus norvegicus cDNA
rc_AA893082 EST196885  Rattus norvegicus cDNA
rc_AA893581 EST197384  Rattus norvegicus cDNA
rc_AI231292 EST227980 Rattus norvegicus cDNA
rc_AI236145 EST232707 Rattus norvegicus cDNA
rc_H33491 EST109547  Rattus norvegicus cDNA
S 45812 monoamine oxidase A
U41164 Rattus norvegicus Cys2/His2 zinc finger protein (rKr1) mRNA 
X67788 R.norvegicus mRNA for ezrin p81
Table 3.5. Mapping and annotation of the 237 genes/ESTs differentially expressed 
between P12 and P12cut
Total number of probes 237 (of which 96 corresponded to ESTs)
Probes mapped to proteins 233 (194 mapped with Biopendium,
39 mapped by hand, 4 unmapped)
Proteins with Gene Symbol 199 (176 unique symbols)
Proteins for which Gene Ontology 
Annotation was available
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Table 3.6.1 Examples of genes up-regulated after nerve cut.
CATEGORY Set P value PI 2 exp. P I2 cut exp. Nr %
CELL M ETABOL./ENERGY 14 20%
AA851223 Eno3 12 0.03821 1158 6544
All 71644 Cox6a2 12 0.04598 1270 8210
AF090867 Gmpr 13 0.04945 164 802
IMMUNE RESPONSE 10 14%
U42719 C4 12 0.03783 618 3075
M15562 MHC-IIRT1-D 12 0.02946 1519 6947
S49491 Penk-rs 1 0.00877 292 573
U65217 MHC-II RT-B1 12 0.03874 87 469
CYTOSKELETON 7 10%
ORGANIZATION
AI638986 NEB 12 0.00119 60 627
U30938 M tap-2 1 0.02762 177 338
AA800735 Svil 1 0.01960 1262 2794
MISCELLANEOUS 6 8%
AA874803 BRAK 1 0.03849 325 959
AI639162 Angpt-1 13 0.02137 289 526
TRANSPORT 5 7%
AI230614 A tplbl 13 0.03483 115 384
AA894296 Pgml 13 0.00076 1197 4102
TRANSCRIPTION FACTORS 5 7%
X60769 Cebpb 12 0.02637 364 1106
AA945867 Jun 13 0.03069 357 1801
M91802 Hox2a 1 0.00573 215 483
UNMAPPED 5 7%
ECM /CELL ADHESION 4 6%
AA893846 Tnn 12 0.00118 60 627
S61865 Sdcl 1 0.03118 214 524
PROTEIN M ETABOLISM 4 6%
L03201 Ctss 13 0.02422 2064 5931
SIGNALLING 4 6%
AI639338 Sla 13 0.00566 294 507
M91599 Fgf4 13 0.00307 132 369
CELL CYCLE/GROW TH 4 6%
REGULATION
D14015 CycE 1 0.00098 174 407
Ml 5428 Rafl 1 0.03913 4534 7110
NUCLEIC ACID 4 6%
METABOLISM
LIPID METABOLISM 1 1%
Set, set in which they cluster (Fig3.11);
P value, value in the ANOVA/Welch t-test (p<0.05);
PI 2 exp., raw level of expression at PI 2;
P12cut exp., raw level of expression after nerve cut;
Nr, number of genes that fall in the category;
%, percentage of genes that fall in the category relative to the total number of 
up-regulated genes.
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Table 3.6.2 Examples o f genes down-regulated after nerve cut.
CATEGORY Set P value P12 exp. P12 cut exp. NR %
LIPID SYNTHESYS- METABOLISM 30 19%
All 77004 Hmgcsl 3 0.00357 11092 343
M89945 Fdps 11 0.02256 7430 1201
AF003835 ldi3 3 0.00764 10122 462
El 2625 Sc4mol 11 0.04212 3423 206
D37920 Sqle 7 0.01301 4802 486
M95591 Fdftl 9 0.00174 1501 270
CELL METABOLISM- ENERGY 22 15%
M23601 Maob 11 0.01661 2844 222
M60322 Aldrl 7 0.04801 8622 3505
AA894345 PEA 15 2 0.04382 4491 1052
J05210 Acly 10 0.01388 2411 726
TRANSPORT 14 9%
AF022819 Kcnkl(TWlK) 11 0.03288 1989 143
AA925248 Scn6a 9 0.02137 3922 489
D 17521 Clcn3 14 0.03041 2777 874
AF005720 Clcn2 4 0.01939 370 68
SIGNALLING 14 9%
AI 103238 Pppr2b2 10 0.00595 714 203
U56839 P2ry2 11 0.02865 1403 330
AA892496 Chn2 4 0.03820 1020 292
CYTOSLELETON ORGANIZATION 11 7%
AF007758 Syn-1 (Snca) 3 0.00659 10652 543
Z29649 Prx 13 0.03604 13791 472
AA800549 PPP1R1-I6b 3 0.00124 1031 204
M55534 Cry-ab 9 0.02256 15504 5379
ECM/ ADHESION 11 7%
AA892798 Usag-1 7 0.00619 3143 464
S53527 SlOOb 3 0.04514 15191 4243
X04070 Cx32 (Gjbl) 11 0.03993 1763 252
U03416 Olfml 2 0.00001 974 280
MYELIN RELATED 8 6%
U31367 Mai 14 0.02237 13170 357
Z49858 Pmlp 3 0.03787 6367 35
Z29649 Prx 13 0.03604 13791 472
AI228110 Ugt8 3 0.02437 17975 905
A1072770 PLP 3 0.00154 3791 359
M22357 Mag 11 0.02723 3769 411
CELL CYCLE- GROWTH REGULATION 8 6%
AA892559 Cntf 11 0.01411 4845 178
U66470 Cgrl 1 9 0.00715 429 158
U09793 Kras2 7 0.04847 771 285
PROTEIN METABOLISM 7 5%
Ml 5944 Enk 14 0.02194 897 199
AA894298 Mme 11 0.02643 369 14
U67914 Cpa3 9 0.03054 1860 1300
MISCELLANEOUS 7 5%
TRANSCRIPTION FACTORS 6 4%
U78102 Krox20 14 0.00097 2820 354
M72711 Oct6 4 0.02127 883 148
AJ001029 Sox10 5 0.04982 1091 373
U 10995 Coup-Tfl 10 0.01564 1622 684
AA893082 Ma£2 15 0.02240 4241 3462
CARTILAGE/BONE RELATED 5 4%
AJ224879 Col2al 4 0.01516 10404 122
AF051425 ChM-1 (Lect-1) 14 0.03232 4204 62
A1639294 Sparc 7 0.00022 509 46
J04215 Ibsp 9 0.00119 273 33
AF104362 Omd 15 0.02201 746 288
UNMAPPED 4 3%
NUCLEIC ACID METABOLISM 2 1%
Set, set in which they cluster (Fig 3.11);
P value, value in the ANOVA/Welch t-test (p<0.05);
P12 exp.,raw level of expression at P12;
P12cut exp., raw level of expression after nerve cut;
Nr, number o f genes that fall in the category;
%, percentage of genes that fall in the category relative to the total number of down- 
regulated genes.
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CHAPTER 4
Novel cartilage/bone related and cytoskeletal genes identified in the
peripheral nervous system
INTRODUCTION
In chapter 3 we have seen that, along with the expected myelin-related genes, a number 
of genes not previously characterised in Schwann cells were up-regulated during 
development and suppressed after nerve injury, a combination that points to them 
possibly being involved in myelination. Two groups were particularly interesting, due 
to the high level of expression and dramatic down-regulation. The first, including 
collagen alphal type II and chondromodulin-1, is composed of genes that encode for 
proteins known to localise in the extracellular matrix (ECM) in cartilage and/or bone, 
and that are involved in both the development and maintenance of these two tissues. 
The second is a small group of genes, such as synuclein-1 and alpha-B-crystallin, 
encoding for proteins that localise in the cytoplasm and could be related to cytoskeleton 
rearrangements and to signalling (see Table 3.6.2).
Both the ECM and cytoskeleton play crucial roles during nerve development and 
myelination, which makes these two groups of genes even more interesting.
The ECM in peripheral nerve
The ECM is a fundamental component of the PNS, where it is involved in cell 
migration, proliferation and maintenance of cell shape. The components of the ECM, 
collagens, glycoprotein and proteoglycans, are synthesised by the surrounding cells, and 
form a complex lattice that provides mechanical strength and acts as a guide for the 
developing neural crest (Chemousov and Carey, 2000). The ECM, and in particular
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fibronectin and laminins, creates a permissive substrate for axon migration, facilitating 
nerve development (Krull and Koblar, 2000). Other molecules, such as tenascin-C and 
collagen types II, III and IX are non-permissive during neural crest migration and axon 
pathfinding (Krull and Koblar, 2000; Perris, 1997). Finally, molecules such as 
aggrecans have an inhibitory role in neural crest migration, meaning that they can either 
directly or indirectly interact with the neural crest and impede cell motility (Perris,
1997). Neural cells interact with the ECM via integrins (see chapter 1), which in turn 
interact with the cytoskeleton and trigger intracellular signalling pathways (Previtali et 
a/., 2001).
Collaeens
Collagens are a major constituent of the mammalian ECM. So far at least 19 different 
collagen molecules have been identified, and can be subdivided into fibrillar and non- 
fibrillar collagens. In fibrillar collagens, such as type I, II and III, a highly stable triple 
helix forms cable like molecules which confer tensile strength to structures like tendons 
and ligaments. Non-fibrillar collagens, like collagen type IV, act as adaptors between 
matrix components (Carey et al., 1983).
Many collagens are expressed throughout the nervous system. In mouse, endoneurial 
collagen type III appears around E l5, and seems to be synthesised by Schwann cells 
(Osawa and Ide, 1986). Type I collagen is instead found mainly in the epineurium, and 
its marked reduction could be at the base of the disrupted integrity of the blood-nerve 
barrier in the desert hedgehog null mouse (Osawa and Ide, 1986; Parmantier et al., 
1999).
Collagen type IV is highly expressed in peripheral nerve, where it forms stable sheets 
within basal laminae (Carey et al., 1983). Together with laminin, collagen type IV is
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organised in a network like structure that provides physical support to the endoneurium 
and forms a potential basis for the selective barrier function of the perineurium 
(Williams et al., 2000).
Schwann cells also synthesise collagen alpha 4 type V (also known as p200), which 
binds with high affinity to heparin-like glycosaminoglycans (Chemousov et al., 2000). 
In culture, this collagen actively promotes the migration of pre-myelinating Schwann 
cells, but inhibits axonal outgrowth (Chernousov et al., 2001). This difference could 
facilitate Schwann cell ensheathment of axons and at the same time restrict the 
movement of axons promoting fasciculation (Chemousov et al., 2001).
Another collagen expressed by Schwann cells is collagen alpha 1 type VI (Col6al) 
(Jaakkola et al., 1989). It interacts with many other components of the ECM, including 
collagen IV, fibronectin, biglycan and decorin (Vitale et al., 2001). Collagen VI is not 
expressed by the neural crest, but is actively synthesised by Schwann cells from around 
E l5 (in the mouse) onwards and the activation of its transcription is stimulated by 
neuregulin, as part of the differentiation program from precursors to Schwann cells 
(Vitale et al., 2001). After the acquisition of the Schwann cell phenotype, the 
expression of col6al becomes independent of neuregulins, and is maximised when the 
cell withdraws from the cell cycle (Vitale et al., 2001).
More recently, collagen alpha 1 type XIII has been localised to CNS neurons and to 
developing PNS (Sund et al., 2001). Its function is not clear yet, but it has been 
suggested that it may facilitate cell-cell and cell-ECM interactions (Kvist et al., 2001).
Fibronectin
Schwann cell synthesise a fibrillar network consisting of laminin, fibronectin and 
collagen type IV, which is believed to be involved in Schwann cell proliferation
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immediately before myelination (Chemousov et al., 1998). Fibronectin deposition 
depends on the presence of collagen IV in the ECM. Treatment with collagenase 
dramatically decreases the amount of fibronectin fibrils, and Schwann cells cultured on 
collagen IV coated coverslips deposit a rich network of fibronectin (Chemousov et al., 
2001). Fibronectin null mice die during gestation, probably as a result of cardiovascular 
defects (George et al., 1993; 1997). Development of the nervous system is also 
disrupted, with absence of the notochord and incomplete closure of the neural tube 
(George et al., 1993).
Tenascins
The tenascin family consists of five members, tenascin-C, R, X, Y and W. They are 
involved in many events such as morphogenesis, tumor metastasis and neural migration 
(Mackie and Tucker, 1999). Tenascin-C and -R  contain repetitive fibronectin III and 
EGF-like domains and, along with tenascin-Y are expressed in the nervous system 
(Joester and Faissner, 2001). Tenascin-R is expressed mainly in the CNS by 
oligodendrocytes during myelination (Xiao et al., 1997), while the expression of 
tenascin-Y has been detected in the developing PNS in chick, although its function 
remains obscure (Joester and Faissner, 2001). Tenascin-C is expressed in both CNS and 
PNS. It has the ability to both stimulate and inhibit growth cone extension and is 
actively involved in sciatic nerve regeneration (Joester and Faissner, 2001). 
Surprisingly, tenascin-C null mice did not present any obvious phenotypic abnormality 
(Forsberg et al., 1996; Kiernan et al., 1999), suggesting a possible redundancy of 
tenascin-C resulting in the ability of tenascin-R or others to take its place. However, a 
more careful analysis of the tenascin-C null mice revealed more subtle phenotypes, such 
as deficits in coordination and hyperlocomotion (Kiernan et al., 1999).
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Laminins
As we have already seen in the general introduction, Schwann cells synthesise large 
amounts of laminins, which are one of the major components of the basal lamina 
(Combrooks et al, 1983; Podratz et al., 2001). In the ECM, laminins associate with 
collagen IV; integrins and dystroglycan are the major receptors for laminins on the 
Schwann cell surface (reviewed in Previtali et a l , 2001). Laminin-2 is produced by 
Schwann cells and appears to be involved in nerve regeneration (Kamiguchi et a l ,
1998). Aberrant expression of laminins has been associated with various muscular 
dystrophies in which normal nerve development, regeneration and function are impaired 
(Gustafsson and Fassler, 2000; Uziyel et al., 2000).
Proteoglycans
In recent years the interest in proteoglycans in the nervous system has increased 
dramatically. This is mainly due to the idea that the environment that favours nerve 
regeneration may involve proteoglycans that have undergone enzymatic cleavage 
(Ferguson and Muir, 2000; reviewed in Hartmann and Maurer, 2001). Among the 
proteoglycans with emerging roles in the PNS are the testicans (Hartmann and Maurer,
2001), although the expression of most proteglycans in sciatic nerve remains to be 
established. In contrast, in the CNS proteoglycan turnover is not present and this could 
be one of the reasons for the lack of neuronal regeneration.
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MMP and TIMPs
The ECM in peripheral nerve is also rich in matrix metalloproteinases (MMP) and in 
tissue inhibitors of matrix metalloproteinase (TIMPs). The role of MMP is probably that 
of remodelling the ECM to allow processes such as migration, wound repair and cell 
death, necessary to maintain the health of the individual (reviewed in Murphy and 
Gavrilovic, 1999). MMP are endopeptidases that can degrade many constituents of the 
ECM. They are synthesised as inactive precursors and become active after removal of 
the propeptide (Stemlicht and Werb, 2001). Excessive activity of MMPs is limited by 
TIMPs (Baker et al., 2002). MMP-2, -3, -9 and -13 are expressed in the nervous system 
during normal development and after injury, as well as in some disease states, such as 
after ischaemia (reviewed in Platt et al., 2001).
The role of cytoskeleton in myelination
There is a strong correlation between the ECM and Schwann cell cytoskeleton. As we 
have already mentioned in Chapter 1, myelinating Schwann cells polarize along the 
axon and the abaxonal membrane directs the formation of the basal lamina, which is 
essential for myelination (Bunge et al., 1986; Bunge 1993). Laminin 2 associates on the 
Schwann cell surface with integrins, in particular with integrin a 6 p l,  and it appears 
likely that integrin pi is necessary to link the laminin-2 in the basal lamina to the 
cytoskeleton (Bunge 1993; Feltri et al., 2002). The severe phenotype observed in both 
laminin-2 and pi mutants (see chapter 1) suggests that the laminin-integrin complex is 
fundamental for the proper onset of myelination (Uziyel et al., 2000; Feltri et al., 2002; 
reviewed in Previtali et al., 2001; Jessen and Mirsky, 2004).
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Neuron-Schwann cell co-cultures have demonstrated that integrin pi interacts with the 
actin-linked protein paxillin and with focal adhesion kinase (Chen et al., 2000). 
Interestingly, in vitro experiments showed that the disruption of the actin cytoskeleton 
blocks myelination (Fernandez-Valle' et al., 1997). In turn, paxillin binds merlin (also 
known as Schwannomin), the product of the neurofibromatosis type 2 tumor suppressor 
gene, a protein that could have a role in the control pf Schwann cell proliferation. 
Merlin, which is related to the ezrin/moesin family of protein, localises in paranodes 
and Schmidt-Lanterman incisures, and interacts with spectrin, a cytoskeletal protein that 
can bind actin. This interaction results in an indirect link between merlin and actin, and 
treatment of Schwann cells with antisense nucleotide to merlin cause dramatic changes 
in the cytoskeleton (Scherer et al., 2001; Scoles et al., 1998). As mentioned in Chapter 
3, the actin cytoskeleton can also be influenced by treatment of cultured Schwann cells 
with LPA and sphingosine 1-phosphate (SIP) (Weiner et al., 2001; Li et al., 2003; 
Barber et al., 2004). Both LPA and SIP determine rearrangements in actin cytoskeleton 
via the small GTPase Racl (Barber et al., 2004). LPA also induces focal adhesion of 
paxillin and vinculin, and induces N-cadherin/catenin mediated Schwann cell-Schwann 
cell interactions (Wanner and Wood, 2002). Rho and its downstream effector Rho 
kinase (ROCK) have been shown to be important regulators of the Schwann cell 
cytoskeleton: pharmacological inhibition of ROCK results in loss of stress fibres and 
microvilli in Schwann cells and in aberrant myelination in neuron-Schwann cell 
cocultures (Melendez-Vasquez et al., 2004). Actin also binds dystonin, and mice with 
mutations in this cytoskeletal protein have an abnormal myelination and disorganized 
cytoskeleton (Bernier et al., 1998).
Besides integrins, laminins also bind to dystroglycan. Mice in which dystroglycan has 
been specifically ablated in Schwann cells present severe neurological dysfunction,
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have slow conduction velocity accompanied by disorganized microvilli, and reduced 
sodium channel density at the Node of Ranvier (Saito et al., 2003). In skeletal muscle, a  
and P-dystroglycans form complexes with the dystrophin-like family of proteins, which 
comprises dystrophin, utrophin (DRP1) and dystrobrevin. These complexes link the 
ECM to the cortical actin cytoskeleton (reviewed in Sherman and Brophy, 2004). 
Schwann cells highly express another member of the dystrophin-like family, DRP2 
(Sherman et al., 2001). DRP2-dystroglycan complexes bind the cytoskeletal protein L- 
periaxin (see chapter 1), and this binding is necessary to stabilize axon-glia interaction 
(Gillespie et al., 2000; Sherman et al., 2001). While periaxin is already present during 
embryonic development, dystroglycan appears perinatally, and DRP2 soon after birth 
(Sherman et al., 2001). It is possible that the formation of the dystroglycan-DRP2- 
periaxin complex alters the cytoskeletal organisation at the moment when Schwann 
cells exit the cell cycle and begin to synthesise myelin (Wrabetz and Feltri, 2001). 
Moreover, recent studies have demonstrated the importance of the complex for the 
formation of cytoplasmic channels and for intemodal length (Court et al., 2004).
Taken altogether, these data show that ECM and cytoskeleton play a crucial role in 
many aspects of Schwann cell biology, such as migration, proliferation, differentiation 
and myelination. The identification of new ECM and cytoskeletal proteins could be 
very helpful in the understanding of these events.
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RESULTS
Cartilage gene expression during peripheral nerve development
Probably the most surprising finding in our array profiling was that a group of genes, 
relevant for cartilage and bone formation, was developmentally regulated in myelinating 
nerves. Collagen alpha 1 type II (Col2al), Chondromodulin-1 (ChM-1) Osteonectin 
(SPARC), Osteoadherin (Omd), and bone sialoprotein II (Ibsp) increased in expression 
levels during nerve development up to P I2, and were strongly down-regulated after 
nerve cut (Table4-1).
Col2al and ChM-1 RT-PCRs
Table4-1 shows that Col2al and ChM-1 were, among the cartilage related ones, the two 
genes with the highest mRNA level of expression, and with the most dramatic fold 
change following nerve transection. For these reasons we chose to analyse them further. 
In Chapter 3 we have seen that RT-PCR experiments confirmed their regulation during 
development and after nerve cut (Fig 3.13A). While Col2al appeared to be evenly 
distributed between myelinating and non-myelinating cells, ChM-1 seemed to be 
enriched in myelinating Schwann cells (Fig 3.14), and both genes were up-regulated 
after stimulation of cultured Schwann cells with dbcAMP (Fig 3.15).
In situ hybridization and multiplex RT-PCR showed that type IIA is the Col2al 
isoform expressed in peripheral nerve
Col2al can be generated in two isoforms, due to alternative splicing of the precursor 
mRNA. Type IIA, the form containing a cysteine-rich domain in the NF^-propeptide 
(exon 2), is expressed by precartilage and also by noncartilage epithelial and
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mesenchymal cells, while type IIB, in which exon 2 is absent, is characteristic of 
chondrocytes only (Sandell, 1994; Zhu et al., 2001). In situ hybridisation on sections 
from PI sciatic nerves, performed with a probe that recognises the fibrillary part of the 
collagen, and thus both isoforms, and with another probe specific for exon 2, showed a 
clear signal in both cases, suggesting that the IIA isoform is the main one in peripheral 
nerve (Fig 4.1 A). To confirm this result we performed multiplex RT-PCR experiments 
(as in Urabe et al., 2003), which clearly showed that the expression of the IIB isoform is 
only marginal compared to that of the IIA form (Fig 4. IB).
Type II collagen protein is down-regulated after nerve injury
The down-regulation of Col2al after nerve cut was confirmed at the protein level too: 
Western blot experiments, performed with an antibody that recognises specifically the 
type IIA collagen, showed a band of the expected size in P12 sciatic nerve extracts, a 
band which is strongly reduced in extracts from nerves subjected to transection (Fig 
4.2A). Often, two bands of smaller molecular weight were also visible, both in whole 
sciatic nerve extract and in protein samples from immunopurified Schwann cells (Fig 
4.2B). These bands are likely to represent cleaved NF^-propeptides of the type IIA 
collagen, as bands of similar molecular weight have been seen in serum (L. Sandell, 
personal communication) and after treatment of type IIA procollagen with matrix 
metalloproteinases (MMPs)(Fukui et al., 2002).
Col2al expression during Schwann cell development
The array results suggested that Col2al, at the mRNA level, was expressed at least as 
early as E l4. To assess when the protein was expressed, we immunolabeled a series of 
cell cultures. These immunolabellings showed that the protein was already detectable in
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the migrating neural crest and its expression was maintained throughout development 
(Fig 4.3). In immature Schwann cells examined in teased E l8 nerves, the protein was 
mainly found in the perinuclear area, while in mature myelinating fibres Col2al 
accumulated in the paranodal region. Prominent staining was also detectable between 
tightly apposed fibres in teased adult nerves (Fig4-4).
Col2al is evenly expressed in myelinating and non-myelinating Schwann cells
It was interesting to notice that although Col2al seemed to be equally distributed in 
myelinating and non-myelinating Schwann cells (Fig 3.14), its expression was 
completely abolished by nerve cut at both mRNA and protein level (Fig 3.13A and 4.2), 
suggesting an axonal regulation in both cell types. In order to confirm that Col2al is 
expressed by both Schwann cell lineages, we immunolabelled a series of teased fibres 
and cultured Schwann cells from the sympathetic trunk, were most of the cells are of the 
non-myelinating type. These experiments confirmed that Col2al is widely expressed in 
non-myelinating Schwann cells in vivo and in vitro (Fig 4.5).
The transcription factor Sox9 is expressed and regulated in peripheral nerve
As already mentioned, to date, only three transcription factors, Sox 10, Oct-6 and Krox- 
20 have been shown to be of crucial importance for Schwann cell development and 
myelination in vivo. It is therefore highly likely that other transcription factors not yet 
identified concur in the regulation of these complex events. The transcription factor 
Sox9 is required for neural crest development and glial fate choice, and controls Col2al 
expression during chondrocyte differentiation (Cheung and Briscoe, 2003; Stolt et al., 
2003; Bell et al., 1997; Akiyama et al., 2002). Therefore we asked if it could have a 
similar function in Schwann cells. Sox9 is not present on the Affymetrix U34A array,
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therefore as a preliminary experiment we performed a series of RT-PCRs to determine 
whether it was expressed in peripheral nerve. Fig 3.13A (Chapter 3) shows that Sox9 
mRNA is expressed as early as E l4 and that it decreases, although not dramatically, 
after sciatic nerve injury. Intriguingly Maf-2, a transcription factor that collaborates 
with Sox9 in controlling Col2al (Huang et al., 2002), was also detected in our 
screening and decreased after nerve transection, a finding confirmed by RT-PCR (Fig 
13.3A) that suggest a possible interaction of these transcription factors in controlling 
Col2al in peripheral nerve.
Sox-9 protein expression in Schwann cells
To verify whether Sox-9 mRNA expression in the peripheral nerve reflected a true 
protein expression, we performed immunolabelling on cell cultures and on teased nerve 
preparations. These experiments showed that the protein was expressed in Schwann cell 
precursors and in Schwann cell cultures from new-born sciatic nerves, with only 
marginal expression detectable in fibroblasts (Fig 4.6). In adult nerves Sox9 remained 
strongly expressed, although, contrary to earlier stages of development, it seemed to 
accumulate more in the perinuclear area than in the nucleus, possibly indicating an 
inactive state (Fig 4.7).
Cytoskeletal genes in peripheral nerve: Snca and Cry-ab
It was extremely interesting to notice that two of the genes that were strikingly up- 
regulated during myelination and down-regulated in cut sciatic nerves, aSynuclein 
(Snca) and alpha-B-crystallin (Cry-ab) (Table 4-2), colocalize in glial cytoplasmic 
inclusions in multiple system atrophy (MSA), and have both been implicated in 
neurological diseases, including Alzheimer's and Parkinson's diseases (Gai et al., 1999;
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Kahle et al., 2002; reviewed in Eriksen et al., 2003). Immunoreactivity to Snca in 
Schwann cells has been previously reported (Mori et al., 2002), and Snca was detected 
in array profiling of mouse sciatic nerve (Nagarajan et al., 2002), while Cry-ab is 
constitutively expressed in the lens of the eye, in kidney epithelium, and has been 
identified as a candidate autoantigen in multiple sclerosis (van Noort et al., 1995). 
However, the expression of these proteins in peripheral nerve has not been investigated 
in detail and their roles remain unknown.
As described earlier, RT-PCR experiments showed a weak band corresponding to Snca 
at E l4, while it was clearly expressed at E l8 and found at much higher levels at P7 and 
PI 2, with sciatic nerve cut resulting in a large down-regulation of mRNA levels. Cry-ab 
was expressed later in development, with a clear band visible only at P7, and there was 
a significant down-regulation in the cut nerve (Fig. 3.13A). Snca appeared to be 
enriched in myelinating Schwann cells at P3, while Cry-ab was equally expressed in 
myelinating and non-myelinating Schwann cells at that stage. Snca, but not Cry-ab, was 
up-regulated after treatment of cultured Schwann cells with dbcAMP (Fig 3.14 and 
3.15).
Snca and Cry-ab proteins are down-regulated after nerve cut
Western blot and immunolabelling experiments confirmed that Snca and Cry-ab were 
highly expressed in mature nerves, and that the down-regulation after nerve injury 
happens at the protein as well as mRNA level (Fig4.8). These western blot experiments 
also suggested that Schwann cells are the main cell type to express the proteins in 
peripheral nerve, since the protein levels in immunopanned Schwann cell cultures are 
comparable to those in the whole sciatic nerve before injury.
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Snca and Cry-ab expression in adult sciatic nerves
To localise the proteins expression in adult sciatic nerve, teased nerve preparation were 
immunolaballed with antibodies against Snca and Cry-ab. Cry-ab immunolabelling was 
detected in the perinuclear area and in the cytoplasmic collar but not in Schmidt- 
Lanterman incisures, while these structures showed Snca immunoreactivity (Fig4-9). 
To confirm this finding, we carried out double immunolabelling with MUPP-1 and 
neurofascin (Nfasc), two proteins known to locate in incisures and in paranodal loops 
(Poliak et al., 2002; Tait et al., 2000). Figure4 .10 shows that Snca colocalised with 
MUPP-1 and Nfasc in incisures and at nodes of Ranvier, suggesting a possible role for 
synuclein in the cyto-architecture of these complex structures.
Snca protein expression is developmentally regulated and enriched in myelinating 
Schwann cells
The RT-PCR experiments previously performed (Fig 3.13 and 3.14) suggested that 
Snca expression is regulated during development and is higher in myelinating Schwann 
cells than in non-myelinating ones. To verify whether the developmental regulation was 
detectable at the protein level too, we cultured E l4 Schwann cell precursors in the 
presence of p-neuregulin, a condition under which they convert to Schwann cells with a 
time course that is broadly similar to that with which Schwann cells appear in 
embryonic nerves in vivo (Dong et a l , 1995). In line with RT-PCR data, we found only 
very low Snca immunoreactivity in E l4 Schwann cell precursors. When E l4 precursors 
were maintained in p-neuregulin for 4 days allowing them to convert to Schwann cells, 
Snca immunoreactivty reached the levels seen in immature Schwann cells from E l8 
nerves (Fig^.. 11). Moreover, to confirm the enrichment of Snca in myelinating cells, we 
performed double immunolabelling of cultured Schwann cells from the sympathetic
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trunk with antibodies against Snca and against the myelinating Schwann cell specific 
protein periaxin (Prx). These experiments showed that Snca in expressed mainly by 
myelinating Schwann cells, although it can also be occasionally found at lower levels in 
non-myelinating Schwann cells (Fig4-12). Similar staining performed with antibodies 
against Cry-ab and the Schwann cell marker S I00, showed that Cry-ab is equally 
expressed by the two Schwann cell types (Fig4.13), in agreement with the RT-PCR 
results.
Snca -/- mice do not show any gross abnormalities in peripheral nerve
The mouse C57BL/6J inbred strain from Harlan UK has a ~2cM deletion in the 
synuclein-1 locus that results in the complete inactivation of the gene (Specht and 
Shoepfer, 2001). We therefore analysed the morphology of the sciatic nerve in these 
mice, to test whether Snca could play a role either during myelination or in the 
maintenance of the myelin sheath. Semi thin sections were obtained from adult (3-6 
month old) sciatic nerves and stained with toluidine-blue (Fig.4.14). No gross 
abnormality in the nerve structure or in myelin thickness was identified in any of the 
animals analysed compared to control mice.
As we have seen previously, in adult rat sciatic nerve, Snca localises in Schmidt- 
Lantermann incisures and in nodes of Ranvier. To test whether the lack of Snca could 
result in an impairement in these structures, we immunolabelled teased nerve fibres 
from Snca -/- and control mice with antibody against Snca, Nfasc and Mupp-1. Fig. 
4.15 shows that in the absence of Snca, Mupp-1 and Nfasc appear to localise correctly 
in Schmidt-Lantermann incisures and nodes, indicating that Snca is probably 
dispensable for the cyto-architecture of these structures.
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DISCUSSION
As mentioned in Chapter 3, in our experimental conditions we found that 110 out of the 
162 genes/ESTs down-regulated after nerve cut, were also induced during the active 
phases of myelination, a combination that strongly indicates that they are myelin 
related. As expected, we found numerous genes already known to be involved in myelin 
synthesis, including the transcription factors Oct6  and Krox20, the myelin proteins PLP, 
MAG and plasmolipin, as well as many genes related to cholesterol and lipid 
metabolism. The presence in the same group of novel genes known to be related to 
cartilage/bone synthesis and maintenance or to cytoskeletal reorganization suggests that 
they may also have a role in peripheral nerve development and myelination.
Cartilage/bone related genes in peripheral nerve
Collagen alphal type II (Col2al)
Type II collagen is a major component of cartilage and provides structural integrity to 
the tissue. Type II procollagen can be expressed in two forms by differential splicing of 
the primary gene transcript. The two mRNAs either include (type IIA) or exclude (type 
IIB) exon 2, which encodes the major portion of the amino (NH2)-propeptide (Ryan and 
Sandell, 1990). The expression of type IIB is spatially correlated with the high level 
expression of the cartilage proteoglycan aggrecan, establishing type IIB procollagen and 
aggrecan as markers for the chondrocyte phenotype (Sandell et al., 1991). Transcripts 
of type II collagen, primarily type IIA, are also expressed in embryonic spinal ganglion 
and in other tissues, including the notochord, during development (Sandell et al., 1991; 
Ng et al., 1993; Sandell et al., 1994; Oganesian et al., 1997).
Mutations in collagen type II in humans cause a variety of diseases such as
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achondrogenesis, hypochondrogenesis, Stickler syndrome, Kniest dysplasia, Wagner 
syndrome and spondyloepiphyseal dysplasa (SED) (Chan et al., 1995; Horton et al., 
1992; Ahmad et al., 1993; Wilkin et al., 1999). In many cases the patients present also 
ocular abnormality, such as myopia and retinal detachment, probably due to the fact that 
type II collagen is also expressed in the vitreous (Ahmad et al., 1991; Korkko et al., 
1993). Collagen type II seems to be also involved in the sensorineural deafness that 
accompanies SED and Stickler syndrome and maybe the target of an autoimmune 
process in cases of acquired bilateral sensorineural hearing loss (Helfgott et al., 1991). 
Mice lacking type II collagen produce abnormal cartilage, develop a skeleton without 
endochondral bone and are unable to dismantle the notochord. They are usually 
delivered vaginally but die either immediately before or soon after birth (Li et al., 1995; 
Aszodi et al., 1998).
Our findings show that type IIA collagen is expressed in peripheral nerve by the 
Schwann cell lineage during embryonic development and by both myelinating and non­
myelinating Schwann cells and is regulated by axonal signals. The expression of col2al 
by the neural crest is surprising since type II collagen is supposed to be non-permissive 
for crest cell migration (Perris, 1997). However, it is possible that the deposition of type 
II collagen is needed to prevent improper migration of the cells, and that col2al is 
therefore involved, together with molecules such as tenascins and aggrecans in 
“migratory directionality” (Perris, 1997). The expression of col2al increases during 
peripheral nerve development. The most obvious role that we can infer is a structural 
one. However, we can also speculate that col2al may have other functions. Intriguingly 
in fact, the NH2-propeptide of type IIA procollagen binds to TGFp-1 and to BMP-2, 
influencing their distribution and action in the extracellular matrix in chondrogenic 
tissue (Zhu et al., 1999). Both of these growth factors can, at least in vitro, divert early
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glia to other lineages (Morrison et al., 2000). Therefore one function of type IIA 
collagen, in particular in embryonic nerves, could be to bind BMP and TGFp, and 
prevent excessive exposure of differentiating glia to these factors, thus favouring 
Schwann cell development. Interestingly, in our analysis we have identified another 
gene, the uterine sensitization-associated gene-1 (Usag-1, annotated with Biopendium™ 
from the EST AA892798, see table 3.6.2), belonging to the cysteine knot-containing 
family, that is likely to accumulate in the extracellular matrix, where it can act as a 
BMP antagonist (Avsian-Kretchmer and Hsueh, 2004; Yanagita et al., 2004). During 
myelination col2 al is highly expressed, and in common with many myelin-related 
genes it is up-regulated by treatment of cultured Schwann cells with cAMP. 
Surprisingly, although it appears to be equally expressed by myelinating and non­
myelinating Schwann cells, nerve cut results in a complete down-regulation of both the 
mRNA and the protein for col2al, meaning that even in non-myelinating Schwann cell 
its expression is axonally dependent. This unusual behaviour is shared by 
galactocerebroside and sulfatide, which are down-regulated in non-myelinating 
Schwann cells after peripheral nerve injury (Scherer and Salzer, 2001).
Chondromodulin-1 (ChM-1)
ChM-1 is cartilage matrix protein that stimulates the growth of chondrocytes and that 
inhibits angiogenesis (Hiraki et al., 1997; Hiraki and Shukunami, 2000). In the chick 
embryo ChM-1 is also expressed in developing heart and eye, and its mRNA has been 
detected in the notochord and in the neural tube (Dietz et al., 1999; Shukunami et al.,
1999). ChM-1 mice do not show any abnormality in vascular invasion, cartilage 
development and endochondral bone formation (Brandau et al., 2002; Nakamichi et al.,
185
2003). However, adult mutant mice showed a significant increase in bone mineral 
density and reduced bone resorption relative to bone formation suggesting that ChM-1 
is a bone remodeling factor in mice (Nakamichi et al., 2003). We have shown that 
ChM-1 mRNA is expressed mainly by myelinating Schwann cells and that it is 
regulated by axonal contact. We were however unable to detect significant levels of 
ChM-1 protein by Western blotting and immonofluorescence. This could mean either 
that the expression and regulation of ChM-1 mRNA in nerves is anomalous and without 
function or that Schwann cells express a ChM-1 variant that is not recognised by the 
ChM-1 antibody. In the latter case, it could be speculated that the function of ChM-1 in 
peripheral nerve was negative control of angiogenesis, and that its down-regulation after 
nerve damage could facilitate revascularization and macrophage recruitment during 
regeneration.
Osteonectin/SPARC. Osteoadherin (OimD and bone sialoprotein (Ibsp ID
Secreted protein acidic and rich in cysteine/osteonectin, or SPARC, is a matrix- 
associated protein that elicits changes in cell shape, inhibits cell-cycle progression, and 
influences the synthesis of ECM (Termine et al., 1981; Bradshaw et al., 2003). 
Osteonectin binds collagen fibrils and accounts for the unique property of bone collagen 
to undergo calcification. Osteonectin deficient mice appear normal until around 6  
months of age, when they develop severe eye pathology characterized by cataract 
formation and rupture of the lens capsule (Gilmour et al., 1998). Moreover, the absence 
of osteonectin in mice gives rise to aberrations in the structure and composition of the 
extracellular matrix that result in generation of cataracts, development of severe 
osteopenia, and accelerated closure of dermal wounds (Bradshaw et al., 2003). 
Osteonectin mRNA had been previously detected in peripheral nerve (Holland et al.,
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1987), and expression profiling experiments have shown that it increases after nerve 
injury (Gillen et al., 1995; Nagarajan et al., 2003).
Omd is a small cell-binding proteoglycan, isolated from rat and bovine bone that 
belongs to the family of leucine-rich repeat proteins (Wendel et al., 1998). It binds 
osteoblasts via the integrin a5|33 and it is located to the mineralized bone matrix, with 
highest concentration of marker at the border between bone and cartilage remnants, with 
a distribution that is highly similar to that of bone sialoprotein (Ramstad et al., 2003). 
Ibsp II is an acidic glycoprotein that constitutes around 12% of non collagenous 
proteins in human bone. It belongs to the SIBLING (Small Integrin-Binding Ligand, N- 
linked Glycoprotein) family of proteins, alongside osteopontin, a protein that, in 
agreement with previous experiments (Jander et al., 2002), we found up-regulated after 
nerve cut. Both Omd and Ibsp are suggested to have a role in bone mineralisation 
(reviewed in Qin et al., 2004).
We have not investigated in detail the distribution of SPARC, Omd, and Ibsp in 
peripheral nerve, and at present it is difficult to speculate on their possible function. 
However one can argue, based on the existing literature, that they may have a role in 
ECM structure and could, for example, link the extracellular matrix to the Schwann cell 
via integrins. Their down-regulation after nerve injury may be involved in creating a 
favourable environment for axon regeneration.
The trascription factor Sox-9 is expressed in Schwann cells in the PNS
The observation that Col2al was so strikingly regulated during Schwann cell 
development raised the question of which transcription factor was responsible for its 
expression in peripheral nerve. During chondrogenesis Sox9 directly regulates the 
expression of Col2al (Bell et al., 1997). Sox-9 plays also an essential role in sex
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determination, being up-regulated in male and downregulated in female genital ridges. 
It is possibly immediately downstream of SRY in mammals, and functions as a critical 
Sertoli cell differentiation factor, perhaps in all vertebrates (Morais da Silva et al., 
1996). Interestingly, recent work has demonstrated a role for Sox9 in neural crest 
development (Mori-Akiyama et al., 2003; Cheung and Briscoe, 2003). In humans, 
mutation in Sox-9 cause Campomelic dysplasia, a disorder of the newborn characterized 
by congenital bowing of long bones, together with other skeletal and extraskeletal 
defects. Up to two-thirds of affected XY individuals have a gradation of genital defects 
or may develop as phenotypic females (Wagner et al., 1994). Heterozygous Sox-9 
mutant mice reproduce most of the skeletal abnormalities of campomelic dysplasia. The 
heterozygous Sox9 mice dies perinatally with cleft palate, as well as hypoplasia and 
bending of many skeletal structures derived from cartilage precursors (Bi et al., 2001). 
The role of Sox-9 in collagen type II control and skeletal development, as well as its 
expression in the neural crest made this transcription factor particularly interesting for 
our studies. I have shown that Sox9 is expressed throughout the development of the 
Schwann cell lineage from the neural crest to adult mature myelinating and non­
myelinating Schwann cells. While in the embryonic and early post-natal stages Sox9 is 
found in the nucleus, in adult Schwann cell we found a strong cytoplasmic 
immunoreactivity. It is possible that this represents an inactive state of the protein, since 
in gonads Sox9 activity is regulated by a nucleo-cytoplasmic shuttling (Gasca et a l ,
2002). Sox-9 mRNA is expressed by both myelinating and non-myelinating Schwann 
cells, and after nerve injury the mRNA levels for Sox-9 drop, although not dramatically, 
indicating that its expression depend on axonal signals. These results, combined with 
the recent findings that Sox9 is determinant in the glial fate choice in the spinal cord
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(Stolt et al., 2003), strongly suggest that Sox9 is involved in Schwann cell 
differentiation.
Expression and localisation of Synuclein-1 and aB-crystallin in peripheral nerve
A central role for the Schwann cell cytoskeleton in the processes of differentiation and 
myelination has long been suggested, and several molecules that play an important part, 
such as actin, periaxin and DRP-2, have been identified (Gillespie et al., 1994; 
Fernandez-Valle et al., 1997; Sherman et al., 2001). Our analysis led us to the 
identification of many cytoskeletal proteins, including synuclein-1 (Snca) and aB - 
crystallin (Cry-ab). Snca is a small protein which forms aggregates in various 
neuropathologies such as Parkinson’s disease (PD), Alzheimer’s disease and multiple 
system atrophy (MSA) (reviewed in Eriksen et al., 2003; Kahle et al., 2002). Snca 
belong to the synuclein family that includes also (3- and y-synuclein (George, 2002). 
The gene for Snca spans about 117 kb and encodes a 14kDa protein that presents 6  
imperfect repeats of 11 aminoacids at the N-terminus. This region acquires alpha-helical 
secondary structure similar to that of A2-apolipoproteins upon lipid binding (Davidson 
et al., 1998; Eliezer et al., 2001). In neurons, Snca is concentrated in presynaptic nerve 
terminals and in cultured hyppocampal neurons it associates with synaptic vesicles 
(Jakes et al., 1994; Murphy et al., 2000), suggesting that Snca could be involved in 
synapse formation. Snca null mice exhibited intact brain architecture and possessed 
normal dopaminergic cell bodies, fibres, and synapses. However they displayed 
enhanced dopamine release at nigrostriatal terminals only in response to paired 
electrical stimuli, and attenuation in amphetamine induced locomotion. These findings 
suggested that Snca is not essential for synapse formation but plays an important role in 
the maintenance of synaptic function (Abeliovich et al., 2000). Snca as been also
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proposed to act as a chaperone since, besides lipids, it interacts with a variety of cellular 
proteins, thus modifying their activity. In particular it shares sequence homology and 
interacts with the molecular chaperone 14-3-3 (reviewed in Recchia et al., 2004). The 
14-3-3 protein plays critical roles in cell signaling events that control progress through 
the cell cycle, transcriptional alterations in response to environmental cues, and 
programmed cell death. Due to the structural similarity and interaction between Snca 
and 14-3-3, it is possible that Snca may be involved in some of these events.
Our data show that Snca expression in peripheral nerve parallels that of most myelin 
genes, being strongly induced from El 6 -El 7 onwards, suppressed in cut nerves and up- 
regulated in Schwann cell cultures by treatment with dbcAMP. Moreover Snca localises 
in Schmidt-Lanterman incisures and in paranodal loops suggesting that it could have a 
role either in the architecture of these complex structures or in the signalling between 
axon and Schwann cell. However, the function of Schmidt-Lanterman incisures is not 
fully understood yet. It is possible that they are involved in myelin formation, but so far 
little evidence of protein or lipid transport through incusures exists (reviewed in Trapp 
and Kidd, 2004). One function of Schmidt-Lanterman incisures could be that of 
facilitating the communication between the outer and inner aspects of the myelin 
intemode, as radial diffusion of small molecules through the gap-j unctions present in 
the incisures membranes has been recently demonstrated (Balice-Gordon et al., 1998). 
Recently we have proposed that the scaffold protein JIP-1 could be a component of the 
pathway by which Krox20 regulates the activity of JNK, controlling Schwann cell death 
and proliferation during development (Parkinson et al., 2004). In neuronal cells 
transfected with Snca under oxidative stress conditions, the levels of JIP-1 are highly 
increased and vice-versa, suggesting that they may interact in response to injury and 
stress (Hashimoto et al., 2002). During peripheral nerve development the expression
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patterns of JIP-1 and Snca are similar, and both proteins accumulate in paranodal loops 
(Parkinson et al., 2004; this work). This raises the possibility of an interaction of these 
two proteins in Schwann cells too and therefore of an involvement of Snca in 
controlling Schwann cell development. We were however unable to detect any 
abnormality in the peripheral nerve of a Snca mutant strain of mice (Specht and 
Shoepfer, 2001). It is possible that Snca is redundant and that either p- or y-synuclein 
take over its function, if any, during myelination. Another possibility is that a subtle 
phenotype is actually present that could not be detected with a simple morphological 
analysis.
In pathological circumstances, such as in MSA, Cry-ab colocalises with Snca. Cry-ab is 
a major component of the lens of the eye, but it is also widely distributed in different 
tissues. It is a member of the alpha-crystallin/small heat-shock protein (alpha/HSP) 
superfamily, characterised by a highly conserved C-terminal "a-crystallin domain" 
(reviewed in de Jong et al., 1998). Therefore, Cry-ab possesses some molecular 
chaperone-like functions (reviewed in MacRae, 2000; Horwitz, 2003). Cry-ab had been 
previously detected in Schwann cells (Iwaki et al., 1990), but its role in peripheral nerve 
has never been investigated. Null mice for Cry-ab have normal lens development, but 
reduced life span with a severe osteoarthritis (Brady et al., 2001). Interestingly, recent 
work has identified mutations of the highly conserved "HSP20/a-crystallin domain" of 
the small heat shock proteins 22 and 27 (HSP22 and HSP27) that cause Charcot-Marie- 
Tooth disease and distal hereditary motor neuropathy in humans (Irobi et al, 2004; 
Evgrafov et al, 2004). Transgenic mice, overexpressing alpha A-crystallin, the other 
alpha-crystallin gene, under the control of the vimentin promoter, develop 
demyelination and axonal dystrophy (De Rijk et a l , 2000), while mutations in Cry-ab 
cause a desmin-related myopathy, a neuromuscular disorder (Vicart et al, 1998). This
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findings, combined with our data that showed that Cry-ab is highly induced during 
peripheral nerve development and that it depends on axonal signals for its expression, 
raises the possibility that Cry-ab is involved myelination.
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TABLE 4.1
Symbol Description mRNA expression levels
Accession number E14 E18 P7 PI 2 PI 2cut
A F051425_at Chm-1 chondromodulin- 7 6.7 19.4 338.1 4204 61.9
A F104362_at Omd osteoadherin 8.4 29.7 62.8 746 .8 288.7
A J224879_at Col2a1 collagen alpha 7 type II 640.1 1263 2243.9 10404 .2 122.7
J04215_at Bsp cell-binding bone sialoprotein 7.4 19.8 42.8 273 .7 32.8
rc_A I639294_at SPARC SPARC/Os teonectin 39.6 19.5 39.7 509.1 46.6
TABLE 4.2
Accession number
AF007758  
A F007758  
M 55534
Symbol Description
Snca Synuclein- 7
Snca Synuclein- 7
Cry-ab alpha-B-crystallin
mRNA expression levels
El 4  El 8 P7 PI 2 P12cut
29.1 253  
6.2 101
28.1 322
1486.9
277.1
2974.1
10652 .6
2674.1
15504 .3
543.4
159
5379.1
CHAPTER 5
TGFp controls Schwann cell death and proliferation during embryonic 
and perinatal development
INTRODUCTION 
The TGFp superfamily
The transforming growth factor p (TGFP) superfamily of cytokines controls many cell 
processes, including cell proliferation, recognition, differentiation and apoptosis, both 
during embryonic development and in mature tissue in a variety of species, ranging 
from flies to mammals (Massague, 1998; Massague et al., 2000; Shi and Massague, 
2003; ten Dijke and Hill, 2004). Disruption or mutations in TGFp pathway component 
are associated with several human diseases, including cancer, fibrosis and auto-immune 
diseases (Derynck et al., 2001; ten Dijke and Hill, 2004).
The TGFp superfamily contains two subfamilies, the TGFp/Activin/Nodal subfamily 
and the bone morphogenetic protein (BMP)/ growth and differentiation factor (GDF) 
subfamily, defined by the specific signalling pathways that they activate (Izzi and 
Attisano, 2004). TGFp signalling is initiated by binding and bringing together type I 
and type II receptor serine/threonine kinases on the cell surface. Usually, the active 
form of a TGFp cytokine is a dimer, the arrangement of which suggests the formation 
of a complex with two type I and two type II receptors. TGFp access to the receptors is 
regulated by a large family of proteins, collectively known as ligand traps (Shi and 
Massague, 2003). After TGFp binding, type II receptor phosphorylates the type I 
receptor kinase domain, which then propagates the signal through phosphorylation of 
Smad proteins.
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There are eight Smad proteins, constituting three functional classes: the receptor 
regulated Smad (R-Smad), the co-mediator Smad (Co-Smad) and the inhibitory Smad 
(I-Smad). The R-Smad class is comprised of Smadl, 2, 3, 5 and 8. These Smads are 
directly activated through phosphorylation by the type I receptor kinase and undergo 
homotrimerization and formation of heterodimeric complexes with the Co-Smad, 
Smad4. These activated complexes are translocated to the nucleus and in collaboration 
with other cofactors regulate the transcription of target genes. I-Smads, Smad6 and 
Smad7, negatively regulate TGFp signalling by competing with R-Smads for Co-Smad 
and by targeting the receptors for degradation (Izzo and Attisano, 2004; Shi and 
Massague, 2003).
In humans, the receptor serine/threonine kinase family comprises 12 members, 7 type I 
and 5 type II receptors (Mannig et al., 2002). They are all organized sequentially into an 
N-terminal extracellular ligand binding domain, a transmembrane region and a C- 
terminal serine/threonine kinase domain. Immediately N-terminal of this kinase domain, 
the type I receptor has a characteristic sequence, termed the GS domain, the 
phosphorylation of which by the type II receptor is required for type I receptor 
activation (Shi and Massague, 2003). Type I receptor activation results in increased 
affinity for the R-Smads, which are directly phosphorylated by the type I receptor 
(Kretzschmar et al., 1997).
While BMP ligands exhibit a high affinity for the extracellular binding domain of the 
type I receptors, TGFp/activin display high affinity for the type II receptors and do not 
interact with isolated type I receptors (Massague, 1998; Kirsch et al, 2000). So in the 
TGFp/activin case, the binding to the type II receptor is necessary to allow the 
subsequent incorporation of the type I receptor, leading to a large complex comprising a 
ligand dimer and four receptor molecules (Shi and Massague', 2003). Interestingly,
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each member of the TGFp superfamily binds to a characteristic combination of type I 
and type II receptors (ten Dijke and Hill, 2004). However, significant variation exists 
for the binding between different type II receptors and their ligands (Hart et al., 2002). 
For example, the activin type II receptor has a broad specificity and can bind to both 
activin and BMP ligands, while the TGFp receptor II has low affinity for the other 
members of the superfamily (Hart et al., 2002).
Ligand access to receptors is also controlled by membrane-anchored co-receptors that 
play an important role in signalling. For example, the membrane-anchored proteoglycan 
beta-glycan, also known as TGFp type III receptor, mediates TGFp binding to the type 
II receptor, a role that is particularly critical for TGFp-2 (Brown et al., 1999).
As mentioned previously, phosphorylation via type I receptors of R-Smads permits their 
association with Co-Smad. Once formed, this complex translocates to the nucleus and 
interacts with the DNA to regulate transcriptional responses. Intriguingly, stimulation 
with TGFps leads immediately to positive and negative changes in the expression of 
several hundred genes (Kang et al., 2003). Since the same set of Smad proteins is used 
for activation and repression of gene expression, the recruitment of co-activator or co­
repressor is required, and probably depends on the cell type and other physiological 
conditions at the time of TGFp stimulation (Massague, 2000). Smad partners in this 
process include the DNA binding factor FoxHl, c-Jun/Fos, CREBP and homeobox 
proteins (e.g. Mixer) (ten Dijke et al., 2000; Attisano and Wrana, 2000; Massague and 
Wotton, 2000; Shi and Massague, 2003). The positive regulation of gene expression is 
achieved by recruitment of positive regulators such as CBP/p300, while the negative 
regulation of gene expression includes direct recruitment by Smads of co-repressors 
such as c-ski and SnoN, two members of the Ski family of protooncoproteins (Liu et al., 
2001; Derynck and Zhang, 2003; Shi and Massague, 2003).
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Once activated, the TGFP signalling needs to be tightly regulated and properly 
terminated. I-Smads (Smad6 and 7) negatively regulate the pathway, by competing for 
Co-Smad. Smad7 also binds to the activated receptors leading to the ubiquitination and 
degradation of the receptors with the help of the E3 ubiquitin ligases, the Smad 
ubiquitination regulatory factors (Smurfs) (Suzuki et al., 2002; Tajima et al., 2003; Izzi 
and Attisano, 2004).
Accumulating data suggest that TGFp also acts through Smad independent pathways. 
For instance, TGFp has been shown to activate mitogen-activated protein kinase 
(MAPKs) signalling pathways, including MKK4/c-Jun N-terminal kinases (JNK) and 
MKK3/p38 kinases pathways (Adachi-Yamada et al., 1999; Massague' and Chen, 
2000). The link between the receptors and these pathways is not clear, but may involve 
TAK1 (TGFp-activated kinase 1), which acts directly on MKKs that activate either JNK 
or p38 (Zhou et al., 1999). Activation of TAK1 has also been linked to induction of 
apoptosis in eye development in Drosophila (Takatsu et al., 2000). Activation of JNK 
and p38 through TGFp signalling can lead to rapid transcriptional responses, by 
activating AP-1 complexes via phosphorylation of the transcription factor c-Jun 
(Hocevar et al., 1999) or CRE (cAMP responsive element) regulatory complexes via 
phosphorylation of ATF-2 (Sano et al., 1999). C-Jun phosphorylation has been linked 
with cell cycle progression and apoptosis in various systems (Watson et al., 1998; 
Wisdom et al., 1999). Interestingly, it has been reported that activated Smad complexes 
can form physical links with Jun or ATF-2 complexes (Wong et al., 1999; Sano et al., 
1999). Moreover, in certain circumstances Smad undergoes activating phosphorylation 
by JNK (Engel et al., 1999). Taken together these observations suggest an interplay 
between the Smad and JNK or p38 pathways indicating diverse forms of integration 
between TGFp signalling and other pathways in the cell (reviewed in Massague, 2000).
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TGFp and Schwann cells
TGFps, and in particular TGFp-1, -2 and -3 are expressed by Schwann cells and exert a 
variety of effects on these cells (reviewed in Scherer and Salzer, 2001; Jessen and 
Mirsky, 2004). In cultured Schwann cells, in the presence of serum or of cAMP 
elevating agents or both, TGFp promotes Schwann cell DNA synthesis and thus 
proliferation (Eccleston et al., 1989; Ridley et al., 1989). Interestingly, the mitogenic 
effect of TGFp is enhanced by low (0.5 pM) concentrations of forskolin, which is a 
potent activator of cAMP, while at higher concentrations of forskolin (5 pM) the 
synergistic interaction of forskolin and TGFp is abolished (Ridley et al., 1989). In the 
same situation, even if applied at concentrations too low to induce Schwann cell 
proliferation, TGFp suppress cAMP-induced Po, galactocerebroside and 0 4  induction 
(Mews and Meyer, 1993; Morgan et al., 1994; Stewart et al., 1995). However, if TGFp 
is applied to DRG neuron/Schwann cell co-cultures, it acts to inhibit Schwann cell 
proliferation induced by contact with neurites (Guenard et al., 1995b; Einheber et a l, 
1995). Moreover, in these co-cultures TGFp suppresses Po and galactocerebroside 
induction and blocks myelination (Guenard et al., 1995a; Einheber et al., 1995).
TGFp and Schwann cell apoptosis
As we have seen in the general introduction, a variety of signals, either axonally derived 
(NRG-1) or of autocrine origin, exert a positive control on Schwann cell survival. In 
addition to these positive signals, there are at least two factors, TGFp and NGF, which 
actively promote Schwann cell death by apoptosis after nerve injury. NGF, acting 
through the p75NTR, promotes Schwann cell death in vitro, and mice lacking p75NTR 
show reduced cell death both after neonatal nerve injury and three weeks after nerve 
crush in the adult (Khursigara et al., 2001; Ferri and Bisby, 1999; Syroid et al., 2000),
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and cultured Schwann cell from p75 null mice survive better than normal ones when 
deprived of growth factors and serum (Soilu-Hanninen et al., 1999; Syroid et al., 2000). 
However, the NGF signalling pathway appears to be extremely complex, since under 
some conditions NGF can promote Schwann cell survival (Khursigara et al., 2001). 
Schwann cell response to NGF signalling strongly depends on the presence of the 
protein RIP-2 (receptor interacting protein-2), which interacts with p75. In the presence 
of RIP-2, Schwann cell death in response to NGF is prevented, while the absence of 
RIP-2, achieved in vitro by expression on dominant negative RIP-2 or by prolonged 
culturing, Schwann cells become sensitive to NGF-induced death (Khursigara et al., 
2001).
Similarly to NGF, TGFp can induce Schwann cell death in a variety of conditions in 
vitro (Skoff et al., 1998; Parkinson et al., 2001). Treatment with TGFp kills freshly 
isolated neonatal Schwann cells, and the apoptotic effect is completely inhibited by the 
combined presence of neuregulin-1 and autocrine signals. The c-Jun phosphorylation 
pathway via JNK is directly involved in TGFp-mediated Schwann cell death, since 
expression of a constitutively active v-Jun promotes Schwann cell death while dominant 
negative c-Jun blocks TGFp induced apoptosis (Parkinson et al., 2001). These data are 
supported by the finding that TGFp is unable to kill Schwann cell from post-natal day 4 
(P4) nerves, due to its inability to phosphorylate c-Jun in myelinating Schwann cells 
(Parkinson et al., 2002, 2004). In vitro, enforced expression of the transcription factor 
Krox-20 is sufficient to block both serum deprivation and TGFp-induced Schwann cell 
death via inactivation of the JNK-c-Jun pathway (Parkinson et al., 2004). The scaffold 
protein JIP-1, identified with the gene profiling described in Chapter 3 and 4, is likely to 
be a component of the mechanism by which Krox-20 regulates JNK activity in 
Schwann cells (Parkinson et al, 2004).
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In vivo, TGFp is expressed by Schwann cell precursors, immature Schwann cells and its 
expression remains sustained in the adult (Scherer et al., 1993; Parkinson et a l, 2001). 
Moreover, TGFp-1 mRNA and protein expression are elevated in the distal stump of 
injured nerves both in neonatal and in adult mice, while TGFp-3 levels are reduced in 
the same circumstances, indicating that TGFp-1 may have a role in the early events 
following nerve damage (Scherer et al., 1993; Parkinson et al., 2001). In agreement 
with this, injection of TGFp increases Schwann cell death in injured, but not normal, 
neonatal nerves (Parkinson et al., 2001). Interestingly, if combined with TNFa, TGFp 
can induce Schwann cell death even in the presence of serum, and the combination of 
these two factors in serum-free conditions kills Schwann cell more potently than TGFp 
alone (Skoff et al., 1998; Parkinson et al., 2004).
Taken together all these data indicate that the effects of TGFp on Schwann cells 
strongly depend on the context, and its role in nerve development is very difficult to 
predict.
Mice in which the gene for TGFp-1 has been knocked out die 3-4 weeks after birth, due 
to a massive inflammatory response that results in lymphocyte and macrophage 
invasion in many organs but in particular in heart and lungs (Kulkami et a l, 1993; 
Geiser et al., 1993). Moreover, about 50% of the homozygous TGFp-1 null mice die 
prenatally, due to defective haematopoiesis and endothelial differentiation (Dickson et 
al., 1995). TGFp-2 and TGFp-3 null mice have also been generated. TGFp-3 deficient 
mice die perinatally, due to delayed pulmonary development and defective 
palatogenesis, implicating TGFp-3 in epithelial-mesenchymal interactions (Kaartinen et 
al., 1995), while TGFP-2 mutants die soon after birth and present a wide range of 
developmental defects that, interestingly, are not overlapping with the defects seen in
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TGFfM and -3 knockouts. They include lung, cardiac, craniofacial, eye and urogenital 
malformations (Sanford et al., 1997).
The early mortality and the number of developmental defects make these animals 
unsuitable to comprehensively study peripheral nerve development in the absence of 
TGFp. Recently, TGFp-1 null mice that can survive into adulthood have been generated 
by breeding TGFp-1 +/' mice with nude mice, which lack T cells and thus inflammatory 
response, which is the major cause of death in TGFp-1 null mice (Day et al., 2003). The 
adult TGFp-1 '^/nude mice thus produced presented hypermyelination and tomacula- 
like structures, with the major abnormalities in the node of Ranvier region, suggesting a 
possible role for TGFp-1 in myelin maintenance (Day et al., 2003). However, axonal 
sorting and myelination in the PNS in those TGFp-1 null mice that are able to survive 
up to 3-4 weeks appears to be normal (McLennan et al., 2000). One possible 
explanation for this is that TGFp-1 has no role in controlling normal myelination. On 
the other hand, this is difficult to verify since until weaning null mice take-up TGFp-1 
through maternal milk (Letterio et al., 1994). Thus, the role of TGFp-1 in nerve 
development remains unclear.
AIMS
To try to bypass these obstacles and to shed some light on the possible functions of 
TGFp in nerve development and myelination we decided to generate a conditional 
knockout mouse in which the TGFp receptor type II (TGFpRII) is specifically ablated 
only in Schwann cells. To do so, we crossed mice carrying a floxed type II receptor 
(Cazac and Roes, 2000) with P0 CRE mice in which the CRE recombinase protein is 
expressed under the control of the Po promoter (Feltri et al., 1999a, 1999b).
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Both these mice have been successfully used in recent years: the TGFp type II receptor 
floxed mouse has been used to specifically inactivate TGFp signalling in B cells (Cazac 
and Roes, 2000), while the PO CRE mouse has been used to ablate p i integrin and 
dystroglycan in Schwann cells (Feltri et al., 2002; Saito et a l , 2003), suggesting that the 
combination of the two should allow us to inactivate TGFp signalling in Schwann cells 
only.
In the following paragraph a brief overview of CRE/loxP technology is provided. 
CRE/loxP technology
Gene targeted mice, derived from embryonic stem cells, are often useful tools to study 
gene function. However, if the gene inactivation results in embryonic lethality, the 
function of the gene in later stages cannot be further studied. Another pitfall of classical 
gene targeting is that the resulting phenotype can be extremely complex, and it can be 
difficult to distinguish cell-autonomous from more complex lesions. The CRE 
recombinase/loxP sites (CRE/loxP) system has been developed to overcome these 
limitations, confining the inactivation of a gene in a tissue- or cell-specific manner. This 
system allows the inactivation of a target gene in a single cell type, thereby allowing the 
analysis of the pathophysiological consequences of genetic alteration in mature animals 
(Ramirez-Solis et al., 1995; Smith et al., 1995; Raiewsky et al., 1996). In the CRE/loxP 
technology a mouse is generated, in which the targeted gene is flanked by two loxP 
sites. The loxP sequences consists of two 13 base pair (bp) inverted repeats and an 8-bp 
asymmetrical core spacer region. The CRE recombinase leads to the site-specific 
recombination between the two loxP sites with consequent inversion or excision of the 
region in between the two loxP sequences (Fig 5.2) (Ramirez-Solis et al., 1995; Li et 
al., 1996; Van Duyne, 2001; Branda and Dymecki, 2004). Indeed, CRE will remove the
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sequence in between two directly repeated target sites, and invert the sequence in 
between two inverted sites. Therefore, only those cells where the CRE recombinase is 
expressed will bear the mutation. One of the first reports of conditional gene 
modification examined the effect on T cells of a null mutation in the essential DNA 
polymerase (3 gene (Gu et al., 1994). Since then, this technology has been used to 
generate a plethora of conditional mutants. Nowadays conditional targeting is 
commonly used not only for gene inactivation but also for the introduction of mutations 
and also for the activation of a gene (Torres et al., 1996; Lakso et al., 1992). In 
particular, ligand-regulated forms of CRE have been developed with the goal of adding 
temporal control to the recombinase activity, enabling the induction of the genetic 
changes late in embryogenesis and/or in adult tissues. One particular successful strategy 
has involved fusing a mutant estrogen receptor (ER) ligand-binding domain to the C- 
terminus of CRE (reviewed in Brenda and Dymecki, 2004). In these mice CRE activity 
is induced only after administration of tamoxifen, allowing temporal and spatial control 
of the recombinase activity. Thus, both cell-type-specific and inducible gene targeting 
are feasible using the CRE/loxP recombination system, and, importantly, the efficiency 
in the system can reach 100% (Kuhn et al., 1995). However, in many cases, gene 
inactivation is not complete, due to a failure of the recombinase to modify the target 
gene in all cells expressing the recombinase. The resulting mosaicism precludes the 
analysis of a null phenotype in the targeted lineage, due to the presence of wild-type 
cells that can mask a potential defect. Is therefore always necessary to carefully 
determine the percentage of recombination. Still, the recombinase tool remains a 
powerful technology that will help to determine the contribution of any given gene in 
development, disease and disability.
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RESULTS
Generation of the PO CRE/TGFpRII^ mice
To disrupt the TGFpRII gene specifically in Schwann cells, TGFpRII^f mice (Cazac and 
Roes, 2000) were crossed with PO CRE mice (Feltri et al., 1999), which induce efficient 
Schwann cell lineage-specific deletion of loxP-flanked target sequences (Feltri et al., 
2002; Saito et al., 2003) (Fig 5.3A and B). In the TGFpRII*^ mouse loxP sites flank 
exon 3 of the TGFpRII gene, which encodes for the membrane-proximal extracellular 
part of the protein (Cazac and Roes, 2000; Fig 5.3A). If exon 3 is ablated the resulting 
protein is truncated and translation terminates before the extracellular domain. This 
should result in a type II receptor complete inactivation.
To determine the recombination efficiency, Southern blot analysis of Schwann cell 
isolated from the sciatic nerve of P21 P0 CRE/TGF|5RII f/+ and P0 CRE/TGF(3RII f,f 
mice was performed (Fig 5.3C). Unfortunately, the purification of the Schwann cells via 
negative immunopanning was not particularly efficient, and the number of fibroblasts in 
the culture, measured with S I00(3 staining, was around 20-25% of the total cells. 
Densitometric analysis of the Southern blot indicated that the recombination efficiency 
was 65 and 67% for the heterozygous and the homozygous respectively. This result 
normalized for the Schwann cells purity (75-80%), means that at this stage the 
recombination is probably somewhere around 90%.
Therefore, to better determine the efficiency of deletion, we decided to use an indirect 
approach. TGFp binding to the type II receptor results in type I receptor recruitment and 
phosphorylation, which in turn phosphorylates R-Smads. Phoshorylated R-Smads then 
form a heterodimeric complex with the Co-Smad Smad4. The activated complex is
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translocated to the nucleus where, in collaboration with various cofactors, it regulates 
the transcription of various genes (see above). Loss of type II receptor should result in 
the absence of Smad nuclear localisation. We therefore cultured P5 Schwann cells from 
TGFf)RIIr/f (from now-on called wild-type (w t», PO CRE/TGFpRIIf/+ and PO 
CRE/TGFpRII mice (from now often referred to as mutants). After 24 h the cells were 
stimulated with 10 ng/ml TGFp-1, fixed and immunolabelled with antibodies against 
Smad2 and Smad4 (Fig 5.4A and B respectively). In the cells isolated from PO
f / fCRE/TGF(JRII mice there is basically no nuclear localisation when compared to wt 
and PO CRE/TGFpRII^ cells, indicating that already at P5 the recombination is almost 
complete.
PO CRE/TGFpRII^mice myelinate correctly
Previous studies had indicated that, in DRG neuron/Schwann cell co-cultures in vitro, 
TGFfM acts to inhibit Schwann cell proliferation, suppresses Po and galactocerebroside 
induction and blocks myelination (Guenard et al., 1995a,b; Einheber et al., 1995). 
Therefore we asked whether TGFp-1 could have a function in negatively controlling 
myelination in vivo. If so, we would expect to find either premature myelination or 
hypermyelination or both. To answer this question we analysed by electron microscopy 
(EM) transverse sections from wt and PO CRE/TGFpRIIf/f sciatic nerves. This analysis 
showed that at PI Schwann cells have started segregating the big caliber axons in a 1:1 
relationship and that in many cases myelination has started, with one or more loops of 
myelin already formed (Fig 5.5), but no significant differences between the wt and the 
mutant mice were detectable. By P5 basically all the big caliber axons are segregated 
and myelination is proceeding correctly (Fig 5.5 and 5.6). At P21, in both wt and 
mutant nerves, myelination is nearly completed and smaller caliber axons are
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segregated in bundles surrounded by a single non-myelinating Schwann cell. Moreover, 
the myelin sheath appears to be morphologically normal and stable in the adult (Fig 
5.7).
Interestingly, in a P21 PO CRE/TGF|3RIIf/f mouse we identified a bundle of smaller 
caliber axons that were surprisingly surrounded by a myelin sheath (Fig 5.8). However, 
only one of these structures was present in this animal, and we never came across this 
kind of abnormality in any of the other mutant mice analysed (more than 30 mutants 
were analysed at time points PI, P5, P I5, P21, P30 and adult). This led us to consider 
this as an unusual but random event, probably not attributable to the lack of TGF|3 
signalling.
Myelin-related protein expression appears to be normal in the mutant mice
As mentioned previously, in vitro TGFfM suppresses the expression of myelin-related 
proteins such as Po and galactocerebroside (Einheber et al., 1995). Lack of TGFfM 
signalling could therefore lead to an over-expression of myelin-related proteins. 
However, the EM analysis described above suggests that an abnormal expression of 
myelin proteins is unlikely since we did not observe any difference in the onset of 
myelination and/or in myelin structure between wt and mutant mice. To confirm this 
observation we immunolabelled newborn sciatic nerves from wt and mutant mice with 
an antibody against the myelinating Schwann cell protein periaxin. No clear difference 
was detectable between the wt and the PO CRE/TGF|3RIIf/f mouse (Fig 5.9A). Similarly, 
no differences were seen when we immunnolabelled new-born sciatic nerves with an 
antibody against the p75NTR (Fig 5.9A). Moreover, western blot experiments 
performed on sciatic nerve extracts during the active phases of myelination (P10, P21 
and P30) and in the adult, showed that there were no gross abnormalities between wt
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and mutant mice in the expression of the myelin specific proteins Po and periaxin or in 
the expression of the non-myelinating Schwann cell specific protein LI (Fig 5.9B).
Schwann cell death is reduced in perinatal normal and injured sciatic nerve in PO 
CRE/TGFpRII^mice
Previous experiments demonstrated that TGFp-1 acts as a Schwann cell killer in freshly 
isolated cells from newborn rat nerves and that injection of TGFp-1 increases Schwann 
cell death into injured, but not normal, neonatal nerves (Skoff et al., 1998; Parkinson et 
al., 2001). These findings suggest that TGFp may have a role as negative regulator in 
the control of Schwann cell numbers during development. To test this hypothesis, we 
immunolabelled transverse sections of sciatic nerves from El 8 wt and mutant mice with 
the TUNEL technique, to detect nuclear fragmentation. These experiments revealed that 
the percentage of TUNEL-positive nuclei was considerably lower in mutant nerves 
compared with the wt ones, decreasing from 0.41% to 0.16% (Fig 5.10 A and B; p< 
0.005). Similarly, Schwann cell apoptosis in P2 nerves is significantly reduced from 
0.34% in the wt controls to only 0.09% in mutant mice (Fig 5.10 A and C; p< 0.001).
In normal neonatal nerve Schwann cell survival depends on the combined action of 
axonally derived NRG-1 and of autocrine signals (Meier et al., 1999). If the neonatal 
nerve is transected the survival of Schwann cells is sustained only by autocrine signals, 
and, although most of the cells survive, death by apoptosis is highly increased 
(Grinspan et al., 1996). Interestingly, this increase in Schwann cell death is not 
observed in null mice for the p75NTR, suggesting that p75 plays a crucial role in 
mediating Schwann cell apoptosis after injury (Syroid et al., 2000). Moreover, if TGF|3 
is injected in the distal stump of a wt transected nerve the number of TUNEL-positive
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nuclei is increased further, indicating that Schwann cells in the distal stump are 
sensitive to TGFp killing (Parkinson et al., 2001).
We therefore asked whether the loss of TGF(3 receptors could result in reduced 
Schwann cell death after axotomy in PI nerves. We performed TUNEL staining on
F/f*nerve sections from wt and PO CRE/TGF|3RII mice 24 hours after nerve transection. 
This experiment showed that in the wt mice cell death increases 13.85 fold, in 
agreement with previous results (Grinspan et al., 1996; Syroid et al., 1996, 2000; 
Parkinson et al., 2001). Similarly, in the mutant nerves Schwann cell death is increased 
13.22 fold, but remains nearly four fold lower than in the wt mouse (Fig 5.10 and 5.11), 
indicating a role for TGFb in the induction of Schwann cell death after nerve injury in 
the neonatal nerve.
Reduced cell death is accompanied by reduced proliferation in E18 P0 
CRE/TGFbRII1" nerves
TGFp, in the presence of serum or of cAMP elevating agents or both, promotes 
Schwann cell DNA synthesis and thus proliferation in vitro (Eccleston et al., 1989; 
Ridley et al., 1989). This, taken together with the finding that in the nerve of P0 
CRE/TGFpRII f/f mice Schwann cell death by apoptosis was reduced by approximately 
2.5 fold raised the possibility that TGFp may have a key role in controlling Schwann 
cell numbers during peripheral nerve development. This hypothesis predicts that, in the 
absence of TGF|3 signalling, the reduction of Schwann cell death should be 
accompanied by a similar reduction in Schwann cell proliferation. This assumption was 
tested by labelling transverse sections of El 8 sciatic nerves from wt and mutant mice 
with an antibody against the phosho-histone-3 (PH3), that specifically labels those cells 
that are actively dividing. Figure 5.12 shows that in the mutant nerves the rate of PH3-
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positive nuclei is 2.3 fold reduced when compared to the wt controls (p< 0.001). This 
reduction rate is very close to the one observed in Schwann cell death, suggesting that 
these two events could be related.
TGFp receptor type II recombination has already occurred at E18
To verify whether the observed reductions in Schwann cell death and proliferation in 
E l8 and in newborn sciatic nerves from mutant mice were attributable to the loss of 
type II receptor and therefore of TGFp signalling, we had to make sure that by E l8 the 
recombination of the floxed segment had already occurred. To do so we used the 
indirect approach already used at P5 and immunolabelled for Smad 2 and Smad 4 
Schwann cells from wt and mutant mice after treatment with TGFp. These experiments 
showed that in the mutant mice there was basically no nuclear localisation of Smad 
proteins (Fig 5.13 and 5.14), indicating that the recombination has already occurred at 
least as early as El 8, pointing at the lack of TGFp receptor as the likely candidate for 
the observed phenotype.
f IfSchwann cells from newborn PO CRE/TGFpRII sciatic nerves are resistant to 
TGFP killing
As already mentioned, treatment with TGFp actively kills freshly isolated Schwann 
cells from newborn rat nerves. Therefore, to further test the hypothesis that the 
reduction in Schwann cell death observed in perinatal nerves of PO CRE/TGFpRIIf/f 
mice is due to the loss of sensitivity to TGFp killing, we performed an in vitro survival 
assay in the presence of TGFp. Freshly isolated Schwann cells from the sciatic nerves 
of newborn mutant and wt type mice were plated at a density of 3000 cells per 
coverslips on a laminin substrate. Cells were allowed to attach to the substrate for about
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3 hours and then exposed to lOng/ml TGFp-1 for one day. At the end of the experiment 
the cultures were fixed and Hoechst stained. The number of living cells is expressed as 
survival percentage, that is the number of living cells present at the end of the 
experiment as a percentage of the number of cells present (i.e that had attached) after 3 
hours. We observed that, as expected, only 33 ± 5% of the Schwann cells from the wt 
sciatic nerves were still alive after 24 hours, while 55 ± 2% of the cells from the mutant 
mice survived (Fig 5.15), a percentage consistent with the number of cells that usually 
survive in this condition in untreated cultures (Parkinson et al., 2001), indicating that 
these cells are not sensitive to TGFp killing.
Schwann cell death and proliferation are not affected in adult nerves from PO 
CRE/TGFpRII ^mice after axotomy
In the normal adult nerve Schwann cells are present in a quiescent state. Following 
nerve injury they undergo a wave of proliferation that is part of the process of Wallerian 
degeneration. However, contrary to what happens in the perinatal nerve (see above), 
Schwann cells in the adult nerve do not undergo rapid apoptosis after axotomy (Scherer 
et al. 1993; Grinspan et al., 1996; Scherer and Salzer, 2001). However, after axotomy 
TGFp-1 mRNA levels are up-regulated in the distal stump (Scherer et al., 1993), 
suggesting that TGFp could have a role in the early events following nerve injury. 
Therefore we tested cell death and proliferation in normal and axotomised nerves from 
PO CRE/TGFpRIIf/f and wt mice. No apoptosis or proliferation were detectable in the 
adult nerves of either wt or mutant mice (Fig 5.16). Moreover, 7 days after nerve cut 
there was basically no apoptosis in the wt or the mutant nerves (Fig 5.17), while there 
was clear proliferation, as indicated by PH3 staining (Fig 5.18). However, no significant 
difference in the proliferation rate was detectable between the wt and the mutant nerves
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suggesting that TGFp does probably not have a role in the control of these events in the 
adult peripheral nerve.
Myelin-related proteins are correctly down-regulated in mutant nerves after 
axotomy
Previous experiments indicated that TGFp, at least in DRG neuron/Schwann cell co­
cultures can inhibit myelin protein expression (Guenard et al., 1995a; Einheber et al., 
1995). Moreover, after nerve injury in the adult nerve, while TGFp-1 mRNA is up- 
regulated, myelin-related gene mRNAs and proteins are strongly down-regulated in the 
distal stump. To test whether TGFp has a role in controlling the down regulation of 
myelin genes, we immunolabelled transverse sections of normal and transected (2 days 
and 7 days after axotomy) adult nerves from wt and mutant mice with antibodies against 
Po and periaxin. We could not detect any clear difference in the levels of expression of 
the two proteins between mutant and wt nerves in any of the conditions analysed (Fig 
5.19 and 5.20).
However, we noticed an interesting difference between mutant and wt nerves in the 
expression of the p75NTR. In fact, in the mutant mouse immunoreactivity for p75 is 
already detectable two days after axotomy, while it is absent at this stage in the wt 
nerve. 7 days after transection the levels of p75 are comparable between wt and mutant 
nerves (Fig 5.21). The meaning of this difference is currently under investigation.
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DISCUSSION
The TGFp superfamily of cytokines is involved in many aspect of the development and 
maintenance of various tissues, and alterations in its signalling pathway are associated 
with a range of human diseases (Massague, 2000). In the peripheral nervous system 
Schwann cells express TGFp-1, -2 and -3 (Stewart et al., 1995), and these factors have a 
variety of proliferative and phenotypic effects on these cells (Scherer and Salzer, 1996; 
Jessen and Mirsky, 2004). The first indication that TGFp-1 and -2 could have a 
proliferative role for peripheral glia came from studies on purified rat Schwann cells 
(Eccleston et al., 1989; Ridley et al., 1989). However, in DRG/Schwann cell co-cultures 
TGFp inhibits Schwann cell proliferation, blocks myelination and suppresses the 
expression of P0 and galactocerebroside (Guenard et al., 1995a,b; Einheber et al., 
1995). Moreover, in a variety of conditions in vitro and in vivo TGFp induces Schwann 
cell death (Parkinson et al., 2001, Skoff et al., 1998). So, what is the real function of 
TGFp in vivo?
In our experiments we have tried to answer this question by generating a conditional 
knockout mouse that does not express functional TGFp receptor type II specifically in 
Schwann cells. In conditional targeting experiments, one of the main pitfalls is that 
sometimes the percentage of recombination is far from being 100% (Rajewsky et al., 
1996; Brenda and Dymecki, 2004). This of course could mask the phenotype, due to the 
presence of wild-type cells.
The first obstacle that we encountered in estimating the percentage of recombination in 
our mice was that the purification of mouse Schwann cells by negative immunopanning 
was not very efficient. In fact, we were never able to obtain Schwann cells at a purity 
greater than 80%. Still, the analysis by Southern blot of the DNA thus obtained 
indicated that the recombination was probably higher than 90%, a value that should
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guarantee that the effects of the lack of TGFp signalling are not masked by the presence 
of unrecombined cells. This was confirmed indirectly by experiments in which we 
tested for Smad nuclear localisation. As we have mentioned in the introduction, one of 
the main consequences of TGFp binding to type II receptors is Smad protein 
phosphorylation and nuclear translocation (Derynck and Zhang, 2003; Shi and 
Massague, 2003). We demonstrated that as early as E l8, and then at P5, in the PO CRE/
f/fTGFpRII mice there is basically no nuclear localisation of the Smad proteins Smad2 
and Smad4. This strongly suggests that the recombination of exon3 of the type II 
receptor has already occurred at this stage. Moreover, in vitro experiments on Schwann 
cells dissociated from PI mutant and wt mice showed that, at this developmental time- 
point, the cells from PO CRE/ TGFpRII^ mice are not sensitive to TGFp mediated 
apoptosis, which is another indirect indication that the recombination has successfully 
occurred. At present, experiments are in progress to try to better purify Schwann cells 
from wt and mutant P3 mice, with the aim of performing a Southern blot that should 
give a definitive answer on the precise percentage of recombination soon after birth.
One of the most interesting effects observed in vitro in DRG-neuron/Schwann cell co­
cultures treated with TGFp was the block of myelination (Guenard et al., 1995a). This 
finding suggests that, in the absence of TGFp signalling, myelination may occur earlier 
than normal. In contrast with this idea, in those TGFp *A mice that survive until 3-4 
weeks after birth the onset of myelination is normal, and myelin appears 
morphologically normal (McLennan et al., 2000). However, these mice can probably 
take-up TGFp from maternal milk and this could mitigate the effects of the mutation. 
The analysis of our mice showed that the onset of myelination does not appear 
prematurely in mice lacking TGFp signalling. Moreover, myelination proceeds 
correctly and myelin maintenance does not present any abnormality, even in 1 -year-old
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mice. This is in contrast with findings in adult (6-13 week old) TGFp _/" nude mice, 
which present striking abnormalities in myelin compaction, with tomacula-like and 
“honeycomb” structures, particularly frequent in the node of Ranvier region (Day et al.,
2003). However, the results of this study are debatable: in fact only 11 TGFp ''' nude 
pups were found out of nearly 1000 pups genotyped, indicating that most of the double 
transgenic die during embryonic development, and suggesting that any phenotype 
observed may not be Schwann cell-autonomous. Moreover, 7 of these pups died at 
weaning, and the autopsies did not show any pathology. Of the remaining 4 mice, one 
was killed when 6 weeks old, and the other three were sacrificed when 13 weeks old. 
Surprisingly, although the mice looked healthy, EM analysis showed a grossly 
abnormal myelin. Unfortunately, no behavioural or elettrophysiological tests were 
performed on these mice, and therefore too many questions about the observed 
phenotype remain unanswered.
In addition to blocking myelination, in DRG/Schwann cell co-cultures, treatment with 
TGFp suppresses the expression of myelin-specific genes, and in purified Schwann cell 
cultures TGFp blocks cAMP induced expression of various myelin genes (Mews and 
Meyer, 1993; Morgan et al., 1994; Stewart et al., 1995; Guenard et al., 1995b; Einheber 
et al., 1995). Moreover, recent experiments have shown that in Schwann cell cultures 
TGFp antagonises the effects of forskolin on the mRNA levels of many myelin-related 
genes as well as of Oct-6 and Krox-20. In contrast with this, TGFp effects on the non­
myelinating Schwann cell specific genes GAP-43, p75, NCAM and LI are complex, 
varying from the induction of NCAM and LI to suppression of p75 and GAP-43 
(Awatramani et al., 2002). Our experiments however suggested that TGFp does 
probably not have a direct effect on the expression level of myelin proteins. In fact 
periaxin and Po expression, tested via immunohistochemistry and western blot did not
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appear to be different between wild-type and mutant mice. Similarly, the developmental 
expression of p75 and LI looked normal.
These results, taken together the observation that myelin is morphologically normal in 
PO CRE/TGFpRII m mice strongly suggest that TGFp is not fundamentally involved in 
the process of myelination in vivo.
In recent years our lab has shown that TGFp, in freshly purified neonatal Schwann cells 
in vitro and in perinatal injured nerve in vivo, actively kills Schwann cells, and that this 
effect can be blocked in vitro through enforced expression of the transcription factor 
Krox-20, that leads to inactivation of the JNK-c-Jun pathway (Parkinson et al., 2001,
2004). In agreement with these observations we found that in PO CRE/TGFpRII mmice 
Schwann cell death is significantly decreased in embryonic (E l8) and perinatal stages, 
both during normal development and after nerve injury. Interestingly, after nerve injury 
at PI, Schwann cell death is increased in the mutant mouse too, although it remains 
nearly 4 fold lower that in the wild-type. It is likely that the increase of Schwann cell 
death even in the absence of TGFp signalling is due to the action of the NGF/p75 
pathway, which has been shown to be crucial in mediating Schwann cell apoptosis after 
neonatal nerve injury (Syroid et al., 2000).
The observed reduction in Schwann cell death was also accompanied by a reduction in 
Schwann cell proliferation of similar magnitude. This is in agreement with previous 
studies that showed that TGFp has a mitogenic effect on Schwann cells (see citations 
above). A control of TGFp on both Schwann cell death and proliferation would also 
account for the normal appearance of the sciatic nerve in the mutant mouse. In fact, it 
can be speculated that if only Schwann cell death was affected we would have probably 
observed some morphological abnormalities. However, to definitely confirm that there
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are no significant differences in the overall number of Schwann cells between wt and 
mutant mice, stereological experiments are currently in progress in the laboratory.
It must be reported that recent work has identified the protooncogene ski as probably 
involved in controlling Schwann cell exit from the cell cycle, differentiation and 
myelination (Atanasoski et al., 2004). Ski is a repressor of TGFp signalling through 
direct interactions with Smad2, 3 and 4. Ski probably interacts with the co-repressor N- 
CoR, thereby negatively modulating gene transcription by Smad complexes, and 
probably interferes with Smad binding to the coactivator of gene transcription 
p300/CBP (Akiyoshi et al., 1999). The work from Atanasoski and colleagues shows 
that ski antagonises the mitogenic effect of TGFp in cultured Schwann cells, and ski 
overexpression in Schwann cell cultures prevents the cells from re-entering the cell 
cycle. On the other hand, in DRG/Schwann cell cocultures ski expression (as well as 
myelination) is blocked by treatment with TGFp. Finally, ski seems to be involved in 
myelination and myelin gene expression. In fact, although ski -/- mice are embryonic 
lethal, late embryonic stages could be analysed, and myelin proteins appeared to be 
reduced at the mRNA level (Atansoski et al., 2004). In this respect, analysis of 
myelination in ski conditional knockouts would be very helpful in determining the 
precise role of ski in this process. It would also be very interesting to evaluate the levels 
of ski in the PO CRE/TGFpRII ^mice, to test whether the lack of TGFp signalling has a 
direct consequence in modulating ski expression.
After injury in the adult sciatic nerve there is a dramatic increase in Schwann cell 
proliferation, while cell death, at least in the first weeks, is not affected (Scherer and 
Salzer, 2001). However, the mechanism involved in controlling these events can be 
different from those modulating the same mechanisms during development. For 
example, while during embryonic development cyclin D1 null mice do not present any
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impairment in Schwann cell proliferation, after nerve injury Schwann cell proliferation 
is basically blocked in these mice, suggesting a role for cyclin D1 in controlling 
Schwann cell de-differentiation and re-entry in the cell cycle (Kim et al., 2000; 
Atanasoski et al., 2001). We showed that TGFp is probably not involved in controlling 
Schwann cell proliferation and death after nerve injury in the adult nerve. As in the 
wild-type, no cell death or proliferation could be detected in the uninjured adult nerve in 
mutant mice. 7 days after sciatic nerve transection the Schwann cells in the distal stump 
are actively proliferating, but no significant differences were visible in the mutant 
mouse when compared with the wild-type. Our findings, taken together the results in 
the cyclin D1 -/- mice, strongly indicate that the molecular mechanisms that regulate 
Schwann cell proliferation during development or after axonal damage are 
fundamentally different.
We also tested the adult mutant nerve for Schwann cell-related proteins expression 
before and after nerve injury. These immunofluorescence experiments showed that there 
was no significant difference in the expression levels of Po or periaxin in the uninjured 
adult nerve between wt and P0 CRE/TGFpRII ^mice. Similarly, 2 or 7 days after nerve 
cut, the levels of Po and periaxin drop in a comparable fashion between mutant and wt 
mice.
However, during these experiments we made an interesting observation regarding the 
p75NTR. In fact, in P0 CRE/TGFpRII f/fmice p75 is already clearly detectable 2 days 
after nerve cut, while it is still undetectable at this time-point in the wild-type mice. P75 
is known to be up-regulated after nerve injury (Heumann et al., 1987). Its up-regulation 
is seen at the mRNA level 24 hours after transection, peaks at around 1 week and is 
maintained for up to 10 weeks, and axon regeneration down-regulates p75 (Robertson et 
al., 1995; Taniuchi et al., 1988). Moreover, TGFp treatment down-regulates p75 in
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cultured Schwann cells (Mews and Meyer, 1993; Awatramani et al., 2002). It is 
therefore possible that the lack of TGFp results in an early and massive up-regulation of 
p75. 1 week after nerve transection p75 levels have probably reached the peak of 
expression in the wild-type nerve too, and no difference is detectable at this stage. As 
we have discussed previously, the role of the NGF/p75 pathway in the PNS is not 
completely clear. P75 is crucial for modulating Schwann cell death after nerve injury 
(above), but no other role has been identified so far. The meaning and consequences of 
the up-regulation that we observed are therefore not clear. The fact that we did not 
detect any Schwann cell death in the transected nerves of the mutant mice indicates that 
in this situation p75 is probably not involved in modulating Schwann cell apoptosis. 
The regulation of other genes, such as LI and NCAM is currently under investigation to 
elucidate if there is any similarity in their control after nerve injury to the one observed 
for p75.
It must be also noted that the pattern of labelling that we observed for p75 raises some 
doubts about the antibody we used. In fact in our experiments p75 appears to be 
localised as bright dots; however, p75 is a surface protein and therefore the labelling 
should be more membrane-associated. More experiments are therefore requested to test 
the antibody specificity.
In conclusion, with this study we provide the first in vivo evidence that TGFp signalling 
is crucially involved in controlling Schwann cell death and proliferation during 
peripheral nerve development. The PO CRE/TGFpRII f/f mouse that we have generated 
could also be a useful tool to study the role of TGFp during the events following nerve 
injury, such as Wallerian degeneration and during nerve regeneration.
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Chapter 6
CONCLUSIONS AND GENERAL REMARKS
The interaction between axon and Schwann cell represents one of the most striking 
examples of cell:cell interaction and the process of myelination is an incredible example 
of cell specialization. During the course of my studies I have tried to add valuable 
information to the knowledge of the molecular mechanisms that control Schwann cell 
differentiation and myelination. To achieve this goal I used two technologies that in 
recent years have radically changed the way researchers address biological questions: 
DNA microarrays and the CRE/loxP system.
DNA microarrays allow the analysis of the expression of thousand of genes 
simultaneously. This means that is possible to examine, in a fairly straightforward way, 
the overall transcriptional response of a tissue or of a cell type in normal conditions or 
in disease state, after biological, genetic or chemical stimuli or during biological 
processes such as cell-cycle progression or development. This kind of analysis is 
commonly referred to as gene expression profiling. The large amount of data generated 
from microarray analysis represents a great strength of the system, but it can also be 
seen as a weakness. This happens because very often gene profiling experiments 
generate more questions than answers. In fact, commonly, hundreds if not thousands of 
genes greatly change their expression levels between two different conditions. How 
should a researcher proceed from here? At present many programs are available for the 
analysis of the data obtained from a comparison. These tools, such as the software 
GeneSpring that we used in our analysis, facilitate the processing of multiple data sets 
and assessment of data quality. Nevertheless, even using these tools, the amount of 
information generated by a microarray analysis remains difficult to handle. For this
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reason it is important to make available to the scientific community the raw data 
obtained from each experiment. The data obtained from our experiments can be a clear 
example: we were interested in those genes up-regulated during myelination and down- 
regulated after nerve injury, since the co-existence of these two conditions indicates that 
a gene may be myelin-related. However, we found that tens of genes are strongly up- 
regulated after nerve injury. They could be of great interest for researchers studying the 
initial events leading to nerve degeneration and to inflammatory response. It is therefore 
important to store them in a database where they can be accessible to the scientific 
community. For this reason our data, combined with experimental information in 
MIAME (minimal information about microarray experiments) compliant format, are 
stored at the Institute of Child Health (ICH) in London, ready for submission to the 
ArrayExpress database (EBI, Hinxton UK).
Another strength/weakness of microarrays is the number of ESTs present on the chips. 
Very often ESTs can represent up to 50% of the sequences that are differentially 
expressed in two or more conditions. If from one point of view this can be exciting, 
since the study of an EST could lead to the discovery of a novel gene, on the other hand 
it greatly reduces the ability to interpret and wholly understand the results of a set of 
experiments. To try to bypass this problem, in collaboration with the biotech company 
Inpharmatica (www.inpharmatica.comL we have mapped and annotated nearly all the 
ESTs that we found differentially expressed in our experimental conditions. This 
allowed us to better analyse our data and to generate and make available a sort of 
database for each one of the probes that changed in the embryonic comparison 
(E14vsE18) or after peripheral nerve injury (P12vsP12cut) (see Appendix). In this 
database we indicated how the gene has been mapped, provide a series of keywords 
related to the gene function and, if  available, the Gene Ontology annotation. Moreover
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we indicate if the gene has a signal peptide that makes the protein likely to be secreted 
or if transmembrane (TM) domains are present. Finally we provide a sequence and a 
structural annotation. To our knowledge this is the first time that such a complete and 
detailed analysis and description of the data sets from a microarray analysis is provided. 
Of course the great challenge now would be to verify whether the predictions made with 
the use of the Biopendium are totally reliable and therefore if the functions inferred for 
the novel sequences identified correspond to the real function of the proteins. 
Nevertheless we believe that this represents a powerful way to handle data obtained 
from microarray analysis and its potential could be investigated further to improve the 
outcome even more.
The gene profiling that we performed also brought to our attention a series of genes, 
already know to be important in other systems, that had not been previously identified 
in peripheral nerve. In particular, the group of genes related to cartilage/bone 
development could represent an intriguing source of new experiments. We have in fact 
shown that type II collagen and the transcription factor Sox9 are highly expressed by 
Schwann cells, and that their regulation probably depends on axonal signals. However 
at present their function in peripheral nerve remains unknown. Unfortunately both type 
II collagen and Sox9 null mutants are embryonic lethal, therefore we could not use 
these animals to study peripheral nerve development in the absence of these genes.
The second technology that we used, the CRE/loxP system, provides a way to overcome 
the problem of embryonic mortality. I believe that it would be extremely interesting to 
study Schwann cell specific knockouts for type II collagen and Sox9 (and of course 
many other genes identified with our screening) by crossing the PO CRE mouse with 
mice in which col2al or Sox9 genes have been floxed. The analysis of mice thus
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obtained should provide strong indications about the functions of these genes during 
Schwann cell development.
On the other hand the analysis of the POCRE/TGFpRH mouse suggested that during 
peripheral nerve development TGFp is probably involved in the control of Schwann cell 
death and proliferation. But what are the molecular mechanisms involved in these 
events? Recent work in our laboratory indicated that the c-Jun/JNK pathway is involved 
in TGFp-mediated apoptosis (Parkinson et al., 2001). Is this the only pathway involved 
or there are other pathways that play a role in this process? And what about TGFp- 
mediated proliferation?
The use of DNA microarrays could be a way to answer these questions. Comparing the 
gene profiling of Schwann cells from normal mice and from mice in which the TGFp 
receptor type II has been specifically ablated, under various conditions, could provide 
important clues in this direction. For example it would give an indication of the down­
stream targets of Smad proteins in Schwann cells, or it could provide a general idea of 
the genes directly controlled by TGFp during peripheral nerve development in vivo.
In conclusion, the experiments here described provide some novel information about 
genes that could play a part in the molecular mechanism involved in Schwann cell 
differentiation and myelination, and represent a broad platform for the plan of future 
experiments.
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APPENDIX
Mapping and structural annotation of the probes found to be differentially 
expressed between E14 and E18 and between P12 and P12cut.
In the following documents, the mapping and structural annotation of the 130 probes 
differentially expressed between E14 and E l8 and of the 237 probes differentially 
expressed between P12 and P12cut is provided.
The probes are divided based on the set in which they clustered in the K-means 
clustering performed with GeneSpring and shown in Figures 3.4 and 3.11.
The 10 sets for the E14vsE18 comparison are provided first, followed by the 15 sets 
resulting from the P12vsP12cut comparison.
These documents have been produced by Dr David Michalovich and Dr Morris 
Paterson, at Inpharmatica.
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Family: C arboxypap tidasa  0 , a  ragu la to ry  dom ain
901 -979
Hrt: Famiy- Cwtiwypephdaee D. a regulaiory domam ain«al (l-79)/P*Secp. 1C
312 src-like adaptor SLAP GENE. SftC-LJKE ADAPTOR 
PROTEIN; CAP TRAPPER. HTC; 
MGC; PHOSPHORYLATION. SH2 
DOMAIN; SH3 DOMAIN. 
ALTERNATIVE SPLICING; 
MYRISTATE
g o  0007242 intracaNuiar *gn4<ng caacadt unlike ly 0 S rc  hom ology  3 d o m ain s
39 96
Hrt amart00326ftCDD: 0 003 (low)
S rc hom ology  2 d o m ain s
96- 182
Hi. *m*l002S2/tCDD 4*18
Family: SH3-dom ain
36 - 96
Hrt Family: SH3-don«n. dlh92a. (2-62yP«Scop. ID 38%
Family: SH2 dom ain
96 - 203
Hrt. Famiy SH2 domain diaSiai (5-111 yPwSccp. ID 31%
S72407_at Pmbe mapped none 1138 Tvwnscan G ene Model unlikely 0 Lam inin G dom ain Super-Fam ily: C oncanavaiin  A-like ie c tin s /g lu can ases
directly wrth low 200-330 195 • 331
Ht: PF000$4*PFAM; 3*12 Hrt. Famiy Lamow G-kke module dlkdka. :(30-l66)/P*Scop, 10 21%
chr1.2l.006a Laminin G dom ain Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
384 523 358 537
Ht. PF00054/iPFAM. le-22 Ht: Famiy Lamiran Gkke modiie dlkdka (10-l77yP»SC0p: ID 21%
Lam inin G dom ain Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
570-711 528 - 711
Hrt: PF00054/iPFAM: 2*16 Hrt. Famiy: Lammn Gkke module dlkdka. (2-165)/P**Scop: ID 21%
Lam inin G dom ain Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
809 937 772-950
Ht: PF00054/IPFAM. 4*23 Hrt Famiy Lamtrun G'kke modUe dlkdka :(M77VP*Scop: ID 21%
Lam inin G dom ain Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
964-1109 980-1109
Ht PF00054/iPFAM. 4e-14 Hrt: Family: Lwn.rwi Gkke module d1kdka_:{3M59)/PaiScop; ID 21%
HGF RECEPTOR; C-MET GENE; 
HEPATOCYTE GROWTH FACTOR. 
GROWTH FACTOR RECEPTOR: 
PROTOONCOGENE. 
TRANSMEMBRANE PROTEIN; 
TYROSINE KINASE; ATP; 
AUTOPHOSPHORYLATION. 
GLYCOPROTEIN; 
PHOSPHOPROTEIN; 
PHOSPHOTRANSFERASE, 
RECEPTOR; TYROSWE-SPECIFIC 
PROTEIN KINASE; ATP-BINDING: 
GLYCOPROTEIN: 
PHOSPHORYLATION. PROTO­
ONCOGENE; RECEPTOR; SIGNAL; 
TRANSFERASE. 
TRANSMEMBRANE; TYROSINE- 
PROTEIN KINASE
GO 0000074 reguUtnn ct cell cycle highly
00:0034672 protan klnaae activrty likely
00:0004674 protan •erwe'threonme kina*
G0:0004713 prolan tyrosine kinase activrty
GO 0004872 recaptor activity
G0 0005006 hepatocyie growth (actor race
G00005524 ATP binding
00:0005615 extracellular apace
GO 0005622 intracellular
G00005624 membrane fraction
GOQ006468 protan ammo acid phoephory
G00007275 development
GO00Q7420 brain develooment
00:0006151 cell growth and/or mamtenan
GO:0016020 membrane
G00016021 integral to membrane
GO:0016740 trareleraee activity
G0.0030534 adult behavior
em aphorin  dom ain
52 488
Ht: amart0063(ViCOO: 4*66
dom ain  fo u n d  in P iex ins, S em ap h o rin s  a n d  Integi
520 - 562
Hrt: im«l00423/>CDO. 1*06
Ig-like, p iex ins, tran sc rip tio n  fac to rs
563 656
Ht smart00429ACDD; 1*06
ig-like, p iex ins, tran scrip tio n  fac to rs
657 - 739
Ht. smart00429/>CDD, 4*67
ig-like, piex ins, tran scrip tio n  fac to rs
742 - 837
Ht: «mart00429/>CDO; 9*07
ig-like, piex ins, tran scrip tio n  fac to rs
839-896
HI: amart00429ACDD. 0 001
T yrosine  k inase, cata ly tic  dom ain
1079-1338
Hrt: emart00219/iCDO; 1e-95
Family: T yrosine k inase
1061 -1338
Hrt: Family: Tyroame kinase. dlk3aa._: (l4-271>/P$iScop; ID 42%
Probe mapped P01830
within 2kb ot 
3‘end with low 
confidence to 
Reteeq 
NM 012673
161 thymus ceil antigen 1, theta Thy1 CELL-SURFACE MARKER; G00005615 extraceHuW space
GLYCOPROTEIN. SIGNAL PEPTIDE; 0 0  0016020 membrsme 
ANTIGEN. CELL SURFACE 
GLYCOPROTEIN; CELL SURFACE 
ANTIGEN; MEMBRANE PROTEIN;
PYROGLUTAMIC ACID, 161AAS,
2863BP: DNA BLOT;
DIFFERENTIATION MARKER ON 
THYMOCYTE; EXON INTRON 
ORGANIZATION; HYDROPHOBIC 
TRANSMEMBRANE SEGMENT; RNA 
BLOT; RAT; SEO DETERMINATION;
THY1 ANTIGEN: CDNA/GENOMIC 
CLONE: THY1 GENE; GPI-ANCHOR;
GLYCOPROTEIN;
IMMUNOGLOBULIN DOMAIN:
MEMBRANE: PYRROLIDONE 
CARBOXYLIC ACID; SIGNAL; T-
cell
highly
likely
Im m unoglobulin  dom ain  variab le  reg ion  (v) subfai Super-Fam ily: Im m unoglobulin
113
t. cd00099/iCOO,0 001 adam ant (ant tody variable domam-kke). iASV'.fuS4t(t-109)/P«iBL
e mapped AAA41868.1 671 protein kinase C, beta 1 176970 MGC; PROTEIN KINASE; PROTEIN G00004672 protom kin*e activity t  
KINASE C-BETA; PROTEW KINASE 0 0  0004674 pm f n sennrfhreonin. kin* 
C-BETA-1. ALTERNATE SPLICING;__
PROTEIN KINASE C; KINASE; GO 0004682 protein kinase CK2 activrty 
PROTEIN KINASE C TYPE BETA; GO 0004691 cAMP-dependent partem kina 
ATP; ALTERNATIVE SPLICING; GO 00O4713 protein tyroeme kin*e activrty
Protein  k inase  C c o n se rv ed  reg ion  1 (C1) dom ains Family: P rotein k inase  cysteine-rich  dom ain  (cys2, pho r
37 - 86 95 - 159
Ht; $mart00109/'>COO: 7e-l2 Hit: Family: Pnaem lonaee cyMeme-nch doman (cys2. phortxrt-binding doman). d
Protein  k in ase  C c o n se rv ed  reg ion  1 (C1 ) dom ains
102- 151
Ht: amartOOl 09ACDO; 6e-11
P robs M apping B iopendlum
A ccession
Lsn. D escription G ene
Sym bol
OMIM K eywords GO SigP
w c n o
TMs S truc tu re  A nnotation
I S e t  3  ..... !I
AF000942_al
medun
P41138 119 Inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein
Id3 600277 103 GENE: 103 PROTEM. CAP 
TRAPPER: HTC; 1 R»1: CA REPEAT 
P0LVI40RPHS4A DIS2S3A. 
01S482; E2F2: HEIR-1; HTO; 108;
GO 0005634 nucMut unlikely 0 helix loop  helix dom ain
42-86
Ht: emart00353ACDO; 3*08
Super-Fam ily: Helix-loop-helix DNA-binding dom ain
42-66
H r Famiy Hefci-<oa**teM DNA-tendmg domain oiNoP. (1*61 VPdScop; ID 24
HELIX-LOOP-HELIX; MGC. 
FU.CONA; GROWTH FACTOR 
WOUCWLE PROTEIN; HEUX-LOOP 
HELIX PROTEM; EARLY 
RESPONSE GENE; 
TRANSCRIPTIONAL FACTOR; DNA 
BMOMG; DIFFERENTIATION; 
PHOSPHOPROTEM; 
TRANSCRIPTION FACTOR; 
ALTERNATIVE SRJCMG; 
TRANSCRIPTION REGULATION;
119AAS. 24806P. ACCNO JC73428; 
EXON X2; GENOM6C 
ORGANIZATION; HUMAN; ID3 
GENE; LOCATION ON 
CHROMOSOME 1P36;SEO 
COMPARISON; SEQ 
DETERMINATION; NUCLEAR 
PROTEM
AF020618 q at AAN96586.1 457 myeloid differentiation primary response
Rdseq
NM_133546
Myd116 - 00*0030154 c*l n m i s r
gene 116
likely 0 Nop14-like family 
221 - 347 pigment)
HI: pten04147/ICO0. 0 004 (low)
no h its
<■ 100*  err
D14014 a  a t BAA03115.1 295 cyclin 01 CAP trapper , htc; mgc c yclin 00:0000074 r e g io n  d  cni cyde unlikely 0 dom ain  p resen t in cy d in e , TFIIB an d  R etinoblastc  Super-Fam ily: Cydln-lilce
UKE PROTEIN; CCND1 GENE; 
CYCLIN 01; CELL CYCLE 
CONTROL; CELL CYCLE; CELL 
DIVISION; CYCUN MULTIGENE 
FAMILY
00:0006468 protein amino add phoephory 
GO:0005829 cytoed
000018538 cydtrvdependanl protein Iona 
GO.0045444 adipocyte dHlerent.te.on 
00:0016301 tenaee ac#v4y 
000005634 nudeue 
GO 0004672 protein lonaee activity 
GO 0000910 cytohmeee 
GO:0005515 protein tenteng 
GO 0007049 cell cyde 
G00000320 re-entry into mitotic cell cyde 
G00000307 cydvi dependent protein Wna 
GO 0003723 RNA tending 
G0:0006634 nudeue 
GO 0003676 nudeic add tendmg 
GO 0005622 intraotekjlw
62 146 
Ht. emart0038S4COO: ie-12
Ht: ptam02964/iCDD; le-14
15-152
Ht: Famiy: Cydtn. dl6qb1: (2-136yPeiScop; 10 25% 
Super-Fam ily: Cyclin-liKe 
156 - 252
HT Famiy: Cydtfl 1G3NCC<133-233yPa«aal; ID 23%
D83948mRNA_a p»*»«"4pp* P70501
.  directly with high
confidence to 
Reteeq
852 RNA binding motif protein 10 300080 CAP TRAPPER; HTC. FU.CONA;
MGC; SM  PROTEIN; NUCLEAR 
PROTEIN; RNA-BINDING, REPEAT; 
ZMC-FMGER
unlikely 0 RNA recognition  motif
67-125
H r amaft0036(ViCOO; 0008 (low)
Zinc coord inating  RNA b inding  dom ain
138-166
Ht: LQAOfiCOO; 1*06 
RNA recognition  motif
224-303
H r amart0036Q4COO; 0.0001
Super-Fam ily: RNA-binding dom ain , RBD
67-119
H t Famiy. C axnca  RBO diI3kai: (22-73yPa£ccp; ID 24%
Super-Fam ily: RNA-binding dom ain , RBD
214 - 317
HT Famiy Canonical R80. d1h2uy_: (27* 124VP*Scop; ID 17%
Ht: PS50157/iPROSITEpro; rVa
glycine rich nucleic  b ind ing  dom ain
778-823
Ht: amart004434CDO; 9e-12
292 nudeophosmin 1 N pm1 164040  CAP TRAPPER. HTC; MGC. G00003676 nucleic aod binding
FLLCONA; NUCLEAR G00003723 RNA tending
PHOSPHOPROTEM; NUCLEOLAR  ___  ^
PROTEM B23 ALTERNATIVE GO 0005515 protem tending
SPUCMG: NUCLEOLAR PROTEM; GO 0005634 nudeue 
NUCLEOPHOSMM; NUMATRIN; B23 00:0005730 nudedue 
GENE; NUCLEOLAR 
PHOSPHOPROTEM; NUCLEOLAR 
PHOSPHOPROTEMB23;
NUCLEOLAR PROTEM N038; RNA- 
BMOMG PROTEM; NUCLEUS:
PHOSPHOPROTEM; NUCLEOLUS:
ALTERNATIVE SPUCMG;
CHROMOSOMAL TRANSLOCATION;
NUCLEAR PROTEM;
PHOSPHORYLATION. PROTO­
ONCOGENE; RNA-BMOMG
unlikely 0 Nucleoplasm in
13-131
Ht: ptam03066rtCDD; 2*34
Family: N ucleoplasm in core
16-116
H r Famiy NuOeopiaarmn core. dlHSjb_: <l-95)/PteScop; ID 50%
J04486- at **** ."*?* . p ’ 2843 304 insulin-like growth faclof binding prolain 2 Igfbp2 - S t l ! ^ P.P.Ei ^ c„'.MS5.JHslJL,N 0 0 0 0 0 5 5 7 6 highly 0 Insulin grow th factor-b inding  pro tain  h om ologue . Family: G row th fac to r m e n to r  dom ain
196 rt>oB gene
G0 0005923 light junchon 
00:0007049 cell Cycle 
G 0 0007242 intrecefluar ugnWmQ caecadi 
G0 0016020 membrane
QTP BINDING: P-LOOP;
LIPOPROTEIN; METHYLATED G0 000552SGTP btfKfrng
CARBOXYL ENO: NUCLEOTIDE G0:0007284 ifflU GTPaaemedeted wgrv
BlNOING; PRENYLATED CYSTEINE; G00007266 Rbo protem signal imduClK
THIOLESTER BOND; ACETYLATED ,w « i
AMINO END. MEWRANE PROTEIN: 0 0  000,151
PROTOONCOGENE;
TRANSFORMING PROTEIN;
IMMEOIATE-EARLY PROTEIN, GTP- 
BlNOING; LIPOPROTEIN:
PRENYLATION; PROTO­
ONCOGENE
Kit: amart00666/tCDD; 1e-09 Hrt Famiy PBi domain 11P9:AA(1-65yGenThread: 10 8%
Domain p re se n t in PSD-95, Dig, and  ZO-1/2 Super-Fam ily: PDZ dom ain-like
157 - 247 157 - 252
Kit smart0022AACDO; le-08 Hrt Famiy POZ dom»n oiicwaa. (3-86VP*Scop. ID 23%
Rho (R as hom ology) subfam ily  o f R as-iike sm all C Family: G p ro te in s
6-161 3-160
Hi amartOOl74/tCDO; 2e-®4 Hrt Famiy G prawns dilbib.: (1 l78yP*Scop ID 68%
XURTGP 210 glutathione S-transferase, pi 2 Gstp2 CAP TRAPPER. HTC; MGC. 
GLUTATHIONE S-TRANSFERASE 
PI; PREADIPOCYTE GROWTH 
FACTOR; GLUTATHIONE S- 
TRANSFERASE SUBUNIT PI; 
GLUTATHIONE TRANSFERASE;
GST PI ENZYME; GLUTATHIONE S- 
TRANSFERASE; TRANSFERASE: 
GLUTATHIONE S-TRANSFERASE II; 
DMER; MULTIGENE FAMILY; 
TRANSFERASE; 30-STRUCTURE: 
MULTIGENE FAMILY: 
TRANSFERASE: 3D-STRUCTURE; 
GLUTATHIONE
GO:oooeiS2 nMaboi«m unlikely 0
GO:0004364 gtutattxone transferase acttvrt- 
G00016740 trrwferaee activity
G lu tath ione S -tran sfe rase , N-terminal dom ain  Fam ily: G lu ta th ione  S -tran sfe ra se  (GST), N-termlnai d o r
1-75 1-79
Hit: PF02798APFAM; la-11 KM. Famiy: Gkrtattaone S-tranaferaee (GST). N-termmai domam. dlglpa2 (1-78yi
Family: G lu ta th ione  S -tran sfe ra se  (GST), C-terminal d o r
l: PF00043/1PFAM;2*13
80 210
Hrt Famiy GluUINane SHraneferaee (GST). C-terminal domam. (
rc_AI236597_at Hand mapped to AAF04619.1 1405 chromosome 1 open reading frame 9
crthdogue- 
AAF04619 1
unlikely 0 no h its
H2afy
Reiseq
NM017182
HTC; FIS (FULL INSERT 
SEQUENCE): OLIGO CAPPING; 
MGC; CORE PROTEIN; HISTONE; 
NUCLEOSOME; ALTERNATIVE 
SPUCING; CHROMOSOMAL 
PROTEIN; DNA-8INOING; 
MULTIGENE FAMILY; NUCLEAR 
PROTEIN. NUCLEOSOME CORE
G00000786 nudeoaome 
00:0005634 nudaua 
G0 0005813 certrosome 
00:0003677 DNA binding 
00:0005694 chromosome 
G00007001 chromosome organization 
G0 0000793 condensed chromosome 
G0 0006334 nudeosome assembly 
G00003682 chromalin binding
unlikely 0 H istone 2A
2-120
Kit: am art00414ACDO, 2*47
Appr-1 **-p p ro c e ss in g  enzym e
205 329
k Kit: smartOOSOfiACDO; 3a-l9
Family: N u d e o so m e  c o re  h is to n e s
4 123
Hit. Family: Nxfeosome core histonee. dHaSc_. (6-i26yPs»Scoo: ID 65%
rc_AI639301_at Proda mapped ENSRNOPOO 773 Ensembl Gene Model 
000018422?end wrtti low
133510; MGC; COCKAYNES SYNDROME; 
234050* ^  PROTEIN; EXCISION
unlikely 0
ENSEMBL
ENSRNOTOOOO
0018422
REPAIR PROTEIN; HELICASE; DNA 
BINDING: DNA REPAIR; NUCLEUS; 
ATP-BINDING; DNA-BINOtNG; 
DEAFNESS; DISEASE MUTATION; 
DWARFISM: HELICASE; 
HYDROLASE; NUCLEAR PROTEIN; 
POLYMORPHISM, TRANSCRIPTION 
REGULATION; XERODERMA 
PIGMENTOSUM
Kit: *mart00487ACDO;;
I «mart0049<yiCOa 2e-06
Super-Fam ily: P-loop  con ta in ing  n uc leo tide  trip h o sp h a t
351 - 491
Hrt. Famiy: Tandem AAA-ATPase domain. 1FUU:B8(1-2lSyPwBlast: ID 16%
Super-Fam ily: P -loop  co n ta in ing  n u c leo tid e  trip h o sp h a t
519 - 705
Hit; Famiy: Tandem AAA-ATPase domain. dlgm5a4: (2-190yP$iScop: ID 17%
rc_H31313_at Handmappedio AAG25939.1 961 signal peptide, CUB domain, EGF-like 1 Scubel G0:0016020 membrane highly
G 0 0007512 adult heart dMiopment likely
G00009791 post-embryonicdeveiapment 
G00007596 blood coagulation 
G0:0004888 tranemembrane receptor aclrv 
00:0009897 external side ol piaema memt 
G0 0005509 catcwm ion binding 
GO 0045446 endothelial cell differentiation 
00:0006954 inflammatory response
C alcium -binding EGF-iike dom ain
33-73
Ht: smarl00179/tCDD; 2*06
C alcium -binding EGF-iike dom ain
74-115
Hi: smart00179/iCDD; 0.0002
C alcium -binding EGF-like dom ain
117-156
Ht: smart00179/iCDD: 0.001
Trypsin Inh ib itor like cy ste in e  rich dom ain 
226-286
Ht: PF0182&iPFAM; 0.003 (low)
Super-Fam ily: EGF/Laminin
33-70
Ht: F»ndy: EGF-type module. 1 WHF:-1(47-86yPs*Blast: 10 26%
Super-Fam ily: EGF/Laminin
72- 102 
Hrt: Famiy: ( am of BfcMO'SPARC/oeteonedm. iNUBAA(l-2SVGenThread: I
l: smartOOl 79/tCDD; 0 0006
Ht amartOOl79/iCDO; 2e-05
C alcium -binding EGF-like dom ain
362 - 401
Ht: smart00l7WCDD; 0 0001
Family: EGF-type m odule
366-403
Hrt Famiy. EGF-type module. lN7DAA(246-262yPsiBlaet: ID 37%
Fold: K nottins (sm all inh ib ito rs, tox ins, lectins)
Probe D escription G ene OMIM K eyw ords GO SigP T ils S eq u en ce  A nnotstion S tru c tu re  A nnotation
A ccession Sym bol Secrtd
Set 4
VASCULAR CEU. AOHESKX 
MOLECULE-1; VCAM1 GENE;
VASCULAR CELL ADHESION 
MOLECULE 1: CELL ADHESION;
TRANSMEMBRANE PROTEW; CELL 000018020 membrane
erectly
contoai
RelMq
730 vascular cell adhesion molecule 1 GO 0016337 criLcaa adhesion 
00:0006886 plaama membrane 
GO 0005615 •
highly
likely
ADHESION; GLYOOPROTEW; 
IMMUNOGLOBULIN DOMAIN; 
REPEAT; SIGNAL; 
TRANSMEMBRANE
GO:0016021 integral to membrane 
GO 0005515 prot*n bmdng 
G0 0005194 cell artesian molecule ectivfl 
GO 0007155 ceil adhesion
Im m unoglobulin
36-113
Ml; •merl0O40a*C0O. 2*06
Ml. sman00406ACDO: 1*09
Ml: emart00409ACDO; 0.006 (tow)
Intercellular adh esio n  m olecule/vascular
401 • 450 (fragment)
Ml: PR014724PRSITS; Se-10 
Im m unoglobulin
519-607
ML amart0040eiCDO; 3*07
GLYCOPROTEIN; HYDROLASE. GOOOQ3824 cat aryl c  ad«Ny
UPID DEGRADATION; LYSOSOME. 000004771 slerd eahraee act* 
S'GML 00:0005764 lyeoeome
GO:0016042 lipid caiabolam 
00:0016787 hydrolase adivrty
Family; I se t do m a in s
26-114
ML Famiy I sal domains. di>f9a2 (2 90VP**Scop. 10 78%
Family: C2 se t d om ains
115 • 220
ML Famiy: C2 aet domarw d1#a1:(1106yP»Soop; ID 68%
Family: I se t do m a in s
236 306
ML Famiy: I eel domams. dlcs6a3 <l9-90yPeScop; 10 33%
Family: I se t do m a in s
313-402
Mt Famiy: I aat domane di«j9a2 (l-90yPa«ccp: ID 52%
cell adhc Family: C2 se t do m a in s
403-508
ML Famiy: C2 aet domane diw eal: (MOeyPaiSccp, 10 56% 
Super-Fam ily: Im m unoglobulin
513-587
Ml: Famiy: I set doman* dics6e4 d-88yPaScco. 10 28%
Super-Fam ily: Im m unoglobulin
604 686
ML Famiy I sal domane. d1*nm_: (1 WVPaScop; O 18%
Lipa highly 0 
likely
ab -hydro lase  a sso c ia te d  lip ase  region 
28 96
Ml: pfam04083rCOO. 5a 24
a lpha /be ta  hyd ro lase  fold
111-385
HM: PF00561APFAM; 5*22
Family: G astric  lipase
28 395
ML Famiy: Gastric Kpaee dUflqaj (*376yPs*Sccp; 10 55%
rc A A 8 7 4 8 0 3 _ g _ H « m « «  AAM74057.1 99 
—-  AAM74057.1
BRAK [Rattus norvegicus] highly 0 
likely
Small sec re ted  cy tokine (in tecrlne/chem oklne) doi Super-Fam ily: Interleukin 8-like chem ok ines
2 4 S 5  2 4 -as
He M00273flCOD: 00007 H t fw ntf. taeUuMn SJika 01 ml2»_.: (M4yP»$o«r, 10 20%
rc H33219 at » « " « « «  AAH52036.1 904 
mouse
NP_852076.1
RIKEN cDNA 9130023F12 gene 9130023F-
12Rik
MGC unlikely 0 no  h its  no  h its
ntt |e  100% GT conMance)
S S J S S i " *  000004736 pyruvae carboxylase activity
GLUCONEOGENESIS: GOOOOSS24 ATP binding
HOMOTETRAMER; 1179AAS; 3.9KB; GO:OOOS737 cyloplaem 
ACC.NO.U04641; HUMAN; 00:0005739 mMochonm
PYRUVATE CARBOXYLASE: RNA
BLOT; SEO COMPARISON SEQ G0.0006094 giuconeogeneas
DETERMINATION; TISSUE G0:0008152 metabolism
DISTRBUTION. CDNA CLONE; ATP- 00:0008610 l*d  btoaydheae
BINDING; BIOTIN; DISEASE q o  0009374 btolm brndtog
MUTATION; GLUCONEOGENESIS;
UGASE; UPID SYNTHESIS; 000016874 hgaae activity
MANGANESE; MITOCHONDRION; GO 0030145
MULTIFUNCTIONAL ENZYME;
TRANSIT PEPTIDE
unlikely 0 P yruvate  carboxy lase
35-1178
ML COG1036ACOO; 0
Family: BC N-terminal dom ain-like
35-150
ML Famiy: BC N terminal doman4*e didv2a2 (3-117yPaiScop: D  50% 
Family: BC ATP-binding dom ain-like
151-389
ML Famiy: BC ATP-bindng dom*n-W«e dldv2a3 (1-216yPaiScap; ID 45% 
Family: BC C-terminal dom ain-like
371-483
ML Famiy: BC Otarmmal domawvMte dibnebi; (2-1 l2yP»Scop. 10 30%
Super-Fam ily: PreA TP-grasp dom ain
538-638
ML Famiy. BC N^ermmal dom»n-i.he. lBXRAA(556-676V'Ps*BUat. ID 8%
Super-Fam ily: G lu tath ione sy n th e ta se  ATP-binding d o n
639 907
Mt: Famiy BC ATP-tondtog domawlrtss. 1BXRAA(677-935yPaeiaaC ID 15%
Family: B iotinyl/lipoyf-carrier p ro te in s  and  d om ains
1096-1177
ML Famiy BtolinytlipoyLcarrier proteins and domains. dio78a_: (1-83yPaiScop;
hit PS50i57/iPROSITEpro; n/a
Zinc finger C2H2 ty p e  dom ain  profile
1137 iim
H*1 PS50i57/iPHOSIT£pro; rv/a
Zinc finger C2H2 typa  dom ain  profile
1307 • 1329
HX PS50l57APROS»TEpro; n/a
rc_AA874803_at Handmapoad io 
mouae 
orthofogua - 
BAA9S097 1
AAQ38330.1 99 chemokine (C-X-C motif) ligand 14 C xcI14 - FtS (FULL INSERT SEQUENCE): 
CAP TRAPPER; HTC
G00005125 cytokine activity 
G00005576 arfracaiiuiar 
GO 0005815 Mraceilular space 
G00006955 immunt reeponee 
GO 0006009 chemokine activity
highly
likely
0 Sm all s ec re ted  cy tokine (Intecrine/chem oklne) doi Super-Fam ily: Interleukin 8-like chem oklnea
24 - 65 24 65
H f cd0O273/iCOO. 0.0003 Hit Farrnfy'Herteukm 8-hke chemohmes dlmi2a_: (8-64)/P*iScop: 10 28%
rc_AA875261_at Probe mapped 
wrtfun 2Kb of 
Tend with tow 
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0015696
ENSRNOPOO 376 
000015896
Ensembl Gene Model MGC unlikely 0 Zinc-binding dom ain  p re se n t in Lin*11, lal-1, M ec- Super-Fam ily: G lucocortico id  receptor-like  (DNA-bindin
185 238 185 213
fit smartOOl32/1CDO. le-11 Hrt Famity- UM doman iB8TAA(i-35yP»i8taai; ID38%
Z inc-binding dom ain  p re sen t in Lin-11, IsM , Mec- Super-Fam ily: G lucocortico id  recep tor-like (DNA-bindin
245 297 214 296
hit: *marl00132'fCDO. 3e-07 Hit Family LSidoman 1B8T AA(36-l00yPs<6iast: ID 16%
Z inc-binding dom ain  p re sen t in Lin-11, lsl-1, Mec- Super-Fam ily: G lucocortico id  receptor-like (DNA-bindin
305 - 366 297 - 337
hit: smari00132/iCDO: 2e-07 Hit Famiy UM domain 1B8TAA(l0l-143yPsiB4a*t; ID 20%
Super-Fam ily: G lucocortico id  recep tor-like  (DNA-bindin
338 374
Hrt. Famiy: LM doman 1B8T AA(i44-192yPnBla*t. to 21%
rc AA891302 q 
at
Hand mapped lo
orthciogue-
CAA70213.1
P70218 827 mitogen activated protein kinase kinase 
kinase kinase 1
Map4k1 SER/THR KINASE: HPK1 GENE; 
ATP BlNOING; KINASE; 
serine/ threonine-protein  
KINASE, TRANSFERASE
G00016301 kinase activity 
G00045610 reguWcn of hemocyte diflare 
G00016740 iransferaee activity 
GO0006468 protom ammo and phaapnory 
00:0004713 pnxem lyroama kmaee activity 
G00005083 small GTPaaa ragutatory/mia 
G0 0005524 ATP bindmg 
GO0007243 protam kinase cascade 
00:0004672 protein Kmaea active y 
G0.0006950 response to stress 
00:0004674 protein sennwlhreonine kmaa
unlikely 0 Serine /T hreon ine  pro tein  k in ase s , cataly tic  dom ai Family: S erine/threonin  k in ases
17 271 12 296
hit: smart0022(y>CDD; 1e-66 Hrt Famiy Sennarthrecrun Kmaaae d1f3mc (17 287yP*Seap, fD 39%
Domain found  in NIKI-like k in ases , m o u se  citron  ;
507 813
H f amarl00036/iCC)0, 3e66
rc_AA891689 g 
at
Probe mapped 
directly with h*gh 
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0011144
ENSRNOPOO 357 
000011144
Ensembl G ene Model unlikely 0 P h osphatidy le thano lam ine-b ind ing  pro tein  Super-Fam ily: PEBP-like
153 - 296 124 - 311
hit: pfamOl 161/iCDD; 2a-11 Hit. Famiy: Phosphahdylethanctamine bmdmg protan. dlbd9b_: (3-183)/P*iScop:
rc_AA893105_at
tranecnpt
rc AA893667 q 
at
Probe mapped 
' wit tun 2Kb of 
Tend with low 
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0025716
ENSRNOPOO 227 
000025716
Ensembl G ene Model CAP TRAPPER; HTC; MGC unlikely 0 Ring finger Super-Fam ily: RING finger dom ain , C3HC4
184 - 222 150 - 222
hit: sm«tOOi84/iCDO; 0.004 (low) hit Family RING ingar domam. C3HC4. d1ldjb_: (l3-77yP*iScop: ID 14%
rc_AA894210_at not mapped to a
rc_AI178208_at Probe mapped 
directly with high
Refseq 
NM 053622
P52591 1199 nuclear pore m em brane glycoprotein 121 
kO
Pom121 INTEGRAL MEMBRANE 
GLYCOPROTEIN: NUCLEAR 
PROTEIN; REPEAT; 
TRANSMEMBRANE: TRANSPORT
00:0005634 nucleus 
GO:0006810 transport 
GO:0016021 integral to membrane
unlikely 1 AF-4 p ro to -oncopro te in  no  h its
255-1123 (a  100% GT oonfidanca) 
hit: pfam05U(yiCDD; 1e-05
rc_AI639045_ai Probe mapped 
within 2Kb of 
Tend wrth low 
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0023902
ENSRNOPOO 453 
000023902
Ensembl Gene Model unlikely 0 M iddle dom ain  o f eukaryotic  in itiation facto r 4G (c Super-Fam ily: ARM repeat
161 -357 159 - 361
hit: smart00543riCDO: 3a-26 Hrt: Famiy: HEAT repaal. d1hu3a_: (1 M85)/PsiSccp; ID 26%
rc_H33093_at not mapped loa
transcria.
Ul6802_at Probe mapped 
directly with high 
confidence to 
Reteeq 
NM_013219
184505 1289 Ca2 +-dependent activator protein Caps ACTIN BINDING unlikely 0 P ieckstrin  hom ology  dom ain  Super-Fam ily: PH dom ain-like
522 - 624 523 635
hit sm«t00233/iCDO; Sa-06 Hrt Famiy Pteckstnn-homotogy doman (PH domain) dltiw b.: (3-i26)/PsiSccp;
Domain of Unknow n Function  (DUF1041)
736 - 933
hit: PF06292/iPFAM, la-27
U95001UTR#1_s
_at
Probe mapped
directly w«h high
AAK29279.1 1/9 dtphospbofnositol polyphosphate 
phosphohydolase type II
Nudt4 FIS (FULL INSERT SEQUENCE); 
OUGO CAPPING: CAP TRAPPER. 
HTC- MTV'
G00006486 diphoaphomoertof-pofyphoeph unlikely 0 
GQ:0019935 cyde-nucfeotide-medialed si<
NUDIX d om ain  Super-Fam ily: Nudix
18-132 5 142
Probe Mapping Biopendium Lan. D escription Gan* OMIM Keyword* GO SigP TM* S eq u en ce  A nnotation S truc tu re  A nnotation
AC***°n Sym bol Secrtd
lSet6 I
Super-Fam ily: HMG-box
103 -182
HR; Famiy; d M  ;  (2-8iyP*Scop; 10 29%
AJ001029_at Pmbemappea 055170 466 SRY-box containing gene 10 277580; so x io  protein; soxiogene 
602229
GO 0005667 transcription fad or complex unlikely 0 
GO:0003700 transcription tad or activity 
GO 0005634 nucleus 
G00003677 DNA txndtag
TRANSCRIPTIONAL MOOULATMG 
PROTEM; CAP TRAPPER; HTC;
CPG ISLANO, HTG. MCT, POL2RF;
PRKCABP; RNA POLYMERASE.
SLC16A. SOX 10: SRY; MGC: DNA- QO«aOl5« cell different.* on 
BMOMG: NUCLEAR PROTEM;
TRANSCRIPTION REGULATION;
DEAFNESS DISEASE MUTATION;
HIRSCHSPRUNG DISEASE
high m obility g ro u p
103-178
Hi: smart00396ACOO. 7e-18
GO 0006355 ragulaMn of tranecnpban. OK
Pmbemapped P38445 382 activin receptor IIB Acvr2b ACTIVM RECEPTOR TYPE 118; 
TRANSMEMBRANE PROTEM; ATP; 
ATP-BMOtNG; GLYCOPROTEM. 
RECEPTOR; SER1NE/THREONME- 
PROTEM KINASE; TRANSFERASE; 
TRANSMEMBRANE
Gpe2
GO 0004672 proton k 
00:0004374 proton •
GO 0004675 transmembrane receptor prott 
G00004682 proton kinase CK2 actfvty 
GO 0004691 cAMP dependent prolan tuna 
00:0004702 racaplor signaling prolain sari 
GO 0004713 proton tyrosine kmaae activrty 
00:0004872 receptor activity 
00:0005024 transforming growth fador-be 
00:0005524 ATP binding 
G 0 0005615 extracellular space 
G0 0006468 proton ammo a 
00:0007178 tr 
G00016020 membrane 
00:0016021 integral to membrane 
GOO016362 type II actrvin racaplor activity 
GO 0016740 transtoaae activity 
00:0019853 sexual reproduction
unlikely 1 , cataly tic  dom al Super-Fam ily: P rotein kinaae-like (PK-llke)
Hi: amartOQ22(MCDO. 6w27 i diiaab(33-320yP»Soop; 10 39%
HL Famty Tyroama tonaaw dlk8ac3: (l3-280yP*Scop; 10 19%
579 cerebroglycan CAP TRAPPER. HTC; 
CEREBROGLYCAN; HEPARAN 
SULFATE PROTEOGLYCAN; 
PROTEOGLYCAN; BLOCKED 
CARBOXYL END; CHONOROITM 
SULFATE PROTEOGLYCAN; 
GLYCOPROTEIN; HEPARAN 
SULFATE; LIPOPROTEIN. 
MEMBRANE PROTEM; 
PHOSPHATOYLMOSITOL 
LMKAGE, PHOSPHOPROTEM; 
2631BP; 580AAS: ACCNOL20468; 
CEREBROGLYCAN: OMHDAD; DNA 
BLOT; DEVELOPMENTAL 
EXPRESSION; PCR 
AMPLIFICATION; PURIFN; OQYADD; 
RNA BLOT; RAT BRAM; SEQ ANAL: 
SEQ COMPARISON; SEO 
DETERMINATION; TRYPSM 
DIGEST; CDNA CLONE; M SITU 
HYBRIDIZATION; GP1-ANCHOR. 
GLYCOPROTEM; HEPARAN 
SULFATE; PROTEOGLYCAN: 
SIGNAL
GO 0005578 extracellular matrix 
00:0016020 membrane
highly
likely
Glypicen
18-566
HI: plamOl 153'CDD; 0
no  h its
(* 100% GT contdenoe)
L29232_at Pmbe mapped P24062 
directly with high
1370 insulin-like growth factor 1 receptor Igf 1 r 147370 glycoprotein; insulin 
RECEPTOR; MSUUN-UKE 
GROWTH FACTOR I RECEPTOR; 
MEMBRANE GLYCOPROTEIN; 
RECEPTOR; TYROSME KMASE; 
ATP; GROWTH FACTOR 
RECEPTOR; KMASE-RELATED 
TRANSFORMING PROTEM; 
TRANSMEMBRANE PROTEM; 
AUTOPHOSPHORYLATION; 
PHOSPHOPROTEM; 
PHOSPHOTRANSFERASE: 
TYROSME-SPECIFIC PROTEM 
KMASE; 3D-STRUCTURE; ATP- 
BMOMG; GLYCOPROTEM; 
PHOSPHORYLATION; RECEPTOR; 
REPEAT; SIGNAL; TRANSFERASE; 
TRANSMEMBRANE: TYROSME- 
PROTEM KINASE
G00005010 inauNn-iike growth factor recei likely
GO:0006468 proton amino add phosphory
G0 0048009 IGF receptor signaling pathw;
00:0030238 male sex detom melton
GO:0005520 rneufirvlike growth (actor bind
00:0005524 ATP binding
G0:0005615 artracslluiar space
GO:0004672 proton ktnaae activity
GOtfX)9687 organogenesis
GO:0007169 transmembrane receptor prot.
GO 0004674 proton senrtothreonine kmas 
GO 0004672 receptor activity 
G00016740 translsrase activity 
G00005006 epidermal growth (actor recap 
GO 0016020 membrane 
GO:0016021 integral to membrane 
GO0005515 proton binding 
GO:0004713 proton tyrosine kinase activity 
G00004714 transmembrane receptor prot.
R eceptor L dom ain
51 -170
Ht: piam01030FCDD; 3e-26
Furin-like cyste ine  rich region
175 - 332
Ht: PF00757/1PFAM; 6e-39
R eceptor L dom ain
363 - 479
Ht: ptam0103QflCDO; 2e-2S
Fibronectin  ty p e  3 dom ain
836 923
Ht: cd00063/iCDO. 3*06
Tyrosine kinase, catalytic dom ain
Family: L dom ain
31-179
Ht: Famiy: Ldomain, dligral: (M49>/PsrScop; ID 97%
Family: Growth factor recep to r dom ain
180-329
HL Famiy: Growth (actor receptor domain. d1«ra3 (M50)/PaiScop; ID 86%
Family: L dom ain
328 - 499
H t Famiy: L domain. diigra2: (i-ieeyPSSoop; ID 94%
Super-Fam ily: F ibronectin  type  III
494-618
H t Famiy: Fferoneclin type IN. dlbqub2: (11-115yPiiScop; 10 12%
Ht: Famiy: Ffcronectm type III lFNH:AA(1-90yPsOa«; ID 19%
Super-Fam ily: F ibronectin  type  III
735 - 833
H t Famiy: Fibronectin type IN lFHt:AA(9M80yPsWael; ID 21% 
Super-Fam ily: F ibronectin  type  III
834-924
Ht: Famiy. Ffcronectn type III. d1qg3a2: (i-99yPs«Scop: 10 19%
Family: T yrosine k inase
311 355
Ht smart00280ACOO; 5*06
Kazal ty p e  se rin e  p ro tea se  Inh ib itors
364-428
HI smart0028Q4CDO. 0 0005
Ht: •mart0028Q4CDD. 0 003 (low)
Kazal ty p e  se rin e  p ro te a se  inh ib itors
525 559
Ht emart00280ACDO; 8*07
Ht: Famty Arvmal KazaHype nhibrtors 1TBQ RR(l-5iyGenThread; 10 26%
Fam ily: Animal K azat-type in h ib ito rs
499 - 558
Ht. Famty: Arwn4 Karaf-type nhibrtars 1TBQ RR(S2-103yGenThread; ID 32^
M86341 g at Hand mapped- Q02589 362 ADP-ribosylarginine hydrolase Adprh MGC: ADP-RIBOSYLARGININE 
HYDROLASE; GLYCOSIDASE; 
HYDROLASE; HYDROLASE; 
MAGNESIUM
Ht: emart00280ACDO; 1*09
Lam inin-type ep iderm al grow th factor-like dom ai Family: Lam inin-type m odule
688 - 726 690-729
Ht:$fn«t0018(V»COO; 20-10 Hrt: Famky. lamir*n-type module 1KLO 1(112 l62VGanThreafl: ID 37%
U am inin-type ep iderm al grow th factor-like dom ai Super-Fam ily: EGF/Laminin
742 - 778 759 - 792
Ht: sm«l0019QACDO; 3*06 Ht: Fam*y EGF-type module 1N7D AA<283-326VGenThfeed: ID 23%
Kazal ty p e  se rin e  p ro tea se  inh ib itors
616-864
Ht: smart00290/iCDO; 9e-08
Dom ain found  in se a  urchin sperm  pro tein , en tero
1023-1143
Hrt: smartOOZOOriCOO; 2*23
C alcium -binding  EGF-like dom ain , p re sen t in a lar Super-Fam ily: EGF/Laminin
1224• 1258 1217-1262
HI: Cd00054/COD, 0.004 (low) Ht: Fam*y EGF-type module 1HAE:-1(1-63yGenThread: 10 24%
Lam inin G dom ain  Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
1286-1419 1246-1439
Ht: smvt00282ACDO; 4*32 HI. Famrfy: Lamirwt G-kKe module, dldyftai: (4-l87yPsiScop: ID 28%
EGF-like dom ain  Super-Fam ily: EGF/Laminin
1444-1476 1437-1480
Ht: pfamOOOO&CDD; 0 002 (low) Ht: Family: EGF-type module. 1FAK:LL(l4-51)/GenThread; ID 15%
A spartic ac id  an d  a sp a rag in e  hydroxylation site  Super-Fam ily: EGF/Laminin
1482-1517 1481 - 1516
Ht: PSOOOIO/iPROSITEre; 0 004 (tow) Hrt: Famiy: EGF-type module 1WHF:-1(47-86)/GenThread; 10 29%
Lam inin G dom ain  Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
1553-1890 1503-1707
Ht: em«l00282ACDO; 2e-24 Ht: Family: Lammm G-ike module, didyfcal: (3-106yPsiScop; ID 22%
C alcium -binding EGF-like dom ain, p re sen t in a lar Family: EG F-type m odu le
1716-1748 1712-1749
Ht: Cd00054/CDD; 3e-07 Hrt: Famiy. EGF-type module. 1A3P:-i(l-45yGenThread; ID 30%
Laminin G dom ain  Super-Fam ily: C oncanavaiin  A-like le c tin s /g lu can ases
1784-1919 1735- 1937
Ht. smartQ0282/iCOG, 3e-22 Hrt. Famiy: Lammm G-Ske module dldykaV. (3-l87yRs»Seop. ID 23%
G0.0000287 magnesium ion binding unlikely 0 
G0:0003875 ADP-riboeylarginine hydrclast 
G0 0005524 ATP binding 
G0:0016787 hydrolase activrty
A D P-ribosytg lycohydro lase
9-344
Ht: pfam03747/CD0; 9e-50
no  h its
(at 100% GT confidence)
rc_AA800686_at Handm*x»dto BAC27100.1 596 growth factor receptor bound protein 10 Grt)10
orthoioQue-
BAC27100.1
CAP TRAPPER: HTC; MGC: 
GROWTH FACTOR RECEPTOR; 
ALTERNATIVE SPLICING. SH2 
DOMAIN
G0:0004872 receptor activity unlikely 0
G0 0005070 SH3/SH2 adwtor protein acti 
00:0005515 protein binding 
G0:0005829 cytoed 
00:0007165 signal transduction 
G0:0007218 neuropeptide signaling pathw 
G00007242 intracellular signaling cascadt 
G0:0048009 IGF receptor signaling pathw.
Ht: smart003l4ACDO; 3e-11
P leckstrin  hom ology  dom ain
294-400
Ht: smart00233'tCDO; 4*07
S rc  hom ology  2 d o m ain s
493 - 580
Ht: smart002S2/iCDD; 1*16
Super-Fam ily: PH dom ain-like
290-407
Ht: Family: Pleckstnn-homotogy domain (PH domain). d1fgya_: (l-l2SyPsiScop;
Super-Fam ily: SH 3-dom ain
437 - 488
Hit: Family: SH3-donain. lG63:AA(1-57yPs«i«t; 10 18%
Super-Fam ily: SH2 dom ain
468-594
Ht: Family: SH2 domain. d1a81a2: (4-12SyP*iSccp: ID 28%
rc AA800790 at "“ pp"  P21451 
~  within 2kb of 
3*end with low 
confidence to 
Reiseq 
NM_017333
442 endothelin receptor type B CAP TRAPPER; HTC; MGC; 
ENOOTHELIN RECEPTOR; G 
PROTEIN-COUPLED RECEPTOR; 
TRANSMEMBRANE PROTEIN; 
19506P; 441AAS; BINDING OF 1125 
ENDOTHELIN 1; ENDOTHEUN 
RECEPTOR: EXPRESSION IN COS 
CELL; G PROTEIN COUPLED 
RECEPTOR; INCREASE OF 
INTRACELLULAR CA; INOSITOL 
PHOSPHATE PROON; NON 
ISOFORM SELECTIVE SUBTYPE; 
RNA BLOT; RAT LUNG; SEO 
DETERMINATION; CDNA CLONE: G- 
PROTEIN COUPLED RECEPTOR, 
GLYCOPROTEIN; UPOPROTEIN; 
PALMITATE; SIGNAL; 
TRANSMEMBRANE
GO 0001564 rhodopsin-like receptor activit highly 
G0:0001600endothehn-B receptor activity likely 
G00004872 receptor activity 
00:0004930 G-protein coupled receptor ac 
G0 0004962 endothelin receptor activity 
G0.0004983 neuropeptide Y receptor activ 
G00005615 extracellular space 
G0:0005624 membrane fraction 
G0 0006885 regulation of pH 
G0 0007186 G-protem coupled receptor pr 
G00007422 peripheral nervous system de 
G0 0008217 regulation of blood pressure 
G0:0016021 integral to membrane 
G0 0016477 cell migration 
00:0030318 melanocyte differentiation
7 tran sm em b ran e  recep to r (rhodopsin  family)
125 - 345
Ht: pfamOOOOI/iCDD; 6*07 Ht: Family; Rhodcpswkk* d1jfpa_: (25-294)/PsiScop: ID 4
HELIX-LOOP -HE LIX: MGC; 
FU_CDNA; GROWTH FACTOR- 
WDUCIBLE PROTEIN; HEUX-LOOP- 
HELIX PROTEIN; EARLY 
RESPONSE GENE; 
TRANSCRIPTIONAL FACTOR. DNA 
BINDING. DIFFERENTIATION; 
PHOSPHOPROTEM; 
TRANSCRIPTION FACTOR; 
ALTERNATIVE SPLICING; 
TRANSCRIPTION REGULATION.
119AAS; 2460BP; ACC.NO.X73428; 
EXON X2. GENOMIC 
ORGANIZATION; HUMAN: ID3 
GENE: LOCATION ON 
CHROMOSOME 1P36; SEQ 
COMPARISON; SEO 
DETERMINATION; NUCLEAR 
PROTEIN. POLYMORPHISM
S uper-Fam ily : EGF/Laminin
72 toe
Hrt Famiy EGF-type module 1ESL-1(1 iSl57yP*iBlast, 10 2S%
Super-Fam ily : O vomucoid/PCl-1 like inh ib itors
109- 150
Hrt Famtfy: Arwnal Kaz*-type nhibrtors iCGJ:ll(i-56yPsiBlae: ID *3%
Super-Fam ily: EGF/Laminin
264 - 320
Hi FamSy EGF-type module, dl hae .. (1-62VPs»Sccp: ID 24%
rc AI639427 at P ^ m icw d
wrtfwi 2fcS<y
3"end wrth to«*
CAB60131.1 373 transm em brane protein w th EGF-like and Tmeffl 
two follistatin-like dom ains 1
603421 NC1 pROTEIN. NC1 GENE;
TOMOREGULIN-1; TR-1 GENE. 
TRANSMEMBRANE PROTEIN 
M736S.MGC
GO. 0004667 senne protease mtvbrtcr a 
GO 0016021 integral to membrane
Kazal ty p e  se rin e  p ro tea se  inh ib ito rs
I. smarl0028(VtCOO; 5e-i
Ht: smart00280riC0O: 2e-08
EGF-like dom ain
269 303
Ht: PFOOOOO^ PFAM. 0 01 (k>w)
PnX* mapped Q62950 
erectly wrth htgh
Retseq
NM 012932
572 coilapsin response mediator protein 1 Crrrtpl 602462 OIHYDROPYRIMIOINASE RELATED GO 0016707 hydrolase a 
PROTEM 1, MGC; FLI CDNA;
DIHYOROPYRIMIDINASE RELATED 
PROTEM 1; UNC-33; UUP3GENE.
PHOSPHOPROTEM
unlikely 0 D ihydroo ro tase  a n d  rela ted  cyclic am idohydrolas* Super-Fam ily: C om posite  dom ain  of m etallo -dependen t
17 -464 17 67
Hrt; COG0044/CDD. 2e-64 Hrt. Famiy O-ammoecyiase dim7jal (4-S5yPsiScop: 10 22%
Fam ily: H ydan to inase (d ihydropyrim id inase), cata ly tic  d
Hit: Family Hydartonase (dfhydropyrmdmase). caafybc dcman d1k1da2: {1-33
Family: H ydan to inase (d ihydropyrim id inase)
396 • 474
Ht. Family Hy6anton*e(c*hydropynm*iinaee) digkpai (4B122yP*Soop. 10 3
Super-Fam ily: M etallo -dependent h y d ro la se s
t: Family- aloha-subunrt d  urease, catalytic doman. lE9Z.BB(481-5e9yPeiBlast
Probe mapped 
directly with fvgt 
confidence lo 
Refseq 
NM 012610
425 nerve growth factor receptor Ngfr 162010 CAP TRAPPER: HTC; MGC; NERVE G00003824 
GROWTH FACTOR RECEPTOR; GO 0004672
G0;0005035 
GO 0005515 
GO 0005615 
00:0006629
DUPLICATION; GLYCOPROTEIN;
HETEROOIMER; MONOMER;
PHOSPHOPROTEM: RECEPTOR: 
TRANSMEMBRANE PROTEM;
3270BP; 424AAS; AMPLIFICATION 
OF EXPRESSION: GENE 
TRANSFER; NGF RECEPTOR; RNA GO OOOS915 
BLOT; RAT; REPEAT X4 OF CYS GO 0006917 
RICH DOMAIN; SEQ GO 0007165
DETERMINATION; CDNA CLONE. 3D 
STRUCTURE; APOPTOSIS; G0 0007399
GLYCOPROTEIN; NEUROGENESIS; G0.0007411 
PHOSPHORYLATION; RECEPTOR: Q0 0007417 
REPEAT; SIGNAL;
TRANKUFURflAMF GOOQ10021
catalytic activity 
receptor activity 
death receptor activrty 
protein binding 
edracellular apace 
iiptd metaboiiam
induction ot apoptoeis 
signal transduction 
neurogenesis 
aucn guidance 
central nervous system d 
integral to membrane
highly
likely
Ht: Cd001&S'<CDD; 9e-20 Hrt F»niy TNF receptor-like lD4V.AA(47-86)/GenThread; ID 12%
T um or n e c ro s is  facto r recep to r / nerve  grow th fac Super-Fam ily: G row th fac to r recep to r dom ain
114-147 102-243
Ht. amart00206/iCDO, 0.0002 Ht Fanny: Growth factor receptor domain 11VO AA(162-310)/PsiBla«: (0 9%
T um or n e c ro s is  facto r recep to r / nerve  grow th  fac
150- 189
Ht: smart00208/iCDD; le-06
DEATH dom ain , found  in p ro te in s  involved in cell Family: DEATH dom ain , DD
334 - 418 334 - 416
Ht: smarlOOOOS'tCDO; 2e-l2 Hit Family: DEATH doman, 00. dlngr „: (1 85yP$iScop: ID 100%
Refcsq
NM 017345
HTG; GLYCOPROTEIN; NEURAL 
CELL ADHESION MOLECULE; 
TRANSMEMBRANE PROTEM; 
ALTERNATIVE SPLICING. CELL 
ADHESION; DUPLICATION; 
MEMBRANE PROTEM; 1260AAS: 
3780BP CELL SURFACE 
GLYCOPROTEIN; CONSERVED 
CYS/TRP; IG SUPERFAMILY; 
NEURAL ADHESION MOL L1; SEO 
COMPARISON; SEO 
DETERMINATION; TOPOL STR 
COMPARISON: BRAM; CELL 
ADHESION; GLYCOPROTEM: 
IMMUNOGLOBULIN DOMAIN; 
REPEAT: SIGNAL; 
TRANSMEMBRANE. ALTERNATIVE 
SPLICING
00:0005194 cell adhesion molecule adiv highly
likely
Ht: smart00409/iCDO; 0 0009
Im m unogiobuiin
143 - 229
HI: smart0040%CDD, 0 0009 
Im m unoglobulin  C-2 Type
2S4 316
Hi: smart00406'iCOO; 5e-13
Im m unoglobulin
338 - 420
Ht: sman00409ACD0: 1*06
Ht: smart00409/>CDO; 1*09 
Im m unoglobulin
523 - 607
Ht: smart00409FiCDO; 5*06
Fibronectin  type  3 dom ain
611-697
Hit: smart00060^1000. 6*06
Fibronectin  type  III dom ain
Hit: Family: I set domains d1cs6a1: (4-9SyPsiScop; ID 27%
Super-Fam ily: im m unoglobulin
135 231
Hit: Family: 1 set domans. 01cs6a2 (4- 103yPsiScop; 10 27%
Ht Famsy. V set doman* (antibody vanable domam-hke). diea|b_: (6-79yPsiScct
Fam ily: I s e t  d o m ain s
243 - 330
Hit Family: I set domains dlcs6a3 (7 91 VP*»Scop; ID 30%
S uper-Fam ily: Im m unoglobulin
327 - 421
Hit; Family: I set damans, dlglca : (l-96yPsiSccp: ID 28%
Family: I se t d o m ain s
429 514
Hrt: Famiy I set domans ditlk... (13-lOiyPsiScap: ID 31%
S uper-Fam ily: Im m unoglobulin
507 - 607
Hrt: Famiy: I set domans. diie5a_. (4-t04yp*Scop. ID 25%
Super-Fam ily: F ibronectin  ty p e  III
606 - 706
Ht: Family: Fibronectin type III. d ldb_l: (i-99)/PaScop; ID 28%
P robe Mopping B iopendium Leo. D escription G ene OMIM K eyw ords GO SigP TMs S eq u en ce  A nnotation S tru c tu re  A nnotation .
Arv’oneinnA ccession Sym bol Secrtd
I Set 7
c_AA799488_at ^  rraooeo to AAH53396 1 1123 expressed sequence AW555814 
mouse 
onhotogue-
NP 776121.2
CAP TRAPPER; HTC unlikely 0 G lutathio
Histidine ac id  p h o sp h a te
S12 - 561 (fragment)
H t plam00328/iCOD. 0.0004
I p ro tein  S6 m odi! Super-Fam ily: PreA TP-grasp dom ain
44- 133
Mr Famiy: OAJarww kgaM Ntermnsf doman. 1E4£AA(1-130yPseiaBt; 10 225 
H t Famiy BC Ntermmal domwrvM* 1KJ9B8<1-11 iyPsiBM: tO 10%
Super-Fam ily: G lu tath ione sy n th e ta se  ATP-binding dorr
1*4-361
Ht Famiy ATP-twxfing doman of pepfrde tyHhf w 1E4E AA(131-*4iyP»8l 
H t Famiy BC ATP-bineng domarvMw 1DV2 B8<1 1*33iyPeO aet; 10 13%
HR. Famiy Syn«wn ta. C-termnet doman 1 AUX B8<1(»292yP»Blae1.10 17%
Super-Fam ily: R udim ent sin g le  hybrid motif
90S 442
H t Famiy. BC C e m r S  d e m an d . 1B68 AA(27*3SiyGenThraad; 10 23%
Super-Fam ily: P hosp h o g ly ce ra te  m utase-like
511-861
H r Famlr Aod p txapham  drnoeb. (34-294yPsiSoop; 1014%
rc_AA818593_at Probe mapped AA095203.1 282 
directly wth high 
confidence to 
Refceq
NM 022536
phosphatidate phosphohydrolase type 2a
re_AA892149_at ENSRNOPOO 260 Ensembl G ene Model
£?£L 000024026
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0024026
G0:0046630 phospholipid dephosphoryian unlikely 5
GO 0008195 phoepnatdaie phoephaUM a
G00006285 negative regulation of cel prot
GO 0005886 plasma membrane
GOOOG5887 integral to plasma membrane
G00030S21 androgen receptor signaling p
G00007166 s>gnal franaducbon
G0 0006470 protein ammo aod dephospht
00:0006661 dncyiglycerci bmsyntheat
00*019216 regulation of kpid metabohsm
GO:0006670 sphingosme metabofism
GO 0006672 oaramide metabolism
GO0007205 protein lonaee C ac*val«n
GO.0016787 hydrolase activity
000006624 membrane traction
"  unliksly 0
A dd  p h o sp h a ta se  h om ologues
112-227
H r amartOOOietCOO. 3*06
no  h its
(d 100% GT
FHA dom ain
1-54
Ht: pt*n00496ftCDO: 2e-06
glycine rich nucleic  b inding dom ain
163-207
Ht. amart00443fiCO0; 2*09
no  h its
( a  100% QT confidence)
rc A1008638 at pr*»™po« 
directly with high
Retseq
NM_012811
P70490 427 milk tat globule-EGF factor 8 protein Mfge8 MIK PAT GLOBULE ---------
OLVCOPnOTEIM MFG-E8 S: CAP 
TRAPPER: HTC; MGC: O-ACETYL 
G03 GANGUOSIOE SYNTHASE; 
ZONA-PELLUaOA-BlNOING 
PRO TEW; EGF-LIKE DOMAW; 
GLYCOPROTEIN; fi«LK; REPEAT;
GO 0006910 phagocytosis, bmding highly 0 
00:0006911 phagocytows. engutfment likely 
G 0 0009697 external side of plasma memt
G0 0019897 extrinsic to plasma mem brant
C alcium -binding EGF-like dom ain , p re sen t in a  lar Family: EGF-type m odule  
26 - 60 26 61
Ht: Cd00064/C00; 0.002 (low) H r Family: EGF-type module. 1WHE:-1(47-66yPsttaat; 10 44%
EGF-like dom ain Super-Fam ily: EGF/Laminin 
68-107 64-106
SIGNAL GO:0005615 edraceliular space 
GO:0005178 mte^m binding 
00:0007155 cell adhesion
C oagulation  fac to r 5/8 C-terminal dom ain, d isco id  Family: O iscoidin dom ain  (FA58C, coagu lation  fac to r 5/1
115-267 110-270
Ht: smartOQ231ACOO; 6e-23 H r Fam4y. Ofecotin domam (FA56C. coagulalion (actor 5/8 Oiarminaf domain).« 
C oagulation  fac to r 5/8 C-term inal dom ain , d isco id  Family: D iscoidin dom ain  (FA58C, coagu lation  factor 5/1
274-427 269-427
Hi: smart00231riCDO; 2e-27 Hit Famiy: Oiscoidin domain (FA58C. coagulalion factor 5/8 C-terminal domain), i
rc AI639308 at P'Wie mapped 
within 2kbof 
Tend with low 
confidence to 
ENSEMBL 
ENSRNOTOOOO 
0019635
ENSRNOPOO 297 
000019635
Ensembl G ene Model unlikely 0 U biquitln-conjugating enzym e E2 an d  UBC hom ol Super-Fam ily: UBC-like
159 - 263 156 - 270
Ht: cd00196flCDD; 0.0004 HR: Famiy: Ubquftn conjugating enzyme. UBC dlqeq*.: (1-1 OOyPs.Scop; 10 25
Hrt Famiy Alpha-macrgglabuiin leceptor doman did«6a_ <i-l36yP«Scep; 10 t
Proto mapped 
tVectty with r»gh
FMaaq
NM^0243S6
241 GTP cyciohydrolase 1 128230' MGC; GTP CYCLOHYDHOLASE I; 
9 'M Q in- TETRAHYDROBJOPTEWN 
Z ^ U IU , METAB0L|SM; GTP 
600225 CYCLOHVDRASE I; HYDROLASE. 
ALTERNATIVE SPLICING; 
PHOSPHOPROTEN. 250AAS; 
2921BP: ACC NO U19523; GTP 
CYCLOHYOROLASE' TYPE 1.
HUMAN PHEOCHROMOCYTOMA: 
SEO OETERMMATION; CDNA 
CLONE. 3 0 STRUCTURE. 
ALLOSTERtC ENZYME; 
HYDROLASE; 
TETRAHYDR06IOPTERIN 
BIOSYNTHESIS: ALTERNATIVE 
SPLICING. DISEASE MUTATION. 
PHENYLKETONURIA; 
PHOSPHORYLATION. 
POLYMORPHISM: ALLOSTERlC 
ENZYME. HYDROLASE: 
PHOSPHORYLATION. ENZYME 
REGULATORY PROTEIN COMPLEX
GO-000362* C*t*yt* activity 
GO 0003934 GTP cydohydroiaM I activity 
GO 0006729 tetrahydrotMptem biosyntnei 
G0 0006917 induction of apoploeis 
GO 0009056 Esosynthee*
GO 0016787 hydrolase activity
unlikely 0 GTP cyclohydrolaM
64 • 240
Ht. COG0302/C0D: 2e-76 [ Fanly GTP cyctohydrctaae I dl*7a ( M X ^ S o a p . ID 100%
rc AA799666 q withm 2W3 oi» ENSRNOPOO 726 Ensembl Gene Model 
^ S S S - 0 0 0 0 1 S 3 0 2
0015302
VARIANt-3 OF Z-BAND 
ALTERNATIVELY SPLICED 
POZMOTIF PROTEIN. VARIANT-3 
OF ZASP PROTEIN. ZASP GENE
unlikely 0 Dom ain p re sen t in PSD-95, Dig, an d  ZO-1/2
1 -84
Hrt: smart00228/^000; le-12
Super-Fam ily: PDZ dom ain-like
Hit: Family: PQZ domain d2pd2A_: (4-86yPaSC0p: 10 30%
Hit Fvnty 16 . d1i16 (33-128yP»Scop; 10 32%
Super-Fam ily: C2H2 an d  C2HC zinc fingers
517 • 546
Ht: Fanty O att*  itc Snger, C2H2. 1TF6.AA(32-ei>/P*Blast; 10 9%
Super-Fam ity: G lucocortico id  receptor-like (DNA-bindin 
544-575
Hit: Fantfy: LIM doman. 1B6T AA(1-35yPuBtast; 10 16%
Z inc-binding dom ain  p re sen t in Lin-11, lsl-1, M ec-Super-Fam ily: C2H2 and  C2HC zinc fingers
550 - 600 576 640
Ht smat00l32/iCD0;9*O9 Hrt; Famiy-Class* z«c ,n9 «  C2H2. 1TF6.AA(92-122yP*i8last: 10 11%
Zinc-W nding dom ain  p re se n t In Lfn-11, lsl-1, M ec-Super-Fam ily: C2H2 a n d  C2HC zinc fingers
609 659 632 659
Ht: sm*t00132/rCDO: Sa-11 Hrt: Fanly O e s c  z>nc Inga. C2H2. lUe0CQ29-56VP».BlaB«; ID 24%
Z inc-binding dom ain  p re se n t in Lin-11, lsl-1, M ec-Super-Fam ily: C2H2 a n d  C2HC zinc fingers
667-720 
I: smat00132/iCOO: 2*11
641 -695
l: Famiy: Class* in c *nga. C2H2 iUB0CC<S7-66VPaBlaBt; ID 14%
rc AA874848 S P**e mapped PC 1830 
* wrtNn 2W) of
3'end with low
161 thymus cell antigen 1, theta Thy1 CELL-SURFACE MARKER: GO:0005615 artracalluia a
GLYCOPROTEIN; SIGNAL PEPTIDE; 00:0016020 membra* 
ANTIGEN; CELL SURFACE 
GLYCOPROTEIN; CELL SURFACE 
ANTIGEN; MEMBRANE PROTEIN;
PYROGLUTAMIC ACID; 161AAS;
2863BP; DNA BLOT;
DIFFERENTIATION MARKER ON 
THYMOCYTE; EXON INTRON 
ORGANIZATION; HYDROPHOBIC 
TRANSMEMBRANE SEGMENT; RNA 
BLOT; RAT; SEQ DETERMINATION:
THY1 ANTIGEN: CONA/GENOMtC 
CLONE; THY1 GENE; GPFANCHOR;
GLYCOPROTEIN:
•rtMUNOGLOBULIN DOMAIN.
MEMBRANE: PYRROLIOONE 
CARBOXYUC ACID; SIGNAL; T- 
CELL
highly 0 Im m unoglobulin  dom ain  variab le  reg ion  (v) subfai Super-Fam ily: Im m unoglobulin
likely
Ht: cd00099'>CDD; 0 001 Hrt: Famiy: Vsat demam* (antibody variabla doman-iiha) iA6V:MM(l-l09)/PsiBl
205 heat shock 27kDa protein 1 Hspbl CAP TRAPPER; HTC; MGC; HSP25 GO:(X)05634 nucleus
GENE. SMALL HEAT SHOCK G00003773 heal shock protan activity
PROTEIN; GROWTH-ASSOOATEO
PROTEIN, PHOSPHOPROTEIN; GO 0005737 cytoplasm 
STRESS PROTEIN; HEAT SHOCK G0:0009408 response to heal 
PROTEIN; HSP27 GENE;
ALTERNATIVE SPLICING; HEAT 
SHOCK; STRESS-INDUCED 
PROTEIN; ALTERNATIVE SPLICING;
HEAT SHOCK; PHOSPHORYLATION
unlikely 0 Hsp2Q/alpha crystallin  family
65-167
Hrt: pfamOOOl 1/rCOD 4«-25
Super-Fam ily: HSP20-iike ch a p e ro n e s
24 - 187
Ht: Family: HSP20. dlgmae.: (3-149yPs*Scop; 10 15%
Probemapped P05942 101 S100 caidum-binding protein A4 S l00a4  114210 metastasin; cap trapper , htc ; GO:0005509cataum ton binding unlikely 0 S-100/ICaBP-like dom ain  F am ilv-S100 p ro te in s
directly with h.gh MGC; PEL98 PROTEIN; S100 1 90 101
confidence to CALCIUM-8IN0ING PROTEIN A4; S-
^••seq 100-RELATEO PROTEIN; CALCIUM- rt,: Cd00213 i^CDD; 9e-30 Hit Family: S100 protan* dlm31a : (MOiyPsiScop ID 91%
P robe M apping Biopendium te n . Description G ene OMIM K eyw ords GO SigP TMs S eq u en ce  A nnotation S tru c tu re  A nnotation
A ccession Sym bol Secrtd
[seta-
o h y d r o la pr-F«mlly: C om posite  dom ain  of m etallo -dependen tDpyaS DIHYDROPYRIMIDINASE RELATED GOO016787 hydrolaM act-vrty 
PROTESI 4; UUP4 GENE;
PHOSPHOPROTEM
unlikely 0  D ihydrooro taee a n d  r I cyclic i
i d1m7je1: (4-S6yPwScop. D  22%
Family: H ydan to inase (d ihydropyrim idinase), cataly tic  d
ao-ar
H t FmMr HrdamomaM (OPyOoc
X56326cds_at CAA3976S.1 147 epsilon 1 globin [Rattus rtorvegicus] CAP TRAPPER; HTC; MGC;
EPSILONGLOBIN; HEMOGLOBIN: 
Y1-GL08IN; BETAGLOBM GERM 
UNE; GLOBM; B1 REPETITIVE 
ELEMENT; L1 REPETITIVE 
SEQUENCE; L1MD REPETITIVE 
SEQUENCE; BET A-GLOBIN 
COMPLEX; LONG INTERSPERSED 
REPEAT; REPETITIVE SEQUENCE; 
BlOOO; CHROMOPROTEIN; 
EMBRYO. ERYTHROCYTE; HEME; 
HETEROTETRAMER; IRON 
METALLOPROTEIN OXYGEN 
CARRIER; CHANGE IN FETUS 
DEVELOPMENT; HPLC; MB: LC; 
PUR1FN. RAT; SEQ COMPARISON; 
SEO OETERMMATION; TIME 
COURSE; EKBRYO 
ERYTHROCYTE; HEME; OXYGEN 
TRANSPORT: TRANSPORT
J. caHytc daman. (J1k1da2 (133
Family: H ydanto inase (d ihydropyrim id inase)
390 - 466
I digapai (46-l22VPalSoop: 10 »
unlikely 0
confidence®
ENSEMBL
ENSRNOTOOOO
0022287
Globin
5-147
HI; p*em00042/CDO; 3*42 HM Fmn#r Gtabms digcvd (1 i36yP»Scop: K> 32%
Probe mapped CAA7 8136.1 8 45  neurofilament 3, medium Nef3 c ap  tr a p p e r ,  h tc : nf-m g o  ooos87i kmeancompta* unlikely 0  Interm ediate filam ent head  (DNA binding) reg ion  no  h its
dwecihr wfch NQh PROTESI; NEUROFILAMENT; GO OOOS882 tmarmeduie Warner* 1-96 (a  100% GT oonidenca)
oonW8nt* ’°  WTER3C0IATE FIAMENT ^  .
ReSeq PROTEW: NEUROFILAMENT Nt: pfam04732ACDO; 0.004 0wr)
nm o 17029 PROTESI c o ile d  co t ;  Interm ediate filam ent pro tein
SITERMEDIATE FIAMENT: COILED 144 - 409
COIL GLYCOPROTEIN;
SITERMEDIATE FIAMENT;
NEURONE; PHOSPHORYLATION
HI: PF00038APFAM; 5 a24
Proto mapped 
diracOy with tvgr 
confidence lo 
Retseq 
NM_01315*
CCAAT/enhancertnnding, protein (C/EBP) Cebpd 
delta
CAP TRAPPER; HTC, 
CCAAT/EF94ANC6R-BINOING 
PROTEIN RELATED; CEBP DELTA 
GENE; CELL DIFFERENTIATION. 
DNA BINCMNG. TRANSCRIPTION 
REGULATION; ACTIVATOR; DNA- 
BINDING; NUCLEAR PROTEIN; 
TRANSCRIPTION REGULATION
GO 0005634 nudeue 
GO 0003677 DNA landing 
G0000551S protein bmdmg 
GO 00063SS regutalon of tranecnplian. DA
unlikely 0 B as ic - ieu d n e  z ipper (bZIP) dom ain  profit#
Hrt PS50217APROSIT Epro; r
Proto mapped 
directly w*h hig 
confidence to 
ReiMq 
NM_012792
P36365 532 flavin containing monooxygenase 1 MGC. FLAVIN-CONTAINING G0:0004497 monooxygenaee activity likely
MONOOXYGENASE J; FAD; GO000*499dimethytamloe monooKyoene
FLAVOPROTEIN; MlCROSOME;  _____ __
MONOOXYGENASE; MULTIGENE ©0:0005215 transporter activity
FAMILY; NADP; OXIDOREDUCTASE; GO0005615 artracetlutar space 
TRANSMEMBRANE GO 0005792 rmcroeome
GO 0006116 electron transport 
G00006610 transport 
GO 0015036 disulfide OMdoraductaee act«r 
GO O016021 integral to membrane 
G0 0016491 cuodoreductase activity
t:  PF00743APFAM, < Hrt: Farnty- Ntermmji doman of adrenodoen reductase lAe dicjca2 (2 165VPstf
S uper-Fam ily: FAD/NAD(P)-binding dom ain
164 - 329
Hrt. FanSy: FAD.rHAD-knked reductases N-termmji and central domane 1EBDB
Super-Fam ily: FAD/NAD(P)-binding dom ain
330 - 40*
Hrt. Famty FAD/NAD-««ked reducUeea. N-termma and ceriral domans. 1EBD B
Super-Fam ily: FAO/NAO-linked red u c ta se s , d im eriaatio r
405 514
Hrt: Fanriy FAD/NAD-lmked dimereation (C-terminal) doman 1EBD
rc_AA799803_at Pf« *  ENSRNOPOO 701
dir^yw thN gh
Ensembl G ene Model unlikely 0 Dom ain first found  In C ir,  01a , uEGF, an d  b o n e  nrSuper-Fam ity: S p erm ad h esin , CUB dom ain
ENSEM8L
ENSRNOTOOOO
0015897
Ht: smart00042/iCDO: 2e-2l
C alcium -binding EGF-like dom ain
Hrt Famty: Spermadheem. CUB doman diappt) (9->07yPsiSccp; ’0 16*
Fam ily: EGF-type m odu le
134 - 186
Ht:smat00179/iCDO. 0 0005 Hrt: Family EGF-type module. d lapq_  (l-S3yP*iScap; ID 69%
Domain first found  in C ir, C1a, uEGF, an d  b o n e  rrSuper-Fam ily : S p erm ad h ea in , CUB dom ain
169 - 297 185 299
Hrt: smart 000*2AC DO. 9e-22 Hrt. Family: Spermadhesin, CUB doman. disfp.. (5-106)/PsiSeop; ID 17%
Dom ain ab u n d an t in com plem ent contro l p ro te in s Fam ily: C om plem ent con tro l m odule/SCR dom ain
303 365 301-396
Hi: smat00032ACDO. 3e07 Hrt: Famty Complement control moduta'SCR domain dlgpza2 (1-68)/P*Scop. I
Domain ab u n d an t in com plem ent contro l p ro te in s  Family: C om plem ent con tro l m odule/SC R  dom ain
370 - 441 399 - 444
HI smart00032ACOO. 0 004 (low)
Trypsin-like se rin e  p ro tea se
457 993
Hrt: amart00020'iCDO: 3e-5*
Ht Famty: Complement control moduiafSCR doman dlgpxa3 (l-99)/PsiScop: I
Fam ily: Eukaryotic  p ro te a se s
445 - 997
Hit; Family: Eukaryotic pro!eases dlgpzbl: (1-23iyPsiSccp: ID 75%
rc_AA859661_at Handmappedto BAC32556.1 362
orthoiogue- 
BAC32556 1
glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase)
G pd CAP TRAPPER: HTC G0:0005615etar*»llul* apace likely 0 G lutam inyl cyc la se
66 - 362
Hrt: pfam03S65/tCDD; le-120
S uper-Fam ily: Z n -dependen t ex o p ep tid a se s
46 - 361
Hrt: Famiy: Transferrin receptor ectodomam. protease like doman. d1c*8a3 (6-29 
Hit: Family: Bacterial dinudea zinc esopeptidaaes. diamp. _ {23-286)/PsiSccp; II
rc_AA892338_at Handmappedto BAC25921.1 326
orthoiogue - 
AAH57402.1
R as association (RaJGDS/AF*6 ) domain 
family 2
Rassf2 CAP TRAPPER; HTC: CPG ISLANO: GO 0007216 neuropeptide Signaling pathw.un ||^ e |y Q 
HTG; KIAA0168; MGC
R as a s s o d a t io n  (RalGDS/AF-6) dom ain
174-262
Ht: smart0O314/iCDO: 5e-10
no  h its
(a 100% GT confidence)
rc_AA893618_s_ prooemappeo QRRTG 795 n udear receptor subfamily 3, group C, Nr3c1 GLUCOCORTICOID RECEPTOR; 
HORMONE; DNA BINDING: 
ALTERNATIVE SPLICING. 
NUCLEUS; STEROID HORMONE 
RECEPTOR; TRANSCRIPTION 
REGULATION; ZINC FINGER; 30- 
STRUCTURE; ALTERNATIVE 
INITIATION; DNA-BINDING; 
NUCLEAR PROTEIN: 
PHOSPHORYLATION; 
POLYMORPHISM; RECEPTOR; 
STEROID-BINDING; TRANS-ACTING 
FACTOR; TRANSCRIPTION 
REGULATION; U8L CONJUGATION; 
ZINC-FING6R; ALTERNATIVE 
SPLICING
G0 0004663 glucocorticoid receptor activil unlikely 0 
GO D003700 Iranecnption (actor activity 
G0 0003707 sterad hormone receptor acti 
GO 0005634 nucleus 
GO 0003677 DNA binding 
G0:0005496 stenxd binding 
G0 0004872 receptor activity 
G0 0004679 ligand-dependent nuclear reo 
G0 0005515 proton binding 
G0:0006355 regutalion of iranecnption. DF
G lucocortico id  recep to r
27-421
Ht: plam02l55/iCOO. 0
c4  zinc finger in n uc lear horm one  recep to rs
436 - 508
Ht: smarl00399/tCOO; *e-27
Hrt: *m«t00430/iCOO. 6e-22
Family: N uclear recep to r
435 - 514
Hit Family: Nuclear receptor. d1glua_: (2-0iyPsiScop. 10 63%
Fam ily: N u d e a r  recep to r ligand-b ind ing  dom ain
545-794
Hrt: Family: Nuclear receptor Ugand-bmding doman d1a28a.: (1-25l)/PaScop. 1C
rc_AA925752 at A47402 472
directly with high 
confidence to
cd36 antigen Cd36 BINDING PROTEIN. TRANSPORT 
PROTEIN; GLYCOPROTEIN; 
TRANSMEMBRANE PROTEIN;
G0.0016020 membrane UOilkdly 2 
G0 0016021 integral to membrane
CD36 family
3-445
n o  h its
(at 100% GT confidence)
Retseq ANTIGEN; CELL ADHESION. G0 0007155 cell aitfiesion Ht: pfam0l130/iCDO; ie-123
NM.031561 GLYCOPROTEIN; LIPOPROTEIN; G0000519* cell adhesion molecule acfcvrt
PAIMITATE; RECEPTOR; 
TRANSMEMBRANE; TRANSPORT
GO:0005504 tatty add binding
GO:0006810 transport
GO.0006631 fatty aod metabolism
G00004872 receptor adrvrty
00:0005764 lyaosome
GOO015909 long-chain tatty acid transport
GO OOOS886 plasma membrane
rc_AI008020_at AAA41563.1 586
within 2kb of 
3*600 wrth low
malic enzyme 1 Mel CAP TRAPPER; HTC; MGC; MALATEG0 0004470 malic »izyme activity unlikely 0 
NADP OXIDOREDUCTASE; MALIC 0 0  0004471 malale dehydrogenase (dec*
ENZYME; NADP; HOMOTETRAMER: (oec*
Malic enzym e, N-terminai dom ain
79 - 266
Family: M itochondrial N A D (P)-dependenent m alic enzyn
13 269
confidence to OXIDOREDUCTASE; GO:0004473 matate dehydrogenwe (oxtaa Hit: pfam00390/CDD. 2e-81 Hit: Family: Mrtochondhaf NAD(P)-dependenent malic enzyme. dlgq2a2: (i-2S7yf
Retseq OXIDOREDUCTASE G0 0006108 matate metabolism Malic enzym e, NAD binding  dom ain Family: A m lnoacid dehydrogenase-like , C -term inal dom
I ^ E G ^ ^ E fc e R A « rp f ^ E f f t  GO X ’9864 (gG banding Ht. •m«rtOO*07^COO; te08 Hrt Famiy Cl Ml doman* (arVfcody contfar* domarviito) diMli <l-9iyP*Sa
MAJOR HtSTOCOMPATBIUTY 
COMPLEX: GLYCOPROTEIN,
RECEPTOR; TRANSMEMBRANE 
PROTEIN; IMMUNOGLOBULW 
RECEPTOR; 15738P. 366AAS. FC 
RECEPTOR P51; RNA BLOT. SEO 
ANAL OF N TERM; SEO 
COMPARISON. SEO 
DETERMINATION; SEQ HOMOL 
WITH MHC I ANTIGEN; SMALL 
COMPONENT AS BETA2 
MICROGLOBULIN; THYMOCYTE 
DIFFERENTIATION ANTIGEN C01A.
CONA CLONE; DEVELOPMENTAL 
REGULATION; IG FC RECEPTOR,
RAT NTESTINE: SIGNAL SEO OF 
22AAS: 3D-STRUCTURE.
GLYCOPROTEIN: K3G-BINDING 
PROTEIN; IMMUNOGLOBULIN 
DOMAIN, RECEPTOR; SIGNAL;
TRANSMEMBRANE.
POLYMORPHISM
rc_A!639420_at Hand mapped to BAC35150.1 1157 hypothetical protein D730008L15 D730008
L15
CAP TRAPPER: HTC unlikely 0 CARO c a s p a s e  recru itm en t dom ain  profile
1 -73
Ht PS5020WPROSfTEpro; 8e-07
T ym ovirus 45/70Kd pro tein
771 • 1155
Hi pfan0325l/<CDD: 8*06
S uper-Fam ily : DEATH dom ain
1 - 61
Hrt Famty: Casoaee recrurtment doman. CARD 3YGS PP(l-97yGerThread. ID
Probe mapped 
directly with htgf 
confidence to 
Gentar* 
U36992
414 cytochrome P450, subfamily 7B, 
polypeptide 1
Cyp7b1 CHOLESTEROL METABOLISM, 
ELECTRON TRANSPORT; 
ENDOPLASMIC RETICULUM; HEME: 
MEMBRANE; MICROSOME; 
MONOOXYGENASE; 
OXIDOREDUCTASE
G00004497 monooxygenase activity 
GO 0005615 extracellular apace 
GO 0005783 endcpiasmie reticulum 
GO.0005792 mieroeome 
GO 0006118 electron transport 
G0 0006203 chdeelerol metabolism 
GO 0016020 membrane 
GO 0016021 integral 10 membrane 
G0 0016491 ooedoreductaee activrty
unlikely 0
HI: P<am00067/CDD. 8a-32
S uper-Fam ily: C ytochrom e P450
50 • 411
Ht: Famiy Cytochrome P4S0 die9xa (iOS449)/P*Scop; ID 17%
Probe mapped P18614
directly wrth high
confidence to
Retseq
NM030994
1180 integrin alpha 1 Itgai CELL ADHESION MOLECULE. 
COLLAGEN RECEPTOR, INTEGRIN; 
LAMININ RECEPTOR: 
TRANSMEMBRANE PROTEIN. CEU. 
ADHESION; CYTOSKELETON; 30- 
STRUCTURE; CALCIUM; CELL 
ADHESION: GLYCOPROTEN: 
WTEGRIN; MAGNESIUM: 
RECEPTOR; REPEAT; SIGNAL; 
TRANSMEMBRANE
G0:0000287 magnesium Km bmdmg highly
GO 0004872 receptor activity likely
GO 0004895 cat) adhesion receptor activity 
G00005194 cdl adhesion molecule activit 
00:0007155 cell adhesion 
G00007160 cell-malnx adhesion 
GO 0007229 irtegrwmediaed signaling pi 
G0:0006305 integnn complex 
00:0016021 integral to membrane 
G0.0030593 neutrophil ehemotans 
G00045123 ceiMar extravasation
von W illebrand facto r (vWF) ty p e  A dom ain
170 - 349
Ht: smart 00327'C DO: 1e-29
Integrin a lp h a  (beta-propellor repea ts)
486 528
Ht smart0019UrCDD; 0.003 (tow)
Ht: smart0019l/iCDO:
Family: Integrin A (or i) dom ain
169 - 363
Hi Famty: Integnn A (or I) doman dlcMb_. (1-l95yPsiScop: ID 100%
Super-Fam ily: Integrin a lp h a  N-terminal dom ain
356 664
Ht' Famty: Integnn «pha N-termma! doman. d1jv2a4: (133-438)/PsiScop; ID 239
Super-Fam iiy: Integrin d o m ain s
666 - 808
Hrt: Famty: Integnn domans d1jv2al: (2-159yPSiScoo; ID 20%
S uper-Fam ily: Integrin d o m ain s
613-943
Hrt: Famty: Integnn domans. d1jv2a2: (4-l38yPsiScoo; ID 17%
S uper-Fam ily: Integrin d o m ain s
949-1106
Hrt: Famty- Integnn domams d1jv2a3 (5-154yPsiScop: ID 18%
t o p p i n g  B io p e n d iu m  
A ccPS -von■ .■.Iii.iii.a ,iM B i  !  UTi.
|Q *n* lOMIM I Keyw ords TL E T lla  [S eq u en ce  A nnotation
ISETt
D14015 q at ENSRNOPOO 455 Ensembl Gone Modal
000020058
likely
ENSEWGL 
ENSRNOT00000 
020058
dom ain  p resen t in c y d in e , TFIIB a n d  R etinoblasto  Super-Fam ily: Cydin-iike
198-279 182 288
Mt «m»i00385/-COO; 4*12 Mt Fum+r CycSn dibu2ai: (2 i26>/PwSmp; C  24%
Cyclin, C -term inal dom ain  Super-Fam ily: C ydin-like
-418
HM: pfamG2964/tCDO. 3*1!
Q64610 885 ectonucleobde
pyrophosphatase/phosphodiesterase 2
Enpp2 601060 GO.0005887 E S t f i  lo plasma membrane |jfcely 
GO 0004528 phoaphodtoeteraae I activity 
GO 0005615 atfraoattul* space 
00:0008678 nucleic and bmdhtg
291 -420
Ml: FamMy Cyctn 1QMZ:D0<i36-2S8>/P»Biast 10 13%
MGC, PD-IALPHA; NUCLEOTiwT”
PYROPHOSPHATASE;
PHOSPHOWESTERASE I;
PHOSPHOOIESTERASE I ALPHA;
AUTOTAX IH, MOTILITY FACTOR;
PHOSPHOOIESTERASE: COENZYME 00:0018021 integral lo membrane 
A; EXONUCLEASE; GLYCOPROTEIN; nni*™
PHOSPHOPROTEIN; PHOSPHORIC G ™ 16787 **■"*
WESTER HYDROLASE: ALTERNATIVE G00004551 mxiecPde pymphoaphtfaee 
SPLICING; GLYCOPROTEM; G00004519 endtmudeM actfvrty
HY0R0LASE: MULTIFUNCTIONAL 
ENZYME: REPEAT; SIGNAL-ANCHOR;
TRANSMEMBRANE
G00003624 catalytic aclvty 
00:0009117 nudeobde metatx
Som atom ed in  B -like do m a in s
58 97
HM: amart00201/KX)0; 3*<J7
Som atom ed in  B -like do m ain s
98- 140
Ml: amart0020lACDO; 1*09
HM: (Mam01883/COO; la-120
DNA/RNA non-specific  en d o n u c lease
837 - 887
HM: amart00477/COO. 2*45
Gap43 -
Mt Family Arytsutfaiaae dllBu_: (3-464yPsScop; 10 10%
Super-Fam ily: Hia-Me finger e n d o n u d e a s e s
919-875
Mt Fam»y Sm endonudaaaa. diqaaa_ (4-228yP»S<ap: 10 12%
226 growth associated protein 43 MGC; CALM00UUN-8INDING 
PROTEIN: GROWTH-ASSOCIATED 
PROTEIN: GAP-43 GENE; NERVE 
GROWTH PROTEM. MEMBRANE 
PROTEM; PHOSPHOPROTEM; 
PROTEM FI; CALMOOULW BMOMG; 
LIPOPROTEIN; TMOLESTER BOND;
1130BP; 228AAS: GROWTH ASSOCO 
PROTEM GAP43; HYDROPATHY PLOT; 
IDENTICAL TO: LOCAUZEO M 
PRESYNAPTC MEMBRANE; NEURON 
SPECIFIC PHOSPHOPROTEM B50; 
RAT BRAM; SEO DETE RMMAT10N 
CDNA CLONE; CALMOOULM-BINOING; 
GROWTH REGULATION;
LIPOPROTEIN; MEMBRANE;
NEURONE; PALMITATE; 
PHOSPHORYLATION
G00007399 n 
GO 0040008 raguMvn of growth 
GOO016020 membrane 
GO 0030424 a w
G00001558 regulation of can growth 
GO.0005516 calmodulin binding
unlikely 0 N eurom odulin (GAP-43) s ig n a tu re  1
1-22
Ml: PS004124 PROSITE ra. rVa
IQ m otif profile
31-80
HM: PS500966PROSTTEpra; n/a
Brain ac id  so lu b le  pro tein  1 (BASP1 protein)
SO 223
Mt PF054884PFAM; 3*09
no  h its
(a  100% GT contdance)
M15428complete P 11345
within 2tt> of_seq_at JmyQ ^  ^
648 murine leukemia viral (v-raf-1) oncogene Raf1 
homolog 1 (3611-MSV)
164760 MGC; PROTEIN KMASE: RAF
PROTEM; RAF PROTO-ONCOGENE; 
ONCOGENE; RAF ONCOGENE: C-M8. 
GENE; KINASE: MIL-ONCOGENE: 
PROTOONCOGENE; ATP; 
AUTOPHOSPHORYLATION. 
PHOSPHOPROTEM; 
PHOSPHOTRANSFERASE: SERINE/ 
THREONINE -SPEC1 FC PROTEIN 
KMASE; SIGNAL TRANSOUCTION 
TRANSFORMING PROTEIN ZINC; 30- 
STRUCTURE; ATP-BINDMG: PHORBOL 
ESTER BMOMG; PHOSPHORYLATION: 
PROTOONCOGENE: 
SERME/THREONME-PROTEM 
KMASE; TRANSFERASE: ZINC
GO 0000074 regulation of cell cyde unlikely 0
GO 0004672 protein kinase activity
GO:0004674 protein sertntfthreonme tonaa
00:0004709 MAP kinase kinase kinaaa ad
GO:0004713 protein tyrosine kinaaa activity
GO 0005057 receptor signaling protein act
GOOOOS515 protem bmdng
GO 0005524 ATP binding
GO0005822 intracelul*
GO 0005626 insoluble Iradion 
GO 0005829 cytosol 
00:0005886 plaama mambrana 
GO 0006468 protain amino add phoephory 
GO:0007165 signal transduction 
GO.0007242 imracaaUar sgnSng cascadi 
GO:0007243 protein kinwe caacada 
GOKXXJ7507 heart development 
GO 0006151 call growth and/or mainlenani 
G0:00i630i kinaaa acbmty 
G00016740 tranateraae activity 
GO:0019992 d< acyl glycerol binding
Raf-like R as-b ind ing  dom ain
57-131
Family: R aa-blnding dom ain, RBD
Hit: smart00455/tCDD; 3a-20 Mt: Family: Ras-bmdng domam. flBO. d1f<a_: (l-78yPs<Soop: 10 98%
Protein  k in ase  C c o n se rv ed  region 1 (C l) dom ains Family: P ro tein  k inase  cysteine-rich  dom ain  (cys2, ph o r
139-184
Mt: smart00109ACDO. 4*4)6
T yrosine k inase, catalytic dom ain
349-606
Mt: amart00219hC0D; 2*52
138-187
Mt: Family: Protam kinaaa cystaina-rich domain (cys2. phorboi-binding domain), d
Super-Fam ily: Pro tein  kinase-like (PK-like)
346-811
Mt Family: S*ma/threonm tonaeas dliaa«_: (32 327/Ps.Scop. ID 29%
Mt Family: Tymama ki i. d2arc 3 (l -269yP*Scop: ID 33%
432 coagulation factor II receptor CAP TRAPPER; HTC: MGC; THROMBM 
RECEPTOR; G-PROTEIN COUPLED 
THROMBIN RECEPTOR G PROTEIN 
COUPLEO RECEPTOR; 
TRANSMEMBRANE PROTEIN; 2858BP; 
427AAS; EXPRESSION M XENOPUS 
OOCYTE; HAMSTER; HYDROPATHY 
PLOT; NEGATIVE CHARGE CLUSTER 
M N TERM; PCR AMPLIFICATION. RNA 
BLOT; SEQ COMPARISON; SEO 
DETERMINATION; ALPHA THROMBIN 
RECEPTOR; CDNA CLONE; BLOOD 
COAGULATION; G-PROTEM COUPLEO 
RECEPTOR; GLYCOPROTEM; SIGNAL; 
TRANSMEMBRANE: POLYMORPMSM
G0 0045028 punnarg<c nucleotide receptor highly 
GO:0007596 blood coagulation likely
G0 0001584 modopsm-hka receptor act.*
G0 0015057 thrombin receptor activity 
G00005615 MracaffUar apace 
G00007186 G-protein coupiad receptor pr 
GO:0004872 receptor activity 
G0.0016021 integral to membrane 
G0:0003801 blood coagulation tact or activt 
G0:0004930 G-protain coupiad receptor ac
7 tran sm em b ran e  recep to r (rhodopsin  family)
139-350
Hit: pfamOOOOI/CDD; 1*09
Family: R hodopsin-like
102-413
Mt Family: toodopawkka d1«8a_: (30-338yPs.Scop; ID 49%
M91802_at Prot»m» p « i P31246
directly with high
372 homeobox A2 HOMEOBOX PROTEIN DNA BMOMG; G0:0001501 •
HOMEOBOX; NUCLEUS;
TRANSCRIPTION REGULATION; DNA- 
BMWNG: DEVELOPMENTAL PROTEIN 0 0  0003700 ,r*nKr,°,,or to o r  * * ^ 7  
HOMEOBOX; NUCLEAR PROTEM. G00006634 nucleus
GO 0003677 DNA binding
unlikely 0 H om eodom ain
139-199
Hit: smarl003894COD: 1*19 i. diqrya (4-78)/PsiScop; 10 39%
PROEWEPHALIN. SPERMATOGENtC- 
SP6CIFIC PROENKEPHALIN. 
NEUROPEPTIDE; OPIOID PEPTIDE; 
NEUROMOOULATOR. 
NEUROTRANSMITTER; 1440BP; 
26PAAS; ACC NO.Y07503, DISTINCT 
5TJNTRAN SLATED REGION; 
EfKEPHAUN PRECURSOR. 
EXCLUSIVE EXISTENCE M GERM 
CEU; RNA BLOT; RAT TESTIS; SEQ 
DETERMINATION; CONA CLONE; 
CLEAVAGE ON PAIR OF BASIC 
RESIDUES; ENDORPHIN 
NEUROPEPTIDE; OPIOID PEPTIOE; 
SIGNAL
S61865 s at Probemwoeo P 26260
d*ec8y h^h 
ccntdenceto 
RflfMQ 
NMO13026
313 syndecan 1 Sdci SYNDECAN; TRANSMEMBRANE 
PROTEIN: GLYCOPROTEIN; HEPARAN 
SULFATE. PROTEOGLYCAN. SIGNAL 
TRANSMEMBRANE
00:0005615 extracellular space h ighly 1 
G0 0006092 cytoahelag* prolain landing |jke]y 
G0 0016020 membrane 
GO 0016021 integral to memtaane
S y ndecan  dom ain
3-311
Hrt: p(am0i034/<CDD. 7e-65
n o  h its
(S 100% GT contdenee)
U30938 at Hendmapeed- S13507
Q64715
1825 microtubule-associated protein 2 Mtap2 ALTERNATIVE SPLICING. 
MICROTUBULE-ASSOCIATED 
PROTEIN; MICROTUBULE- 
ASSOCIATED PROTEIN 2; 
MICROTUBULE BINDING. TANDEM 
REPEAT
GO 0016358 dendnie morphogenesis unlikely 0
G00005856 cyloekeleion
00:0005875 micrctubuie associated comp
GO 0007026 micrcNubule ataWizanon
00:0001578 micttSutMe bundling
G00005516 calmodulin binding
G0.0005519 cytoslraioul regulatory protam
C aldesm on  no  h its
51 - 460 (Iragmern) (at 100% GT conftdence) 
Hit pfam0202»>C0D. 0 0007
C aldesm on
922 1659
Hrt. pfam02029/COO; 6*07
Tau a n d  MAP pro tein , tubulin -b ind ing  repea t
1664 1669
Hrt PF00418/iPFAM. 4e-05
Tau a n d  MAP p ro tein , tubulin -b ind ing  repea t
1690-1720
Hit. pfam004l&'iC00. 2e-07
T au an d  MAP p ro te in s  tubulin -b ind ing  dom ain  sig n a tu re
1739- 1751
Hrt: PS00229/iPROSlTEre; n/a
P ro b e M apping jB iopendium  L an. D escription 
1 A ccession
G ene  iOMIM Ikeyw ords |GO ISigP |TMs S eq u en ce  A nnotation
Ise c r td  1
|S tru c tu re  A nnotation
IS E T  3 ■
227 isopentenyl-diphosphate delta isom en
CAROTENOIO BIOSYNTHESIS. 
CHOLESTEROL BIOSYNTHESIS; 
(SOME RASE ISOPRENE 
BIOSYNTHESIS; MAGNESIUM. 
PEROXISOME; STEROL 
BIOSYNTHESIS
Snca 168601- MGC;RJ CDNA. AD AMYLdiD; G00005737
' AL2HEIMERS DISEASE; NACP;
AMYLOID; SYNELFM; ALTERNATIVE 
SPLICING; TANOEM REPEAT.
PHOSPHORYLATION; REPEAT.
ALTERNATIVE SPLICING; AMYLOID;
DISEASE MUTATION
G0 0005777 p 
G0*006694 atorotd bioeynihaae 
G00008299 ieoprenoid bioeyntheeis 
00:0006895 chdealerol bioayntheae 
GO 0016853 laomeraea activity 
GO0004452 .eopwrtwV dphoephw. c 
GO:0018117 carotandd biosynthew 
00*018126 sterol teoaynthaaw
unlikely 0 Iso p en ten y ld ip h o sp h a te  iso m erase
19 208
Hit COG14434COO, 3e42
Super-Fam ily: Nudix
m_: (l-171)/PaiSoop; ID 24%
140 synudein, alpha
163890
unlikely 0 Synuclein no  h its
<« 100% GT
Hrt ptamOl387/iCDO; 6*51
PPP1R1 • REPEAT; ' 
COILED C O t LIPOPROTEIN: 
MEMBRANE; PRENYLATION REPEAT
rc_AA800549_at Handmappadto Q96T49 
human orthologue 
- AAK52796 1
567 protein phosphatase 1, regulatory 
(inhibitor) subunit 16B
unlikely 0
HI CM00204/fCOD; <*23
ankyrin rep ea ts
212-314
Hrt ca0020rt/iCOO. 2e13
Super-Fam ily: Ankyrin repeat
SS - 333
Hr. Ejmrty Mynrt rapM 01M *l : <l-220)/PsSccp; 10 23%
rc AI072770 s a 1’" " ™ * * "  MPHUPL
.  directly with high
conftdence to
277 proteolipid protein Pip 3 1 2 9 2 0  PLP GENE. MYELIN PROTEOLIPID 
'W U n i-  PROTEIN; MVELM; PROTEOLIPID 
J W W I ’ PROTEIN SATELLITE DNA. MGC; 
3 1 2 0 8 0  UPOPHXJN; ALTERNATIVE SPLICING; 
MYEUN PROTEIN; UPOPROTEM. 
THKXESTER BONO; 
TRANSMEMBRANE PROTEIN; 
ACETYLATED AMMO END; 
OUGOOENOROCYTE; STRUCTURAL 
PROTEIN; 1330BP; 277AAS; EFOMT; 
MYELM PROTEOLIPID; 
OLIGONUCLEOTIDE PROBE; RAT 
BRAIN; SEO OETERMMATION; CDNA 
CLONE; ALTERNATIVE SPLICING; 
LIPOPROTEIN. MYELIN: PALMITATE: 
STRUCTURAL PROTEM; 
TRANSMEMBRANE. DISEASE 
MUTATION 
142 9 4 0  CAP TRAPPER; HTC: FIS (FULL 
INSERT SEQUENCE); OUGO 
CAPPMG; MGC; FLI.CONA. 3- 
HYDROXY-3-METHYLGLUTARYL 
COENZYME A SYNTHASE; HMG-COA 
SYNTHETASE; SYNTHETASE: 
CYTOSOLIC 3-HYDROXY 3- 
METHYLGLUTARYL COENZYME A 
SYNTHASE;
HYDROXYMETHYLGLUTARYL COA 
SYNTHASE: CARBON-CARBON LYASE; 
CHOLESTEROL BIOSYNTHESIS; 
OOENZYME A; ENOOPLASftAC 
RETICULUM; GLYCOPROTEM; 
MEMBRANE PROTEIN; OXO-AC1D- 
LYASE; CYTOSOL; CHOLESTEROL 
BIOSYNTHESIS; MULTIGENE FAMN.Y; 
TRANSFERASE
GO:0042S62 myaftnafton 
GO:0016021 integral lo membrane 
GO 0005887 ireagral lo ptaama membrane 
GO*006198 structure molecule ac»v«y 
GOOOOeaee nerve enaheelhment 
GO 0007268 eynaptc Irwrnteawn
unlikely 4 Myelin pro teo lip id  pro tein  s ig n a tu re  1
28-37
Ht: PS00575APROSITEre; rVa
Myelin pro teo lip id  pro tein  (PLP o r  lipophilin)
179 - 238
HM: smart00002ACOO; le-23
no  h its
(al 100% GT
rc_A1177004_s_a mapped P i 7425 
.  drectty with high
conftdenceto
520 3-hydroxy-3-methylglutaryl-Coenzyme A Hmgcsl 
synthase 1
G00005737 cyloptaam u n |jk e |y  0
GO 0005667 tranacripiion lector complax
GO.0003700 transcription (actor activity
GO-0016829 lyase activity
G0:0006700 C21 etenwJ hormone btoaynd
GQ0005634 nudeue
G0*003677 DNA binding
00:0016740 iranaleraae activity
GO:0007548 te> diflwentiaton
GO 0006695 cndesterdbrosynthese
G0;0004421 hydroxymethytglutaryl-CoA ay
GO 0006084 acetyl-CoA mettfcdiam
G0 0006355 rogulaiion ot tranacnption. DA
H ydroxym ethyiglutaryi-coenzym e A sy n th a se  Super-Fam ily: Thiolaee-like
HM; ptamOl 154/iCDO. 0 Ht; Family TNdaee-rekaled. dimajal: (7-l75yPaiScop; 10 19% 
Super-Fam ily: Thiolase-like
191 • 331
Ht; Famrty Ttvolaaa ralatod. 1H4J.AA(17S317VPai0Moi: 10 8%
541 UDP-glucuronosyltransf erase  8 “ O g ti  601291 MGC; CERAMIDE UDP--------------------
GALACTOSYLTRANSFERASE; UDP 
GALACTOSE CERAMIDE 
GALACTOSYLE TRANSFERASE; CGT 
GENE; GLYCOPROTEM; 
GLYCOSYLTRANSFERASE; 
HEXOSYLTRANSFERASE; 
GLYCOPROTEM; 
GLYCOSYLTRANSFERASE: 
MICROSOME; SIGNAL; 
TRANSFERASE; TRANSMEM8RANE
G00042552 myebnation 
00:0009247 gtycdipid doaynthaee 
GO:0005792 microeome 
GOrO016757 iranaleraae activity, tranafemr 
GO:0016758 transleraae activity, transferrir 
GO:0008120 ceramide gtucosyitransleraee 
GO.0005615 extracetlulw space 
G0:0003851 2-hydnxyacylaphingaaine 1-b 
GO O016740 transleraae activity 
G0:0016021 integral lo membrane 
G0:0008152 metabdiam
likely U DP-glucoronosyl an d  UOP-glucosyl tran sfe ra se  Super-Fam ily: U D P-G lycosyttransferase/glycogen phosf
33 - 502 33 - 453
Hit: p<am00201/»CDO; le-63 Ht: Family: UOP-glucoayttranalaraaa Gt6. d1wa_: (12 381 yPw Scop; ID 13%
rc_H33426_g at mapped Q02769
within 2kb d  
3’and with low 
conftdence to
416 famesyt diphosphate famesyl transferase 1 Fdftl CAP TRAPPER; HTC; SQUALENE--------
SYNTHASE; TRANSFERASE; 
TRANSMEMBRANE PROTEIN; 1.6KB: 
418AAS: ACC.NO.D29016;
EXPRESSION M E.COU; I40USE: SEQ 
COMPARISON; SEQ DETERMINATION; 
SQUALENE SYNTHASE; CDNA CLONE; 
CHOLESTEROL BIOSYNTHESIS; 
ENOOPLASA6C RETICULUM;
ISOPRENE BIOSYNTHESIS: 
MAGNESIUM; MULTIFUNCTIONAL 
ENZYME: NADP: OXIDOREDUCTASE
G0:0000287 magneaium ion binding unlikely 0
G0 0003824 catalytic activity
G0 0004310 (ameeyi-diphosphate tvneayft
GO 0005783 endopiasmtc reticulum
G0*006695 chdeateroi btoeyntheaia
G0.0008051 tameeyi-dtphoapheie lamaayl
GO 0008299 .aoprenodbtosynt hew.
00*000610 lipid bioeynthaa*
GO:0009058 btoeynthea*
S q u alene /phy toene  sy n th ase
47-334
Hit: ptam00494/iCDD; 2*67 Ht: Family: Squalana synthase dlerfa : (1-323)/P»Scop: 10 72%
P robe M apping B lopendium  [Len. [D escription 
A ccession  I I
[G en# [01AIM | K eyw ords r S igP  TMs 1 S eq u en ce  A nnotation S ecrtd  I JS tructune A nnotation
IS E T  4 m
AF005720m RNA 1 907 chloride channel 2 CHLORIDE CHANNEL PROTI 
CHANNEL-FORMING PROTEW;
907AAS. ACC NO X64139. 00:0006811 ion transport
EXPRESSION IN XENOPU8 OOCYTE: GO"0006821 chloride trnport 
RNA BLOT; RAT HEART/BRAN. SEQ
COMPARISON; SEO DETEHMNATtON: « M 0 1 « » 0  n e n tw e  
SKELETAL MUSCLE CONA AS PROBE; 000016021 integral to membrane 
TBSUE DISTRIBUTION; VOLTAGE 
GATEO CL CHANNEL CLC2; CONA 
CLONE; 31206P; 866AAS;
ACC NO U15652; ACTIVATION BY 
PROTEIN KMASE A; CL CHANNEL;
ELECTROPHYSIOL STUOY;
PHOSPHORYLATION SITE X2. RABBIT 
GASTRIC MUCOSA; CBS DOMAIN.
CHLORIDE; CHLORIDE CHANNEL; ION 
TRANSPORT; IONIC CHANNEL;
REPEAT; TRANSMEMBRANE.
VOLTAGE-GATED CHANNEL
HR: ptam00664/COO. 1e-87 HR: Famrfy- Oc chlortde channal dHp*_ 0-438yPs«ccp; 10 21%
Super-Fam ily: CBS-dom ain
560 663
HR: Family C8S4om«n 1ZFJAA(9«-1S7yPgBMM; 10 11%
Super-Fam ily: CBS-dom ain
664 706
HR; Family CBS-doman. 1ZFJ AA< 158-219yPaOaat: 10 10%
Super-Fam ily: Inoaine m o n o p h o sp h a te  d e h y d ro g en ase
703 - 846
H r Family Inaeme monaphoaphaM dehydrogenase OMPOH) 1B30:B8<19*414y
AF009604_al AAF36700.1 312 SH3 domain protein 2 C1 SH3P13S.COK.ED COl. UULTKjENE OaOOOSSISmMX bmtng 
FAMILY; SH3 DOMAIN
unlikely 0 BAR dom ain
AJ224879_al P»ob.m«»M AAA79780.1 1419 procollagen, type II, alpha 1
directly with
-206
HK: amarT00721ACOO; 6e37
S rc  hom ology  3 do m ain s
261 -307
H r emart003264COO; 16-11
Family: SH3-dom ain
255 306
HT Family: SH3dom»n diMus. (S-SSyPvSoop: 10 37%
183900  MGC. COLLAGEN. COLLAGEN TYPE II 
1 M p co! ALPHA 1 TYPE II COLLAGEN.
1 paht* in e .cD c rjc ir  m  i *r.
120140; COLLAGEN ALPHA; COLLAGEN ALPHA 
200C i o  1 TYPE «; ALTERNATIVE SPUCING; 
‘ ^ 1 '  COILED COT; EXTRACELLULAR 
108300  MATRIX GLYCOPROTEIN; TRIMER. 
TRIPLE HELIX; 3D-STRUCTURE. 
CARTILAGE: COLLAGEN;
CONNECTIVE TISSUE; DEAFNESS; 
DISEASE MUTATION: DWARFISM; 
EXTRACELLULAR MATRIX: 
GLYCOPROTEIN; HYDROXYLATION; 
REPEAT; SIGNAL; STICKLER
G00030020 extracellular main* structural highly
GO:000661S aMiracdMuiar apace likely
GO 0008029 proteoglycan mettbofcam
GO 0007155 call adhesion
G00005737 cytoplasm
G00005578 axtracallular matrix
GO:0005201 extracellular matrix structural
GO 0001502 cartilage condensation
GO 0005581 collagan
00:0030199 colleen fibril organization
GO 0005585 coHagan type II
Fibrillar c o llag en s  C-term inal dom ain
1184-1419
HR: amartOOOSSriCOO; 2*90
n o  h its
(M 100% GT confidence)
REPRESSOR OF MYEUN-SPECIFIC 
GENES; POU-HOMEODOMAIN 
PROTEIN; HOMEOBOX PROTEIN; OCT- 
6 GENE; OCT AME R-BINOMG 
TRANSCRIPTION FACTOR; POUBOX 
SOP; TRANSCRIPTION FACTOR; 
OCTAMER-BMDMG PROTEIN. DMA 
BINDING; HOMEOBOX NUCLEUS; 
TRANSCRIPTION REGULATION: DNA- 
B IN DING HOMEOBOX NUCLEAR 
PROTEIN; REPRESSOR;
Probe mapped A40168
directly with tvgh
451 POU domain, c lass  3, transcription factor 1 Pou3f1 602479 0 transcription factor activity unlikely 0GO 000370 i 
GO 0005634 nucleus 
GO.0006355 regulation at tranacnpbon. OK 
GO 0003677 DNA bmding 
00:0005667 transcription factor complex 
GO 0045449 regulation of transcription
H om eodom ain
339 397
HR: smart00389/iCDD. 3e-11
Family: PO U -apedfic  dom ain
247-321
Ht: Family PODspecHfc doman d1e3oc2. (l 75yP*Scop, ID 73%
Family: H om eodom ain
339-401
H t Family. Homeodomain. d1hdp_: (1-63VPaiScop; 10 60%
M 76767 S ; 2505 fatty acid synthase MGC; ACYL CARRIER PROTEIN. BETA 
KETOACYL REDUCTASE; BETA- 
KETOACYL SYNTHASE; DEHYDRASE; 
ENOYL REOUCTASE; FATTY ACID 
SYNTHASE; THOESTERASE; 
TRANSACYLASE; FAS GENE: FATTY 
ACID SYNTHASE; NADP; 
ACYLTRANSFERASE: CAR80N- 
OXYGEN LYASE: CARRIER PROTEIN; 
COENZYME A; FATTY ACJO 
BIOSYNTHESIS: HOMOOtMER. HYDRO- 
LYASE: MAMMARY GLANO: 
OXIDOREDUCTASE; 
PHOSPHOPANTETHEWE: 
PHOSPHOPROTEIN; THIOLESTER 
HYDROLASE; FATTY ACID 
BIOSYNTHESIS; HYDROLASE; LYASE; 
MULTIFUNCTIONAL ENZYME; 
OXIDOREDUCTASE: 
PHOSPHOPANTETHEWE; PYRIOOXAL 
PHOSPHATE; TRANSFERASE
G0:0004320 oleoyHacyl-carrier protein] hy unlikely
GO:0004024 alcohol dehydrogenase active
GO 0016740 translaraee activity
G00009058 txoayntneaia
GO 0016829 lyaae activity
GOO016787 hydrolaae activity
GO O016788 hydrolaae activity, acting on a
GO 0004312 fatty-acid synthase activity
GO0004314 [acyi-camer pratem] S-matom
G00008152 metabolism
GO:0006270 zinc ion binding
G00003824 catalytic activity
G 0 0006415 acyftransferaae activity
GO0006633 tatty aod biosynthesis
G00016491 ondoreductaae activity
G00048037 cofactor binding
G0:0016295 mynstoyl-f acyl-earner protein]
GO O016296 palmrtoyi I acyl-earner protein]
GO 0016297 [acyi-camer protein] hydraiaet 
GO 0008757 S-adenoaytmettvorvn^deperv
H t COG3321ACDO; 0
Z inc-binding deh y d ro g en ase
1532-1848
HR: pfamOOl 07/CDD Se40
H t Family: Thwlase-reiaied dle5ma1: (2-248)/PsiScop; ID 22%
Super-Fam ily: Thiolase-like
241 -404
H t Family: Thwlaae r aiatad. die6ma2. (M57yPaiScop; ID 25% 
Super-Fam ily: FabO /lyaophospholipaae-like
494 709
Ht: Family: FabDHe. d lm tO  (4-225yPnScop; 10 17%
Super-Fam ily: FabD /lysophospholipaae-like
678 - 798
H t Family: FabOMe. 1NM2;AA(187-305yGenThreed; 10 22%
Super-Fam ily: S -edenosyl-L -m eth ionine-dependent metl
1217-1383
H t Family: Mycotic aod cyctopropeie synthase. dil1eb_: (32-196yP* Scop; 10 1C 
H t Family: Hypothetical Protein Yjhp. d1nkva_: (17 179)/Ps»Scop: 10 14%
Super-Fam ily: QroES-like
1613 -1883
HR: Family: Alcohol dehydrogenase-like. N-tenminal domam. dljqbal (16-188yP»
Super-Fam ily: NAD(P)-binding R ossm ann-fo ld  d o m ain s
1859-1789
Ht: Family: Alcohol/glucose dehydrogenaaes. C-terminal domain. d1qora2: (3-125)
Super-Fam ily: GroES-like
1791 • 1848
P robe jM apping Biopendium
A ccession h D escription G eneSym bol OMIM K eyw ords I00 t L L1 {Structure A nnotation
ISET 5 i
AJ001029_at Probe mapped 
dkaciy with high
RaNeq
MI_01*18S.
055170 466 SRY-box containing gene 10 Sox 10 277580;
602229
SOX10 PROTEIH SOX 10 GENE. 
TRANSCRIPTIONAL MOOULATING 
PROTEIN; CAP TRAPPER; HTC; CPG 
ISLANO HTG. MCT. POL2RF 
PRKCA8P RNA POLYMERASE: 
SLC16A; 80X10; SRY; MGC; ONA- 
BlNOiNG. NUCLEAR PROTEM: 
TRANSCRIPTION REGULATION; 
DEAFNESS; DISEASE MUTATION; 
HIRSCHSPRUNG DISEASE
GO 0005667 tranacnptnn lector oomptot unlikely
G00003700 tranacnption tad or activity
GO0005834 nudeue
GO 0003677 DNA landing
GO 0030154 oall drftoenttoon
GO 0006355 regutoion of tranacnpttoi. OK
0 h igh m obility g ro u p
1 « - 173
HK: amart00388*COO; 7*18
Super-Fam ily: HMG-box
103 182
to t Family toyt&bm. d2toh_: (2-6iyPwScop. ID 25%
L15011_at
within 2kb of 
3*0*6 with low 
confidence to 
Rafaeq 
NM 017267
035094 453 translocator of inner mitochondrial 
m embrane 44
Timm44 605058 T»M4. MGC; MITOCHONDRION; ATP- 
B IN DING. INNER MEMBRANE; 
MITOCHONDRION; PROTEN 
TRANSPORT; TRANSIT PEPTIDE; 
TRANSLOCATION, TRANSPORT
go  0006810 irarwpon unlikely
GOO019866 inner membrane 
GQ0005744 mKochondriaf inner mam bran 
000005738 mKochondnon 
GO0015031 proton tranaport
0 M itochondrial im port inner m em brane, t ran si ocas, no  hits
112 -443 (a 100%QT oorSdanea) 
tot. ptam04280*CDO; 1*117
GO 0008565 proton im porter activity
GO 0006886 mtraceKUar proton im port
00:0003723 RNA binding
GO 0005524 ATP bindmg
GO 0015450 proton tranalocaM activity
GO 0006605 proton targeting
GO 0006355 regulation of tranacnption. OK
rc AA859479 at not mapped to a .
Iranacript
rc AA875362 at Hand mapped to AAN76808.1 993 CUB domain and EGF-iike repeat CEGF3 - highly 0 C alcium -binding EGF-iike dom ain
human othologue 
-AAN768081 containing 3 likely a mm  amanOOl7WC00:7*07
Calcium -binding EGF-iike dom ain
70-110
HK: amart00179ACOO: 2*05
Calcium -binding EGF-iike dom ain
112-151
HK: «n«l00179flCOO: 0.0002
T rypsin Inhibitor liks cy s te in e  rich dom ain
212 • 281
HK PF01826APFAM; 0003 (kw)
Calcium -binding EGF-iike dom ain
277 - 317
H t amart00179*COO: 2*05 
Calcium -binding EGF-iike dom ain
318 355
HK: amartO0179*000; 2*05
Calcium -binding EGF-iike dom ain
357 - 387
HK am arlO0179*000; 0.0005
T um or n e c ro s is  fac to r recep to r (TNFR) dom ain  Super-Fam ily: TNF receptor-like
639 785 873 -710
HK: cd00165*CDD; 2*07 to t Family: TNF racapKr-*to. lD4V:AA(47-86)/GenThread; 10 18%
Super-Fam ily: TNF receptor-like
711-752
to t Family: TNF m plor-lto . 1D4V:AA<S7-1l7yGenThiead; © 24%
D omain first fo u n d  in C lr ,  C ls ,  uEGF, an d  b o n e  n  Super-Fam ily: Sperm adhesin , CUB dom ain
804 - 913 804 - 913
HK: «mart00042*COD; 3*15 to t FwrWy Sparmadhasm. CUB domain. d1appb_: (8- 107yPaiScop; 10 20%
Super-Fam ily: S p erm adhesin , CUB dom ain
919-990
HK: Family: Sparmadhaam. CUB domain. 1SPP:BB(1-112yPSBUBl; ID 13%
425 nerve growth factor receptor Ngfr 162010 cap  t r a p p e r ;  h tc : mgc. n e rv e  
GROWTH FACTOR RECEPTOR; 
DUPLICATION; GLYCOPROTEN; 
HETEROOIMER. MONOMER; 
PHOSPHOPROTEIN: RECEPTOR;
G0 0003824 catalytic activity 
G0 0004872 recaptor activity 
G0 0005035 death receptor activity 
G00005515 proton binding
TRANSMEMBRANE PROTEIH 3270BP; 00:0005615 ertracelluto • 
424AAS; AMPLIFICATION OF 
EXPRESSION; GENE TRANSFER; NGF 0 0  0006629 matabotiam 
RECEPTOR; RNA BLOT; RAT; REPEAT GO:0006915 apoptOM 
X4 OF CYS RICH DOMAIN; SEO G0 0006917 induction of apopKxo
DETERMINATION: CONA CLONE: 30- 
STRUCTURE: APOPTOSIS: GO:0007165 signal transduction
highly
likely
T um or n e c ro s is  factor recep to r (TNFR) dom ain Super-Fam ily: TNF receptor-like
33-128 88-124
tot: odOOiaSACDO; 9*20 to t Family: TNF mptor-toa. 1 D4V:AA<47-86yGen Thread; © 12%
T um or n ec ro s is  factor recep to r / nerve grow th fac  Super-Fam ily: G row th factor recep to r dom ain
114-147 102 - 243
tot: smarlOQ206ACOO; 0.0002 to t F«n*y. Growth factor racapta domwn. 11VOAA( 162-31OyPafllaat; ID 9%
Tum or n ec ro s is  fac to r recep to r / nerve grow th fac
150-189
tot: smart00206*CDO; 1*06
P ro b s  M apping B iopendium  [Lon. D escrip tion  
A ccession  1
I G en s OMIM Keyw ords 
ISvmboi • 1“  . . S igP  iTMs tS eq u en ce  A nnotation jS tru c tu re  A nnotation
[SET 7  U
AR ni 54X> s  at Probe mapped Ot¥Vl1 fi A t?  ti imnr-aasre-iataH nrnlain 1 TA1 finOIR? LAT1 IL-TYPE AMWO ACID unlikelv 9 Amino ac id  tran ao o rte ra no  hHs
TRANSPORTER 1): 4F2 LC; 4F2/CD96 
UOMT CHAIN 4F2 LIGHT CHAM; L- 
TYPE AMMO AOD TRANSPORTER 1. 
HLAT1; C086 LIGHT CHAIN. 
TRANSMEMBRANE PROTEIN MGC; 
AMINO-ACID TRANSPORT; 
TRANSMEMBRANE; TRANSPORT
80 - 436
Ht COG0631/COO 1
Dhcr7 270400; 
268670; 
602858
7 OEHYDROCHOLESTEROL 
REDUCTASE; RD7R. MGC; 
CHOLESTEROL BIOSYNTHESIS: 
ENOOPLASMIC RETICULUM; NAOP; 
OXIOOREOUCTASE: STEROL 
BIOSYNTHESIS; TRANSMEMBRANE; 
DISEASE MUTATION
GO 0047598 not lound 
G0 00'6020 mamtxane 
GO0018021 integral to membrane 
GO 0016126 sterol biosynthesis 
00:0045640 raguMon of cholesterol busy 
00:0018491 owdoreductaee activity 
GO 0005783 endoplasmic reticulum 
GO 0008696 cholaatartf Bosynthesw
unlikely 6 E rgoste ro l b io sy n th e s is  ERG4/ERG24 family
115-471
H t ptamO1222/COO. 2*48
AB016800 q  at P**»mappao AAM45144.1 471 7-dehydrocholesterol reductase
confidence to
Dhcr7 270400; 
268670; 
602858
7-DEHYDROCHOLESTEROL 
REDUCTASE; RD7R: MGC: 
CHOLESTEROL BIOSYNTHESC; 
ENDOPLASMK: RETICULUM; NAOP. 
OXIOOREOUCTASE; STEROL 
BIOSYNTHESIS. TRANSMEMBRANE; 
OISEASE MUTATION
AF004218_s_at p™d. ™ sp« i AAD01198.1 2 2 3  opio id  rec ep to r , sigm a 1 
erectly wKhtxgh
GO 0047596 not lound 
GO 0016020 membrane 
00:0018021 integral to membrane 
00:0016128 alartf dosynthesw 
GO 0045540 regulalion of cholesterol bioay 
GO:0016491 oodoreductaae activity 
00:0005783 endoptan* reticulum
GO 0008895 chdeeterd boaymheaa
unlikely 6 E rgostero l b io sy n th e s is  ERG4/ERG24 fsmlly
11S- 471
He: pUmOI222nCOO, 2 b «
no  h its
tS  100% OT
O prsl 601978
AJ005396_at ' “ • " " m e  CAA06511.1 473 collagen alpha 1 (XI)
directly with high
COLLAGEN ALPHA 1 TYPE XI; COILED 
COIL; EXTRACELLULAR MATRIX: 
GLYCOPROTEIN TRMER TRIPLE 
HELIX; COLLAGEN; CONNECTIVE 
TISSUE; EXTRACELLULAR MATRIX; 
GLYCOPROTEIN HYDROXYLATION; 
REPEAT
GO 0007399 neurogenesw highly
G00005887 integral to deema membrane likely 
GO 0005615 edraceiluiw space 
00:0000247 C-fl Sterol aomeraee activity 
GO 0004872 receptor activity 
00:0005783 endoplasmic reticulum 
00:0004985 opioid receptor activity 
GO 0008696 ergosterol biosynthesis
1 ERG2 an d  S igm al recep to r like protein
7-219 
HK: PF04622/IPFAM; 3e-43
no  h its
<* 100% GT confidence)
G0 0030020 extracellular matrix structural unlikely 0
GO 0006029 proteoglycan metabofiam
GO:0007155 cell adhesion
GO 0005196 structural molecule activity
00:0005578 edraceHular matrix
00:0005201 exlracellular matrix structural
GO.0001502 caniiage condensation
G0:0005581 coltagen
GO:0030199 collagen fitxa organisation
Fibrillar c o ltag en s  C-term inal dom ain
243 - 472
HK: smwl00038ACDD; 9a-77
Super-Fam ily: F ibrinogen  C-terminal dom ain-like
270-411
Hit Family: Fwmogan CmrmmS OonmMlm. 1 JCSJW(1.220KS«nTI»Ma: 10 1«
245 tyrosine 3-monooxygenase/tryp»ophan 5- 
m onooxygenase activation protein, theta 
polypeptide
Y w haq 14-3-3 PROTEM THETA-SUBTYPE. 14- 
3-3 TAU: PROTEM KINASE 
REGULATOR KINASE RELATED 
PROTEIN 14-3-3 PROTEM 
ZET A/THETA-SUBTYPE; 245AAS;
ACC NO.D17614/017615. M SITU 
HYBRIDIZATION. RAT BRAM; SEQ 
COMPARISON SEO DETERMINATION; 
TISSUE DISTRIBUTION; CONA CLONE: 
BRAM; MULTIGENE FAMILY; 
NEURONE; PHOSPHORYLATION
00:0003754 chaperone activity 
GO 0006605 protein targeting 
00:0007165 signal transduction 
GO 0007264 smaM GTPase mediated sign 
GO:0006372 cellular ,component unknown 
GO 0019904 protein domwn specific bmdr
unlikely 0 14-3-3 ho m o lo g u es
3-242
HK: smartOOiOlriCOO; 4*82
Family: 14-3-3 protein
1 -228
H t Family: 14-3-3 pmtem. dia38a..: (1-216)/PsiScop; 10 72%
D26154UTR#1_a Pn*®mapp«d Q9ERE6
.  directly with high
confidence to 
RafBeq 
NM 053814.
1029 Rho interacting protein 3 Rhoip3 CAP TRAPPER; HTC; COILED COfl_ GO 0005871 Unesin complex
GUANME-NUCLEOTIDE RELEASING 
FACTOR REPEAT
unlikely 0 P leckstrin  hom ology  dom ain Super-Fam ily: PH dom ain-like
ology domain (PH domain). dUaoej <15-93)/PsiScop. I
Pleckstrin  hom ology  dom ain
394-486
HK: smart00233riCDD; 2a-10
Super-Fam ily: PH dom ain-like
H t Family Phosphotyraeme-bincfing domwn (PTB). dlqqgbl: (S-KttyPwScop; 1C 
H t Family: Piecfcatnrvhomology domain (PH domain). d1lb6*_: (4-98yPs*Scop. It
Super-Fam ily: PH dom ain-like
488-550
H t Family: Phoephotyroeine-bmding domain (PTB). lQOG:AA(104-207yGenThre
Probe mapped Q63151 
directly with high 
confidence to
720 fatty acid Coenzyme A ligase, long chain 3 Facl3
P52020 5 7 3  sq u a le n e  e p o x id a se Sqle
602371 CAP TRAPPER; HTC; MGC; BRAM G0 0000287 magnesium ton b ir* ^  unlikelv 1
ACYL-COA SYNTHTASE II; ACYL-COA Q0 0003824 cWafylic activity
SYNTHETASE 3; FATTY ACID „
METABOLISM: LK5ASE: MAGNESIUM; 0 0  0003987 acetale-CoA figaee acbvKy
MULTIGENE FAMK.Y; ALTERNATIVE G00004467 long-chwn-My-add CoA-ltga
MITIATION 00:0006629 lipid metabolism
G0.0006631 (any add metabolism 
GO0008633 M y add biosynthesis 
G0 0008152 metabolism 
G00016874 tigaae activity 
SE: SQUALENE EPOXIDASE; FAD. G00004506
HK: COG1022/CDD. la-118 HK: Family: Firefly ludtarase-like. dlmd9a_: (44-496)/PsiScop; 10 20%
aguwene monooxygenase ad likely 2-polyprenyt-6-m ethoxyphenol hydroxylase  and  n  Super-Fam ily: FAO/NAO(P>-binding dom ain
NM_017340. OXIDATION: FLAVOPROTEIN: 
OXIDOREDUCTASE; PEROXISOME. 
ALTERNATIVE SPLICING; FATTY ACIO 
METABOLISM; FLAVOPROTEIN. 
OXIDOREDUCTASE; PEROXISOME: 
OXIOOREOUCTASE
A cy l-C o A  o x id a s e
526-661
Hrt pfamOlTSe'COO. 7e-46
Hrt. Family: Msdum chan acyt-CoA dehydrogenass. NM (N-termmaf and middle) c
F a m ily : P e r o x is o m a l a cy l-C o A  o x id a s e - l i ,  d o m a in s  3  anc
272 - 460
FH Family. Perqasomai acyl-CoA omasa II. domans 3 and 4 dlis2a1 (1-169VP
F a m ily : P e r o x is o m a l sc y l-C o A  o x id a s e - l l ,  d o m a in s  3  an<
475 - 665
Hrt Family Peroaeomal acyt-CdA oedaswll. domams 3 and 4 di«2a2 (1-i6iyP
rc_AA859980_at Probe mapoed 
drectly wrth
ENSEbBL
ENSRNOTOOOOO
026053
ENSRNOPOO 371 
000026053
Ensembl G ene Model CAP TRAPPER. HTC. MGC unlikely 0 A ce ty l-C o A  a c e ty l t r a n s f e r a s e
41 - 370
Hit COGOiSS'CDD: 7e-84
F a m ily : T h io la a e - r e la t e d
24 - 247
Hrt Famrty- tncSms rstesd 0im3kai (46-267yPsiScco. 10 57%
F a m ily : T h io la s e - r e la te d
249 370
Hrt Family Thataee-'etated dldiua2 (M23yPtiScop: ID 53%
rc_AA891810_at Hand mapped to 
human orthoiogue 
- AAF 67007 1
AAF67007.1 276 ring finger protein 130 RNF130 - MGC unlikely 2 R in g  f in g e r
121 - 161
Hrt smartO0184/>CD0. 3e-07
S u p e r -F a m ily :  RING f in g e r  d o m a in , C 3H C 4
99 167
Hrt: Family RING Inge floman. C3HC4 d1yn7a (3 70VP*Scop; ID 2S%
rc_AA892798_al Probe mapped 
directly with h j^h 
confidence to
AAN45848.1 206 uterine sensitization-associated gene 1 
protein
Usagl HTC; CAP TRAPPER. MGC GO 0007566embryo implantation highly 0 
likely
S d e r o s t i n  (S O S T )
6 206
Hit PF0546a*PFAM. 3e-96
n o  h i ts
(a 100% GT confidence)
rc_AA892829_at Probe mapped ENSRNOPOO 406 
000015077
confidence to 
ENSEKCL 
ENSRNOTOOOOO 
015077
Ensembl G ene Model unlikely 0 A T P -s u lfu ry ta s e
77-403
Hit: pfam0l747/C00: 0
S u p e r -F a m ily :  PK  b e ta - b a r r e l  d o m a in - l ik e
3- 173
Hrt: Family ATP sirtturyiaee N-terrmnaf domam dlmSpat (9-170yP»iScop; ID 21
S u p e r -F a m ily :  N u d e o t id y ly l  t r a n s f e r a s e
178 400
Ht Family: ATP suffurytaee central domain dlg8ta2 (4-220>/PsiScop: ID 28%
rc AA893982 at Hand mapped to 0AC35929 1 478 
mouse orthoiogue
BAB24461 1
RIKEN cDNA 1700010P07 gene 1700010 - 
P07Rik
CAP TRAPPER GO 0005554 molecular, function unknown unlikely 6 
GO 0006665 sphingakCMl metabol«m 
00:0008686 sphmQomyelln bweynthesa 
GO 0016021 integra to membrane
S te r i le  a lp h a  m o tif
75 139
Hrt: am in 00454/iCDD 0 001
S u p e r -F a m ily :  S A M /P o in te d  d o m a in
75- 139
Hrt Family SAM (sterile alpha motif) dom»n. d1kw4e ' (8-70)/PsiSccp: ID 25%
rc AI013107 at PioOe mapped 
wrthm2Vtoof 
SendWtMOW 
confidence to 
Genbank 
AF083330
AAC33291.1 797 kinesin-like protein KIF3C 602845 **NESIN, MGC; GTP BINDING. P-LOOP; GO 0003774
NUCLEOTIDE BINDING; ATP-BINDING. 0 0  0003777 mootubule motor actrvrty
COILED COIL; MICROTUBULES; ______
MOTOR PROTEIN. NEURONE 0 0  00070' 7
GO:0005524 ATP binding 
GO 0005871 Wneein complex 
GOD005875 microtubule Associated comp
unlikeiy 0
I. smart00l29rrCDD. 1*106
F a m ily : M o to r  p r o te i n s
9-374
Hit: F»n.ty Motor prdcms. dl»6b_. (2-335)/P*iScop; ID 38%
rc_AI639196_at *obemapped CAB65966.1 493 collybistin I
directly with Ngh 
confidence to 
Retseq 
NM_0239S7
Arhgef9 300429 KIAA0424; COLLYBISTIN LGEPHYRIN; G0:0007264 smaH GTPac
FLI CDNA
mediated S r^v unlikely 0 S r c  h o m o lo g y  3  d o m a in s
20-70
Hit: sm»t00326/'iCOD: 2e-07
G u a n in e  n u d e o t i d e  e x c h a n g e  f a c to r  fo r
114-293
Hit: smart0032SACOO. 6e-*9
Hit: •mart0023y<COO. le-06
F a m ily : S H 3 -d o m a in
22-70
Hrt: Family: SH3-dom*n. d1h6ka_: (6-54yP*iScop; ID 34%
R h o /R a c /t S u p e r -F a m ily :  D BL h o m o lo g y  d o m a in  (D H -d o m a in )
104 - 299
Hrt: Family: DBL homology domain (DH-domax) dltoeel: (l-205)/PsiScop; ID 28
S u p e r -F a m ily :  PH  d o m a in - iik e
301 -435
Hit. Family. Plecfcatnrvhomotogy domain (PH domain). d1dbha2: (2-l32)/PsiScop;
rc_AI639294_at Haro maoort»  Q9ER58
mouse arthotogue 
-NP .443720.1
423 sparc/osteonectin, cv»cv and kazal-like 
dom ains proteoglycan 2
Spock2 TESTICAN; TESTICAN-2 PROTEIN: GO:0030196 extracellular matrix organizaiK highly
MGC; K1AA0275; CALCIUM-BINDING; QO0005509 cSoum ion binding |jk e |v
EXTRACELLULAR MATRIX;__________ __ _____
GLYCOPROTEIN. HEPARAN SULFATE. 0 0  0006615 ®tfrac®llL'i4f •Pace
PROTEOGLYCAN; SIGNAL GO:0O45595 regulation of ceil diflerentiatioi
GO000741$ synaptogeneas 
G00005578 aaraceiiuiar matrix
Hit: smart00290ftCOO: 4e-08
S P A R C _ E C
198 - 314
Hit; cd002S2/CDD; 6e-40
T h y ro g lo b u lin  ty p e  i r e p e a ts
333 - 378
Hit: smart00211ACDD; 8e-14
S u p e r -F a m ily :  O v o m u c o id /P C I-1  lik e  in h ib i to r s
114 • 171
Hrt Family Animat KazaMype nhrtxtors 1BMO:08(25-82yP&BlaS. ID 8%
S u p e r -F a m ily :  E F -h a n d
199-317
Hrt Family Osteonectin dinubal: (3-142yPs»Scop. 10 25%
F a m ily : T h y ro g lo b u lin  ty p e -1  d o m a in
311 - 377
Hit: Family: Thyrogkatxim type-1 domain d1ic*_: (3-64)/PsiScop: 10 38%
rc_AI639387_at ENSRNOPOO 113 Ensembl G ene Model
dtfacfly wrth tow 0 0 0 0 0 2 7 5 2
unlikely 0 R ib o s o m a l p r o te in  S 6
ENSEMBL
ENSRNOTOOOOO
Hit: COG036Q/CDD; 5*05
S u p e r -F a m ily :  R ib o s o m a l p r o te in  S 6
I: Family: Ribosomal pratem S6 d ltjha j (14-92yPsiScop; ID 2
rc_H31859_at Hand maooed - AAB47755.1 1215 neuron-glia-CAM-related cell adhesion
AAB47755.1 _  , ,molecule
601581 KIAA0343; HTG; ALTERNATIVE
SPLICING; NRCAM GENE; NRCAM 
PROTEIN; FLI CDNA
00:0016337 cell-cell adhesion 
00:0009897 external aide of plasma 
00:0045162 clustering of vottaQe gated to  
G0:0005886 plasma membrane 
GO:OOOS887 integral to plasma membrane 
G00030506 ankyrin binding 
00:0043005 not found 
G0 0030516 regulation of a»n  extension 
G0 0001764 not found 
00:0005515 protein binding 
GO:004S666 positive regulation of neuron c 
G0 0007413 fasoculatcn of neuron 
GO:0005194 cell adhesion molecule activit 
GO 0007155 cell adhesion 
GO:0007416 synaptogenesis 
GO 0007417 central nervous system devefc 
G00007409 axonogenesis
likely I m m u n o g lo b u l in
I: smart00409*000; 5e-05
Hrt: smart00408*CDD: 7s-l1
I m m u n o g lo b u l in  C -2  T y p e
375 - 440
Hrt: smwt00408ACDD; 4e-08
I m m u n o g lo b u l in  C -2  T y p e
468 - 533
S u p e r -F a m ily :  Im m u n o g lo b u l in
46-141
Hrt: Family: I set domains d1cs6a1: (4-96VPs*Scop; ID 2S%
S u p e r -F a m ily :  V ir u s e s  a n d  v i r u s - re c e p to r  c o m p le x e s
49 - 444
Hrt: Family: Viruses and wrus-receptor compte»s. 1QGC:44(1-436yPsiBJast; ID 1
S u p e r -F a m ily :  Im m u n o g lo b u l in
146-243
Hrt: Family I set domains. d1cs6a2. (6-l04)/Ps*Scop; ID 21%
F a m ily : I s e t  d o m a in s
284 360
Hit: Family: I set domains. 01cs6s3: (18-9iyPsiScop; ID 32%
S u p e r -F a m ily :  Im m u n o g lo b u l in
362 452
Hit: Family I set domains. dlcs6a4: (2-69yPsiScop: ID 28%
S u p e r -F a m ily :  Im m u n o g lo b u l in
454 - 543
EF-HAND 5 PROTEIN; UBKXJfTIN; 
COUKTE RPART OF RAT CAM 1; CAM 
GENE: CAM A GENT:; CAMF-1 GENE; 
CA2« BINDING; EF HANO; CALCIUM 
BINDING; OUPUCATION;
METHYLATED AMINO ACID; 
ACETYLATED AMINO ENO; BLOCKEO 
AMINO END. BOVNE UTERUS; SEO 
DETERMINATION; SIMILAR SEO WITH 
MODULATOR PROTEIN; TROPONIN C- 
LIKE PROTEIN; (ASP-GLY)2 IN CA 
BINDING LOOP; 148 AAS; BOVINE 
BRAIN; CALMOOUUN; COMPARISON 
WITH PARVALBUMIN. SECONDARY 
STR PREDICTION; 148AAS; AC ALA AT 
N-TERM; ADDUCTOR MUSCLE; 
PREDICTED SECONDARY STR; 
SCALLOP; SEO COMPARISON; 
BLOCKED N TERM. IDENTICAL WITH 
PHOSPHORYLASE KINASE; RABBIT SK
121 - 148
Hrt: •m«l00054ACOD; 0 002 (low)
M73714_at Probe mapped 
directly w*h rvgh 
confidence to 
Refseq
NM_031731
P 30839 484 aldehyde dehydrogenase family 3, 
subfamily A2
Aldh3a2 - ALDEHYDE DEHYDROGENASE: 
INTEGRAL MEMBRANE PROTEM. 
NAD; OXIDOREDUCTASE. 
TRANSMEMBRANE PROTEIN.
enooplasmk: reticulum.
MtCROSOME; OXIDOREDUCTASE. 
TRANSMEMBRANE
00:0004029 atdebyde dehydrogenase (NA unlikely
GO 0005783 endopieemic reticulum
GO-0005792 mcroeame
GO 0006152 metabolism
0 0  0016021 integral to membrane
GO 0016491 oedoreductaee activity
1 Aldehyde d eh y d ro g en ase  family
1 -428
Hit pUmOOl7ViCDO; 0
Family: ALDK-iike
2 444
Hrt Family ALDH-t*# diad3a. (3-445yPwScco 10 65%
M89945mRNA_g
_ a '
Probe mapped 
Orecfly wrth hign 
confidences 
Refseq 
f*t_03i840
A34713 353 f arensy l d ip h o sp h a te  sy n th a se Fdps CAP TRAPPER. HTC. MGC. 
CHOLESTEROL-REGULATED 
PROTEIN. FARNESYL 
PYROPHOSPHATE SYNTHETASE. 
CHOLESTEROL BIOSYNTHESIS. 
HOMOOIMER. TESTIS. TRANSFERASE; 
CHOLESTEROL BIOSYNTHESIS; 
ISOPRENE BIOSYNTHESIS:
transferase
GO 0004161 dwnethytafiyeranslerase actw unlikely 
GO 0004311 lameeyttrmatraneteraee activt 
GO 0004337 geranyftranetransferase ecfvn 
GO0006695 choleeterd txeynlhesa 
GO:0006299 isoprerwd taoeyntheers 
GO:0016740 transferase activity
0 Polyprenyf sy n th e ta se
45-314
Hit ptvn00346'iCDD. 6e-66
Family: Isoprenyl d ip h o sp h a te  sy n th a se s
9 353
Hit family Isooranyt dphoapbaN stmrthasas difes (4-348>/P*iSccp. ID 66%
M95591_at Probe mapped 
drecfy wrth tvgh
confidence to 
Retseq 
W .019236
Q02769 416 fam e sy l d ip h o sp h a te  farnesy l t r a n s fe ra se  1 Fdftl CAP TRAPPER; HTC. SQUALENE 
SYNTHASE: TRANSFERASE. 
TRANSMEMBRANE PROTEIN. 1.6KB: 
416AAS; ACCNO.D29016: 
EXPRESSION IN E .COLI. MOUSE. SEO 
COMPARISON. SEQ DETERMINATION; 
SQUALENE SYNTHASE: CDNA CLONE: 
CHOLESTEROL BIOSYNTHESIS. 
ENDOPLASMIC RETICULUM. 
ISOPRENE BIOSYNTHESIS: 
MAGNESIUM: MULTIFUNCTIONAL 
ENZYME. NAOP; OXIOOREOUCTASE; 
TRANSFERASE; TRANSMEMBRANE
G0 0000267 magnesium ion binding unlikely
G0 0003624 catalytic activity
00:0004310 lameeyi-diphoephate famesyfi
GO 0005783 endoplasmic reticulum
GO 0006695 cholesterol tvosynttiesis
G00006051 famesyl-diphosphate famesyl
GO:0006299 rsoprancrtJ broeyntheeie
GO.0006610 lod biosynthesis
G00009058 tkosynthesis
GO O016021 integral lo membrane
GO:0016491 aodoreductaae activity
GO 0016740 iraneferaee actrvrty
0 S qu a len e /p h y to en e  sy n th a se
47 - 334
Ht pfam00494/iCDD; 2e-67
Family: S qu a ien e  sy n th a se
38 • 370
Hrt Family Squalene synthase d'erta (l-323yPsiSccp; ID 72%
M95591_g_al Probe mapped 
directly wrth Ngh 
confidence to 
Retseq 
NM_019238
Q02769 416 f am e sy l d ip h o sp h a te  fam e sy l t r a n s fe ra se  1 F dftl CAP TRAPPER. HTC; SQUALENE 
SYNTHASE; TRANSFERASE; 
TRANSMEMBRANE PROTEIN: 1.6KB: 
416AAS; ACC.NO.D29016. 
EXPRESSION IN E.COLI; MOUSE: SEQ 
COMPARISON. SEQ DETERMINATION. 
SQUALENE SYNTHASE: CDNA CLONE; 
CHOLESTEROL BIOSYNTHESIS; 
ENOOPLASMIC RETICULUM; 
ISOPRENE BIOSYNTHESIS; 
MAGNESIUM. MULTIFUNCTIONAL 
ENZYME: NADP; OXIOOREOUCTASE; 
TRANSFERASE; TRANSMEMBRANE
00:0000287 magnesium ion binding unlikely 
G 0 0003824 catalytic activity 
G00004310 (ameeyi-dipho6pbaie fameeyk 
GO 0005783 endopiasme reticulum 
G0:0006695 cholesterol bioeyntheea 
GO 0006051 famesyl-diphosphate famesyl 
G0 0006299 leoprenoid braeyntheeia 
G0 0008610 irpKj tMcyntheM 
G00009058 tkosynthee*
GO OO16021 integral to membrane 
GO:0016491 agedoreductaee activity 
G0:0016740 transferase actrvrty
0 S qu a len e /p h y to en e  sy n th ase
47-334
Hrt. ptam00494yCDD; 2e-67
Family: S q u a len e  sy n th a se
38 - 370
Hrt: Family: Squalene synthaee dla*fa_: (1-3231/PsiScop. ID 72%
rc_AA891797_at Probe mapped 
directly with Ngh 
confidence to 
ENSEMBL 
ENSRNOTOOOOO 
009049.
1 N3K:A 130 p h o sp h o p ro te in  e n ric h ed  in a s tro c y te s  15 PEAT 5 603434 PEA-15 GENE; ASTROCYTIC 
PHOSPHOPROTEIN: CAP TRAPPER; 
HTC; MGC; FU CDNA; PED GENE; 
PHOSPHOPROTEIN ENRICHED IN 
DIABETES: DIABETES MELLITUS: 
APOPTOSIS; PHOSPHORYLATION; 
SUGAR TRANSPORT; TRANSPORT; 
ALTERNATIVE SPLICING; OEATH 
EFFECTOR DOMAIN; SIX HELIX 
BUNDLE
GO:OOOS351 sugar porter activity unlikely
G0 0005515 protein binding
G00005675 micfotubiie associated comp
G0:0006810 transport
00:0006916 ant<-apoptosis
G0 0042961 not found
GQ0046325 negative regdaion of glucose
0 Death effector dom ain
1 - 81
Hrt: smart0003UiCDD; 1e-17
Family: DEATH e ffec to r dom ain , DED
1 - 130
Hit: Family: DEATH effector domain. DED d1n3ka_ (1-130yP*iScop: ID 100%
rc_AA892400_at Hand mapped to 
mouse orthoiogue 
•AAF35695.1
AAF35895.1 419 cDNA sequence AF229032 AF2290 - 
32
FIS (FULL INSERT SEQUENCE); OLIGO G0 0008372 c«M » component unknown unlikely 
CAPPING; CAP TRAPPER; HTC; MGC 00:0000004 biologicalJtmcass unknown 
G0 0004176 ATP-dependent peptriase ad 
G0:00065l0 ATP-dependent proteolysis 
00:0005554 molecutarjunction unknown
0 ATP<dependent p ro te a se  La (LON) dom ain
58 294
Hit: PF02190/iPFAM; 2e-06
n o  h its
(efi 100% GT confidence)
rc_AA892557_at Hand mapped- 
AAP92663 1
AAP92663 1 183 Da2-17 CAP TRAPPER; HTC, MGC unlikely 3 no  h its n o  hits
(at 100% GT confidence)
rc_AA893670_at Probe mapped 
ENSEMBL
ENSRNOPOO 222 
000015327
Ensembl G ene Model unlikely 0 T um our pro tein  D52 family
46 - 206
Hrt pfam04201/iCDD; 1e-27
no h its
(« 100% GT confidence)
rc_AA894258_at Hand mapped to 
mouse orthoiogue 
- BAA96078.1
Q9JMC8 527 erythrocyte protein band 4.1 -like 4b Epb4.1l4 - 
b
EHM2; CYTOSKELETON G0 0005215 transporter activity unlikely 
G000056S6 cytoekaletan 
G00006810 transport 
G00016020 membrane
0 Band 4.1 ho m o lo g u es
87 - 277
Hit: smart00295/iCOD; 7*48
Family: First dom ain  o f FERM
85 165
Hit: Family: First dom«n of FERM d1gg3a3: (1 -80)/Psi$COp; ID 46%
Super>Family: S eco n d  dom ain  of FERM
162 - 272
Hrt. Family: Second dom»n of FERM. dlmixal (1-114yPsiScop; ID 26%
Family: Third dom ain  o f FERM
273 - 366
Hit: Family: Ttwd domain of FEFtM. d1gg3a2: (1-92)/F^iScop: ID 36%
rc_AA925248_at Probe mapped 
directly with high 
confidence to 
Retseq 
NM_031686.
CAA70364.1 1702 sodium channel, voltage-gated, type 6, 
alpha polypeptide
S c n 6 a SODIUM CHANNEL GO:0016020 membrane unlikely
GO:0016021 integral to membrane
G0 0005216 ion channel activity
G0 0001518 voltage-galed sodium channe
G 0 0005261 cation channel activity
G00006811 ion transport
16 ion tran sp o rt p ro tein
143 - 393
Hit; PF0052(ViPFAM; 4e-26
Ion tran sp o rt p ro tein
558-749
Hit. pfam00520/iCDD; 2e-23
no  h its
(at 100% GT confidence)
F i b ro n a c t in  ty p e  3  d o m a in  S u p e r -F a m ily ;  F i b ro n a c t in  ty p e  III
649 936 849 *50
Hrt smartOOOeorrCOD. 4*08 Ht Farvly F<yonec»n type IN aiqg3ai (4-92VP»Sccp. 10 25%
F ib ro n a c t in  ty p a  3  d o m a in  S u p e r -F a m ily :  F ib ro n a c t in  ty p a  III
953 - 1038 952 1049
Hrt. •mjrtOOOOOftCOO. 8e-06 Hrt Famrty Foronecan typ* IH dtqg3a2 p -lO U ^Scoc. 10 28%
X55286_at Probe mapped S33175 
dvectiy with mg* 
confidence 10 
Genbar*
XS5286
244 3-hydroxy-3*methylglutaryl-Coenzyme A 
reductase
Hmgcr HMG-COA reductase. 
HYDROXYMETHYLGLUTARYL-COA 
REDUCTASE; NADP; COENZYME A; 
OXIDOREDUCTASE. CHOLESTEROL 
BIOSYNTHESIS. ENDOPLASMIC 
RETICULUM. GLYCOPROTEIN; 
OXIOOREOUCTASE; 
TRANSMEMBRANE
GO 0004420 hydroKymetftytQiutaryl-CaA re unlikely 0 
00:0016021 integral lo membrane 
G00009058 bmeyirthee*
GO 0006629 tiprtJ metabd<em 
GO 0009790 embryorac development 
G00016491 ondoreductaee activity 
00:0005783 endoplasmic reticulum 
G0:0006695 cholesterol btoeynthese 
GO 0005789 endoplaamic reticulum memt
H y d ro x y m e th y tg iu la ry l- c o e n z y m e  A r a d u c t a a a s  fa  F a m ily : S u b s t r a te - b i n d in g  d o m a in  o f  H M G -C oA  r e d u c ta t
8 - 227 11 - 227
Hrt PS5006&APRO$lTEpn>. rVa Hrt Family Subetrae-bmdng doman d  HAG-CoA reductase 0idQac4 (73 288V
X68101_at Probe mapped 160486
directly with high
confidence lo
Genbank
X68101
738 Thyroid regulating gene Trg TRG GENE. GUANINE-NUCLEOTIDE 
RELEASING FACTOR
unlikely 0 n o  h i t s n o  h i ts
(a 100% GT confidence)
GO 0007399 neurogenee*
G0.0005888 plasma membrane 
GO 0005887 imagrtf lo plasma membrane 
GO 0004721 pratan phoephaaee actively 
GO 0005615 earacellular *peoe 
GO 0004725 protan tyrosine phosphatase 
G00004727 prenylaled protan tyrosme ph 
G00006470 prolain am no aod dephoephi 
GO 0007185 transmembrane receptor pros 
G00005001 transmembrane racapior pro*- 
GO 0004872 racapior activity 
G0 0016021 integral lo membrane 
GO0016787 hydrolase activity 
GOQOOSSIS protan binding 
G0.0007155 call adhesion 
G0.0007156 homoptvlic call adhesion
unlikely 1
P r o te in  ty r o s in e  p h o s p h a ta s e ,  c a ta ly t ic  d o m a in
308 563
Hit: smart00194/i000: 3#-94
P r o te in  ty r o s in e  p h o s p h a ta s e ,  c a ta ly t ic  d o m a in
599 856
Hrt: smartOOi94ACDO: te-9i
F a m ily : E u k a r y o tic  g lu ta th io n e  s y n th e t a s e  A T P -b in d in g
306 - 474
Hrt F amity EiAaryctc gMe teone syiilhaf s  ATP-Qmdmg domain 2HGS AA(30G
S u p e r -F a m ily :  F i b ro n e c t in  ty p e  III
1 56
Hrt Family FOronacttniypam 1FNA 1(1-91>/Ps«*ast. ID 19%
S u p e r -F a m ily :  F ib ro n e c t in  ty p e  III
55 199
tat: Family Ftvtrwctm typa ill iFNHAA(i8i-2©9yP*eiasl. <0 15%
F a m ily : H lg h e r- m o le c u la r -w e ig h t  p h o s p h o ty r o s in e  p r o t i
323 806
tat Family Hgner-molecular wa^N phoaphotyroame protan pnosphMaaes dliart
F a m ily : H ig h e r- m o le c u la r -w e ig h t  p h o s p h o ty r o s in e  p r o t i
611 859
Hrt: Family Fftgher-molecular-we^hf pnoapnctyroama prolain phosphataMS ditan
M82824 s at Probe mapped pg7526
dvectly wrth tvgh 
contdenceto 
fteteeq 
tart 012609
2820 neurofibromatosis 1 Nf1 193520' NF1; NEUROFIBROMIN; GTPASE 
1fiP?On' STIMULATORY PROTEIN.
'® “ UU NEUROFIBROMATOSIS type 1.NF1 
GAP-RELATE0 PROTEIN. NF1 GENE 
PRODUCT; TYPE 1 
NEUROFIBROMATOSIS PROTEIN; 
NEUROFIBROMATOSIS PROTEIN 
TYPE 1; TUMOR SUPPRESSOR; 
ALTERNATIVE SPLICING; 
ALTERNATIVE SPLICING; ANTI­
ONCOGENE; OISEASE MUTATION; 
GTPASE ACTIVATION; RNA EDITING
G0.0005096 GTPase activator activity unlikely 0 
GO 0045685 reguialion of glut celt differs**
G T P a s e - a c t iv a to r  p r o te in  fo r  R a s - lik e  G T P a s e s
1207 - 1538
Hrt: smart00323ACO0; 7e-93
D o m a in  in  h o m o io g u e s  o f  a  S
1568- 1704
Hit smart005l6/tCDD; 5e-’2
F a m ily : p 1 2 0 G A P  d o m a in - i ik e
1208 - 1531
Hit Family pi20GAP domam-kka. dlnfla . (i-260VPt»Sccp. 10 79%
S u p e r -F a m ily :  C - te rm in a l  d o m a in  o f  p h o s p h a tid y l in o s f t c
1563 - 1708
Hrt: Famtfy C-tammai domam of phoepftaodytinoertoi transfer protan eeci4p 1AU
S u p e r -F a m ily :  ARM  r e p e a t
1835 - 2440
Hrt. Family: Armadiio repeat. 1QGKAA(1 -876>/GenThread. ID 9%
Hrt: Family: HEAT reoee lB3UAA(1-588VGenThread; ID 10%
M86341 at Hand mapped Q02589 
AAA40691.1
362 ADP-ribosylarginine hydrolase Adprh MGC; ADP-RIBOSYLARGININE 
HYDROLASE; GLYCOSIDASE; 
HYDROLASE: HYDROLASE; 
MAGNESIUM
G00000287 magnesium ton binding unlikely 0 
G0:0003875 ADP-nbosyUrgmme hydrolasi 
GOOOOSS24 ATP binding 
GO 0016787 hydrolase actrvrty
A D P - r ib o s y tg iy c o h y d ro la s e
9-344
Hit: ptam03747/iCDD; 9e-50
n o  h i ts
(a 100% GT confidence)
c_AA799488_at Hanomappedto AAH53396.1 1123 expressed sequence AW555814
mouse orthoiogue 
-NP 7761212
CAP TRAPPER: HTC unlikely 0 G lu ta th io n e  s y n th a s e /R ib o s o m a i  p r o te in  S 6  m o d i!  S u p e r -F a m ily  : P r e A T P -g r a s p  d o m a in
51-337 44-133
Hit: COG0189/CD0; 3a-07 Hit Famity. D-Alanme tease N-ierminal doman 1E4E AA(1 130yPaiBlast. ID 227
Hrt: Family: BC N-tamtrta dom«n-like. 1KJ9.BB(1-t 11)/PsiBlast; 10 10%
S u p e r -F a m ily :  G lu ta th io n e  s y n th e t a s e  A T P -b in d in g  d o r r
134 - 351
Hrt: Family: ATP-bmd»ng domain of peptide synthetases. lE4E:AA(131-341)/PsiBL 
tat: Family: BC ATP-tendmg domain-Ske. 1DV2:B8<116-331)/PsiBlaet; ID 13%
Hrt Family Synapain la. C-terminal domain 1AUX:88(i03-292yPsiBla6l; 10 17%
S u p e r -F a m ily :  R u d im e n t  s in g l e  h y b r id  m o tif
365 442
tat FamHy: BC C-terminal doman-like. lB6S:AA(273-35iyGenThread; 10 23%
S u p e r -F a m ily :  P h o s p h o g ly c e r a te  m u ta s e - l ik eH is t id in e  a c id  p h o s p h a ta s e
512-581 (fragment)
Hrt; pf*n00328/iCDD: 0.0004
511
l: Family- Aod phosphatase. dind6b : (34-294)/PsiScop: 10 14%
rc_AA800711_at Hand mapped to 
mouse orthoiogue 
- XP 283372.1
none 276 RiKEN cDNA 1700110N18 gene 1700110 - 
Nl8Rik
unlikely 0 n o  h its n o  hits
(a 100% GT conidence)
rc_AA859627_at Hand mapped • 
AAP92586.1
AAP92586.1 793 Ab2-064 HTC likely 1 n o  h its n o  hits
(a  100% GT confidence)
rc_AI010581_at Probe mapped 
directly wrth tegh 
confdence lo 
Refseq
NZRT 87 diazepam binding inhibitor Dbi CAP TRAPPER; HTC; MGC; DIAZEPAM G0 0000062 acyl-CoA binding 
BINDING ItaHBITOR; GO 0006810 trwtsport 
BENZOOIAZEPINE RECEPTOR
LIGAND; MULTIFUNCTIONAL ACYL- G0:0006289 lipid binding
unlikely 0 A cyi C o  A b in d in g  p r o te in  (A C B P) b in d s  th io l  e s t e i  F a m ily : A cy l-C oA  b in d in g  p r o te in
1-64 1-64
Hit: cd00435/iCDD; 9e-23 Hit: Family: Acyl-CoA tending protein d1aca._: (1 -63yP*Sccp; ID 82%
COA-BINDING PROTEIN; ACETYLATED 
AMINO END; ACYL-COA BINDING: 
BRAIN; 456BP; 87AAS: DIAZEPAM 
BINDING WHIB1TOR; LIGAND FOR 
GABA RECEPTOR; MULTIGENE 
FAMILY; RAT; SEO COMPARISON; SEQ 
DETERMINATION; TISSUE SPECIFIC 
EXPRESSION; ACETYLATION; LIPI0- 
B IN DING; TRANSPORT
rc_AI103238 at *obe mapped P36877
within 2kb of 
3"end wrth low
443 protein phosphatase 2 (formerly 2A), Pppr2b2 604325; p ro te in  p h o sp h a ta s e  2A G0:000860i pn*em phosphatase type 2a. unlikely 0
regulatory subunit B (PR 52), beta  isoform 604326 ^ ^ s e m n c e i ^ o l i g o  G00007' 65 t>ar»ouct«n
CAPPING; CAP TRAPPER; HTC; MGC; protan phosphatase type 2A.
S e r in e / th r e o n in e  p r o te in  p h o s p h a ta s e  2A, r e g u ia tm o  h i ts
22 - 438 (a 100% GT confidence)
Hrt . COG5170fiCDD; 1e-126
Z83757mRNA_g Pft*»mapoea P16310 638 growth hormone receptor
drectly •rtf’ high 
— confcoenceto
Re*»eq 
NM_017094.
PROTEIN DISULFIDE I SOME RASE GO 0005615 artraalluia apace
BETA; EC1. U.11.2. EXPRESSION IN
INSECT CELL. MOUSE. PRO 4
HYDROXYLASE; RNA BLOT; SEQ
COMPARISON; SEO DETERMINATION
SIGNAL SEO OF 19AAS; TISSUE
DISTRIBUTION; ALPHA(IT) SUBUNIT;
CONA CLONE; ALTERNATIVE 
SPLICING; DOXYGENASE:
ENOOPLASMIC RETICULUM.
GLYCOPROTEIN: IRON;
OXIDOREDUCTASE; SIGNAL. VITAMIN 
C
F a m ily ; F ib ro n e c t in  ty p e  III
50- 14*
Hrt Family Fibronectin tyoe til 03Wvdi (l -93yP*Seop ID 7J%
F a m ily : F ib ro n e c t in  ty p e  III
147 - 254
Hrt Family Frtjronectm type III <3Hd9d2 (1-106)/P*»Scop: 10 71%
S u p e r -F a m ily :  I m m u n o g lo b u l in
297 409
Fkt Famrty Ci Mt dcmane (antibody constant doman-i*e) ' H7H HH(233-349|/F
S u p e r -F a m ily :  Im m u n o g lo b u l in
410 - SOS
Hrt Family C1 set doman* (anbody constant doman-iAe) 1HZH FW(350-457yF
GROWTH HORMONE RECEPTOR; GO 0019696 aannaic to membrane 
TRANSMEMBRANE PROTEIN. GO0005615 etfwellul* soace
GLYCOPROTEIN: RECEPTOR. SIGNAL;  ____ ___
TRANSMEMBRANE G0 0004672 receptor activrty
GO 0004696 hematopotetiryintertemn-ciai
GO 0016020 membrane
GO 0016021 mtegra to membrane
highly
likely
F i b ro n e c t in  ty p e  3  d o m a in
Hrt cdOOOWCOD. 60-06
COM POSIT JON, CILIARY 
NEUROTROPIC FACTOR 
DEVELOPMENTAL EXPRESSION, 
OLIGONUCLEOTIDE PRIMER. RNA 
BLOT. RAT ASTROCYTE; SEO ANAL 
OF TRYPSIN/BRCN DIGEST. SEO 
DETERMINATION; SURVIVAL OF 
CILIARY NEURON CDNA CLONE: 
1BS5BP; CHROMOSOMAL 
LOCALIZATION; CILIARY 
NEUROTROPIC FACTOR GENE; 
HUMAN SCIATIC NERVE. GROWTH 
FACTOR NEURONE: 3D-STRUCTURE; 
PHARMACEUTICAL, POLYMORPHISM
GO 0046668 rtQuUion NtrW pmgramn 
GO 004000? growth
l. PF0l073/iPFAM. 7*-72 Hrt Family Tyteeme^MpenderS oodoreductaeee diEutt).: (2-32SyP*Scop; I
rc AA893032 at Protem acoec ENSRNOPOO 362 Ensembl Gen© Model - mgc. c h o le s t e r o l  b io sy n th es is . - unlikely 1
“  ~  wrtNr2W»ol f w w v M o c  NAD. OXIDOREDUCTASE
Tew wrth fee ° 000 2 ^ 85
ENSEL©L_______________ _____________________________________________________________________________________________________________________________ _______ ___________ ___________________ _________________________________
750 mem brane metallo endopeobdas© Mme 120520 c ap  t r a p p e r ;  h tc : mgc. common go:ooo4245 nepniywn activity unlikely 1 P r e d ic t e d  m e ta l io e n d o p e p t id a s e
ACUTE LYMPHOBLASTIC LEUKEMIA 0 0  0006508 proteolysis «*J pephdalysra 72 - 750
PROTON- Er^^CLlFM^^NEUTRAL 0 0  0006237 ™«a1lopeptdase activrty Hrt COG3590/C0D. ie-113 Hrt F»n.iy Neutral endopecbdaae (nepnyam) dldmta. (i-696)/P*iScop. ID 94%
ENOOPEPTIOASE. CD10 NEUTRAL G00006270 line wn binding
ENOOPEPTIDASE 24 11. ZN- GO 0016020 membrxie
ENOOPEPTIOASE; ENOOPEPTIOASE, ^ _  ,___
MET.UOPROTEH ANTIGEN. GO 00.6021 im^rN «, m m ta n .
COMMON ACUTE LYMPHOCYTC G0 0016787 hydrolase activity
LEUKEMIA ANTIGEN GLYCOPROTEIN 
METAL BINDING PROTEIN, ZINC 
FINGER PROTEIN HYDROLASE 
MET ALLOP ROTE INASE;
OLIGOPEPTIOASE; SURFACE 
ANTIGEN: TRANSMEIvSRANE 
PROTEIN; ZINC; GLYCOPROTEIN.
HYDROLASE. METALLOPROTEAS6.
SIGNAL-ANCHOR: TRANSMEMBRANE:
ZINC. 3D-STRUCTURE
rc_H3t 897_at Hand mapped to AAH17534.1
mouse orthoiogue 
-AAH17S34.1
463 expressed sequence AW212394 likely N u c le o s id e  H+ s y m p o r te r
96 - 275 (fragment)
Hrt. PF0382SfiPFAM: Ie05
n o  hH s
(X 100% GT cenMence)
rc H33426 at *<*» mapped QQ2769 416 famesyl diphosphate famesyl transferase 1 Fdftl CAP TRAPPER; HTC; SOUALENE 
SYNTHASE:TRANSFERASE. 
TRANSMEMBRANE PROTEIN: 1.6KB: 
416AAS; ACC NO.029016; 
EXPRESSION IN E.COU, MOUSE; SEQ 
COMPARISON; SEQ DETERMINATION; 
SQUALENE SYNTHASE; CDNA CLONE; 
CHOLESTEROL BIOSYNTHESIS; 
ENDOPLASMIC RETICULUM: 
ISOPRENE BIOSYNTHESIS; 
MAGNESIUM; MULTIFUNCTIONAL 
ENZYME; NAOP; OXIDOREDUCTASE; 
TRANSFERASE; TRANSMEMBRANE
G00000287 magnesium ion binding unlikely 0 
G00003824 cXXytic activity 
GO:0004310 famesyi-diphosphale lameeyfl 
GO 0005783 endoplasmic relicUum 
00:0006695 cholesterol biosynthesis 
G0 0006051 ftmesyi-diphosphate famesyl 
G00006299 isoprerod biosynthesis 
G0:00066i0 liprtj biosynthesx 
G00009058 biosynthesis 
GO;0016021 integral to membrane 
00:0016491 ondoreductase activity 
G00016740 lr
S q u a le n e /p h y t o e n e  s y n th a s e
Hit: pfan>00494/iCD0; 2e-67
F a m ily : S q u a le n e  s y n th a s e
38 • 370
Hrt Family: Squalene synthase dlezfa.: (1-323yPs»Scap; ID 72%
Probe mapped 
directly with high
374 purinergic receptor P2V, G-protein coupled P2ry2 600041 C4p t r a p p e r ;  h tc ; mgc, a tp
2  RECEPTOR. G PROTEIN-COUPLED
RECEPTOR; TRANSMEMBRANE 
PROTEIN; 1380BP; 374AAS; P2U 
PUfllNOCEPTOR; RNA BLOT; RAT 
HEART; RESPONSE TO UTP/ATP; SEQ 
DETERMINATION; TISSUE 
DISTRIBUTION; CDNA/GENOMIC 
CLONE; IN SITU HYBRIDIZATION; G- 
PROTEIN COUPLED RECEPTOR: 
GLYCOPROTEIN; TRANSMEMBRANE
G0 0001584 modcpem-hke receptor activit unlikely 7
G00004930 G-protem coupled receptor ac
G0:0005524 ATP bincfeng
G0 0005887 integral to plasma membrane
GO;0007186 G-protein coupled receptor pr
G00016021 integral to membrane
GO:0016323 baeoJXeral plasma membrar*
G0 0016324 ap*x plasma membrane 
GO 0045028 pumergic nucleotide receptor
7  t r a n s m e m b r a n e  r e c e p to r  ( rh o d o p s in  fam ily )
66 - 305
Hrt PFOOOOl/iPFAM; le-10
n o  h i ts
(a  100% GT oonSdence)
Probe mapped R08033
directly with high 
confidenceto
283 gap junction m em brane channel protein 
beta 1
Gjb1 CX32 GENE: ALTERNATIVE SPLICING; G0:0005243 gx>-|unction terming chxmei |jk©|y 
CONNEXIN: MGC; TRANSMEMBRANE GO0005615e*racellulW apace 
PROTEIN: GAP JUNCTION PROTEIN,
GAP JUNCTION; PHOSPHOPROTEIN; GOOWSWI 0*P Nhction 
CALCIUM; LIVER; GAP JUNCTION; G0 0005922 ccnnenon complex 
TRANSMEMBRANE GO 0007154 cell cwn mumcalion
G00007267 oert-celf signXing 
G0 001S285 connexon channel activity 
G0 0016021 integral to membrane
Hrt: smart00037/iCOD; 7e-l3
Hit: PS004087iPROSITEre: 7e-09
n o  h i ts
(X 100% GT confidence)
Probe mapped S39262
directly with high 
conSdenceto 
Genbank 
X76489.
226 CD9 antigen 143030 MGC; DIPHTHERIA TOXIN RECEPTOR G0:0009966 cell surface
ASSOCIATED PROTEIN; ANTIGEN; 00:0016021 integral to membra
MEMBRANE PROTEIN; CD9 ANTIGEN;
MRP-1; MOTIUTY RELATED PROTEIN; <*°:0005515 prtMrn binding 
TRANSMEInCRANE TYPE CELL GQ 000716S signX transduction
T e t ra s p a n in  fam ily
9-192
Hit. pfam00335^CDO: 4e-05
S u p e r -F a m ily :  T e t ra s p a n in
110- 190
Hrt: Family Tetrasparwv d1g8qa_ (2-89yP$iScop; ID 15%
P ro b e  |M apping jB iopendium  |Len. |D escrip tion [G ene
ISvm bol
OMIM | K eyw ords GO ie. r S eq u en ce  A nnotation (S truc tu re  A nnotation
[SET 12 I
K03039m RNA s AAA41513.1 962 protein tyrosine phosphatase, receptor- 
type, c polypeptide (antigen Cd45, 
leukocyte-common antigervT200 
glycoprotein)
Ptprc
COMMON ANTIGEN
GO 0009697 external nd( of plaema memt unlikely 
000006886 plasma membrane 
000004721 proMtn p 
000008815 «
GO 0004725 p 
000004727 p
G00006470 protem am no aod dephoaphi 
GO0007165 transmembrane receptor pn*
GO 0018021 mtegrtt lo membrane 
GO 0008968 ceMUar deNnee reeponee 
GO0016787 hydrolaae activity 
GO 0005515 pratein bnding
F ib ro n e c t in  ty p e  3  d o m a in
50-120
Ht smart0006Q4COO. 4*06
F ib ro n e c t in  ty p e  3  d o m a in
143-223
Ha cd00063/C00. 1*06
P r o te in  ty r o e in e  p h o s p h a ta s e ,  c a ta ly t ic  d o m a in
311-570
HR amartO0194AC00. 9*64
P r o te in  t y r o s in e  p h o s p h a ta s e ,  c a ta ly t ic  d o m a in
602 883
HK sm*l00194ACOO. 9e-7l
F a m ily : F ib ro n e c t in  ty p e  III
55-138
MC FamSy roranacen type M ditan_: <7-90VPsi6cap. 10 33%
S u p e r -F a m ily :  F ib ro n e c t in  t y p e  III
146 - 230
Mt Famty- Fferonecan type M 1TEN:-1(1 tOyP i t taat. 10 20%
F a m ily : H ig h e r-m o ie c u ia r -w e ig h t  p h o s p h o ty r o s in e  p r o t i
296 - 811
HK: Family: Hgher-mclecuiar-wsKjhi phoaphatyroame protem phoapheaaaa dlian
Hrt: Family Hgher-motecular-wertjN phot
~Mic3 160780 CAP TRAPPER; HTC. MGC; MYOSIN. 000016456 rr 
MYOSIN LIGHT CHAIN; ALTERNATIVE 
SPLICING; MLC3 PRO TEW;
IMMUNOGLOBULIN LIGHT CHAW; MLC- 
3F GENE; MYOSW LIGHT CHAIN 3;
FAST SKELETAL MUSCLE; EF HAND;
CALCIUM BWDWG; MUSCLE.
SKELETAL MUSCLE; ACETYLATED 
AMINO ENO. DUPLICATION; MUSCLE 
CONTRACTION; 15CV195AAS;
S42/8888P; HUMAN. MYOSW ALKALI L 
3F71S8. SEQ COMPARISON; SEO 
DETERMINATION; CONA CLONE;
ALTERNATIVE SPLICING; MULTIGENE 
FAMK.Y; MUSCLE PROTEW; MYOSIN;
ACETYLATION
L00088expanded ^ " w d  AAA98534.1 150 fast myosin alkali light chain
_cds#2_at
unlikely 0 C a 2 + -b in d ln g  p ro te in  (E F -H a n d  su p e rfa m ily )  F a m ily : C a lm o d u l in - l ik e
1-148 
HK; COQ5126ACDO; 2e-18 HK Family: C*modubrvl*e d1br1b_: (l-l47yPa»Scap: 10 62%
Ml5562_g_al
directly with high
Genbank
Y00480.
S06316 255 class II histocompatibility antigen RT1 -0  
alpha(u) chain precursor - rat
tJHC CLASS II ANTIGEN; RT1-0 ALPHA 
GENE; MAJOR HISTOCOMPATIBKJTY 
COMPLEX; CLASS II ANTIGEN; 
TRANSMEMBRANE PROTEW
likely 1 C l a s s  II h is to c o m p a tib i l i ty  a n t ig e n ,  a lp h a  d o m a in  F a m ily : MHC a n tig e n - r e c o g n i t io n  d o m a in
29-109 29-106
HK: plam00993/iCDO; 8*28 Hrt: Family: MHC anbgen-recogneon doman. dUnea2: (1 SiyPaScop. 10 91%
I m m u n o g lo b u l in  C -T y p e  F a m ily : C1 s e t  d o m a in s  ( a n t ib o d y  c o n s t a n t  d o m a in - lik e )
127-196 107-207
HK: aman00407ACOO-. 2a-17 H t Famiy: Cl Ml domana (anteorty constant domen-Uke) a imeel: (1-101 yPaU
M37942exon#2-
3_s_at
Hanamappeo- 
PI0758
P10759 747 adenosine monophosphate deam inase 1 Ampdl 102770 amp deam inase, m yoa d en y la te  g o  0003876 amp deaminase ac*v«y unlikely 0
DEAMINASE; ADENOSINE 00:0006144 purine b ~  mat-ddrsm
MONOPHOSPHATE DEAMWASE1; _ . .
HYDROLASE; MUSCLE; SKELETAL 0 0  0009117 m « * * * •"
MUSCLE; HYOROLASE; MULTIGENE G0:0009i68 purine hbonudeosrde monopt 
FAMK.Y; NUCLEOTIDE METABOLISM; 00:0016787 hydrtfase activity 
DISEASE MUTATION; POLYMORPHISM
A d e n o s in e /A M P  d e a m in a s e
289 - 438 (fragment)
HK: PF00962APFAM; 9e-17
A d e n o s in e /A M P  d e a m in a s e
448-702
HR: ptam00962/iCO0: 2*40
S u p e r -F a m ily : M e ta l lo -d e p e n d e n t  h y d r o la s e s
293 892
H t Family: A d e e m  dewn.naae (ADA). d1*>_ (2-332yPeScop; ID 14%
S u p e r -F a m ily : C o m p o s i te  d o m a in  o f  m e ta l lo - d e p e n d e n t
710 - 747
HK: Family: Cytcwne deammaae lK6W AA*37S423yGanThtaad; ID 13%
AAA42149.1 182 troponin 1, type 2 GO:0003779 echo bmdmg unlikely 0
GO:0005200 structural constituent oI cytos 
GO 0005524 ATP binding 
G0 0005861 troponin complex 
G00006818 hydrogen transport
191043 TFW12 GENE; FAST SKELETAL
MUSCLE TROPONIN I; MGC; ACTW- 
BWDING PROTEIN; CONTRACTILE 
PROTEW; CONTRACT l £
REGULATORY PROTEW; FAST 
TWITCH FBER. TROPONW I;
TROPONW; ACETYLATED AMWO END; r^ . noofl!W7 H
ACTIN BINDING MUSCLE; SKELETAL GO.OXWnT co re *
MUSCLE; BLOCKEO AMINO END: 00:0007517 m u** d m * * ™ .
IAJSCLE CONTRACTION. GO:OOOB553 hydiOQefi-eiqxxtinQ ATPas®
PHOSPHOPROTEW: 180AAS; 570BP;
EXPRESSION W E.COLI; MUTANT 
C48A/C84A/C133S; NO EFFECT ON 
INTERACTION WITH TNC/TNT; RABBIT 
FAST SKELETAL MUSCLE;
REGULATION OF ACTO-S1 ATPASE;
SEO DETERMWATION; SMLARITY W 
FUNCTION; TROPONW I; 30- 
STRUCTURE; ACETYLATION; ACTW 
BINDING MUSCLE PROTEW;
PHOSPHORYLATION
T ro p o n in
15-135
HK: p<am00992fiCDO; 3e-07
n o  h i ts
(a  100% g t
M99223_at Probe mapped 
drrecHy with lew
ENSEMBL 
ENSRNOTOOOOO 
rc_AA851223_at P™ be"wd
ENSRNOPOO 152 
000025087
Ensembl G ene Model likely C a tio n  tr a n s p o r t i n g  A T P a se , C - te rm in u s
2-150
HK: p<am00689/C0D; 3e-4i
n o  h i ts
<a 100% g t
Eno3 131370 c ap  t r a p p e r ,  h tc ,  mgc; en03 
GENE; BETA-ENOLASE: ENOLASE; 
BETA-ENOLASE GENE; MUSCLE 
SPECFIC ENOLASE: GLYCOLYTIC 
ENZYME; ISOFORM; MUSCLE
F a m ily : E n o la s e  N -te rm in a l d o m a in - lik e
2-140
HK: Family: Enotaae Ntarmmal domairHika. dlebga2: (l-139yP»Scop: 1061%
F a m ily : E n o la s e
434 enolase 3, beta GOOOOOOl 5 phoephopya
GO 0000287 magnesum ion tMnding 
G0.0004634 phosphopyruvate hydratase a 
GO 0006096 glycolysis 
SPECIFIC PROTEW; ENOLASE BETA 00:0016829 lyase aebvrty
HK: COG0148ACDO; 0
m »diT. r o u n c o w v n /
ULYGOPHOIfcIN, SiKfcLfclALMUSCLfc; 
CALCIUM-BMDMG: GLYCOPROTEM, 
MUSCLE: SIGNAL
likely 5-390
Hrt plamOi2ieCDO. 0 Hrt F«v»rty
F a m ily : C a ls e q u e s t r in
155 256
a6y. 1 (M24yP»Scoo 10 96%
hM Family (
F a m ily : C a ls e q u e s t r in
257 • 375
i-102VP*Sccp 10 79%
l2yP»Scop 10 75%
AAD51613.1 182 type 2X myosin heavy chain MGC: MYOSIN. MYOSIN HEAVY CHAM. 
SKELETAL; EMBRYONIC HEAVY 
CHAM. NEONATAL HEAVY CHAIN.
ATP; ACTIN BMDMG. CO9.E0 COIL: 
MUSCLE: SKELETAL MUSCLE: THICK 
FILAMENT. HYDROLASE; MUSCLE 
CONTRACTION. 231AAS: 6306P; 
EXPRESSION. FIBER TYPING: HUMAN 
SKELETAL MUSCLE; SEO ANAL OF 
TYPE MX MYOSIN H; SEQ 
COMPARISON. SEQ DETERMINATION. 
TYPE IIA MYOSIN H; CONA CLONE; M 
SITU HYBRIDIZATION, ATP-BINDING; 
ACTIN-BINDING. COILED COIL. 
MULTIGENE FAMILY. MUSCLE 
PROTEIN; MYOSIN. THICK FILAMENT
unlikely 0 no  h its
U42719_at Probe mapped 
dvectly with tvgh 
conidenceto 
Genbank 
U42719.
AAA91231.1 105 C4 complement protein C4a G0 0003811 complement activrty unlikely 0 
G000069S6 complement activator 
00:0016064 humoral defense mechanism
N e trin  C - te rm in a l D o m a in
1 - 62 (IraQment)
Hit smart00643/iCDD. 7e-14
n o  h i ts
(at 100% GT contdencei
U65217_i_at Hand mapped • 
P29626
P29826 263 RT1 class II histocompatibility antigen, B-1 • 
beta chain precursor (RT1 B-beta(1))
CLASS M ANTIGEN. INTEGRAL 
MEMBRANE GLYCOPROTEIN; 
GLYCOPROTEIN; HETEROOIMER; 
TRANSMEMBRANE PROTEIN; 
GLYCOPROTEIN; MHC II; SIGNAL; 
TRANSMEMBRANE
highly 1 
likely
C l a s s  II h is to c o m p a t ib i l i ty  a n t ig e n ,  b e ta  d o m a in
39 - 112
Hrt: pfam00969/CDD: 3e-30
Im m u n o g lo b u l in  C -T y p e
138 209
Hit. smart00407ACOD 1e-l7
F a m ily : MHC a n t ig e n - r e c o g n i t io n  d o m a in
32-118
Hit. Family kA-tC ant^en-recognrtion domain. diee0b2 (i-67yPs*Scop. ID 81%
F a m ily : C1 s e t  d o m a in s  ( a n t ib o d y  c o n s t a n t  d o m a in - lik e )
120-217
Hrt Family C1 set domains (arttody constant domam-iike). dlGjbl: (l-98yPsiSc
X !2554cds_s_at Probe mapped 
directly wrth Ngh 
conidenceto 
Refeeq 
NM012812.
CAA31068.1 86 cytochrome c oxidase, subunit Via, Cox6a2 - 
polypeptide 2
CAP TRAPPER; HTC; MGC: 
CYTOCHROME C OXIDASE: 
CYTOCHROME C OXIDASE SUBUNIT 
VIA; CARDIAC MUSCLE; ELECTRON 
TRANSFER; HEART; MEMBRANE 
ASSOCIATED COMPLEX; 
OXIDOREDUCTASE; RESPIRATORY 
CHAM: TRANSMEMBRANE PROTEIN: 
INNER MEMBRANE: MfTOCHONORON; 
OXIDOREDUCTASE: TRANSIT 
PEPTIDE
G0 0019866 inner membrane likely 1 
00:0005751 respiratory chan complex IV •
G0 0005739 mitochondrion 
GO 0016491 oodoreductaee activity 
G00004129 cytochrome c aedaee activity 
G00006116 electron transport 
GO0005615 extracellular space 
G0 0005740 mitochondrial membrane
C y to c h r o m e  c  o x id a s e  s u b u n i t  Via
14-64
Hit: pfam02046/CD0; 8e-22
F a m ily : M ito c h o n d r ia l c y to c h r o m e  c  o x id a s e  s u b u n i t  Vli
1 - 8S
Hrt: Family Mtochondnaf cytochrome c ondaee subunt Via. dioccg.. (l-64yPsiS
X60769mRNA_at *<** AAB21102.1
directly with Ngh 
confidence lo 
Refeeq 
NM_024125.
CCAAT/enhancer binding protein (C/EBP), Cebpb 
beta
INTERLEUKIN 6 OEPENDENT BINDING 00.0005737 cytoplasm
PROTEIN; LAP GENE; LIVER- 
ENRICHED TRANSCRIPTIONAL 
ACTIVATOR PROTEIN; 
TRANSCRIPTIONAL ACTIVATOR 
PROTEIN; DNA BMDMG: UVER; 
TRANSCRIPTION REGULATION; 
ACTIVATOR; ONA-BMDING; NUCLEAR 
PROTEIN, TRANS-ACTING FACTOR; 
TRANSCRIPTION REGULATION
G0 0042803 not found 
G00006916 anti-apoptoeie 
00:0045406 regulation oI interieukin-6 b «  
G0:0006917 induction of apoptoeit 
00:0030182 neuron differentiation 
G0:0005634 nucleus 
00:0016506 apoptosis activator activity 
G0 0003677 DNA binding 
GO:0016563 transcriptional activator activit 
G0 0005515 protein binding 
G0:0006355 regulation of transcnption, Dh
likely n o  h i t s
(al 100% GT conSdence)
Hit: PS50217/iPROSfTEpro; r
241 GTP cyclohydrolase 1 128230 W00 ' GTP CYCLOHYDROLASE I; 
233910' TETRAHYDROe,OPTER,N
GO 0016787 hydrolase activrty
G00003824 c««y1>c adivrty unlikely
G00003934 GTP cyclohydrolase I activity
METABOLISM; GTP CYCLOHYDRASE I ;  _________________________ _
600225 HYOROLASE; ALTERNATIVE 00-0006729 letohydwtoopienn bdsynthei
SPUONG: PHOSPHOPROTEW. GO 0006917 induction of apoptwa
2S0AAS; 2921 BP. ACC NO U19523: GTP 00:0009058 feosynthews 
CYCLOHYDROLASE I TYPE 1. HUMAN 
PHEOCHROMOCYTOMA; SEQ 
DETERMINATION; CONA CLONE. 30  
STRUCTURE; ALLOSTERC ENZYME.
HYOROLASE;
TETRAHYDROBIOPTERJN 
BIOSYNTHESIS; ALTERNATIVE 
SPLICING. DISEASE MUTATION;
PHENYLKETONURIA;
PHOSPHORYLATION;
POLYMORPHISM; ALLOSTERIC 
ENZYME: HYDROLASE;
PHOSPHORYLATION. ENZYME- 
REGULATORY PROTEIN COMPLEX
G T P  c y c lo h y d r o la s e  I
I COG0302/CD0 2a-76 l Family GTPcydtfT^SrataaaI di*7a (1 194yP»Scoc ID 100%
M58587_at Protw mapped 
dvectiy with htgn 
confidence to 
Refeeq 
Fat _017020
A37986 462 interleukin 6 receptor H6r INTERLEUKN 6 RECEPTOR: 
INTERLEUKIN RECEPTOR; ACUTE 
PHASE: CYTOKINE RECEPTOR; 
TRANSMEMBRANE PROTEIN; 
GLYCOPROTEIN; IMMUNOGLOBULIN 
DOMAIN: RECEPTOR. REPEAT; 
SIGNAL; TRANSMEMBRANE
G00004872 receptor activity highly 
G0 0004896 hemaopoetirvtnterferon-ciaaf jjkely 
G0 0004907 interleukin receptor activKy 
G00005615 ttdraceiiuier space 
G00005887 integral to plasma membrane 
GO 0007166 cell Surface receptor linked sx 
GO 0016020 membrane 
G0 0016021 integral lo membrane
2 Im m u n o g lo b u l in  C -2  T y p e  F a m ily : 1 s e t  d o m a in s
38 - 92 2S-106
Hrt smart00406ACOD. 2e-06 Hrt Family 1 set domane din26ai (6-93VPwSccc>. 10 5t%
L o n g  h e m a to p o le t i n  r e c e p to r ,  s o lu b l e  a lp h a  c h a in  F a m ily : F ib ro n e c t in  t y p e  III
196 - 227 (fragment) 109 - 206
Hrt: PS01354/iPROSITEre 0 0003 Hrt Family Fdronectm type III d1n26a2 (1-97yPs<Scop: ID 56%
F a m ily : F i b ro n e c t in  t y p e  III
212 - 311
Hrt: Family: Fferonectm type IH d'n26*3 (l-100yPsiScop. 10 42%
M91599mRNA_g
at
Hand mapped - 
AAA41157.1
JC1450 650 fibroblast growth factor receptor 4 Fgfr4 FIBROBLAST GROWTH FACTOR 
RECEPTOR, ATP; 
ALTTOPHOSPHORYLATION; 
DUPLICATION; GLYCOPROTEN; 
GROWTH FACTOR RECEPTOR; 
MAGNESIUM. PHOSPHOPROTEIN. 
PHOSPHOTRANSFERASE; 
TRANSMEMBRANE PROTEIN; 
TYROSINE-SPECIFIC PROTEIN 
KINASE
GO 0006468 protein n n o  acxJ pnoephory unlikely
GO 0005524 ATP bmdmg
G0.0005615 edraceliuiar space
G0 0007165 Signal transduct«n
GO 0004672 protem Kinase activity
GO 0004674 protein sermafthreonne krnas
G00004872 receptor activity
G0 0016740 transferase activity
00:0005007 fibroblast growth factor recap!
00:0016021 integral to membrane
GO 0004713 protem tyrosme Kinase activity
0 Im m u n o g lo b u l in  C -2  T y p e
1 • 77
Hit. emarl0040MCDD; ie-11
Im m u n o g lo b u l in
102 197
Hit smart00409ACDD; Se-10
T y r o s in e  k in a s e ,  c a ta ly t ic  d o m a in
315 591
Hit: smart00219/iCOD; 7*97
F a m ily : 1 s e t  d o m a in s  
1 89
Hrt Famrty 1 set domans didpai (16- i04)/P«Scop: 10 71%
F a m ily : 1 s e t  d o m a in s
90- 196
Hat Family 1 set domans d1nunb2. (M09yPs»Scop; 1067%
F a m ily : T y r o s in e  k in a s e
301 595
HK: Family. Tyrosme Kinase dlgjoa_- (i-277yP*iScop. ID 73%
rc„ AA799729j  
at
Proto mapped 
within 2kb of 
3'end wrth low 
confidence to 
Refeeq 
NMJJ17031.
P14646 721 phosphodiesterase 4B Pde4b 600127 P0E48 GENE; ALTERNATIVE
SPLICING; PHOSPHOOIESTERAS6 48. 
CAMP SPECIFIC; 
PHOSPHODIESTERASE:
ALTERNATIVE SPUCING; 
HYDROLASE; MULTIGENE FAMILY; 
CAMP; 3D-STRUCTURE
G00005829 cytosoi unlikely 
G0 0007165 signal transduction 
G0;0004114 T.S-Cycbc-nudeotide phoeph 
G0:0004115 cAMP-speofic phosphodiesle 
G00016787 hydrotaee activity 
G0 0003624 catalytic activity
0 M etal d e p e n d e n t  p h o s p h o h y d r o l a s e s  w ith  c o n s e r  F a m ily : C a ta ly t ic  d o m a in  o f  c y c l ic  n u c le o t id e  p h o s p h o d
390 - 563 309 645
Hit: smart0047i/iCOD; 9e-06 Hrt Family Catalytic domam of cyclic nucleotide phosphodiesterase 4b2b di 8Djt>
rc_AA800245_at Proto mapped 
within 2Kb of 
3'end with low 
confidence lo 
Refeeq 
NM..019150.
P55090 122 urocortin Ucn 122AAS; ACC.NOU33935; HOMOL TO 
UROTEINSIN l/CRF; RAT BRAIN; SEQ 
COMPARISON; SEQ DETERMINATION; 
TISSUE DISTRIBUTION; UROCORTIN; 
CDNA CLONE; IN SITU 
HYBRIDIZATION; AMIDATION; 
CLEAVAGE ON PAIR OF BASIC 
RESIDUES; HORMONE; SIGNAL
G00005576 eidracefluiar highly 
G0 0006979 response to oxidative stress likely 
G0:0007218 neuropeptide signaling pathw 
G0:0005615 extracellular space 
00:0001664 G-prolan-coupled receptor d  
00:0005179 hormone activity
0 c o r t i c o t r o p in - r e le a s in g  fa c to r
81 • 114
Hit: smart0003SfiCOD; 6*07
n o  h i ts
(at 100% GT confidence)
rc_AA866299_at Proto mapped 
within 2Kb of 
3'end with low 
confidence lo 
ENSEMBL
ENSRNOPOO
000009972
196 Ensembl Gene Model MGC unlikely 0 E F - h a n d  c a lc iu m - b in d in g  d o m a in
15-57
Hit: PSOOOl8/iPROSrTEre; 1e-18
n o  h i ts
(at 100% GT confidence)
rc_AA866299_g_ 
at
Proto mapped 
within 2Kb of 
3'end with low 
confidence to 
ENSEMBL
ENSRNOPOO
000009972
196 Ensembl G ene Model MGC unlikely 0 E F - h a n d  c a lc iu m - b in d in g  d o m a in
15-57
Hit: PS00018/iPROSITEre; le-18
n o  h i ts
(at 100% GT confidence)
rc_AA874784_s_
at
Proto mapped 
directly with high 
confidence to 
Refeeq 
NM_012732.
064194 397 lipase A, lysosomal a d d Lipa GLYCOPROTEIN; HYDROLASE: LIPID 
DEGRADATION; LYSOSOME; SIGNAL
G0:0003824 catalytic activity highly 
G0:000477i sterol esterase activity likely 
G0 0005764 lysosome 
G0 0016042 lipid catabolism 
G0:0016787 hydrolase activity
0 a b - h y d r o la s e  a s s o c i a t e d  l ip a s e  r e g io n
28-96
Hit: pfam04083/iCDD: 5e-24
a lp h a /b e ta  h y d r o la s e  fo ld
111 - 385
Hit: PF00561/tPFAM; 5e-22
F a m ily : G a s t r i c  l ip a s e
28 - 395
HK: Family: Gastric lipase dikBqaj (9-376yP*Scop; ID 55%
rc_AA893000_at Hand mapped - 
BAC28404.1
BAC28404.1 1038 RIKEN cDNA 1300010F03 gene 1300010
F03Rik
CAP TRAPPER; HTC; MGC G0 0000166 nucleotide binding likely 
G00005524 ATP binding 
G0 0005615 extracellular space
0
M oxR -like  A T P a s e s
444 - 718
Hit: COG0714/iCD0; 2*09
M oxR -like  A T P a s e s
762 - 966
Hit: COG0714/iCDD; 2+09
S u p e r -F a m ily :  P - lo o p  c o n ta in in g  n u c le o t id e  t r ip h o s p h a t
65 - 391
Hrt: Family: Extended AAA-ATPasedoman. 1KSF:XX(143-406yPsiBlast; ID 12%
S u p e r -F a m ily :  P - lo o p  c o n ta in in g  n u c le o t id e  t r ip h o s p h a t
392 - 666
Hrt: Family: Extended AAA-ATPase domain. 1KSF XX(409-714yPsiBlast; ID 14%
S u p e r -F a m ily :  P - lo o p  c o n ta in in g  n u c le o t id e  t r ip h o s p h a t
775 • 1005
Hrt: Family- Extended AAA-ATPase doman. U7K:AA(1-224)/P»Blast; ID 14%
rc__AA893691_at Proto mapped
within 2Kb of
ENSRNOPOO 284 
000010889
Ensembl Gene Model unlikely 1 C - ty p e  le c tin  (CT L ) o r  c a r b o h y d ra te - r e c o g n i t i o n  d< S u p e r -F a m ily :  C - ty p e  ie c tin -i ik e
107 - 151 (fragment) 105 - 179
FBROBLAST; IMMUNOBLOT; GO 0005634 nucleus
OLIGONUCLEOTIDE PROBE: SEQ 
DETERMINATION, SEO HOMOL SEO 
SPECIFIC TRANS ACTIVATOR;
SIMILARITY TO API, C-JUN 
ONCOGENE; CONA CLONE. 2S70BP.
334AAS; ACTIVATION DURING GO/Gt 
TRANSITION; MOUSE FIBROBLAST;
RNA BLOT; SEO COMPARISON.
TRANSCRIPTION IN QUIESCENT 
FIBROBLAST; C-JUN GENE; 23306P;
EXPRESSION OF C-JUN GENE;
INDUCTION BY SERUM/PH0R80L 
ESTER; MOUSE; ONCOGENE JUWAP1.
30-STRUCTURE; DNA-BINDING;
NUCLEAR PROTEIN;
PHOSPHORYLATION;
POLYMORPHISM; PROTOONCOGENE;
TRANSCRIPTION REGULATION
rc_AI112173_at mapped AAA40780.1 304 ATPase Na+/K+transporting beta 1
dsectty wrth tegh 
confidence to polypeptide
Atp1b1 NA« K♦-ATPASE BETA 1 SUBUNIT;
CAP TRAPPER; HTC; MGC; ATPASE; 
NA.K-ATPASE; NA«. K* -ATPASE BETA 
SUBUNIT; GLYCOPROTEIN; ATPASE 
BETA; (NA*.K4)-ATPASE BETA; 
TRANSMEMBRANE PROTEIN. 
HETEROOIMER; HYDROLASE: ION 
TRANSPORT. POTASSIUM 
TRANSPORT; SODIUM TRANSPORT 
2570BP; 303AAS; AA SEQ ANAL: 
ARGKAKEEG. HYDROPATHY PLOT; 
NA/K ATPASE BETA, 
OLIGONUCLEOTIDE PROBE. SEQ 
DETERMINATION. SEO HOMOL;
SHEEP KIDNEY; CDNA CLONE: 
302AAS: MEMBRANE SPANNING 
REGION. PIG KIDNEY; SEQ ANAL OF 
TRYPTIC DIGEST; GLYCOPROTEIN: 
SIGNAL-ANCHOR; 
SOOIUM/POTASSIUM TRANSPORT. 
TRANSMEKfiRANE; MULTIGENE 
FAMILY
Hrt: pfam00287/rCDD; 9e-90
g o  0006813 oa«wum«niran»port unlikely 1 S o d iu m  / p o t a s s iu m  A T P a se  b e ta  c h a in
GO 0006814 sodium on transport 1 - 299
G00005890 sodium/polassium-eachangin.
G00018020 membrane 
GO 0Q16021 integral to membrane 
GO 0001666 reeponee to hypoooa 
GOOOOS391 •odium/potMSum-eachenoi^
rc__AI169612_at Prooemappeo AA037371.1 150 fatty acid binding protein 4
directly with high 
confidence to 
Refseq 
NM0S3365.
rc_AI170268^at PTOt*  m»oeo P07151
directly with 
medium 
confidence to 
Refseq 
NM_012512.
Fabp4
119 beta-2 microglobulin BETA-2-MICROGLOBUUN. GERM LINE; 
MICROGLOBULIN; SIGNAL PEPTIDE; 
BETA 2 MICROGLOBULIN. 
HETEROOIMER; 30-STRUCTURE; 
IMMUNOGLOBULIN DOMAIN; MHC I; 
SIGNAL
G0000521S transporter activity 
G00005488 bmdr<Q 
G00006810 transport 
G0:0006289 Itpid tending
G000056l5e>rtracellutar space highly
00:0005886 plasma membrane likely
G0;0005887 integral lo plasma membrane 
G0:0006952 defense response 
00:0006968 cellular defense response 
GO 0019683 antigen presentation, endoger 
G0 0019885 antigen processing, endogerx 
G0:0030106 MHC class 1 receptor activity
l: PF00061/iPFAM; 5e-26
Im m u n o g lo b u l in  C -T y p e
Hit: smart00407/iCDD: -
Hrt: Family: Fatty aod tendmg pratan-l*e d la l8 _ : (M3tyP*Scop; 10 93%
F a m ily : C1 s e t  d o m a in s  ( a n t ib o d y  c o n s t a n t  d o m a in - lik e )
24-119
Ht: Family: C1 set domains (antibody constant doman-lihe) difitb_. (4-99yPsiSc«
rc_AI230614_s_a Probe maoced 
I directly wrth high
confidence to 
Refseq 
013113.
AAA40780.1 304 ATPase Na+/K+ transporting beta 1 
polypeptide
Atp1b1 NA+ K+-ATPASE BETA-1 SUBUNIT. 
CAP TRAPPER; HTC; MGC; ATPASE: 
NA.K-ATPASE: NA4, K+ -ATPASE BETA 
SUBUNIT; GLYCOPROTEIN; ATPASE 
BETA; (NA+.K+)-ATPASE BETA; 
TRANSMEMBRANE PROTEIN; 
HETEROOIMER; HYDROLASE: ION 
TRANSPORT; POTASSIUM 
TRANSPORT; SODIUM TRANSPORT; 
2570BP; 303AAS; AA SEO ANAL; 
ARGKAKEEG; HYDROPATHY PLOT; 
NA/K ATPASE BETA; 
OLIGONUCLEOTIDE PROBE; SEQ 
DETERMINATION; SEO HOMOL;
SHEEP KIDNEY; CDNA CLONE; 
302AAS: MEMBRANE SPANNING 
REGION; PIG KIDNEY; SEQ ANAL OF 
TRYPTIC DIGEST; GLYCOPROTEIN; 
SIGNAL-ANCHOR: 
SOOIUM/POTASSIUM TRANSPORT; 
TRANSMEMBRANE; MULTIGENE 
FAMILY
I: pfam00287/iCDD: 9e-90
G0  0006813 potassium ion tranepon unlikely 1 S o d iu m  / p o t a s s iu m  A T P a se  b e ta  c h a in
G0:0006814 sodium ion transport 1-299
G0:0005890 sodium/potassium-exchangirv 
GO 0016020 membrane 
G0 0016021 integral to membrane 
G0:0001666 response to hypoxia 
G0:000539i sodium/potaesium-a>changir»
n o  h i t s
{at 100% GT confidence)
rc_AI639088_s_a
t
nrt mapped to a 
transcript
rc_AI639107_al Probe mapped 
within 2Kb of 
3‘end wrth low 
confidence lo 
ENSEMBL
ENSRNOPOO 173 
000019646
Ensembl G ene Model CAP TRAPPER; HTC unlikely 0 A R F -like  sm a ll  G T P a s e s
13-173
Hit: smart00177/iCDD, Se-33
F a m ily : G  p r o te in s
12 - 167
Hit: Family: G proteins. d1m2od_: (2-l56VP»iScop, ID 36%
rc_AI639162_at Probe mapped 
within 2M> of 
3'end wrth low 
confidence to
035460 497 angiopoietin 1 Angptl 601922- ANGK)POIETIN-2; CAP TRAPF'ER; HTC; GO;000152S angiogenesi6 hiqhly 0 
601667’ ANGOGENESIS;TEK;VEGF; 00:0005871 kmesin complex |jkely
ANGIOGENESIS; COILED COIL; ____ I,IWI7
GLYCOPROTEIN; SIGNAL; G0 0048014 Tie receptor signaling pathwa
F ib r in o g e n - re la te d  d o m a in s  (F R e D s)
280 - 495
Hrt: sman00186/iCDO; 6e-90
F a m ily : F ib r in o g e n  C - te rm in a l d o m a in - l ik e
275 - 496
Hrt: Family: Fibrinogen C-lermmat doman-Jike. dimijcl: (2-249)/PsiScop; ID 37%
615-656
Hrt amartOQ326ACDD 0 001
S r c  h o m o lo g y  2 d o m a in s
i vn m oeaxfcoo . 2»t;
Hrt. Family SH3-doman dikii
F a m ily : 5 H 2  d o m a in
662 • 769
Hrt Family SH2 daman o ’b*
F a m ily : S H 3 * d o m a in
785 837
Ht FarrWy SH3-domain <jl*n
(i 78VP«*Scop 10 84%
1 yPaScop; 10 35%
O M ^ S c o p  JO 48%
U75411cds q at *<*»"«»
directly with 
conSdencett 
Genbar*
M21782
82 ig Iambda2-like chain - rat (fragment) C-REGlON; MMUN0GL06ULM 
LAMBDA; IMMUNOGLOBULIN LIGHT 
CHAIN; LAV©DA2-LIKE PROTEIN; 
PROCESSED GENE; 
HETEROTETRAMER; 
IMMUNOGLOBULU
unlikely 0 I m m u n o g lo b u l in  C -T y p e
I smart00407ACD0. S*-1»
F a m ily : C1 s a t  d o m a in s  ( a n t ib o d y  c o n s t a n t  d o m a ln - iik e )
1 - 79
Hrt Family C1 m i domane (artOQOy constant doman-!**) dig64a (26-104yPt
X17053mRNA_s * " " « « «  p  14644
. directly with hgh
— ccrttoence to
Refseq 
hSt_031530.
148 small indudble cytokine A2 Scya2 CHEMOATTRACTANT PROTEIN-1. JE 
GENE; tMMEOlATE-EARLY SERUM- 
RESPONSIVE GENE; SERUM- 
RESPONSIVE GENE. CHE MOT AX IS; 
CYTOKINE; GLYCOPROTEM. 
NFLAMMATORY RESPONSE 
PYRROUDONE CAR0OXYLIC ACID; 
SIGNAL
GO000S576 edracalluiar 
G0 0006935 chemotus 
GO 0006954 inflammatory response 
G00006955 immune response 
GO 0006009 chemofcine activity
hiqhly
likely
i n te r c r in e  a lp h a  fa m ily  ( sm a ll c y to k in e  C-X -C) (c h e  F a m ily : In ta r ia u k in  ft-like  c h e m o k in e s
31 90 24 - 99
Hrt. smart00i99^CDD. 2e-20 Hr Family Interleukin 6-i*e chsmotanes didoma (1 76yPs«Scap. ID 55%
X98517_at Probe mapped Q63341
directly with r*gh 
confidence to 
Refseq 
NM 053963
465 matrix m etalloproteinase 12 Mmp12 MACROPHAGE METALLOELASTASE. 
CALCIUM; EXTRACELLULAR MATRIX. 
GLYCOPROTEIN. HYDROLASE; 
METALLOPROTEASE; SIGNAL; ZINC: 
ZYMOGEN
GO 0004222 metalloendooeptidaee activity highly 
GO 0005615 extracellular spec* likely
GO 0006506 proteolysis and pephdofys*
GO 00D5S76 ertraceflutar 
GO 0005578 erfracefluiar m am 
00:0016787 hydrolaae activity 
G00004234 macrophaoe slestaes activity 
GO 0006233 peptidase activity 
GO 0006270 rmc -on binding 
G00005509 celaum on bmdmg 
GO 0006237 meUftopeptidase activity
M a trix  m e ta l lo p r o te a s e ,  ^ - te r m in a l  d o m a in
14-92
Hrt p(ar>03933/CDD 7e-232in c - d e p a n d a n t  m e ta l lo p r o te a s e
104 -260
Hit smart00235ACOD 2e-24
H e m o p e x in
328 - 370
Hit. PF0004^iPFAM: 0 001
Hrt smartOOl2Q/iCOO: 7*06
Hit Family MnlP N-termmal doman dic*7a6 (ii-77yPs*Sccp: 10 39%
F a m ily : M atrix  m e ta l lo p r o te a s e s ,  c a ta ly t ic  d o m a in
95 - 261
Hrt Family- M*n> metaltopral eases. caalytc daman disim 2 (2-i«9VPs*Scop
F a m ily : H a m o p a x in - lik a  d o m a in
278 - 465
Ht. Family Hemopeoon-iSie daman d'pex (5-'92yPsiScap. ID 37%
Hit pfam0004SCDD. 0 002 (tow)
153 myelin and lymphocyte protein 188860 CAP TRAPPER. HTC. MGC. I
VIP17/MAL PROTEOLIPID; OPEN 
READING FRAME. EXON. T-C6LL; 
ALTERNATIVE SPLICING. 
ENOOPLASMIC RETlCU-UM: 
GLYCOPROTEIN. TRANSMEMBRANE 
PROTEIN: LIPOPROTEIN. MYELIN. 
TRANSMEMBRANE. ALTERNATIVE 
SPUCING
membrane unlikely 4  n o  h i t s
GO 0010020 membrane
GO 0016021 intagra to membrane
G0 0019911 structural constituent of my#
Probe map# 
drectty with 
confidenceK
470 early growth response 2 Egr2 FINGER PROTEIN KROX 2CVEGR 000003677 ONA bndrng
GO 0007622 rhythm* behanor 
GO 0042SS2 my#nalK)rGROWTH FACTOR. NERVE GROWTH FACTOR-INDUCE0 GENE; KROX-24 
PROTEIN: EGR-1 GENE; GROWTH 
FACTOR-WDUCI81E PROTEIN. 
TRANSCRIPTION FACTOR. ONA 
BINDING PROTEIN: ZINC-FINGER 
PROTEIN. ZINC FWGER PROTEIN. 
ACTIVITY REGULATE0: ZINC FWGER 
ONA BINDING PROTEIN; DNA BINDING. 
ALTERNATIVE SPLICING. IMMEDIATE 
EARLY PROTEW; TRANSCRIPTION 
REGULATION. ZINC FWGER. 3D- 
STRUCTURE; ACTIVATOR: DMA- 
BINDING, METAL-BINOING: NUCLEAR 
PROTEIN; REPEAT; TRANSCRIPTION 
REGULATION. ZINC-FINGER: 
ALTERNATIVE SPLICING
G0 0003700 tranecr#«jn factor acttvtty 
GO 0006355 reguUoi of trenecnpt.or\ DA 
GO 0005634 nucleus
Z in c  f in g e r  C 2H 2  ty p e  d o m a in  p ro f i le F a m ily : C l a s s i c  z in c  f in g e r , C 2H 2
337 • 366 325 363
Hrt: PS50157/lPROSITEpro. rva Hrt Family Classic nncinger. C2H2 OH^gl (1 39VP»Scop: 10 78%
Z in c  f in g e r  C 2H 2  ty p e  d o m a in  p ro f i le F a m ily : C l a s s i c  z in c  f in g e r ,  C 2H 2
367 - 394 354 - 391
Hrt. PS50157/1PROSfTEpro. fVa Hrt Famwy Q — c m c Ingar. C2K2 d O g ’ (2 39|/PaScop 10 44%
Z in c  f in g e r  C 2H 2 ty p e  d o m a in  p ro f i le F a m ily : C l a s s i c  z in c  f in g e r ,  C 2H 2
395 422 361 -417
Hrt PS50157/lPROSITEpro rva Hrt Family Cl— ic finC finger, C2H2 0ll2»gl (i 37^*Scop. 10 40%
Probe mapped P17425 
directly wrth high 
confidence lo 
Refseq 
NM 017268
520 3-hydroxy-3-methylglutaryl-Coenzyrne A 
synthase 1
Hmgcsl 142940 c ap  t r a p p e r ;  h t c ; f i s  ( f u l l  G0:0005737 cytoplasm unlikely
WSERT SEQUENCE); OLK30 G 0 0005667 transcnption to o r  compa*
CAPPING. MGC; FLI.CDNA; 3- _
HYDROXY 3-METHYLGLUTARYL 0 0  0003700 «f»»cr<X'0n tecior activity
COENZYME A SYNTHASE. HMG-COA G0 0016629 lyeee activrty
SYNTHETASE: SYNTHETASE. GO 0006700 021 -Cterod hormone CMtyNI
CYTOSOLIC 3-HYDROXY 3 _ -  (W^ , , 1 _
METHYIGLUTARYL COENZYME A GO 0005634 nudM
SYNTHASE; GO 0003677 ONA tandmg
HYDROXYMETHYIGLUTARYICOA GO 0016740 transferal activity
SYNTHASE. CARBONCARBON LYASE; g q .0007548 -
0 H y d ro x y m e th y lg lu ta ry l- c o e n z y m e  A s y n th a s e  S u p e r -F a m ily :  T h io la e e -l ilte
I pfamOl 1S4/CDD. 0 Hit. Fam-iy TNtfaee rented dlmzjal (7-t75yPsSccp. <0 19%
S u p e r -F a m ily . T h io la se - iik e
191 -331
Hrt: Family. Thdae^relaied 1HNJ AA(l7S-3l7yPs^laM. 10 8%
CHOLESTEROL BIOSYNTHESIS:
COENZYME A; ENDOPLASMIC 
RETICULUM; GLYCOPROTEIN;
MEMBRANE PROTEIN; OXO-ACID-
IYASE; CYTOSOL CHOLESTEROL ___  M
BOSYNTHESIS; MULTIGENE FAMILY; G0:°006355 reoti«<« o» Iranecnpeon. DA 
TRANSFERASE
GO 0006695 choleeleroi l>oeynthes« 
G00004421 hydroxymethylQkjIaryl-CaA sy 
GO 0006064 acetyt-CoA metabolism
Probe mapoed
medium 
confidence to 
Refseq 
NM 023976.
PERIAXIN; ALTERNATIVE SPLICING 
MEMBRANE: NUCLEAR PROTEIN: 
REPEAT
G00016Q20 membrane
GO 0005515 protein binding
GO OOOS634 nucleus
GO 0007242 intracellular signaling caacadt
G0:0005866 plaema membrane
unlikely 0 D o m a in  p r e s e n t  in  P S D -9 5 , D ig, a n d  ZO -1 /2
19-96
Hrt: smart00228^000: 0 001
D y s tr o g ly c a n  ( D y s t r o p h l n - a s s o d a t e d  g ly c o p ro te ir
206 - 365 (fragment)
Hrt: PF05454/iPFAM: 0 006 (low)
C o m if in  (S P R R ) fam ily
432 - 555
Hit: pfam02389/C00: 3e-06
S u p e r -F a m ily :  PD Z  d o m a in - l ik e
l: Family Heneukm 16 01i16 .. (26 128)^fiiSccp: 10 17% 
I: Fam<iy PDZ doman. dqawb, (M02)/P*Scop. ID 20%
t: pfam02389*CD0: le-07
279 ATPase, Na+/K+ transporting, beta 3 
polypeptide
NA*.K*-ATPASE BETA 3 SUBUNIT. 
GLYCOPROTEIN, MULTIGENE FAMILY. 
SIGNAL-ANCHOR
SOOJUfct'POTASSAJM TRANSPORT. 
TRANSMEMBRANE
GO 0015355 monocarbatytaH porter «diwr
GO0015711 oroanc mon transport
G00016021 mtegral lo membrane
GO 0005391 eodmnvpott mm-aachengmi unlikely 1
GO 0005690 aodium/potaw.*n wcharyni
GO 0006813 potaawum -on transport
G000068U sodium on transport
GO 0016020 membrane
G00016021 integral to membrane
S o d iu m  / p o t a s s iu m  A T P a s e  b e ta  c h a in
Hit PF00287APFAM. 9*-7$
Probe mapped 
directly with htgh 
confidences
448 ornithine decarboxylase antizyme inhibitor Oazi CAP TRAPPER; HTC. MGC. FU_CDNA. 
ANTIZYME INHIBITOR; POLYAfirttNE
biosynthesis
GO 0003624 ca ts**  activity unlike ly 0
G00006595 pctyamme mstaboiien!
GO 0006596 pdyamme b**yrthee*
G0 0006073 omrtNne d
I ptam02784/CDD; 6*58 I C-termnai domen 1D7K B8<i-37yPa>Bl4M K
I pt«n002787COD. Ae-25 Hrt Family manna ~a a n tes fie  N-termvwf dom*n d'd7V*2 (I 240yPaiScop
F a m ily : A la n in e  ra c e m e s e - l i k e ,  C - te rm in a l d o m a in
niiy Aiamne n » C-tarmrtal oomari did7itf>i (3-i85)/P*»Secp.
1216 phosphoiipase C, beta  1 607120 PLC81 GENE. PHOSPHOLIPASE C 
B6TA-1A, PHOSPHOLIPASE C-BETA 
IB; PHOSPHOUPASE C. 
PHOSPHOUPASE. 
PHOSPHOPROTEIN PHOSPHORIC
GO 0000074 regimen of cell cyde 
GO 0005737 cytapiaam 
GO 0006629 lod metabolism 
GO 0004671 signal transducer activity
unlikely 0
WESTER HYOROLASE. ALTERNATIVE 00:0016042 KpidcattfxMm 
SPLIONG. 1216AAS. BOVINE BRAIN 
EXPRESSION IN COS1 CEa;
HYDROPATHY PLOT;
PHOSPHOLIPASE C 154; RNA BLOT;
SEQ DETERMINATION; STR 
COMPARISON. CONA CLONE;
CALCIUM; HYDROLASE. LIPID
DEGRADATION; PHOSPHORYLATION: GO 0005634 nucleus 
TRANSDUCER; ALTERNATIVE 
SPLICING
GO 0004435 l-0baeonaxJyiinoartai-4.5-b«! 
GO 0016787 hydrolase actiWy 
GO 0007242 intraceHutar s^nating caacadt 
G0 0004629 phoephcfipase C activrty 
G0 0007165 atgnai tranedudion
P h o s p h o i ip a s e  C , c a ta ly t ic  d o m a in  (p a r t)
316 467
Hit: smartOOl46*CDO. 2e-(6
P h o s p h o i ip a s e  C , c a ta ly t ic  d o m a in  (p a r t)
540-656
Hrt. sm«i00149/tCO0. 6e-47
P r o te in  k in a s e  C  c o n s e r v e d  r e g io n  2 (C a lB )
677 - 776
Hit sman0023S'tCDD, 8*06
S u p e r -F a m ily :  PH  d o m a in - l ik e
13 - 139
Hrt Famity Piackstnn-hcmotogy domaxi (PH damam) 1MAI 1(1 1 i9VP*4MaBt; 1C
S u p e r -F a m ily :  E F -h a n d
17? 3?8
Hi Family EF hand modiAes m mJMomar< prolans d'dtgbl (S-l4iyP»$cop.
F a m ily : M a m m a lia n  P L C
320-667
Hrt Family Mamnutan PLC dN*ga3 (2 278VP*Soop ID 37%
S u p e r -F a m ily :  C 2  d o m a in  (C a lc iu m /l ip id -b in d in g  d o m a ir
677 - 797
Hrt: Family: PLC Me (P variant) dlqaea2' (5-l26vP»Scop. 10 28%
rc_AA799340_at *obe mapped
wrthmZkbof 
3‘end witt! kwr 
confidence to 
Refseq
220 tissue inhibitor of metalioproteinase 2 Timp2 188825 TIMP-2 GENE. TISSUE INHIBITOR Of 00:0008191 metStoendopept'd 
METALIOPROTEINASE TYPE 2. CAP 00:0005578 extracellular m*m
TRAPPER; HTC; MGC; 
METALLOPROTEINASE-2 INHIBITOR; 
MATRIX METAUOPROTEINASE 
INHIBITOR; METALLOPROTENASE 
INHtBlTOR; EXTRACEUULAR 
PROTEIN. TISSUE INHIBITOR OF 
METALIOPROTEINASE; INHIBITOR OF 
MATRIX METALLOPROTENASES. 
TISSUE INHIBITOR OF 
MET ALLOP ROTE INASES. TYPE 2; 
ERYTHROPOIESIS; EXTRACEUULAR 
MATRIX; MITOGEN; 3D-STRUCTURE; 
METAUOPROTEASE NHBITOR. 
SIGNAL
G0 0005615 extracellular space 
G00005604 basement membrane 
GO 0006047 enzyme activator activity
< highly 
likely
T is s u e  in h ib i to r  o f  m e ta l io p r o te in a s e  fam ily
27-203
Hrt smart00206rtC0D. 6e-71
F a m ily : T is s u e  in h ib i to r  o f  m e ta i lo p r o te i n a s e s ,  TIM P
27 218
Hrt. Family Tasue rtvbrtor of metaftaproiwnaeas. TiMP diQxdc.: (M92)/PtiScoi
rc_AA800005_at Probe mapped 
directly witn high 
confidence to
NM.022523.
Q9QZA6 253 C0151 antigen Cd15l 602243 MGC; FU CONA, C0151; MEMBRANE 
GLYCOPROTEIN; TRANSMEMBRANE 4 
SUPERFAMILY; SFA-1; PETA-3. TM4SF 
PROTEIN; PlATELET-ENOOTHELIAL 
TETRASPAN ANTIGEN; 
TRANSMEMBRANE GLYCOPROTEN: 
GLYCOPROTEIN, TRANSMEMBRANE; 
POLYMORPHISM
00:0005886 plasma membrane 
GO: 0016021 integral to membrane
unlikely 4 T e t ra s p a n in  fam ily
15-220
Hrt: pfam0033S'C0D: 5e-i9
n o  h i t s
(at 100% GT confidence)
rc_M 800576_at Hand mapped- 
NP_060664.1
AAH19544.1 266 RIKEN cDNA 1200015A19 gene 1200015 - 
Al9Rik
CAP TRAPPER; HTC; MGC unlikely 0 n o  h i t s n o  h i ts
(at 100% GT confidence)
rc_AA875288_at Hand mapped to 
mouse orthoiogue 
- NP_766331.1
BAC30557.1 1030 RIKEN cDNA A430081P20 gene A430081 - 
P20Rik
CAP TRAPPER; HTC unlikely 0 PH  d o m a in  p ro f i le
Jan-45
Hit; PS50003/iPROSITEpro: n/a
n o  h i t s
(tf 100% GT confidence)
rc_AA892234_at Hand mapped- 
NP 079645.1
AAH29669.1 153 microsomal glutathione S-transferase 3 Mgst3 604564 CAP TRAPPER; HTC; MGC; 
MICROSOME; POLYMORPHISM, 
TRANSFERASE; TRANSMEMBRANE
G00000004 bidogical.procees unknown 
G0 0005554 motecular_function unknown 
G00006372 celiular_componerl unknown 
GO 0016740 transferase activity
likely 4 M A PEG  fam ily
6-136
Hit: pfam0l124/tCOD; Se-11
n o  h i ts
(at 100% GT confidence)
rc_AA892557_g_
at
Hand mapped - 
AAP92663.1
AAP92663.1 183 Da2-17 CAP TRAPPER. HTC; MGC unlikely 3 n o  h i ts
n/a
n o  h i ts
(at 100% GT confidence)
rc_AA893082_at Probe mapped
within 2kbof
P54844 369 v-maf musculoaponeurotic fibrosarcoma 
(avian) oncogene homolog (c-maf)
Mai C-MAF PROTO-ONCOGENE PRODUCT. G00000074 regulation of cell cycle 
TRANSCRIPTION FACTOR; C-MAF 00:0045449 regulation of trwiscnptiai 
i nun  popu- dna niNntNrv i pi k-.inp
unlikely 0 bZ IP  M af t r a n s c r ip t io n  f a c to r
253 - 362
F a m ily : A D N A -b in d in g  d o m a in  in  e u k a r y o tic  t r a n s c r ip t i i
258 - 297
563 617
HI F«rwy Q«wc pnc ingar C2H2 <]if2tg1 {3-39>/P*Scop <0 35%
Prot»m«pp«3 P 3 1 9 7 7  160  vrlfin 2 Vil2 ezrin . rvROswe k inase  GOooo55i5pr<a«nB.nij«g unlikely 0  E z r ln /r a d ix in /m o e s ln  fam ily  F a m ily : M o e a ln  ta il  d o m a in
d»«ctty witfi Ngh SLBSTRATE; ACTIN BINDING: G0 0016324 «j*cR plwn* 40 • 160 (Ir^jrrnni) 74-160
coniOence 10 CYTOSKELETQN: MEMBRANE
r-jmt-fc-L PROTEIN PHOSPHOPROTEIN GO 0005196 *ructurtl motecuH ■cUvrty Hrt PF007»iPFAM. 9e-34 Hrt Far»rty Mown t»l dom»o d itfic : (4-90VR*»Scno 10 36%
X67788 CYTOSKELETON. GO 0005856 cyto«tf«on
PHOSPHORYLATION; STRUCTURAL 
PROTEIN
